<SEC-DOCUMENT>0001213900-20-022334.txt : 20200814
<SEC-HEADER>0001213900-20-022334.hdr.sgml : 20200814
<ACCEPTANCE-DATETIME>20200814171618
ACCESSION NUMBER:		0001213900-20-022334
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200814
DATE AS OF CHANGE:		20200814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		201106585

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0620_actiniumpharma.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Mark One)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#9746;<B>&nbsp;&nbsp;&nbsp;&nbsp;QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the quarterly period ended <B>June 30, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#9744;<B>&nbsp;&nbsp;&nbsp;&nbsp;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from __________ to
__________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: <B>001-36374</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ACTINIUM PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>74-2963609</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of<BR>
Incorporation or Organization)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<BR>
Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>275 Madison Ave, 7<SUP>th</SUP> Floor</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New York, NY</B></P></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10016</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(646) 677-3870</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s Telephone Number, Including
Area Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>Securities registered
pursuant to Section&nbsp;12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol</B>&nbsp;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of exchange on which registered</B></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock, par value $0.001</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATNM</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NYSE American</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. &#9746;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). &#9746;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. &nbsp;See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 28%">&nbsp;</TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards, provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#9744;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9746;&nbsp;No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: right; text-indent: 0.55in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate the number of shares outstanding of each of the issuer&rsquo;s
classes of common stock, as of August 13, 2020: 13,585,222</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the six months ended June 30, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART I &ndash; FINANCIAL INFORMATION</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 82%"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART II &ndash; OTHER INFORMATION</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults Upon Senior Securities</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART I - FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_001"></A><B>ITEM 1. &nbsp;FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (which include only normal recurring
adjustments) necessary to present fairly the financial position at June 30, 2020 and December 31, 2019, and the results of operations
and cash flows for the three and six months ended June 30, 2020 and 2019, respectively, have been made. Certain information and
footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction
with the financial statements and notes thereto included in the Company&rsquo;s audited financial statements for the year ended
December 31, 2019 in the Company&rsquo;s Annual Report on Form 10-K. The results of operations for the three and six months ended
June 30, 2020 are not necessarily indicative of the operating results for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(amounts in thousands, except share and per
share data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Current Assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 76%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">53,466</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,254</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Restricted cash &ndash; current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">786</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left">Total Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,508</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,088</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and equipment, net of accumulated depreciation of $260 and $237, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating leases right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">738</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">807</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Finance leases right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">181</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Security deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Restricted cash</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">391</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">391</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">55,958</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,670</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">Liabilities and Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,092</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,598</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">381</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Operating leases current liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">286</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Finance leases current liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">82</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">79</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Current Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,656</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,344</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Long-term operating leases obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">419</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">531</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;&nbsp;&nbsp;&nbsp;Long-term finance leases obligations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">109</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">151</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,184</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,026</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders&rsquo; Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; text-indent: -10pt">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; text-indent: -10pt">Common stock, $0.001 par value; 1,000,000,000 shares authorized;
13,171,824 and 5,490,038 shares issued and outstanding, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">269,815</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">214,397</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(219,054</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(208,758</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Stockholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">50,774</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,644</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">55,958</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,670</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Consolidated Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(amounts in thousands, except share and per
share data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six Months Ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left; padding-left: 10pt">Research and development, net of reimbursements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,508</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,010</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7,659</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,345</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,154</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,076</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,686</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,440</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,662</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,086</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,345</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,785</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,662</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,086</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,345</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,785</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Interest income - net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">59</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">50</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">88</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total other income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">59</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">50</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">88</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(4,625</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(5,027</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(10,295</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(10,697</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Deemed dividend for warrant down-round protection provision</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss applicable to common stockholders</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(4,626</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(5,028</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(10,296</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(10,698</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss per share of common stock&nbsp;&ndash; basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.41</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1.20</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2.39</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Weighted average shares of common stock&nbsp;outstanding, including outstanding pre-funded warrants&ndash; basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,379,345</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,051,471</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,559,385</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,476,215</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Consolidated Statement of Changes in Stockholders&rsquo;
Equity </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Three and Six Months Ended June 30,
2020 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(amounts in thousands, except share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional Paid-In</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stockholders&rsquo;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold">Balance, January 1, 2020</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">5,490,038</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">5</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">214,397</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">(208,758</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">5,644</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">372</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">372</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left">Sale of common stock, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,673</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,674</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,670</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,670</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Balance, March 31, 2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,827,982</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">217,442</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(214,428</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,240</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left">Issuance of common stock from exercise of pre-funded warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left">Sale of common stock and pre-funded warrants, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,138,602</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,165</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left">Deemed dividend for warrant down-round protection provision</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,625</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,625</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Balance, June 30, 2020</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13,171,824</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">269,815</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(219,054</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">50,774</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Consolidated Statement of Changes in Stockholders&rsquo;
Equity </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Three and Six Months Ended June 30,
2019 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(amounts in thousands, except share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional Paid-In</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stockholders&rsquo;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold">Balance, January 1, 2019</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">3,856,768</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">4</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">195,666</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">(186,857</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">8,813</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">316</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock from exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,542</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,504</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,504</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sale of common stock, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,817</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">380</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,670</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,670</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Balance, March 31, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,971,201</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">197,866</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(192,527</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,343</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">277</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">277</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock from exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,249</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Sale of common stock and warrants, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,428,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,107</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,108</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Deemed dividend for warrant down-round protection provision</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,027</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,027</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Balance, June 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,401,117</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">213,251</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(197,555</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">15,701</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">See accompanying notes to the consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Consolidated Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(amounts in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For&nbsp;the&nbsp;Six&nbsp;Months Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>June 30,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Cash Flows From Operating Activities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(10,295</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(10,697</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">582</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">593</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Depreciation &amp; amortization expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">209</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(208</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">280</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(506</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,111</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(154</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(127</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used In Operating Activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,365</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,853</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; font-weight: bold; text-align: left">Cash Flows Used In Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(59</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used In Investing Activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(59</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Payments on note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(227</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(148</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Payments on finance leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(39</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Sales of shares of common stock and pre-funded warrants, net of costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,839</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Sales of shares of common stock and warrants, net of costs&#9; &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,488</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from exercise of pre-funded warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt">Proceeds from exercise of warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,504</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Provided By Financing Activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">54,577</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,808</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net change in cash, cash equivalents, and restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,212</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,896</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash, cash equivalents, and restricted cash at beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,693</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,104</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash, cash equivalents, and restricted cash at end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">53,905</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Cash paid for interest on note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Cash paid for taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Supplemental disclosure of non-cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Deemed dividend for warrant down-round protection provision</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 1 - Description of Business and Summary
of Significant Accounting Policies</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Nature of Business -</B>
Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;, &ldquo;Actinium&rdquo;, or &ldquo;We&rdquo;) is a clinical-stage, biopharmaceutical
company applying its proprietary platform technology and deep understanding of radioimmunobiology to the development of novel targeted
therapies known as ARCs or Antibody Radiation-Conjugates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Basis of Presentation
- Unaudited Interim Financial Information -</B> The accompanying unaudited interim consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S.
GAAP&rdquo;) for interim financial information, and in accordance with the rules and regulations of the United States Securities
and Exchange Commission (the &ldquo;SEC&rdquo;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do
not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim
consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in
the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are
not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be
read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company&rsquo;s annual
report on Form 10-K for the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Reverse Stock Split
- </B>On April 29, 2020, the Company received a deficiency letter from the NYSE American LLC, or NYSE American, indicating that
the Company was not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE
American Company Guide because its shares of common stock had been selling for a substantial period of time at a low price per
share. Pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the NYSE American staff determined that the Company&rsquo;s
continued listing is predicated on the Company effecting a reverse stock split of its common stock or otherwise demonstrating sustained
price improvement within a reasonable period of time, which the staff determined to be no later than October 29, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 18, 2019, the
Company&rsquo;s board of directors, or the Board, unanimously approved, subject to stockholder approval, an amendment to the Company&rsquo;s
certificate of incorporation to effect a reverse stock split of its outstanding common stock by combining outstanding shares of
common stock into a lesser number of outstanding shares of common stock by a ratio of not more than 1-for-75 prior to December
18, 2020, with the exact ratio to be set within this range by the Board at its sole discretion. At its Annual Meeting of Stockholders
held on December 18, 2019, the Company&rsquo;s stockholders approved such amendment to its certificate of incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 7, 2020, the Board unanimously approved a reverse
stock split of its outstanding common stock by combining outstanding shares of common stock into a lesser number of outstanding
shares of common stock by a ratio of 1-for-30, and on August 10, 2020, the Company filed with the Secretary of State of Delaware
a certificate of amendment to its certificate of incorporation to effect the reverse stock split. The reverse stock split became
effective as of 5:00 p.m. Eastern Time on August 10, 2020, and the Company&rsquo;s common stock began trading on a split-adjusted
basis when the market opened on August 11, 2020. Accordingly, all common share and per common share data in these consolidated
financial statements and related notes hereto have been retroactively adjusted to account for the effect of this reverse stock
split for all periods presented. In addition, at the effective time of the reverse stock split, the number of shares of our common
stock reserved for issuance upon exercise of all options and warrants to acquire common stock have been proportionally decreased,
and the exercise price of all options and warrants to acquire common stock have been proportionally increased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Principles of Consolidation
-</B> The consolidated financial statements include the Company&rsquo;s accounts and those of the Company&rsquo;s wholly owned
subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Use of Estimates in
Financial Statement Presentation</B> - The preparation of these consolidated financial statements in conformity with U.S. GAAP
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of
the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ
from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Impact of COVID&ndash;19
Pandemic on Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In December 2019, a novel
strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China to other
countries has resulted in the World Health Organization (&ldquo;WHO&rdquo;) declaring the outbreak of COVID-19 as a &ldquo;pandemic,&rdquo;
or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictions
on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses, and many local jurisdictions
continue to have such restrictions in place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As local jurisdictions
continue to put restrictions in place, the Company&rsquo;s ability to continue to operate its business may also be limited. Such
events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of
which could materially affect the Company&rsquo;s business, financial condition and results of operations. In response to COVID-19,
the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations as
it relates to the clinical development or drug production of our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The spread of COVID-19,
which has caused a broad impact globally, may materially affect the Company economically. While the ultimate economic impact brought
by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, including new information which may emerge
concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others, the pandemic has resulted
significant disruptions in the general commercial activity and the global economy and caused financial market volatility and uncertainty
in significant and unforeseen ways in the recent months. A continuation or worsening of the levels of market disruption and volatility
seen in the recent past could have an adverse effect on the Company&rsquo;s ability to access capital, which could in the future
negatively affect the Company&rsquo;s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19
could materially affect the Company&rsquo;s business and the value of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, COVID-19
may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with IRB&rsquo;s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To date, COVID-19 has not
had a financial impact on the Company. However, COVID-19 has caused severe disruptions in transportation and limited access to
the Company&rsquo;s facility, resulting in limited support from its staff and professional advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Cash, Cash Equivalents
and Restricted Cash -</B> The Company considers all highly liquid accounts with original maturities of three months or less to
be cash equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2020 and December 31, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">53,466</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,254</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Restricted cash &ndash; current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Restricted cash &ndash; long-term</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">391</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">391</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">53,905</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,693</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Current restricted cash
relates to credit card accounts, while long-term restricted cash relates to a certificate of deposit held as collateral for a letter
of credit issued in connection with the Company&rsquo;s lease for corporate office space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Leases </B>&ndash; The
Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporate office
space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is
recognized on a straight-line basis over the lease term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Fair Value of Financial
Instruments</B> - Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,
in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives
the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable
inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Research and Development
Costs -</B> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product,
the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities
and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Share-Based Payments
-</B> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Net Loss Per Common
Share</B> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted
average number of common shares outstanding during the reporting period. For periods of net income, and when the effects are not
anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average
number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common shares underlying
common stock options and warrants using the treasury stock method. The Company issued pre-funded warrants in April 2020 and June
2020 that are considered outstanding shares for the purposes of calculating net loss per common share, see Note 4 for additional
information. Since the shares underlying the outstanding 2.3 million pre-funded warrants are issuable for negligible consideration
and are fully vested and exercisable, they are considered outstanding for the calculations of both basic and diluted loss per
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For periods of net loss,
diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares
is anti-dilutive. For the six months ended June 30, 2020 and 2019, the Company&rsquo;s potentially dilutive shares, which include
outstanding common stock options and warrants have not been included in the computation of diluted net loss per share as the result
would have been anti-dilutive.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">365</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">264</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,871</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,878</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,236</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,142</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Accounting Standards
Recently Adopted</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2018, FASB issued
ASU 2018-13, <I>Fair Value Measurement - Disclosure Framework (Topic 820).</I> The updated guidance improves the disclosure requirements
on fair value measurements, primarily associated with Level 3 fair value measurements and is effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the standard
for disclosures modified or removed with a delay of adoption of the additional disclosures until their effective date. The Company
adopted this standard effective January 1, 2020 and the standard did not have a significant impact to the Company&rsquo;s financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November 2018, FASB
issued ASU 2018-18, C<I>ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, </I>which,
among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted
for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years,
beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard effective January&nbsp;1, 2020
and the standard did not have a significant impact to the Company&rsquo;s financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 2 - Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has entered
into agreements with third parties for the rights to certain intellectual property, manufacturing and clinical trial services under
which the Company may incur obligations to make payments including upfront payments as well as milestone and royalty payments.
Notable inclusions in this category are:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oak Ridge National Laboratory (&ldquo;ORNL&rdquo;) &ndash; The Company is contracted to purchase radioactive material to be used for research and development, with a renewal option at the contract end. During the six months ended June 30, 2020 and 2019, the Company purchased material from ORNL of $0.1 million in each period. In November 2019, the Company signed a contract with ORNL to purchase $0.3 million of radioactive material during calendar year 2020.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&ldquo;FHCRC&rdquo;) to build upon previous and ongoing clinical trials with BC8 (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial with BC8. The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC. A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed BC 8 antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Collaborative Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2018, the
Company entered into a research and option agreement with Astellas Pharma Inc. (&ldquo;Astellas&rdquo;) to develop ARCs using the
Company&rsquo;s AWE Technology Platform. Under this collaboration, the Company will utilize its AWE Platform to conjugate and label
selected Astellas targeting agents with an Actinium-225 payload. The Company is also responsible for conducting preclinical validation
studies on any ARCs generated. Payments from Astellas under this agreement are accounted for as a reduction to research and development
expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 3 - Leases </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company adopted ASC
842 as of January 1, 2019, using a modified retrospective approach and applying the standard&rsquo;s transition provisions at January
1, 2019, the effective date. The Company made an accounting policy election to exclude from balance sheet reporting those leases
with initial terms of 12 months or less.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company determines
if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company
the right to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset
is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic
benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which
the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable
lease components are recognized when the obligation is probable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and
liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires
a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily
determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company&rsquo;s leases,
the incremental borrowing rate is used based on the information available at commencement date in determining the present value
of lease payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The lease term for all
of the Company&rsquo;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a
Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend
(or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and
lease liability) for the majority of the Company&rsquo;s leases as the reasonably certain threshold is not met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2020, the Company
has an operating lease for corporate office space and two finance leases for office equipment and furniture located in the corporate
office space. In addition, the Company has auxiliary corporate office space that it rents on a month-to-month basis; this rental
is accounted for as an operating lease with the same term as the Company&rsquo;s main office in the same building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The components of lease expense are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three months ended</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">(in thousands)</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<BR>
2020</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<BR>
2019</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<BR>
2020</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<BR>
2019</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; width: 52%; text-align: left">Operating lease expense</TD><TD STYLE="padding-bottom: 4pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">93</TD><TD STYLE="padding-bottom: 4pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">93</TD><TD STYLE="padding-bottom: 4pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">186</TD><TD STYLE="padding-bottom: 4pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">186</TD><TD STYLE="padding-bottom: 4pt; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Finance lease cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Amortization of right-to-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">41</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Interest on lease liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-align: left">Total finance lease cost</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">25</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">26</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">50</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">52</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Supplemental cash flow information related to
leases are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash flow information:</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six months ended</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in thousands)</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30,<BR>
2020</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30,<BR>
2019</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid for amounts included in the measurement of lease liabilities:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 71%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating cash flow use from operating leases</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">188</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">172</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating cash flow use from finance leases</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing cash flow use from finance leases</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-cash activity:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use assets obtained in exchange for lease obligations:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating leases</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,177</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance Leases</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">302</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Weighted average remaining lease terms are as
follows at June 30, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average remaining lease term:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 89%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating leases</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 years</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance Leases</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 years</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As the Company&rsquo;s
leases do not provide an implicit rate, the Company used its incremental borrowing rate based on the information available at adoption
date in determining the present value of lease payments. Below is information on the weighted average discount rates used:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average discount rates:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 89%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating leases</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance Leases</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><B>&nbsp;&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in
    thousands)<BR>
    Year ending December 31,</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating
    Leases</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Finance
    Leases</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020 (excluding six months
    ended June 30, 2020)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">187</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">377</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">252</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease payments</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">816</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">209</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less imputed interest</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(69</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of lease liabilities</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">747</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">191</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 4 - Equity&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 7, 2020,
the Board unanimously approved a reverse stock split of its outstanding common stock by combining outstanding shares of common
stock into a lesser number of outstanding shares of common stock by a ratio of 1-for-30, and on August 10, 2020, the Company filed
with the Secretary of State of Delaware a certificate of amendment to its certificate of incorporation to effect the reverse stock
split. Accordingly, all common share and per common share data in these consolidated financial statements and related notes hereto
have been retroactively adjusted to account for the effect of this reverse stock split for all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 24, 2020,
the Company issued and sold 4.3 million shares of common stock and 2.8 million pre-funded warrants to purchase shares of common
stock. The price to the public in this offering for each share of common stock was $4.50 and for each pre-funded warrant was $4.497.
Each pre-funded warrant has an exercise price of $0.003 per share and is exercisable immediately upon issuance. The pre-funded
warrants are subject to certain limitations on beneficial ownership. Gross proceeds from this offering to Actinium were $31.6 million,
before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this
offering were $29.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2020, holders
of 1.2 million pre-funded April 2020 warrants exercised their warrants at $0.003 per share and received 1.2 million shares of common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 19, 2020, the
Company issued and sold 1.9 million shares of common stock and 0.7 million pre-funded warrants to purchase shares of common stock.
The price to the public in this offering for each share of common stock was $9.75 and for each pre-funded warrant was $9.747. Each
pre-funded warrant has an exercise price of $0.003 per share and is exercisable immediately upon issuance. The pre-funded warrants
are subject to certain limitations on beneficial ownership. Gross proceeds from this offering to Actinium were $25.0 million, before
deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this offering
were $23.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018, the
Company entered into the Amended and Restated At Market Issuance Sales Agreement with B. Riley FBR, Inc. and JonesTrading Institutional
Services LLC, pursuant to which the Company conducted its at-the market program. During the six months ended June 30, 2020, the
Company sold 0.3 million common shares through its at-the-market program, resulting in net proceeds of $2.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2018, the
Company and Lincoln Park Capital Fund, LLC (&ldquo;Lincoln Park&rdquo;) entered into a purchase agreement and a registration rights
agreement, pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&rsquo;s common stock having
an aggregate value of up to $32.5 million, subject to certain limitations and conditions set forth in the agreement. During the
six months ended June 30, 2020, the Company elected to sell to Lincoln Park 27 thousand shares and received $0.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2020, the Company
issued 5 thousand shares of restricted common stock, valued at $30 thousand, for consulting services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the six months
ended June 30, 2019, holders of March 2018 series A warrants exercised 83 thousand shares, resulting in the Company receiving $1.5
million. The remaining March 2018 series A warrants expired in March 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has outstanding
warrants to purchase 1,907 shares of common stock that include down-round protection. For warrants with down-round protection,
a deemed dividend is recorded for the change in fair value of the warrants when the down-round provision is triggered. As result
of the April 2019 offering, the exercise price of the warrant was reset from $37.50 per share to $26.40 per share. As a result
of the April 2020 offering and June 2020 offering, the exercise price of the warrant was reset from $26.40 per share to $15.60
per share. The down-round protection provision in the above warrants created a deemed dividend to common stockholders of $1 thousand
in the six months ended June 30, 2020 and 2019, which are reflected in the accompanying consolidated statement of operations and
consolidated statement of changes in stockholders&rsquo; equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Stock Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the six months ended June 30, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> Average <BR> Exercise <BR> Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> Average <BR> Remaining <BR> Contractual <BR> Term <BR> (in years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <BR> Intrinsic <BR> Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Outstanding, December 31, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">380</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">35.10</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7.88</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(15</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">15.86</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Outstanding, June 30, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">365</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">36.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">7.49</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">519</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Exercisable, June 30, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">194</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">56.43</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">6.47</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">112</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months
ended June 30, 2020, options to purchase 15 thousand shares were cancelled upon the termination of employment for several employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair values of all
options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense
at June 30, 2020 was $1.5 million related to unvested options, which is expected to be expensed over a weighted average of 2.8
years. During the six months ended June 30, 2020 and 2019, the Company recorded compensation expense related to stock options of
$0.5 million and $0.3 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Pre-funded Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the April
2020 offering and the June 2020 offering, the Company issued pre-funded warrants. Each pre-funded warrant has an exercise price
of $0.003 per share and is exercisable immediately upon issuance. The pre-funded warrants are subject to certain limitations on
beneficial ownership. The pre-funded warrants do not have an expiration date. Management determined that the pre-funded warrants
are freestanding instruments and that the pre-funded warrants should be classified as permanent equity in accordance with authoritative
guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following is a summary
of pre-funded warrant activity for the six months ended June 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> Average <BR> Exercise <BR> Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <BR> Intrinsic <BR> Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding, December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%">Granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,459</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.003</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">0.003</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt">Outstanding, June 30, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,259</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">0.003</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">23,814</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Exercisable, June 30, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,259</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">0.003</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">23,814</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following is a summary
of warrant activity for the six months ended June 30, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> Average <BR> Exercise <BR> Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> Average <BR> Remaining <BR> Contractual <BR> Term <BR> (in&nbsp;years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <BR> Intrinsic <BR> Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Outstanding, December 31, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,871</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20.71</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.95</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">301</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Cancelled/Expired</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Outstanding, June 30, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,871</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">20.71</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">2.45</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">497</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Exercisable, June 30, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,865</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">20.37</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">2.45</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">496</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2020, holders
of 0.4 million pre-funded April 2020 and June 2020 warrants exercised their warrants at $0.003 per share and received 0.4 million
shares of common stock. Holders of 2 thousand April 2019 warrants exercised their warrants at $15.00 per share and received 2 thousand
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the
Company filed a registration statement including a base prospectus which covers the offering, issuance and sale of up to $500 million
of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus covering the offering,
issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued and sold under
the Capital on Demand&trade; Sales Agreement with JonesTrading Institutional Services LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since June 30, 2020, the
Company has issued stock options for 357,189 shares to employees and 33,332 shares to non-employee directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR STYLE="clear: both">
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_002"></A><B>ITEM 2. &nbsp;MANAGEMENT&rsquo;S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>FORWARD-LOOKING STATEMENT NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Form 10-Q contains
certain forward-looking statements.  For this purpose, any statements contained in this Form 10-Q that are
not statements of historical fact may be deemed to be forward-looking statements. &nbsp;Without limiting the foregoing, words such
as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate&rdquo;
or &ldquo;continue&rdquo; or comparable terminology are intended to identify forward-looking statements. &nbsp;These statements
by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of
factors, many of which are not within our control. &nbsp;These factors include but are not limited to economic conditions generally
and in the industries in which we may participate; competition within our chosen industry, including competition from much larger
competitors; technological advances and failure to successfully develop business relationships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Description of Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Actinium Pharmaceuticals,
Inc. is a clinical-stage, biopharmaceutical company applying its proprietary platform technology and deep understanding of radioimmunobiology
to the development of novel targeted therapies known as ARCs or Antibody Radiation-Conjugates. Radiation is an effective therapeutic
modality that is used in the treatment of over fifty percent of all cancer patients and often combined with chemotherapy and immunotherapy
for greater therapeutic effect. Radiation is typically administered from outside the body, which constrains the amount that can
be administered to patients due to dose-limiting toxicities. In addition, due to the diffuse nature of the external radiation beam,
its usage is limited to solid tumors and cannot be used in blood cancers, which are diffuse. ARCs combine the cell-killing ability
of a radioisotope payload with a targeting agent, such as a monoclonal antibody, or mAb, to deliver radiation inside the body to
specific cells, to potentially generate greater efficacy and less toxicity. ARCs usage is broader than external delivered radiation
as they can be used for both solid tumors and blood cancers. Blood or hematologic cancers are highly sensitive to radiation and
our clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic
cancers. Our clinical programs are focused on two primary areas: targeted conditioning prior to a cell or gene therapy procedure
and therapeutics, either in combination with other agents or as a monotherapy. Our product development strategy is actively informed
by clinical data with our ARCs in over 500 patients, including the ongoing SIERRA trial. Our clinical pipeline has emanated from
our AWE, or Antibody Warhead Enabling technology platform, which is protected by over 120 issued and pending patents, trade secrets
and know-how and is being utilized in a collaborative research partnership with Astellas Pharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are advancing the only
multi-target, multi-indication clinical-stage pipeline for targeted conditioning and the only ARC-based targeted conditioning regimens
in development. Our ARCs for targeted conditioning are intended to potentially enable improved access to cell-based therapies with
curative potential, including BMT, or bone marrow transplant, ACT, or adoptive cell therapy such as CAR-T, and Gene Therapy, as
well as improved outcomes. Conditioning in the context of BMT, ACT or Gene Therapy is the act of depleting certain blood and immune-forming
cells, including bone marrow stem cells and, in some cases, diseased cells prior to transplanting new cells into a patient. Currently,
conditioning is accomplished using a combination of chemotherapeutic agents and external radiation. These non-targeted conditioning
regimens may prevent a patient from receiving a potentially curative therapy and hinder outcomes due to their toxicities. ARCs
have the potential to increase patient access and outcomes by way of their ability to selectively deplete targeted cells while
sparing normal healthy cells. We use our ARCs at high isotope dose levels to achieve myeloablation, which fully depletes bone marrow
stem cells and at lower isotope dose levels to achieve lymphodepletion, which spares bone marrow stem cells from depletion. In
addition, dosing may be titrated downward from myeloablative doses to achieve partial myeloablation, which may be appropriate for
certain gene therapy programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>CD45 Targeted Conditioning Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our CD45 ARC is comprised
of the anti-CD45 monoclonal antibody known as apamistamab (formerly BC8) and the radioisotope I-131 or Iodine-131. CD45 is an antigen
expressed on leukemia, lymphoma and myeloma cancer cells, as well as nucleated immune cells, but is not expressed outside of the
hematopoietic, or blood, system. This unique expression on blood cancer and immune cells enables simultaneous depletion of both
cell types, making CD45 an optimal antigen for targeted conditioning applications. CD45 is a cell surface antigen with an average
expression of 200,000 copies per cell, however, it only internalizes at a rate of 10-15%. We believe our ARC approach is the most
effective method to target CD45 positive cells, as the radioisotope payload linear energy transfer can readily ablate a targeted
cell without requiring payload internalization like an antibody drug conjugate or rely on biological effector function processes
like a naked antibody. Furthermore, since CD45 expression level varies from low to high antigen density as the immune cells become
more terminally differentiated, we can selectively condition depending on the therapeutic application, from full myeloablation
to transient lymphodepletion, by adjusting the dose or intensity of the I-131 isotope payload. Full myeloablation can be achieved
with high doses of I-131, as its energy pathlength and crossfire effect can penetrate into bone marrow niches to target and deplete
blood and immune system forming bone marrow stem cells. Myeloablation is applicable to autologous or allogeneic BMT and to autologous
gene-edited or modified therapies that can reconstitute a patient&rsquo;s blood and immune systems. Alternatively, low doses of
I-131 can be transiently lymphodepleting and spare a patient&rsquo;s bone marrow stem cells, which we believe is ideal for ACT
applications such as CAR-T. We intend to develop our CD45 targeted conditioning program for BMT, ACT and Gene Therapy applications
for malignant and non-malignant diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our lead CD45 targeted
conditioning product candidate is Iomab-B, which uses high doses of I-131 to achieve myeloablative conditioning prior to a BMT.
Iomab-B is currently being studied in the pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory AML, or SIERRA, clinical
trial for targeted conditioning prior to an allogeneic BMT for patients with active, relapsed or refractory (r/r) Acute Myeloid
Leukemia, or AML, who are age 55 or older. Patients with active, r/r AML are not normally considered eligible for BMT and the SIERRA
trial is the only randomized Phase 3 trial to offer BMT as a treatment option for this patient population. The SIERRA trial compares
outcomes of patients randomized to receive Iomab-B and a BMT (the study arm) to those patients randomized to receive physician&rsquo;s
choice of salvage chemotherapy (the control arm). Salvage chemotherapy is also defined as conventional care, as no standard of
care exists for this patient population. Patients who fail to achieve a CR or Complete Response on the control arm are ineligible
to proceed to a BMT, but the trial design permits these patients to &ldquo;cross over&rdquo; to receive the study arm treatment
if they meet the eligibility criteria. The primary endpoint of the SIERRA trial is durable Complete Remission, or dCR, of six months
and the secondary endpoint is one-year Overall Survival, or OS. When the crossover patients receive Iomab-B and BMT, they have
not achieved remission with their salvage therapy and are considered to be failures for the primary endpoint of the study. The
SIERRA trial is currently active at 20 sites in the United States and Canada, which includes many of the leading BMT sites based
on volume. We expect to complete enrollment of the SIERRA trial and have topline data that we believe will support the submission
of a Biologics License Application, or BLA, with the U.S. Food and Drug Administration, or FDA, in 2021. If approved, we expect
our initial commercial launch would target the leading 50-100 BMT and medical centers that perform the vast majority of BMT&rsquo;s
in the United States. In the European Union or EU, we received favorable feedback from the European Medicines Agency or EMA via
their scientific advice program that the trial design, primary endpoint and planned statistical analysis from the SIERRA trial
are acceptable as the basis for a Marketing Authorization Application or MAA. Additionally, the EMA commented that it does not
anticipate the need for further standalone preclinical toxicology or safety studies. Overall, transplant procedures in the EU are
approximately fifty percent higher than in the United States with a similar market dynamic with a majority of BMT volume being
conducted in a concentrated number of leading medical centers. We intend to secure a partner for Iomab-B in the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Safety and feasibility
data from the first 75 patients enrolled on the SIERRA trial, which represents 50% of the total of 150 patients to be enrolled
in the trial, was presented in an oral presentation at the Transplantation &amp; Cellular Therapy Meetings of the American Society
for Transplantation and Cellular Therapy (ASTCT) and Center for International Bone &amp; Marrow Transplant Research (CIBMTER) in
February 2020. It was reported that 100% of patients (31/31) on the study arm that received a therapeutic dose of Iomab-B received
a BMT, with a median time to BMT of 30 days, and all patients achieved neutrophil and platelet engraftment in a median time of
20 days despite a high median blast count of 30%. On the control arm, only 18% of patients (7/38) achieved remission after salvage
therapy, and then received a BMT with a median time to BMT of 67 days and median blast count of 26%. Of the 82% of patients failing
to achieve a CR with conventional care (31/38), 20 patients were eligible to cross over to the study arm. These patients are considered
as having failed the primary endpoint of the study. All crossover patients who received the therapeutic dose of Iomab-B (20/20)
received a BMT, with a median time to BMT of 64 days and all patients achieved engraftment in a median time of 19 days despite
high median blast count of 35% at time of crossover. It was also reported that 100-day non-relapse transplant-related mortality
(100-day TRM) of the study or Iomab-B arm was 6% (2/31) of patients that received a BMT compared to 29% of patients (2/7) who received
a BMT after salvage therapy on the control arm. The universal engraftment rate and low 100-day TRM rate of the Iomab-B arm resulted
in 29 patients potentially evaluable for the primary endpoint compared to 5 patients in the control arm, a nearly six times difference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SIERRA trial is
powered for up to two interim analyses of the primary endpoint of dCR of 180 days exercisable at our discretion and triggered by
an enrollment range of 70 to 110 patients. We exercised a single ad-hoc analysis in the second quarter of 2020, based on the data
reported from SIERRA thus far and the status of enrollment at the time of triggering our ad hoc analysis. The ad hoc analysis is
expected to be completed by the end of 2020, which could generate topline data for the primary endpoint and early termination of
the trial if positive. Based on the statistical plan of the study, a single ad-hoc analysis would result in a minimal alpha spend
of no more than 0.00925, depending on the number of patients included in the ad-hoc analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Iomab-ACT program is
intended for targeted conditioning prior to ACT or Gene Therapy and uses the same <SUP>131</SUP>I-apamistamab ARC construct as
Iomab-B at varying doses. At lower doses of one-eighth to one-sixth of the myeloablative dose, it is applicable for lymphodepletion
prior to CAR-T or certain Gene Therapy applications where stem cell myeloablation is not necessary. At higher doses it is applicable
for Gene Therapy applications where stem cell myeloablation is necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In January 2020, we announced
a collaboration with University of California Davis to utilize Iomab-ACT conditioning in an ongoing Phase 1/2 trial with a novel
anti-HIV autologous stem cell gene therapy for patients with HIV-related lymphoma. We believe this to be the first Gene Therapy
trial to use an ARC-based conditioning regimen. <SUP>131</SUP>I-Apamistamab has clinical proof of concept as a targeted conditioning
regimen for patients with high-risk, relapsed or refractory lymphoma prior to an autologous stem cell transplant from a previous
study, where a favorable safety profile with no dose-limiting toxicities and minimal non-hematologic toxicities were observed and
promising efficacy with median overall survival not reached (range: 29 months to not reached) and 31% of patients in prolonged
remission at a median of 36 months follow up (range: 25 &ndash; 41 months). In this study, Iomab-ACT is intended to replace the
chemotherapy-based condition regimen known as BEAM (BCNU/carmustine, etoposide, cytarabine, and melphalan) to simultaneously kill
the patient&rsquo;s lymphoma cells and deplete the patient&rsquo;s stem cells to make room for the transplant. Upon engraftment,
the transplanted gene-modified autologous stem cells containing three anti-HIV genes are intended to equip the patient with a new
immune system that is resistant to the HIV virus. Iomab-ACT will be substituted for BEAM in the ongoing Phase 1/2 trial and we
expect to have clinical proof of concept data in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe our Iomab-ACT
program is highly differentiated when compared to Fludarabine and Cyclophosphamide or Flu/Cy or other chemotherapy-based regimens
that are used as the standard of practice today for lymphodepletion prior to CAR-T. CD45 is an antigen expressed on certain immune
cell types that are relevant to the mechanism of CAR-T therapies including lymphocytes, regulatory T cells and macrophages that
have been associated with clinical responses that may limit the safety, efficacy and durability of response of these CAR-T therapies
including Cytokine Release Syndrome, or CRS, and neurotoxicity. Some of these limitations may be attributable to the chemotherapy-based
conditioning agents that are being used prior to CAR-T therapies. Preclinical data supporting the rational for our Iomab-ACT program
was presented at multiple medical conferences in 2019. Unlike chemotherapy, preclinical data suggests Iomab-ACT is targeted in
nature and, due to this targeted effect, we expect we can improve CAR-T cell expansion more efficiently, potentially resulting
in responses that are more durable, but also resulting in reduced CAR-T related toxicities. Importantly, we expect the Iomab-ACT
program construct to enable lymphodepletion through a single-dose, outpatient administration versus Flu/Cy or other chemotherapy-based
lymphodepletion regimens that can require multiple infusion cycles over several days. Because of this potentially superior profile,
the Iomab-ACT construct could result in improved access to CAR-T therapy and better outcomes. We intend to begin a clinical trial
with <SUP>131</SUP>I-apamistamab as a targeted conditioning agent prior to CAR-T, subject to identifying a suitable partner and
we expect to have Phase 1 clinical proof of concept data in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CD33 Program: Targeted Conditioning, Combinations
and Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our CD33 program is evaluating
the clinical utility of an ARC comprised of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225
or Ac-225. CD33 is expressed in the majority of patients with AML and myelodysplastic syndrome, or MDS, as well as approximately
one third of patients with multiple myeloma. Our CD33 development program is driven by data obtained from over one hundred treated
patients, including results from a Phase 1/2 trial that was conducted in 58 patients with newly diagnosed AML, which was completed
in 2018. This clinical data, as well as our experience with Iomab-B, is shaping a two-pronged approach with our CD33 program, where
at high doses we are exploring its use for targeted conditioning and at low doses we are exploring its use for therapeutic purposes
in combination with other modalities, such as chemotherapy, targeted agents or immunotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Actimab-MDS is our second
clinical trial focused on targeted conditioning, in this case for patients with high-risk MDS and is our second pivotal program.
Actimab-MDS is informed by prior experience with our CD33 ARC in multiple trials for patients with AML, MDS and for patients that
have progressed from MDS to AML, which is also known as secondary AML. Data from these trials showed that our CD33 ARC had single-agent
activity capable of producing complete remissions (CRs) in certain patients at varying dose levels with minimal non-hematologic
extramedullary toxicities. However, dose-dependent myelosuppression, a class effect of CD33 directed therapies, was seen in many
of these patients. Given that myelosuppression is necessary prior to a BMT and that a BMT can rescue patients with myelosuppression,
we decided to pursue a trial in targeted conditioning in high-risk MDS patients with this ARC in combination with Reduced Intensity
Conditioning, or RIC, regimens. RIC regimens are comprised of low doses of chemotherapies such as fludarabine, cytarabine, busulfan
or melphalan. A BMT is the only curative treatment option for these patients with high-risk MDS who have poor, or very poor cytogenetics.
However, these patients have poor outcomes due to high relapse rates following a BMT. Based on our interactions with FDA to date,
we will conduct a Phase 1 dose-finding clinical trial that will be followed by a randomized trial that, depending on the results
observed, may potentially serve as a pivotal trial to support the submission of a BLA. We are currently finalizing discussions
with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are also studying our
CD33 ARC construct at various dose levels and dosing regimens in combination with other therapeutic modalities such as chemotherapy,
targeted agents or immunotherapy in CD33 expressing hematologic disease indications. We believe that radiation can be synergistic
when used in combination with these modalities based on mechanistic rationale supported by our own clinical data, preclinical research
and scientific and clinical evidence in the literature. We have prioritized our efforts and resources in favor of combination trials
for our CD33 program development strategy rather than single agent trials, which we are no longer advancing at this time. Our CD33
ARC development program encompasses the following ongoing and planned trials:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Combination Trials</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase&nbsp;1 investigator initiated Actimab-A + CLAG-M combination trial with the salvage chemotherapy regimen CLAG-M (cladribine, cytarabine, filgrastim and mitoxantrone) for patients with relapsed or refractory AML at the Medical College of Wisconsin. At the 2019 American Society of Hematology Annual Meeting, it was reported that 86% of patients (6/7) receiving 0.50 &micro;Ci/kg of Actimab-A, and CLAG-M achieved a complete remission after receiving Actimab-A + CLAG-M, which is nearly 60% greater than the 55% remission rate observed in a study of CLAG-M alone conducted at MCW in the same r/r AML patient population. In addition, 71% of these patients (5/7) achieved negative minimal residual disease status, indicating that these are deep remissions. The 0.50 &micro;Ci/kg dose of Actimab-A was shown to be subtherapeutic as a single agent. Since the combination to date has been well tolerated, the study progressed to the third and final cohort for the study of Actimab-A at a dose of 0.75 &micro;Ci/kg in March 2020 and we expect to complete this trial by the end of 2020. Upon completion, we intend to explore a regulatory pathway for a pivotal trial that could potentially support a registration. The combination of Actimab-A + CLAG-M is supported by mechanistic rationale for combining inhibitors of DNA replication and/or repair processes such as mitoxantrone, a topoisomerase-II inhibitor, and radiation, as imparted by tumor targeting of Ac-225 with Actimab-A. The Actimab-A + CLAG-M combination study has provided proof of principle that the addition of subtherapeutic doses of Actimab-A to other AML therapies can lead to well tolerated regimens with improved responses.&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1 Actimab-A + Ven combination trial with the BCL-2 inhibitor Venetoclax (Ven) for patients with relapsed or refractory AML. This trial will be led by UCLA Medical Center and will be conducted at three additional trial sites. This combination is supported by mechanistic evidence in preclinical studies using Ven-resistant AML tumor cell lines. In these models, we have demonstrated that Actimab-A can deplete Mcl-1 and Bcl-XL, two proteins implicated in mediating resistance to venetoclax, in addition to causing potentially lethal double-stranded DNA breaks in these CD33 targeted cells. Furthermore, in vivo studies in animal models of Ven-resistant AML demonstrated robust tumor regression and improved survival in cohorts receiving the Actimab-A Ven combination compared to Ven alone. The rationale for this clinical study is that the addition of Actimab-A will; 1) have a direct anti-tumor effect via double-stranded DNA breaks and 2) deplete Mcl-1 and BCL-XL making the AML cells more susceptible to Ven. We expect to initiate the trial and have preliminary proof of concept clinical data from this combination study by the end of 2020.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1 Actimab-A + 7+3 combination trial in patients with newly diagnosed AML with intermediate or high-risk cytogenetics or molecular markers. In February 2020, we announced plans to initiate this combination trial to add Actimab-A to 7+3, which is the standard of care chemotherapy regimen comprised of cytarabine and daunorubicin for patients with newly diagnosed AML who are fit for intensive therapy. As we have seen with the combination of Actimab-A + CLAG-M chemotherapy, we believe that Actimab-A will have synergistic and potentiating properties when added to 7+3, which causes DNA damage and has radiation sensitizing properties since daunorubicin is an anthracycline antibiotic that cytotoxically inhibits DNA replication and repair and RNA synthesis through inhibition of topoisomerase II. The rationale for studying Actimab-A in combination with 7+3 is the potential for both additive and synergistic effects due to the interplay of various mechanisms including DNA damage from alpha radiation and the chemotherapy combination, radiation sensitization, and prevention of DNA damage repair. We expect to initiate this Phase 1 trial by the end of 2020 and have proof of concept data in 2021.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Antibody Warhead Enabling Technology Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our proprietary Antibody
Warhead Enabling, or AWE, Technology Platform is supported by intellectual property, know-how and trade secrets that cover the
generation, development, methods of use and manufacture of ARCs and certain of their components. Our AWE technology patent portfolio
includes 29 patent families comprised of over 120 issued and pending patent applications, of which 9 are issued and 25 pending
in the United States, and 92 are issued or pending internationally. The effective life of the patents in our portfolio range from
expirations between 2021 and 2040. Our technology enables the direct labeling, or conjugation and labeling, of a biomolecular targeting
agent to a radionuclide warhead and its development and use as a therapeutic regimen for the treatment of diseases such as cancer.
Our AWE intellectual property covers various methods of use for ARCs in multiple diseases, including indication, dose and scheduling,
radionuclide warhead, and therapeutic combinations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Impact of COVID&ndash;19 Pandemic</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In December 2019, a novel
strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China to other
countries has resulted in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a &ldquo;pandemic,&rdquo; or
a worldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictions
on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses, and as of the date of this
prospectus, many local jurisdictions continue to have such restrictions in place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As many local jurisdictions
continue to have such restrictions in place, our ability to continue to operate our business may also be limited. Such events may
result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could
materially affect our business, financial condition and results of operations. In response to COVID-19, we implemented remote working
and thus far have not experienced a significant disruption or delay in our operations as it relates to the clinical development
of our drug candidates. Such government-imposed precautionary measures may have been relaxed in certain countries or states, but
there is no assurance that more strict measures will be put in place again due to a resurgence in COVID-19 cases. Therefore, the
COVID-19 pandemic may continue to affect our operation, may further divert the attention and efforts of the medical community to
coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The spread of COVID-19,
which has caused a broad impact globally, may materially affect us economically. While the ultimate economic impact brought by,
and the duration of, the COVID-19 pandemic may be difficult to assess or predict, including new information which may emerge concerning
the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others, the pandemic has resulted significant
disruptions in the general commercial activity and the global economy and caused financial market volatility and uncertainty in
significant and unforeseen ways in the recent months. A continuation or worsening of the levels of market disruption and volatility
seen in the recent past could have an adverse effect on our ability to access capital, which could in the future negatively affect
our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our
business and the value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, the Phase
3 SIERRA trial for our lead program, Iomab-B, continues to remain active at a majority of our clinical trial sites, with investigators
providing feedback that recruitment and enrollment will remain active because of the acute nature of the disease, the high unmet
needs of patients with relapsed or refractory AML, the potentially curative nature of BMT and the differentiated profile of Iomab-B.
Certain sites that had not been actively enrolling due to COVID-19 have resumed recruitment and enrollment, and we currently anticipate
that other sites that have not been actively enrolling due to COVID-19 will likely resume recruitment and enrollment in the summer
timeframe. We also believe our earlier stage clinical trials for our CD33 program will also continue to recruit and enroll patients
given the acute nature of relapsed or refractory AML. The continuation of the pandemic could adversely affect our planned clinical
trial operations, including our ability to conduct the trials on the expected timelines and recruit and retain patients and principal
investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if their geography is impacted
by the pandemic. Further, the continuation and/or resurgence of the COVID-19 pandemic could result in delays in our clinical trials
due to prioritization of hospital resources toward the pandemic, restrictions in travel, potential unwillingness of patients to
enroll in trials at this time, or the inability of patients to comply with clinical trial protocols if quarantines or travel restrictions
impede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract
research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out
our preclinical studies and clinical trials, and the pandemic may affect their ability to devote sufficient time and resources
to our programs or to travel to sites to perform work for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, COVID-19
may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with IRB&rsquo;s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To date, COVID-19 has not
had a financial impact on our company. However, COVID-19 has caused severe disruptions in transportation and limited access to
our facility, resulting in limited support from our staff and professional advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The ultimate impact from
COVID-19 on our business operations and financial results during 2020 will depend on, among other things, the ultimate severity
and scope of the pandemic, the pace at which governmental and private travel restrictions and public concerns about public gatherings
will ease, the rate at which historically large increases in unemployment rates will decrease, if at all, and whether, and the
speed with which the economy recovers. We are not able to fully quantify the impact that these factors will have on our financial
results during 2020 and beyond, but developments related to COVID-19 may materially affect us in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Reverse Stock Split</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 29, 2020, we received
a deficiency letter from the NYSE American LLC, or the NYSE American, indicating that we are not in compliance with certain NYSE
American continued listing standards. The deficiency letter stated that our shares of common stock have been selling for a low
price per share for a substantial period of time. Pursuant to Section 1003(f)(v) of the Company Guide, the NYSE American staff
determined that our continued listing is predicated on us effecting a reverse stock split of our common stock or otherwise demonstrating
sustained price improvement within a reasonable period of time, which the staff determined to be until October 29, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The letter further stated
that as a result of the foregoing, we have become subject to the procedures and requirements of Section 1009 of the NYSE American
Company Guide, which could, among other things, result in the initiation of delisting proceedings, unless we cure the deficiency
in a timely manner. Our common stock will continue to be listed on the NYSE American while we attempt to regain compliance with
the listing standards, subject to our compliance with other continued listing requirements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the NYSE American
has advised us that its policy is to immediately suspend trading in shares of, and commence delisting procedures with respect to,
a listed company if the market price of its shares falls below $0.06 per share at any time during the trading day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 18, 2019, our
board of directors unanimously approved, subject to stockholder approval, an amendment to our certificate of incorporation to effect
a reverse stock split of our outstanding common stock by combining outstanding shares of common stock into a lesser number of outstanding
shares of common stock by a ratio of not more than 1-for-75 prior to December 18, 2020, with the exact ratio to be set within this
range by our board of directors at its sole discretion. On December 18, 2019, at our 2019 Annual Meeting of Stockholders, our stockholders
approved such proposed amendment to our certificate of incorporation. The primary intent of effecting the reverse stock split,
would be to ensure that we are able to maintain compliance with the listing standards of the NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 7, 2020,
the Board unanimously approved a reverse stock split of its outstanding common stock by combining outstanding shares of common
stock into a lesser number of outstanding shares of common stock by a ratio of 1-for-30, and on August 10, 2020, we filed with
the Secretary of State of Delaware a certificate of amendment to its certificate of incorporation to effect the reverse stock split.
The reverse stock split became effective as of 5:00 p.m. Eastern Time on August 10, 2020, and our common stock began trading on
a split-adjusted basis when the market opened on August 11, 2020. Accordingly. all common share and per common share data in these
consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of this reverse
stock split for all periods presented. In addition, at the effective time of the reverse stock split, the number of shares of our
common stock reserved for issuance upon exercise of all options and warrants to acquire common stock have been proportionally decreased,
and the exercise price of all options and warrants to acquire common stock have been proportionally increased. In addition, we
adjusted and proportionately decreased the total number of shares of our common stock that may be the subject of the future grants
under our stock plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Results of Operations
&ndash; Three Months Ended June 30, 2020 Compared to Three Months Ended June 30, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets
forth, for the periods indicated, data derived from our statements of operations:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>June 30,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left">Research and development, net of reimbursements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,508</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,010</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,154</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,076</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,662</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,086</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Interest income &ndash; net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">59</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total other income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">59</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,625</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,027</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We recorded no commercial
revenue for the three months ended June 30, 2020 and 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Research and Development Expense</B>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses decreased $0.5 million to $3.5 million for the three months ended June 30, 2020 compared to $4.0 million for the three
months ended June 30, 2019. The decrease in expenses was primarily due to manufacturing related to the antibody component of Iomab-B,
as in prior periods we have manufactured sufficient antibody supply for the SIERRA trial and other planned trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General and Administrative Expenses</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses of $1.2 million for the three months ended June 30, 2020 increased $0.1 million from the $1.1 million recorded for the
three months ended June 30, 2019, primarily attributable to higher professional fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Other Income</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other income is comprised
of net interest income in both reporting periods. The amount for the three months ended June 30, 2020 of $37 thousand fell from
$59 thousand for the three months ended June 30, 2019, primarily due to lower interest rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Net Loss</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">Net loss of $4.6 million
for the three months ended June 30, 2020 decreased by $0.4 million from the prior-year comparison period due to lower research
and development expenses. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><B>Results of Operations
&ndash; Six Months Ended June 30, 2020 Compared to Six Months Ended June 30, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets
forth, for the periods indicated, data derived from our statements of operations:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>June 30,</B></P></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in thousands)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development, net of reimbursements</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,659</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,345</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,686</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,440</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,345</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,785</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest income &ndash; net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total other income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,295</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,697</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We recorded no commercial
revenue for the six months ended June 30, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Research and Development Expense</B>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses decreased $0.6 million to $7.7 million for the six months ended June 30, 2020 compared to $8.3 million for the six months
ended June 30, 2019. The decrease in expenses was primarily due to manufacturing related to the antibody component of Iomab-B,
as in prior periods we have manufactured sufficient antibody supply for the SIERRA trial and other planned trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><B>General and Administrative
Expenses</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses of $2.7 million for the six months ended June 30, 2020 increased $0.3 million compared to $2.4 million for the six months
ended June 30, 2019, primarily attributable to higher professional fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Other Income</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other income is comprised
of net interest income in both reporting periods. The amount for the six months ended June 30, 2020 of $50 thousand fell from $88
thousand for the six months ended June 30, 2019 primarily due to lower interest rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Net Loss</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">Net loss of $10.3 million
for the six months ended June 30, 2020 decreased $0.4 million from $10.7 million reported in the prior-year comparison period,
primarily due to lower research and development expenses, slightly offset by higher general and administrative expenses. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our
operations primarily through sales of our common stock and warrants. The following tables sets forth selected cash flow information
for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For&nbsp;the&nbsp;Six Months&nbsp;Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>June 30,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(10,365</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(10,853</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(59</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">54,577</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,808</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net&nbsp;change in cash, cash equivalents and restricted cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">44,212</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,896</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities for the six months ended June 30, 2020 of $10.4 million decreased by $0.5 million from $10.9 million in the prior-year
period, reflecting the lower net loss due to lower research and development expenses, as well as the timing of payments to vendors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities was $54.6 million for the six months ended June 30, 2020, reflecting sales of common stock and pre-funded warrants.
During the six months ended June 30, 2019, net cash provided by financing activities was $16.8 million, reflecting $15.5 million
in proceeds from the sale of common stock, plus $1.5 million in proceeds from the exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 24,
2020, we issued and sold 4.3 million shares of common stock and pre-funded warrants to purchase 2.8 million shares of common
stock. The price to the public for each share of common stock sold in the offering was $4.50, and the price to the public for
each pre-funded warrant sold in the offering was $4.497. The pre-funded warrants are exercisable at an exercise price of
$0.003 per share and are subject to certain limitations on beneficial ownership. Gross proceeds from this offering were $31.6
million, before deducting underwriting discounts and commissions and other offering expenses payable by us. Net proceeds from
the offering were approximately $29.1 million. In June 2020, holders of 1.2 million pre-funded April 2020 warrants exercised
their warrants and received 1.2 million shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 19, 2020, we
issued and sold 1.9 million shares of common stock and pre-funded warrants to purchase 0.7 million shares of common stock. The
price to the public in this offering for each share of common stock was $9.75 and for each pre-funded warrant was $9.747. Each
pre-funded warrant has an exercise price of $0.003 per share and is exercisable immediately upon issuance. Gross proceeds from
this offering to us were $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable
us. Net proceeds from this offering were approximately $23.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018, we
entered into the Amended and Restated At Market Issuance Sales Agreement with B. Riley FBR, Inc. and JonesTrading Institutional
Services LLC, pursuant to which we conducted our at-the market program. During the six months ended June 30, 2020, we sold 0.3
million common shares through its at-the-market program, resulting in net proceeds of $2.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;In October 2018,
we and Lincoln Park Capital Fund, LLC (&ldquo;Lincoln Park&rdquo;) entered into a purchase agreement and a registration rights
agreement, pursuant to which we have the right to sell to Lincoln Park shares of our common stock having an aggregate value of
up to $32.5 million, subject to certain limitations and conditions set forth in the agreement. During the six months ended June
30, 2020, we elected to sell to Lincoln Park 27 thousand shares and received $0.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not have any off-balance
sheet arrangements that have, or are reasonably likely to have a current or future effect on our financial condition, changes in
financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources that is material
to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Critical Accounting Policies and Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management&rsquo;s
discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which
have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of
these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities
and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements during the reporting
periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates
could occur in the future. We base our estimates on historical experience, known trends and events, and on various other factors
that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported
results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions
or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our significant accounting
policies are described in detail in the notes to our consolidated financial statements appearing in our Annual Report filed on
Form 10-K for the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Fair Value of Financial Instruments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Fair value is defined as
the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants.
A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets
for identical assets or liabilities and the lowest priority to unobservable inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Research and Development Costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development
costs are expensed as incurred. These costs include the costs of manufacturing drug components and final drug product, the costs
of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by us as a reduction of research and development costs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Share-Based Payments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We estimate the fair value
of each stock option award at the grant date by using the Black-Scholes option pricing model. The fair value determined represents
the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange
for the award. We account for forfeitures of stock options as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><B>Accounting Standards
Recently Adopted </B>-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2018, FASB issued
ASU 2018-13, <I>Fair Value Measurement - Disclosure Framework (Topic 820).</I> The updated guidance improves the disclosure requirements
on fair value measurements, primarily associated with Level 3 fair value measurements and is effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the standard
for disclosures modified or removed with a delay of adoption of the additional disclosures until their effective date. We adopted
this standard effective January 1, 2020 and the standard did not have a significant impact to our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November 2018, FASB
issued ASU 2018-18, C<I>ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606,</I>
which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be
accounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2019, with early adoption permitted. We adopted this standard effective January 1, 2020 and
the standard did not have a significant impact to our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_003"></A><B>ITEM 3. &nbsp;QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_004"></A><B>ITEM 4. &nbsp;CONTROLS AND PROCEDURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Evaluation of Disclosure
Controls and Procedures</I>. &nbsp;Under the supervision and with the participation of our management, including our chief executive
officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness, as of June 30, 2020, of
our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934,
as amended, or the Exchange Act. Based upon such evaluation, our chief executive officer and principal financial and accounting
officer have concluded that, as of June 30, 2020, our disclosure controls and procedures were effective to provide reasonable assurance
that the information we are required to disclose in our filings with the Securities and Exchange Commission, or SEC, under the
Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC&rsquo;s rules and
forms and (ii) accumulated and communicated to our management, including our chief executive officer and principal financial and
accounting officer, as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Changes in Internal
Control over Financial Reporting</I>. There were no changes in our system of internal controls over financial reporting during
the period covered by this report that has materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II &ndash; OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_005"></A><B>ITEM 1. LEGAL PROCEEDINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_006"></A><B>ITEM 1A. RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>In analyzing our company,
you should consider carefully the following risk factors, together with all of the other information included in this Quarterly
Report on Form&nbsp;10-Q. Factors that could cause or contribute to differences in our actual results include those discussed in
the following subsection, as well as those discussed above in &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations&rdquo; and in our Annual Report filed on Form 10-K for the year ended December 31, 2019. Each of the
following risk factors, either alone or taken together, could adversely affect our business, operating results and financial condition,
as well as adversely affect the value of an investment in our company. The risks and uncertainties described below are not the
only ones we face. Additional risks not currently known to us or other factors not perceived by us to present significant risks
to our business at this time also may impair our business operations.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We are a clinical-stage company and have generated no revenue
from commercial sales to date. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage
biopharmaceutical company with a limited operating history. We have no products approved for commercial sale and have not generated
any revenue from product sales to date. We will encounter risks and difficulties frequently experienced by early-stage companies
in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We have incurred net losses in every year since our inception
and anticipate that we will continue to incur net losses in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are not profitable and
have incurred losses in each period since our inception. As of June 30, 2020 and December 31, 2019, we had an accumulated deficit
of $219.1 million and $208.8 million, respectively. We reported a net loss of $10.3 million and $10.7 million for the six months
ended June 30, 2020 and June 30, 2019, respectively. We expect to continue to operate at a net loss as we continue our research
and development efforts, continue to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities.
There can be no assurance that the products under development by us will be approved for sale in the United States or elsewhere.
Furthermore, there can be no assurance that if such products are approved, they will be successfully commercialized, which would
have an adverse effect on our business prospects, financial condition and results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we fail to obtain additional financing,
we will be unable to continue or complete our product development and you will likely lose your entire investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 24, 2020,
we issued and sold 4.3 million shares of common stock and pre-funded warrants to purchase 2.8 million shares of common stock. Gross
proceeds from this offering to us were $31.6 million, before deducting underwriting discounts and commissions and other offering
expenses payable by us. On June 19, 2020, we issued and sold 1.9 million shares of common stock and 0.7 million pre-funded warrants
to purchase shares of common stock. Gross proceeds from this offering to us were $25.0 million, before deducting underwriting discounts
and commissions and other offering expenses payable us. As of the date of filing this report, we expect that our existing resources
will be more than sufficient to fund our planned operations for more than 12 months following the date of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business or operations
may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may
be required to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business
or technologies or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment
or a change in preferred cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorable
terms or indeed on any terms. In addition, from time to time, we may not be able to secure enough capital in a timely enough manner
which may cause the generation of a going-concern opinion from our auditors which can and may impair our stock market valuation
and also our ability to finance on favorable terms or indeed on any terms.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To raise additional capital,
we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common
stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share
that is equal to or greater than the price per share paid by investors, and investors purchasing shares or other securities in
the future could have rights superior to existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we cannot raise adequate
funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development activities,
clinical studies or future operations. We may also be required to obtain funds through arrangements with collaborators, which arrangements
may require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing, including
rights to future product candidates or certain major geographic markets. We may further have to license our technology to others.
This could result in sharing revenues which we might otherwise have retained for ourselves. Any of these actions may harm our business,
financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The amount of funding we
will need depends on many factors, including the progress, timing and scope of our product development programs; the progress,
timing and scope of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the
time and cost necessary to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter
into and maintain collaborative, licensing and other commercial relationships; and our partners&rsquo; commitment of time and resources
to the development and commercialization of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have limited access to the capital
markets and even if we can raise additional funding, we may be required to do so on terms that are dilutive to you.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have limited access
to the capital markets to raise funds. The capital markets have been unpredictable in the recent past for radioisotope and other
oncology companies and unprofitable companies such as ours. Furthermore, the COVID-19 pandemic has created significant economic
uncertainty and volatility in the credit and capital markets. A continuation or worsening of the levels of market disruption and
volatility seen in the recent past could have an adverse effect on our ability to access capital. In addition, it is generally
difficult for development-stage companies to raise capital under current market conditions. The amount of capital that a company
such as ours is able to raise often depends on variables that are beyond our control. As a result, we may not be able to secure
financing on terms attractive to us, or at all. If we are able to consummate a financing arrangement, the amount raised may not
be sufficient to meet our future needs. If adequate funds are not available on acceptable terms, or at all, our business, including
our technology licenses, results of operations, financial condition and our continued viability will be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are highly dependent on the success
of Iomab-B and the SIERRA trial and we many not able to complete the necessary clinical development or our development efforts
may not result in the data necessary to receive regulatory approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Iomab-B, which we licensed
from the Fred Hutchinson Cancer Research Center in June 2012 is our lead program to which we allocate a significant portion of
our resources. We are currently enrolling patients in the pivotal Phase 3 SIERRA trial (Study of Iomab-B in Elderly Relapsed or
Refractory AML), a 150-patient multi-center randomized trial that will compare outcomes of patients who receive Iomab-B and a BMT
to those patients receiving physician&rsquo;s choice of salvage chemotherapy, defined as conventional care, as no standard of care
exists for this patient population. The SIERRA trial may be unsuccessful and fail to demonstrate a safety and efficacy profile
that is necessary to receive favorable regulatory approval. The trials DMC or Data Monitoring Committee may recommend that the
trial be stopped early for safety or efficacy concerns, which could prevent us from completing the SIERRA trial. Even if Iomab-B
receives favorable regulatory approval, we may not be successful in securing adequate reimbursement or establishing successful
commercial operations. Any or all of these factors could have a material adverse impact on our business and ability to continue
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be unable to establish sales,
marketing and commercial supply capabilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not currently have,
nor have we ever had, commercial sales and marketing capabilities. If any of our product candidates become approved, we would have
to build and establish these capabilities in order to commercialize our approved product candidates. The process of establishing
commercial capabilities will be expensive and time consuming. Even if we are successful in building sales and marketing capabilities,
we may not be successful in commercializing any of our product candidates. Any delays in commercialization or failure to successfully
commercialize any product candidate may have material adverse impacts on our business and ability to continue operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our business could be adversely affected
by the effects of health epidemics, including the global COVID-19 pandemic.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In December 2019, a novel
strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China to other
countries has resulted in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a &ldquo;pandemic,&rdquo; or
a worldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictions
on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses, and many local jurisdictions
continue to have such restrictions in place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As many local jurisdictions
continue to have such restrictions in place, our ability to continue to operate our business may also be limited. Such events may
result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could
materially affect our business, financial condition and results of operations. In response to COVID-19, we implemented remote working
and thus far have not experienced a significant disruption or delay in our operations as it relates to the clinical development
of our drug candidates. Such government-imposed precautionary measures may have been relaxed in certain countries or states, but
there is no assurance that more strict measures will be put in place again due to a resurgence in COVID-19 cases. Therefore, the
COVID-19 pandemic may continue to affect our operation, may further divert the attention and efforts of the medical community to
coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The spread of COVID-19,
which has caused a broad impact globally, may materially affect us economically. While the ultimate economic impact brought by,
and the duration of, the COVID-19 pandemic may be difficult to assess or predict, including new information which may emerge concerning
the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others, the pandemic has resulted in significant
disruptions in the general commercial activity and the global economy and caused financial market volatility and uncertainty in
significant and unforeseen ways in the recent months. A continuation or worsening of the levels of market disruption and volatility
seen in the recent past could have an adverse effect on our ability to access capital, which could in the future negatively affect
our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our
business and the value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, the Phase
3 SIERRA trial for our lead program, Iomab-B, continues to remain active at a majority of our clinical trial sites, with investigators
providing feedback that recruitment and enrollment will remain active because of the acute nature of the disease, the high unmet
needs of patients with relapsed or refractory AML, the potentially curative nature of BMT and the differentiated profile of Iomab-B.
Certain sites that had not been actively enrolling due to COVID-19 have resumed recruitment and enrollment, and wecurrently anticipate
that other sites that have not been actively enrolling due to COVID-19 will likely resume recruitment and enrollment in the summer
timeframe. We also believe our earlier stage clinical trials for our CD33 program will also continue to recruit and enroll patients
given the acute nature of relapsed or refractory AML. The continuation of the pandemic globally could adversely affect our planned
clinical trial operations, including our ability to conduct the trials on the expected timelines and recruit and retain patients
and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if their geography
is impacted by the pandemic. Further, the continuation and/or resurgence of the COVID-19 pandemic could result in delays in our
clinical trials due to prioritization of hospital resources toward the pandemic, restrictions in travel, potential unwillingness
of patients to enroll in trials at this time, or the inability of patients to comply with clinical trial protocols if quarantines
or travel restrictions impede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators,
contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying
out our preclinical studies and clinical trials, and the pandemic may affect their ability to devote sufficient time and resources
to our programs or to travel to sites to perform work for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, COVID-19
may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with
IRB&rsquo;s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors
due to limitations in employee resources or forced furlough of government employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">COVID-19 has caused severe
disruptions in transportation and limited access to our facility, resulting in limited support from our staff and professional
advisors. The small size of our accounting staff and the additional responsibilities emanating from COVID-19 presented difficulties
to our ability to complete our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended March 31,
2020, resulting in the delay of filing of each of those reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The ultimate impact from
COVID-19 on our business operations and financial results during 2020 will depend on, among other things, the ultimate severity
and scope of the pandemic, the pace at which governmental and private travel restrictions and public concerns about public gatherings
will ease, the rate at which historically large increases in unemployment rates will decrease, if at all, and whether, and the
speed with which the economy recovers. We are not able to fully quantify the impact that these factors will have on our financial
results during 2020 and beyond, but developments related to COVID-19 may materially affect us in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our business is subject to cybersecurity risks.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our operations are increasingly
dependent on information technologies and services. Threats to information technology systems associated with cybersecurity risks
and cyber incidents or attacks continue to grow, and include, among other things, storms and natural disasters, terrorist attacks,
utility outages, theft, viruses, phishing, malware, design defects, human error, and complications encountered as existing systems
are maintained, repaired, replaced, or upgraded. Risks associated with these threats include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">theft or misappropriation of funds;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss, corruption, or misappropriation of intellectual property, or other proprietary, confidential or personally identifiable information (including supplier, clinical data or employee data);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption or impairment of our and our business operations and safety procedures;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage to our reputation with our potential partners, patients and the market;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure to litigation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased costs to prevent, respond to or mitigate cybersecurity events.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we utilize various
procedures and controls to mitigate our exposure to such risk, cybersecurity attacks and other cyber events are evolving and unpredictable.
Moreover, we have no control over the information technology systems of third parties conducting our clinical trials, our suppliers,
and others with which our systems may connect and communicate. As a result, the occurrence of a cyber incident could go unnoticed
for a period time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not presently maintain
insurance coverage to protect against cybersecurity risks. If we procure such coverage in the future, we cannot ensure that it
will be sufficient to cover any particular losses we may experience as a result of such cyberattacks. Any cyber incident could
have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Regulation&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The FDA or comparable foreign regulatory
authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our products are subject
to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. The process of seeking
regulatory approval to market an antibody radiation-conjugate product is expensive and time-consuming, and, notwithstanding the
effort and expense incurred, approval is never guaranteed. If we are not successful in obtaining timely approval of our products
from the FDA, we may never be able to generate significant revenue and may be forced to cease operations. In particular, the FDA
permits commercial distribution of a new antibody radiation-conjugate product only after a BLA for the product has received FDA
approval. The BLA process is costly, lengthy and inherently uncertain. Any BLA filed by us will have to be supported by extensive
data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data, to demonstrate to
the FDA&rsquo;s satisfaction the safety and efficacy of the product for its intended use. The lengthy approval process as well
as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our
product candidates, which would significantly harm our business, results of operations and prospects. In addition, even if we were
to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than
we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of
costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims
necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially
harm the commercial prospects for our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The approval process in
the United States and in other countries could result in unexpected and significant costs for us and consume management&rsquo;s
time and other resources. The FDA and other foreign regulatory agencies could ask us to supplement our submissions, collect non-clinical
data, conduct additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications. In
addition, even if we obtain approval to market our products in the United States or in other countries, the approval could be revoked,
or other restrictions imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty
how, or when, the FDA or other regulatory authorities will act. If we are unable to obtain the necessary regulatory approvals,
our financial condition and cash flow may be materially adversely affected, and our ability to grow domestically and internationally
may be limited. Additionally, even if we obtain approval, regulatory authorities may approve any of our product candidates for
fewer or more limited indications that we request. The Company&rsquo;s products may not be approved for the specific indications
that are most necessary or desirable for successful commercialization or profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have not demonstrated that any of
our products are safe and effective for any indication and will continue to expend substantial time and resources on clinical development
before any of our current or future product candidates will be eligible for FDA approval, if ever.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect that a substantial
portion of our efforts and expenditures over the next few years will be devoted to development of our existing and contemplated
biological product candidates. Accordingly, our business currently depends heavily on the successful development, FDA approval,
and commercialization of such candidates, which may never receive FDA approval or be successfully commercialized even if FDA approval
is received. The research, testing, manufacturing, labeling, approval, sale, marketing, and distribution of our biological product
candidates are, and will remain, subject to extensive regulation by the FDA and other regulatory authorities in the United States
and other countries, as applicable. We are currently not permitted to market any of our current or future product candidates in
the United States until we receive FDA approval (of each) via the BLA process. To date, we have two product candidates &nbsp;in
clinical development and have not-yet submitted a BLA for any of our candidates and, for many such candidates, do not expect to
be in a position to do so for the foreseeable future, as there are numerous developmental steps that must be completed before we
can prepare and submit a BLA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the United States, the
FDA regulates pharmaceutical and biological product candidates under the Federal Food, Drug and Cosmetic Act (&ldquo;FDCA&rdquo;)
and the Public Health Service Act (&ldquo;PHSA&rdquo;), as well as their respective implementing regulations. Such products and
product candidates are also subject to other federal, state, and local statutes and regulations. The process of obtaining regulatory
approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the
expenditure of substantial time and financial resources. The process required by the FDA before a drug or biological product may
be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of preclinical laboratory tests and animal studies in accordance with FDA&rsquo;s good laboratory practices (&ldquo;GLPs&rdquo;) and applicable requirements for the humane use of laboratory animals or other applicable regulations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of an IND, which must become effective before human clinical trials in the United States may begin;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate and well-controlled human clinical trials in accordance with FDA&rsquo;s IND regulations, good clinical practices (&ldquo;GCPs&rdquo;), and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of a BLA for marketing approval that meets applicable requirements to ensure the continued safety, purity, and potency of the product that is the subject of the BLA based on results of preclinical testing and clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced, to assess compliance with current good manufacturing processes (&ldquo;cGMPs&rdquo;) and assure that the facilities, methods and controls are adequate to preserve the biological product&rsquo;s identity, strength, quality and purity;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval, or denial, of the BLA.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Before testing any biological
product candidate in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations
of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product
candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical
trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available
clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue
even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises
concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time period.
In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA
may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns
or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under
terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical
trials to begin or that, for those that have already commenced under an active IND, that issues will not arise that suspend or
terminate such trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Clinical trials involve
the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor&rsquo;s control. Clinical trials are conducted under protocols
detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria,
and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped
if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of
the IND. Clinical trials must be conducted and monitored in accordance with the FDA&rsquo;s regulations composing the GCP requirements,
including the requirement that all research subjects provide informed consent. Further, each clinical trial must be reviewed and
approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will
be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether
the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits.
The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or
her legal representative and must monitor the clinical trial until completed. Human clinical trials are typically conducted in
three sequential phases that may overlap or be combined:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in subjects.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Post-approval clinical
trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials
are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for
long-term safety follow-up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After the completion of
clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product.
The BLA must include results of product development, laboratory and animal studies, human trials, information on the manufacture
and composition of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission of
data, or full or partial waivers. The testing and approval processes require substantial time and effort and there can be no assurance
that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.
Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the
product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will
typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements
and GCP requirements. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort
in the areas of training, record keeping, production, and quality control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the submission
of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval
and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than
we interpret the same data. Our product candidates are in the earliest stages of clinical development and, therefore, a long way
from BLA submission. We cannot predict with any certainty if or when we might submit a BLA for regulatory approval for our product
candidates or whether any such BLA will be approved by the FDA. Human clinical trials are very expensive and difficult to design
and implement, in part because they are subject to rigorous regulatory requirements. For example, the FDA may not agree with our
proposed endpoints for any clinical trial we propose, which may delay the commencement of our clinical trials. The clinical trial
process is also lengthy and requires substantial time and effort.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In December 2015, the FDA
cleared our IND filing for Iomab-B (for acute myeloid leukemia or AML), and we are currently enrolling patients in a randomized,
controlled, pivotal Phase 3 clinical trial under such IND to study Iomab-B in patients 55 years of age or older with relapsed or
refractory AML. Assuming the Phase 3 trial meets its endpoints and there are no unexpected issues or delays, it will form the basis
for a BLA in the reasonably near future for Iomab-B for use in preparing and conditioning AML patients for bone marrow transplants
(BMTs). Additionally, there are physician IND trials at the Fred Hutchinson Cancer Research Center (FHCRC) that have been conducted
or are currently ongoing at FHCRC with Iomab-B (for other target indications) and the BC8 antibody we licensed. And, we have multiple
Phase 1 and Phase 2 clinical trials ongoing and others that we have planned but not-yet commenced, for our other drug candidates
under our own sponsorship and multiple investigator-initiated trials ongoing. Except for Iomab-B (for patients with AML), we expect
that the clinical trials we need to conduct to be in a position to submit BLAs for our product candidates currently in-development
will take, at least, several years to complete. Moreover, failure can occur at any stage of the trials, and we could encounter
problems that cause us to abandon or repeat clinical trials. Also, the results of early preclinical and clinical testing may not
be predictive of the results of subsequent clinical trials. A number of companies in the biopharmaceutical industry have suffered
significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising
results in earlier studies. And, preclinical and clinical data are often susceptible to multiple interpretations and analyses.
Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials
have, nonetheless, failed to obtain marketing approval of their products. Success in preclinical testing and early clinical trials
does not ensure that later clinical trials, which involve many more subjects, and the results of later clinical trials may not
replicate the results of prior clinical trials and preclinical testing. Any failure or substantial delay in our product development
plans may have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may encounter substantial delays in
our clinical trials or may not be able to conduct our trials on the timelines we expect.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
we will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory authorities to delay,
suspend, or discontinue clinical trials or to delay the analysis of data from ongoing clinical trials. Any of the following could
delay or disrupt the clinical development of our product candidates and potentially cause our product candidates to fail to receive
regulatory approval:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 19.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in receiving, or the inability to obtain, required approvals from institutional review boards (IRBs) or other reviewing entities at clinical sites selected for participation in our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in enrolling patients into clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a lower than anticipated retention rate of patients in clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the need to repeat or discontinue clinical trials as a result of inconclusive or negative results or unforeseen complications in testing or because the results of later trials may not confirm positive results from earlier preclinical studies or clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate supply, delays in distribution, deficient quality of, or inability to purchase or manufacture drug product, comparator drugs or other materials necessary to conduct our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable FDA or other foreign regulatory inspection and review of a clinical trial site or records of any clinical or preclinical investigation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials, which may occur even if they were not observed in earlier trials or only observed in a limited number of participants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a finding that the trial participants are being exposed to unacceptable health risks;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the placement by the FDA or a foreign regulatory authority of a clinical hold on a trial; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining regulatory agency authorization for the conduct of our clinical trials.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may suspend, or the
FDA or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate at any time if
we or they believe the patients participating in such clinical trials, or in independent third-party clinical trials for drugs
based on similar technologies, are being exposed to unacceptable health risks or for other reasons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, individuals involved
with our clinical trials may serve as consultants to us from time to time and receive stock options or cash compensation in connection
with such services. If these relationships and any related compensation to the clinical investigator carrying out the study result
in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected interpretation
of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the
clinical trial itself may be jeopardized. The delay, suspension or discontinuation of any of our clinical trials, or a delay in
the analysis of clinical data for our product candidates, for any of the foregoing reasons, could adversely affect our efforts
to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses and have a material
adverse effect on our financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Clinical trials may also
be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or
terminated by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or DSMB
(Data Safety Monitoring Board)/DMC (Data Monitoring Committee), overseeing the clinical trial at issue, or other regulatory authorities
due to a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 19.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying interpretation of data by the FDA or similar foreign regulatory authorities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to achieve primary or secondary endpoints or other failure to demonstrate efficacy;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen safety issues; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate funding to continue the clinical trial.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Modifications to our product candidates may require federal
approvals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The BLA application is
the vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and marketing in
the United States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications of our products
may require additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions and premarket
approvals before we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new approvals for
a particular use or indication, we may be required to conduct additional clinical studies, which would require additional expenditures
and harm our operating results. If the products are already being used for these new indications, we may also be subject to significant
enforcement actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Conducting clinical trials
and obtaining approvals is a time-consuming process, and delays in obtaining required future approvals could adversely affect our
ability to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business prospects,
financial condition and results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The FDA or comparable foreign regulatory
authorities may disagree with our regulatory plans, and we may fail to obtain regulatory approval of our product candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2012, we acquired
rights to BC8 (Iomab), a clinical stage monoclonal antibody with safety and efficacy data in more than 300 patients in need of
a BMT. Iomab-B is our product candidate that links I-131 to the BC8 antibody that is being studied in an ongoing Phase 3 pivotal
trial. Product candidates utilizing this antibody would require BLA approval before they can be marketed in the United States.
We are also evaluating a lower dose of the BC8 antibody and I-131 for lymphodepletion prior to CAR-T or adoptive cell therapy.
We are currently evaluating clinical trials that would use our construct for lymphodepletion. Our lintuzumab-Ac-225 product candidate
is also being studied in several Phase 1 trials under our sponsorship and investigator-initiated trials in patients with AML, myelodysplastic
syndrome and multiple myeloma. Product candidates utilizing the lintuzumab antibody would require BLA approval before they can
be marketed in the United States. We are in the early stages of evaluating other product candidates consisting of conjugates of
Ac-225 with human or humanized antibodies for pre-clinical and clinical development in other types of cancer. The FDA may not approve
these products for the indications that are necessary or desirable for successful commercialization. The FDA may fail to approve
any BLA we submit for new product candidates or for new intended uses or indications for approved products or future product candidates.
Failure to obtain FDA approval for our products in the proposed indications would have a material adverse effect on our business
prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Clinical trials necessary to support
approval of our product candidates are time-consuming and expensive. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Initiating and completing
clinical trials necessary to support FDA approval of a BLA for Iomab-B, CD33 program candidates, and other product candidates,
is a time-consuming and expensive process, and the outcome is inherently uncertain. Moreover, the results of early clinical trials
are not necessarily predictive of future results, and any product candidate we advance into clinical trials may not have favorable
results in later clinical trials. We have worked with the FDA to develop a clinical trial designed to test the safety and efficacy
of Iomab-B in patients with relapsed or refractory AML who are age 55 and above prior to a BMT. This trial is designed to support
a BLA filing for marketing approval by the FDA, pending results from the trial. We have also worked with the FDA to develop a regulatory
pathway for our Actimab-MDS trial that consists of a dose-confirming Phase 1 trial that can be followed by a randomized, controlled
pivotal trial that could support a BLA filing. There can be no assurance that the data generated during the trial will meet our
chosen safety and effectiveness endpoints or otherwise produce results that will eventually support the filing or approval of a
BLA. Even if the data from this trial are favorable, the data may not be predictive of the results of any future clinical trials.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our clinical trials may fail to demonstrate
adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if our clinical trials
are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or
foreign authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does
not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results
of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe
and effective for the proposed indicated uses. If FDA concludes that the clinical trials for Iomab-B, lintzumab-Ac-225, or any
other product candidate for which we might seek approval, have failed to demonstrate safety and effectiveness, we would not receive
FDA approval to market that product candidate in the United States for the indications sought. In addition, such an outcome could
cause us to abandon the product candidate and might delay development of others. Any delay or termination of our clinical trials
will delay or preclude the filing of any submissions with the FDA and, ultimately, our ability to commercialize our product candidates
and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that
are not currently part of a product candidate&rsquo;s profile.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The intellectual property related to
antibodies we have licensed has expired or likely expired</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The key patents related
to the humanized antibody, lintuzumab, which we use in our CD33 program product candidates have expired. It is generally possible
that others may be eventually able to use an antibody with the same sequence, and we will then need to rely on additional patent
protection covering alpha particle drug products comprising Ac-225. Our final drug construct consists of the lintuzumab antibody
labeled with the isotope Ac-225. We have licensed issued patents that relate to the linker technology we use to conjugate the isotope
to the antibody. Further, we own issued and pending patents related to methods for drug conjugation and isotope labeling and for
methods of isotope production. In addition, we possess trade secrets and know how related to the manufacturing and use of isotopes.
Any competing product based on the lintuzumab antibody is likely to require several years of development before achieving our product
candidate&rsquo;s current status and may be subject to significant regulatory hurdles but is nevertheless a possibility that could
negatively impact our business in the future. We own an issued patent in the US relating to composition of the Iomab-B product
candidate. Five related patents are also pending in the US and internationally. We have and may continue to file patents related
to Iomab-B that can provide barriers to entry but there is no certainty that these patents will be granted or such granting thereof
will adequately prevent others from seeking to replicate and use the BC8 antibody or the construct. We have pending patents related
to radioimmunoconjugate composition, formulation administration, and methods of use in solid or liquid cancers. This matter includes
composition, administration, and methods of treatment for our products Actimab-A and Iomab-B. Any competing product based on the
antibody used in Iomab-B is likely to require several years of development before achieving our product candidate&rsquo;s current
status and may be subject to significant regulatory hurdles but is nevertheless a possibility that could negatively impact our
business in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our CD33 program clinical trials are
testing the same drug construct </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our CD33 program is comprised
of several clinical trials including several investigator-initiated trials including AML, MDS and Multiple Myeloma that are studying
the same drug construct consisting of lintuzumab-Ac-225. Negative results from any of these trials could negatively impact our
ability to enroll or complete our other trials studying lintzumab-Ac-225. Additionally, negative outcomes including safety concerns,
may result in the FDA discontinuing other trials utilizing lintuzumab-Ac-225.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be unable to obtain a sufficient
supply of isotopes to support clinical development or at commercial scale.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Iodine-131 is a key component
of our Iomab-B drug candidate. We currently source medical grade I-131 from three suppliers including two leading global manufacturers.
Currently, there is sufficient supply of I-131 to advance our ongoing SIERRA clinical trial, support additional trials we may undertake
utilizing I-131 and for commercialization of Iomab-B. We continually evaluate I-131 manufacturers and suppliers and intend to have
multiple qualified suppliers prior to the commercial launch of Iomab-B. While we consider I-131 to be commoditized and obtainable
through several suppliers, there can be no guarantee that we will be able to secure I-131 or obtain I-131 on terms that are acceptable
to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Actinium-225 is a key component
of our CD33 ARC program, AWE platform and other drug candidates that we might consider for development with the Ac-225 payload.
There are adequate quantities of Ac-225 available today to meet our current needs via our present supplier, the Department of Energy,
or DOE. The current Ac-225 currently supplied to Actinium&rsquo;s clinical trials from the DOE is derived from the natural decay
of thorium-229 from so-called &lsquo;thorium-cows&rsquo; and is able to produce sufficient quantities that are several multiples
of the amount of Ac-225 we require to supply our clinical programs through to early commercialization phase. The DOE is also producing
Ac-225 from a recently developed alternative route for Ac-225 production via a linear accelerator that is currently being evaluated
by Actinium. Initial preclinical and modelling results have indicated that the linear accelerator sourced Ac-225 does not impact
labelling efficiency and expected distribution. Per representations made by the Department of Energy, the capacity of Ac-225 from
this route is expected to be sufficient to supply all of Actinium&rsquo;s pipeline and commercial Ac-225 needs and support new
program expansion by not just Actinium but also other companies that are developing Ac-225 based products. Additional routes of
Ac-225 production are being pursued by the DOE including the generation of new thorium cows and production via a cyclotron. The
cyclotron production method for Ac-225 production leverages Actinium&rsquo;s proprietary technology and know-how and presents an
additional path towards production of high-quality Ac-225 that would be able to satisfy commercial needs. In addition, we are aware
of at least six other government and non-government entities globally including the U.S., Canada, Russia, Belgium, France and Japan
that have, or expect to have ability to supply Ac-225 or equipment for its production within the timeframes relevant to first commercial
approval of our Ac-225 ARC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our contract for supply
of this isotope from the DOE must be renewed yearly, and the current contract extends through the end of 2020. While we expect
this contract will be renewed at the end of its term as it has since 2009, there can be no assurance that the DOE will renew the
contract or that change its policies that allow for the sale of isotope to us. Failure to acquire sufficient quantities of medical
grade Ac-225 would make it impossible to effectively complete clinical trials and to commercialize any Ac-225 based drug candidates
that we may develop and would materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our ability to conduct
clinical trials to advance our ARC drug candidates is dependent on our ability to obtain the radioisotopes I-131, Ac-225 and other
isotopes we may choose to utilize in the future. Currently, we are dependent on third party manufacturers and suppliers for our
isotopes. These suppliers may not perform their contracted services or may breach or terminate their agreements with us. Our suppliers
are subject to regulations and standards that are overseen by regulatory and government agencies and we have no control over our
suppliers&rsquo; compliance to these standards. Failure to comply with regulations and standards may result in their inability
to supply isotope could result in delays in our clinical trials, which could have a negative impact on our business. We have developed
intellectual property, know-how and trade secrets related to the manufacturing process of Ac-225. While we have manufactured medical
grade Ac-225 of a purity compared to the cyclotron sourced material in the past, this activity was terminated due to operating
cost reasons and we currently do not have experience in manufacturing medical grade Ac-225 and may not obtain the resources necessary
to establish our own manufacturing capabilities in future. Our inability to build out and establish our own manufacturing facilities
would require us to continue to rely on third party suppliers as we currently do. However, based on our current third-party suppliers
and potential future suppliers of Ac-225 we expect to have adequate isotope supply to support our current ongoing clinical trials,
current AWE program activities and commercialization should our drug candidates receive approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we encounter difficulties enrolling
patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The timely completion of
clinical trials in accordance with their protocols depends on our ability to enroll a sufficient number of patients who remain
in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of
reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and nature of the patient population;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patient eligibility criteria defined in the protocol;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of the study population required for analysis of the trial&rsquo;s primary endpoints;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proximity of patients to trial sites;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the trial;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and expertise;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing clinical trials for similar or alternate therapeutic treatments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinician&rsquo;s and patients&rsquo; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain patient consents; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that patients enrolled in clinical trials will not complete a clinical trial.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, refractory
patients, which several of our trials are enrolling, participating in clinical trials are seriously and often terminally ill and
therefore may not complete the clinical trial due to reasons including comorbid conditions or occurrence of adverse medical events
related or unrelated to the investigational products, or death. Even if we are able to enroll a sufficient number of patients in
our clinical trials, delays in patient enrollment will result in increased costs or affect the timing of our planned trials, which
could adversely affect our ability to advance the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>FDA may take actions that would prolong,
delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent us from commercializing our
product candidates on a timely basis.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that the data generated in our clinical trials will be acceptable to FDA or that if future modifications during the trial are necessary,
that any such modifications will be acceptable to FDA. Certain modifications to a clinical trial protocol made during the course
of the clinical trial have to be submitted to the FDA. This could result in the delay or halt of a clinical trial while the modification
is evaluated. In addition, depending on the quantity and nature of the changes made, FDA could take the position that some or all
of the data generated by the clinical trial is not usable because the same protocol was not used throughout the trial. This might
require the enrollment of additional subjects, which could result in the extension of the clinical trial and the FDA delaying approval
of a product candidate. If the FDA believes that its prior approval is required for a particular modification, it can delay or
halt a clinical trial while it evaluates additional information regarding the change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 19.95pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any delay or termination
of our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining
required approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial,
and delays or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause
an increase in costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of our
product candidates or result in the failure of the clinical trial, which could adversely affect our business, operating results
and prospects. Lengthy delays in the completion of our Iomab-B clinical trials would adversely affect our business and prospects
and could cause us to cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have obtained orphan drug designation
from FDA for two of our current product candidates and intend to pursue such designation for other candidates and indications in
the future, but we may be unable to obtain such designations or to maintain the benefits associated with any orphan drug designations
we have received or may receive in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have received orphan
drug designation for Iomab-B and lintuzumab-CD33 ARC for treatment of AML in both the United States and the EU. Under the Orphan
Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a
disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals
in the United States, there is no reasonable expectation that the cost of developing and making available a drug or biologic for
this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Similarly, the EMA
grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention, or treatment
of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Orphan drug designation
neither shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage
in the regulatory review or approval process. In the United States, orphan drug designation entitles a party to financial incentives,
such as opportunities for grant funding towards clinical trial costs, tax advantages, and application fee waivers. In addition,
if a product candidate receives the first FDA approval for the indication for which it has orphan designation, such product is
entitled, upon approval, to seven years of orphan-drug exclusivity, during which the FDA may not approve any other application
to market the same drug for the same indication, unless a subsequently approved product is clinically superior to orphan drug or
where the manufacturer is unable to assure sufficient product quantity in the applicable patient population. In the EU, orphan
drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity
following drug or biological product approval. This period may be reduced to six years if the orphan drug designation criteria
are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market
exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if we obtain (or have
obtained) orphan drug designation for certain product candidates, we may not be the first to obtain marketing approval for such
candidates for the applicable indications due to the uncertainties inherent in the development of novel biologic products. And,
an orphan drug candidate may not receive orphan-drug exclusivity upon approval if such candidate is approved for a use that is
broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States
may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable
to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Finally, even if we successfully
obtain orphan-drug exclusivity for an orphan drug candidate upon approval, such exclusivity may not effectively protect the product
from competition because (i) different drugs with different active moieties can be approved for the same condition; and (ii) the
FDA or EMA can also subsequently approve a subsequent product with the same active moiety and for the same indication as the orphan
drug if the later-approved drug if deemed clinically superior to the orphan drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Even if we receive regulatory approval
of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals
that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate.
The FDA may also require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail
requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory
authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting,
storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing
regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration,
as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. In addition, the FDA
could require us to conduct another study to obtain additional safety or biomarker information. Later discovery of previously unknown
problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party
suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, warning letters or holds on clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FDA&rsquo;s and other
regulatory authorities&rsquo; policies may change, and additional government regulations may be enacted that could prevent, limit
or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation
that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable
to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain
regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Coverage and reimbursement may be limited or unavailable in
certain market segments for our product candidates which could limit our sales of our product candidates, if approved.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The commercial success
of our product candidates in both domestic and international markets will be substantially dependent on whether third-party coverage
and reimbursement is available for patients that use our products. However, the availability of insurance coverage and reimbursement
for newly approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even
if our products are approved by the FDA as safe and efficacious. Patients using existing approved therapies are generally reimbursed
all or part of the product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations and
other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement
of new drugs, and, as a result, they may not cover or provide adequate payment for these products. Submission of applications for
reimbursement approval generally does not occur prior to the filing of a BLA for that product and may not be granted until many
months after BLA approval. In order to obtain coverage and reimbursement for these products, we or our commercialization partners
may have to agree to a net sales price lower than the net sales price we might charge in other sales channels. The continuing efforts
of government and third-party payors to contain or reduce the costs of healthcare may limit our revenue. Initial dependence on
the commercial success of our products may make our revenues particularly susceptible to any cost containment or reduction efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Healthcare legislative reform measures
intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal
regulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results
of operations.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the United States, the
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the MMA, changed the way Medicare covers and
pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a
new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided
authority for limiting the number of drugs that will be covered in any therapeutic class. As a result of this legislation and the
expansion of federal coverage of drug products, we expect that there will be additional pressure to reduce costs. These cost reduction
initiatives and other provisions of this legislation could decrease the scope of coverage and the price that we receive for any
approved products and could harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private
payors often follow Medicare coverage policies and payment limitations in setting their own reimbursement rates, and any reduction
in reimbursement that results from the MMA may cause a similar reduction in payments from private payors. This legislation may
pose an even greater risk to our drug candidates as a significant portion of the target patient population for our drug candidates
would likely be over 65 years of age and, therefore, many such patients will be covered by Medicare.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 23, 2010, President
Obama signed the &ldquo;Patient Protection and Affordable Care Act&rdquo; (P.L. 111-148) and on March 30, 2010, the signed the
&ldquo;Health Care and Education Reconciliation Act&rdquo; (P.L. 111-152) (collectively, the &ldquo;Healthcare Reform Law&rdquo;).
The Healthcare Reform Law included a number of new rules regarding health insurance, the provision of healthcare, conditions to
reimbursement for healthcare services provided to Medicare and Medicaid patients, and other healthcare policy reforms. Through
the law-making process, substantial changes have been and continue to be made to the current system for paying for healthcare in
the U.S., including changes made to extend medical benefits to certain Americans who lacked insurance coverage and to contain or
reduce healthcare costs (such as by reducing or conditioning reimbursement amounts for healthcare services and drugs, and imposing
additional taxes, fees, and rebate obligations on pharmaceutical and medical device companies). This legislation was one of the
most comprehensive and significant reforms ever experienced by the U.S. in the healthcare industry and has significantly changed
the way healthcare is financed by both governmental and private insurers. This legislation has impacted the scope of healthcare
insurance and incentives for consumers and insurance companies, among others.&nbsp;Additionally, the Healthcare Reform Law&rsquo;s
provisions were designed to encourage providers to find cost savings in their clinical operations. Pharmaceuticals represent a
significant portion of the cost of providing care. This environment has caused changes in the purchasing habits of consumers and
providers and resulted in specific attention to the pricing negotiation, product selection and utilization review surrounding pharmaceuticals.
This attention may result in our current commercial products, products we may commercialize or promote in the future, and our therapeutic
candidates, being chosen less frequently or the pricing being substantially lowered.&nbsp;At this stage, it is difficult to estimate
the full extent of the direct or indirect impact of the Healthcare Reform Law on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These structural changes
could entail further modifications to the existing system of private payors and government programs (such as Medicare, Medicaid,
and the State Children&rsquo;s Health Insurance Program), creation of government-sponsored healthcare insurance sources, or some
combination of both, as well as other changes. Restructuring the coverage of medical care in the U.S. could impact the reimbursement
for prescribed drugs and pharmaceuticals, including our current commercial products, those we and our development or commercialization
partners are currently developing or those that we may commercialize or promote in the future. If reimbursement for the products
we currently commercialize or promote, any product we may commercialize or promote, or approved therapeutic candidates is substantially
reduced or otherwise adversely affected in the future, or rebate obligations associated with them are substantially increased,
it could have a material adverse effect on our reputation, business, financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Extending medical benefits
to those who currently lack coverage will likely result in substantial costs to the U.S. federal government, which may force significant
additional changes to the healthcare system in the U.S. Much of the funding for expanded healthcare coverage may be sought through
cost savings. While some of these savings may come from realizing greater efficiencies in delivering care, improving the effectiveness
of preventive care and enhancing the overall quality of care, much of the cost savings may come from reducing the cost of care
and increased enforcement activities. Cost of care could be reduced further by decreasing the level of reimbursement for medical
services or products (including our current commercial products, our development or commercialization partners or any product we
may commercialize or promote, or those therapeutic candidates currently being developed by us), or by restricting coverage (and,
thereby, utilization) of medical services or products. In either case, a reduction in the utilization of, or reimbursement for
our current commercial products, any product we may commercialize or promote, or any therapeutic candidate, or for which we receive
marketing approval in the future, could have a material adverse effect on our reputation, business, financial condition or results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Several states and private
entities initially mounted legal challenges to the Healthcare Reform Law, and they continue to litigate various aspects of the
legislation. On July 26, 2012, the U.S. Supreme Court generally upheld the provisions of the Healthcare Reform Law at issue as
constitutional. However, the U.S. Supreme Court held that the legislation improperly required the states to expand their Medicaid
programs to cover more individuals. As a result, the states have a choice as to whether they will expand the number of individuals
covered by their respective state Medicaid programs. Some states have not expanded their Medicaid programs and have chosen to develop
other cost-saving and coverage measures to provide care to currently uninsured individuals. Many of these efforts to date have
included the institution of Medicaid-managed care programs. The manner in which these cost-saving and coverage measures are implemented
could have a material adverse effect on our reputation, business, financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, the healthcare
regulatory environment has seen significant changes in recent years and is still in flux.&nbsp;Legislative initiatives to modify,
limit, replace, or repeal the Healthcare Reform Law and judicial challenges continue, and may increase in light of the current
administration and legislative environment.&nbsp;We cannot predict the impact on our business of future legislative and legal challenges
to the Healthcare Reform Law or other changes to the current laws and regulations. The financial impact of U.S. healthcare reform
legislation over the next few years will depend on a number of factors, including the policies reflected in implementing regulations
and guidance and changes in sales volumes for therapeutics affected by the legislation. From time to time, legislation is drafted,
introduced and passed in the U.S. Congress that could significantly change the statutory provisions governing coverage, reimbursement,
and marketing of pharmaceutical products. In addition, third-party payor coverage and reimbursement policies are often revised
or interpreted in ways that may significantly affect our business and our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since taking office, President
Trump has continued to support the repeal of all or portions of the Healthcare Reform Law. President Trump has also issued an executive
order in which he stated that it is his administration&rsquo;s policy to seek the prompt repeal of the Healthcare Reform Law and
in which he directed executive departments and federal agencies to waive, defer, grant exemptions from, or delay the implementation
of the provisions of the Healthcare Reform Law to the maximum extent permitted by law. Congress has enacted legislation that repeals
certain portions of the Healthcare Reform Law, including but not limited to the Tax Cuts and Jobs Act, passed in December 2017,
which included a provision that eliminates the penalty under the Healthcare Reform Law&rsquo;s individual mandate, effective January
1, 2019, as well as the Bipartisan Budget Act of 2018, passed in February 2018, which, among other things, repealed the Independent
Payment Advisory Board (which was established by the Healthcare Reform Law and was intended to reduce the rate of growth in Medicare
spending).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, in December
2018, a district court in Texas held that the individual mandate is unconstitutional and that the rest of the Affordable Care Act
is, therefore, invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holding on the individual mandate but remanded
the case back to the lower court to reassess whether and how such holding affects the validity of the rest of the Affordable Care
Act. Substantial uncertainty remains as to the future of the Affordable Care Act after the U.S. Supreme Court declined to expedite
its review of the Fifth Circuit&rsquo;s holding on January 21, 2020. It is, thus, unlikely that these issues will be resolved before
the next presidential election in November 2020. The current administration may seek to pass additional reform measures before
the upcoming election. We cannot predict the outcome of the election, nor can we predict the healthcare-reform-related initiatives
that the newly elected (or re-elected, as applicable) administration will put forth thereafter. There is no way to know whether,
and to what extent, if any, the Affordable Care Act will remain in-effect in the future, and it is unclear how judicial decisions,
subsequent appeals, election-related measures, or other efforts to repeal and replace or, possibly, to restore the Affordable Care
Act will impact the U.S. healthcare industry or our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We rely on third parties to conduct our
clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply
with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not have the ability
to independently conduct our pre-clinical and clinical trials for our product candidates and we must rely on third parties, such
as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials.
Our reliance on these third parties for clinical development activities results in reduced control over these activities. Moreover,
the FDA requires us to comply with regulations and standards, commonly referred to as GCPs (good clinical practices), for conducting,
recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that
the trial participants are adequately protected. Our reliance on third parties does not relieve us of these responsibilities and
requirements. If we or any of our third-party contractors fail to comply with applicable GCPs, the clinical data generated in our
clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional
clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority,
such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical
trials must be conducted with product produced under current good manufacturing practice, or cGMP, regulations. Our failure to
comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our consultants, contract
research organizations and other similar entities with which we are working do not successfully carry out their contractual duties,
meet expected deadlines, or comply with applicable regulations, we may be required to replace them. Although we believe that there
are a number of other third-party contractors, we could engage to continue these activities, we may not be able to enter into arrangements
with alternative third-party contractors or to do so on commercially reasonable terms, which may result in a delay of our planned
clinical trials and delayed development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, our third-party
contractors are not our employees, and except for remedies available to us under our agreements with such third-party contractors,
we cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfully
carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the quality or accuracy of the data
they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons,
our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be
able to obtain regulatory approval for, or successfully commercialize, our product candidates on a timely basis, if at all, and
our business, operating results and prospects would be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The antibodies we use in our antibody
radiation-conjugate product candidates may be subject to generic competition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are not aware of any
existing or pending regulations or legislation that pertains to generic radiopharmaceutical products such as our antibody radiation-conjugate
product candidates. Our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these
products pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated
pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal
authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &ldquo;interchangeable&rdquo;
based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved
by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted
and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. Even if a
biosimilar gets approved for one of the antibodies that we use, the final constructs of our drug candidates consist of an antibody,
radioisotope and in some cases a linker. Therefore, we do not believe that the final drug product of our candidates can be subject
to competition from a biosimilar as outlined in BPCIA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our product candidates may never achieve
market acceptance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Iomab-B, CD33 ARC program
candidates and future product candidates that we may develop may never gain market acceptance among physicians, patients and the
medical community. The degree of market acceptance of any of our products will depend on a number of factors, including the actual
and perceived effectiveness and reliability of the product; the results of any long-term clinical trials relating to use of the
product; the availability, relative cost and perceived advantages and disadvantages of alternative technologies; the degree to
which treatments using the product are approved for reimbursement by public and private insurers; the strength of our marketing
and distribution infrastructure; and the level of education and awareness among physicians and hospitals concerning the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that oncologists
and other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical data, and published
peer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other means of treating
specific cancers. Patient studies or clinical experience may indicate that treatment with our product candidates does not provide
patients with sufficient benefits in extension of life or quality of life. We believe that recommendations and support for the
use of each product candidate from influential physicians will be essential for widespread market acceptance. Our product candidates
are still in the development stage and it is premature to attempt to gain support from physicians at this time. We can provide
no assurance that such support will ever be obtained. If our product candidates do not receive such support from these physicians
and from long-term data, physicians may not use or continue to use, and hospitals may not purchase or continue to purchase, them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Failure of Iomab-B, CD33
ARC program candidates or any of our other product candidates to significantly penetrate current or new markets would negatively
impact our business financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be subject to claims that our
third-party service providers, consultants or current or former employees have wrongfully used or disclosed confidential information
of third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have received confidential
and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology
or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have
inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&rsquo; former employers.
Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation
could result in substantial cost and be a distraction to our management and employees.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We currently depend on a single third-party manufacturer to
produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party manufacturer,
or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not currently operate
manufacturing facilities for pre-clinical or clinical production of any of our product candidates. We rely on third-party manufacturers
to supply, store, and distribute pre-clinical and clinical supply of the components of our drug product candidates including monoclonal
antibodies, linkers and radioisotopes, as well as the final construct which comprises our drug product candidates. We expect to
continue to depend on third-party manufacturers for the foreseeable future. Any performance failure on the part of our existing
or future manufacturers could delay clinical development, cause us to suspend or terminate development or delay or prohibit regulatory
approval of our product candidates or commercialization of any approved products. Further avenues of disruption to our clinical
or eventual commercial supply may also occur due to the sale, acquisition, business reprioritization, bankruptcy or other unforeseen
circumstances that might occur at any of our suppliers or contract manufacturing partners including an inability to come to terms
on renewal of existing contracts or new contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently rely on single
manufacturers to manufacture our pre-clinical and clinical trial drug supplies. With a view to maintaining business continuity
we are evaluating alternatives and second and even third sources of supply or manufacturing for our core suppliers and manufacturing
partners, however there can be no assurances that we will be able to identify such suppliers or partners and assuming we did, that
we would be able to enter into contracts that are on favorable terms or on terms that will enable sufficient supply to ensure business
continuity and support our growth plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our product candidates
require precise, high-quality manufacturing. Failure by our current contract manufacturer or other third-party manufacturers we
may engage in the future to achieve and maintain high manufacturing standards could result in patient injury or death, product
recalls or withdrawals, delays or failures in testing or delivery, cost overruns, or other problems that could seriously hurt our
business. Contract manufacturers may encounter difficulties involving production yields, quality control, and quality assurance.
These manufacturers are subject to ongoing periodic and unannounced inspections by the FDA and corresponding state and foreign
agencies to ensure strict compliance with cGMPs and other applicable government regulations and corresponding foreign standards;
we do not have control over third-party manufacturers&rsquo; compliance with these regulations and standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We depend on vendors with
specialized operations, equipment and know-how to manufacture the respective components of our drug candidates. We have entered
into manufacturing and supply agreements with these third-parties, and in some instances, we have agreed that such vendor be the
exclusive manufacturer and supplier. If any of the third-parties we depend on encounter difficulties in their operations, fail
to comply with required regulations or breach their contractual obligations it may be difficult, or we may be unable to identify
suitable alternative third-party manufacturers. While we identify and evaluate third-party manufacturers from time to time, even
if we do identify suitable alternative third-parties, we may fail to reach agreement on contractual terms, it may be prohibitively
expensive and there can be no assurance that we can successfully complete technology transfer and development work necessary or
complete the necessary work in a timely manner. Any of which could prevent us from commencing manufacturing with third-parties.
which could cause delays or suspension of our clinical trials and pre-clinical work that may have a negative impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Furthermore, these third-party
contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shut downs, employee strikes,
or any other unforeseeable acts that may delay or limit production. Our inability to adequately establish, supervise and conduct
(either ourselves or through third parties) all aspects of the formulation and manufacturing processes, and the inability of third-party
manufacturers to consistently supply quality product when required would have a material adverse effect on our ability to develop
or commercialize our products. We have faced delays and risks associated with reliance on key third party manufacturers in the
past and may be faced with such delays and risks in the future. Any future manufacturing interruptions or related supply issues
could have an adverse effect on our company, including delays in clinical trials.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are successful in obtaining marketing
approval from the FDA and/or other regulatory agencies for any of our product candidates, we anticipate continued reliance on third-party
manufacturers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To date, our product candidates
have been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers. If the FDA or other
regulatory agencies approve any of our product candidates for commercial sale, we expect that we would continue to rely, at least
initially, on third-party specialized manufacturers to produce commercial quantities of approved products. These manufacturers
may not be able to successfully increase the manufacturing capacity for any approved product in a timely or economic manner, or
at all. Significant scale-up of manufacturing may require additional validation studies, which the FDA must review and approve.
If third party manufacturers are unable to successfully increase the manufacturing capacity for a product candidate, or we are
unable to establish our own manufacturing capabilities, the commercial launch of any approved products may be delayed or there
may be a shortage in supply, which in turn could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the facilities
used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that
will be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependent
on, our contract manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture
material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities,
they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable
foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws
any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our
ability to develop, obtain regulatory approval for or market our product candidates, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may have conflicts with our partners
that could delay or prevent the development or commercialization of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may have conflicts with
our partners, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the
interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual property
developed during our collaboration. If any conflicts arise with any of our partners, such partner may act in a manner that is averse
to our best interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent
the development or commercialization of our product candidates, and in turn prevent us from generating revenues: unwillingness
on the part of a partner to pay us milestone payments or royalties we believe are due under a collaboration; uncertainty regarding
ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into
additional collaborations; unwillingness by the partner to cooperate in the development or manufacture of the product, including
providing us with product data or materials; unwillingness on the part of a partner to keep us informed regarding the progress
of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating
litigation or alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate
the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We face significant competition from
other biotechnology and pharmaceutical companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our product candidates
face, and will continue to face, intense competition from large pharmaceutical and biotechnology companies, as well as academic
and research institutions. We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving industry
standards, (iii) emerging competition and (iv) new product introductions. Our competitors have existing products and technologies
that will compete with our product candidates and technologies and may develop and commercialize additional products and technologies
that will compete with our product candidates and technologies. Because several competing companies and institutions have greater
financial resources than us, they may be able to (i) provide broader services and product lines, (ii) make greater investments
in research and development, or R&amp;D, and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater development
capabilities than we do and have substantially greater experience in undertaking preclinical and clinical testing of product candidates,
obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. They also have greater name recognition
and better access to customers than us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our product candidates may cause undesirable
side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their
commercial potential, or result in significant negative consequences </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Undesirable side effects
caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could
result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities.
The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result
in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.
Even if any of our product candidates receives marketing approval, as greater numbers of patients use a product following its approval,
an increase in the incidence of side effects or the incidence of other post-approval problems that were not seen or anticipated
during pre-approval clinical trials could result in a number of potentially significant negative consequences, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may withdraw their approval of the product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may elect, or we may be required, to recall or withdraw product from the market;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for harm caused to patients; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any of these events could
substantially increase the costs and expenses of developing, commercializing and marketing any such product candidates or could
harm or prevent sales of any approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We depend upon securing and protecting critical intellectual
property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are dependent on obtaining
and maintaining patents, trade secrets, copyright and trademark protection of our technologies in the United States and other jurisdictions,
as well as successfully enforcing this intellectual property and defending this intellectual property against third-party challenges.
The degree of future protection of our proprietary rights is uncertain for product candidates that are currently in the early stages
of development because we cannot predict which of these product candidates will ultimately reach the commercial market or whether
the commercial versions of these product candidates will incorporate proprietary technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our patent position is highly uncertain
and involves complex legal and factual questions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accordingly, we cannot
predict the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we or our
licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents;
we or our licensors might not have been the first to file patent applications for these inventions; others may independently develop
similar or alternative technologies or duplicate any of our technologies; it is possible that none of our pending patent applications
or the pending patent applications of our licensors will result in issued patents; our issued patents and issued patents of our
licensors may not provide a basis for commercially viable technologies, or may not provide us with any competitive advantages,
or may be challenged and invalidated by third parties; and, we may not develop additional proprietary technologies that are patentable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result, our owned
and licensed patents may not be valid, and we may not be able to obtain and enforce patents and to maintain trade secret protection
for the full commercial extent of our technology. The extent to which we are unable to do so could materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We or our licensors have
applied for and will continue to apply for patents for certain products. Such applications may not result in the issuance of any
patents, and any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore,
it is possible that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitive
position because of such patents, such preferred position would be lost. If we are unable to secure or to continue to maintain
a preferred position, we could become subject to competition from the sale of generic products. Failure to receive, inability to
protect, or expiration of our patents for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies that we
license from third parties, or subsequent related filings, would adversely affect our business and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Patents issued or licensed
to us may be infringed by the products or processes of others. The cost of enforcing our patent rights against infringers, if such
enforcement is required, could be significant, and we do not currently have the financial resources to fund such litigation. Further,
such litigation can go on for years and the time demands could interfere with our normal operations. There has been substantial
litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry. We may
become a party to patent litigation and other proceedings. The cost to us of any patent litigation, even if resolved in our favor,
could be substantial. Some of our competitors may be able to sustain the costs of such litigation more effectively than we can
because of their substantially greater financial resources. Litigation may also absorb significant management time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unpatented trade secrets,
improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success.
Although we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret laws
and the use of confidentiality agreements with our partners, collaborators, employees and consultants and other appropriate means,
these measures may not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently,
or obtain access to, the same or similar information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain of our patent rights
are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights to those patents
may be terminated, and we will be unable to conduct our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are found to be infringing on patents
or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue
the development or sale of our products, and/or pay damages.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our manufacturing processes
and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities
or others, or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are issued,
the risk increases that our processes and potential products may give rise to claims that they infringe the patents or trade secrets
of others. These other persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing
and marketing of the affected product or process. If any of these actions are successful, in addition to any potential liability
for damages, we could be required to obtain a license in order to continue to conduct clinical tests, manufacture or market the
affected product or use the affected process. Required licenses may not be available on acceptable terms, if at all, and the results
of litigation are uncertain. If we become involved in litigation or other proceedings, it could consume a substantial portion of
our financial resources and the efforts of our personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our ability to protect and enforce our
patents does not guarantee that we will secure the right to commercialize our patents.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A patent is a limited monopoly
right conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious
invention. This monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making and/or
using its invention. While a patent gives the holder this right to exclude others, it is not a license to commercialize the invention
where other permissions may be required for commercialization to occur. For example, a drug cannot be marketed without the appropriate
authorization from the FDA, regardless of the existence of a patent covering the product. Further, the invention, even if patented
itself, cannot be commercialized if it infringes the valid patent rights of another party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We rely on confidentiality agreements
to protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become
known to our competitors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We rely on trade secrets
that we seek to protect through confidentiality agreements with our employees and other parties. If these agreements are breached,
our competitors may obtain and use our trade secrets to gain a competitive advantage over us. We may not have any remedies against
our competitors and any remedies that may be available to us may not be adequate to protect our business or compensate us for the
damaging disclosure. In addition, we may have to expend resources to protect our interests from possible infringement by others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The use of hazardous materials, including
radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject
us to liability for claims arising from the use or misuse of these materials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our research, development
and manufacturing activities involve the controlled use of hazardous materials, including chemicals, radioactive and biological
materials, such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulations
governing, among other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot completely
eliminate the risk of contamination or injury from these materials and we could be held liable for any damages that result, which
could exceed our financial resources. We currently maintain insurance coverage for injuries resulting from the hazardous materials
we use; however, future claims may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup
and removal. Currently the costs of complying with such federal, state, local and foreign environmental regulations are not significant,
and consist primarily of waste disposal expenses. However, they could become expensive, and current or future environmental laws
or regulations may impair our research, development, production and commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may undertake international operations,
which will subject us to risks inherent with operations outside of the United States.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we do not have
any international operations at this time, we intend to seek market clearances in foreign markets that we believe will generate
significant opportunities. However, even with the cooperating of a commercialization partner, conducting drug development in foreign
countries involves inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations;
unexpected changes in regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting,
acquiring, enforcing and litigating intellectual property rights; fluctuations in currency exchange rates; and potentially adverse
tax consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we were to experience
any of the difficulties listed above, or any other difficulties, any international development activities and our overall financial
condition may suffer and cause us to reduce or discontinue our international development and registration efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are highly dependent on our key personnel,
and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement
our business strategy. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future operations and
successes depend in large part upon the continued service of key members of our senior management team whom we are highly dependent
upon to manage our business. If any member of our current senior management terminates his employment with us and we are unable
to find a suitable replacement quickly, the departure could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future success also
depends on our ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial, technical, clinical
and regulatory personnel. There can be no assurance that such professionals will be available in the market, or that we will be
able to retain existing professionals or meet or continue to meet their compensation requirements. Furthermore, the cost base in
relation to such compensation, which may include equity compensation, may increase significantly, which could have a material adverse
effect on us. Failure to establish and maintain an effective management team and workforce could adversely affect our ability to
operate, grow and manage our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Managing our growth as we expand operations
may strain our resources.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.55pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to need to grow
rapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our product candidates,
which will place a significant strain on our financial, managerial and operational resources. In order to achieve and manage growth
effectively, we must continue to improve and expand our operational and financial management capabilities. Moreover, we will need
to increase staffing and to train, motivate and manage our employees. All of these activities will increase our expenses and may
require us to raise additional capital sooner than expected. Failure to manage growth effectively could materially harm our business,
financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may expand our business through the
acquisition of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilute
current stockholders&rsquo; ownership interests in our company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business strategy includes
expanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies or technologies to do so.
Acquisitions involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity securities;
incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition;
difficulties in assimilating acquired technologies or the operations of the acquired companies; diverting our management&rsquo;s
attention away from other business concerns; risks of entering markets in which we have limited or no direct experience; and the
potential loss of our key employees or key employees of the acquired companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We can make no assurances
that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired
product, company or business. In addition, our future success would depend in part on our ability to manage the rapid growth associated
with some of these acquisitions. We cannot assure that we will be able to make the combination of our business with that of acquired
products, businesses or companies work or be successful. Furthermore, the development or expansion of our business or any acquired
products, business or companies may require a substantial capital investment by us. We may not have these necessary funds, or they
might not be available to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferred
or common stock, which could dilute each current stockholder&rsquo;s ownership interest in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Risks Related to Ownership of Our Common
Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The sale of securities by us in any equity
or debt financing could result in dilution to our existing stockholders and have a material adverse effect on our earnings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have financed our operations
primarily through sales of stock and warrants. It is likely that during the next twelve months we will seek to raise additional
capital through the sales of stock and warrants in order to expand our level of operations to continue our research and development
efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any sale of common stock
by us in a future offering could result in dilution to our existing stockholders as a direct result of our issuance of additional
shares of our capital stock. In addition, our business strategy may include expansion through internal growth or by establishing
strategic relationships with targeted customers and vendors. In order to do so, or to finance the cost of our other activities,
we may issue additional equity securities that could dilute our stockholders&rsquo; stock ownership. We may also assume additional
debt and incur impairment losses related to goodwill and other tangible assets if we acquire another company and this could negatively
impact our earnings and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our common stock is subject to price
volatility which could lead to losses by stockholders and potential costly security litigation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The trading volume of our
common stock has been and may continue to be extremely limited and sporadic. We expect the market price of our common stock to
fluctuate substantially due to a variety of factors, including market perception of our ability to achieve our planned growth,
quarterly operating results of other companies in the same industry, trading volume in our common stock, changes in general conditions
in the economy and the financial markets or other developments affecting our competitors or us. This volatility has had a significant
effect on the market price of securities issued by many companies for reasons unrelated to their operating performance and could
have the same effect on our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The trading price of our
Common Stock may be highly volatile and could fluctuate in response to factors such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations in our operating results;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of developments by us or our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of IND and/or BLA approval, the completion and/or results of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory actions regarding our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption of new accounting standards affecting our industry;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of new products by us or our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our Common Stock or other securities in the open market; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or factors, many of which are beyond our control.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The stock market is subject
to significant price and volume fluctuations. Moreover, the COVID-19 pandemic has resulted in significant financial market volatility
and uncertainty in recent months. In the past, following periods of volatility in the market price of a company&rsquo;s securities,
securities class action litigation has often been initiated against such a company. Litigation initiated against us, whether or
not successful, could result in substantial costs and diversion of our management&rsquo;s attention and our resources, which could
harm our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We do not intend to pay dividends on
our common stock, so any returns will be determined by the value of our common stock. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have never declared
or paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated from
our operations will be used to finance the growth of our business, and that no dividends will be paid to holders of our common
stock. As a result, the success of an investment in our common stock will depend upon any future appreciation in its value. There
is no guarantee that our common stock will appreciate in value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Certain provisions of our Certificate
of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult
to complete, even if such a transaction were in our stockholders&rsquo; interest.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Provisions of our certificate
of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change
in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions
that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the
price of our stock. Among other things, the certificate of incorporation and bylaws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that the authorized number of directors may be changed by resolution of the board of directors; </FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">divide the board of directors into three classes; </FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and meet specific requirements as to the form and content of a stockholder&rsquo;s notice; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we are governed
by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware corporation from engaging
in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years after the date
of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed
manner. A &ldquo;business combination&rdquo; includes mergers, asset sales or other transactions resulting in a financial benefit
to the stockholder. An &ldquo;interested stockholder&rdquo; is a person who, together with affiliates and associates, owns, or
within three years, did own, 15% or more of the corporation&rsquo;s outstanding voting stock. These provisions may have the effect
of delaying, deferring or preventing a change in our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Compliance with the reporting requirements
of federal securities laws can be expensive.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are subject to the information
and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley
Act. The costs of preparing and filing annual and quarterly reports and other information with the Securities and Exchange Commission
and furnishing audited reports to stockholders are substantial. In addition, we will incur substantial expenses in connection with
the preparation of registration statements and related documents with respect any offerings of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our ability to utilize our net operating
loss carryforwards and certain other tax attributes may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our ability to utilize
our federal net operating loss and tax credit carryforwards may be limited under Sections 382 and 383 of the Internal Revenue Code
of 1986, as amended, or the Code.&nbsp; The limitations apply if we experience an &ldquo;ownership change&rdquo;, generally defined
as a greater than 50 percentage point change in the ownership of our equity by certain stockholders over a rolling three-year period.&nbsp;Similar
provisions of state tax law may also apply. We have not assessed whether such an ownership change has previously occurred.&nbsp;If
we have experienced an ownership change at any time since our formation, we may already be subject to limitations on our ability
to utilize our existing net operating losses and other tax attributes to offset taxable income. In addition, future changes in
our stock ownership, which may be outside of our control, may trigger an ownership change and, consequently, the limitations under
Sections 382 and 383 of the Code.&nbsp;As a result, if or when we earn net taxable income, our ability to use our pre-change net
operating loss carryforwards and other tax attributes to offset such taxable income may be subject to limitations, which could
adversely affect our future cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Failure to establish and maintain adequate
finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and
internal controls requirements for publicly traded companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a public company, we
operate in an increasingly demanding regulatory environment, including with respect to more complex accounting rules. Company responsibilities
required by the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, include establishing and maintaining corporate
oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls
are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our compliance with Section
404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant management efforts.
We complied with Section 404 at December 31, 2019 and 2018 and while our testing did not reveal any material weaknesses in our
internal controls, any material weaknesses in our internal controls in the future would be required us to remediate in a timely
manner so as to be able to comply with the requirements of Section 404 each year. If we are not able to comply with the requirements
of Section 404 in a timely manner each year, we could be subject to sanctions or investigations by the SEC, NYSE American or other
regulatory authorities which would require additional financial and management resources and could adversely affect the market
price of our common stock. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business and results
of operations could be harmed, and investors could lose confidence in our reported financial information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If securities or industry analysts do
not publish research or publish inaccurate or unfavorable research about our business, the price of our common stock and trading
volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The trading market for
our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business.
Multiple securities and industry analysts currently cover us. If one or more of the analysts downgrade our common stock or publish
inaccurate or unfavorable research about our business, the price of our common stock would likely decline. If one or more of these
analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which could
cause the price of our common stock and trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our amended and restated&nbsp;bylaws,
as amended,&nbsp;designate the U.S.&nbsp;federal&nbsp;district courts as the&nbsp;exclusive forum&nbsp;for the resolution of any
complaint asserting a cause of action arising under the Securities Act of 1933, as amended. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our amended and restated&nbsp;bylaws,
as amended,&nbsp;provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts
of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under
the Securities Act of 1933, as amended. In addition, our amended and restated bylaws, as amended, state that any person purchasing
or otherwise acquiring any interest in our security shall be deemed to have notice of and to have consented to such provision.
Such choice of forum provision may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable
for disputes with us or our directors, officers or other employees, which may discourage such lawsuits, if successful, might benefit
our stockholders. Stockholders who do bring a claim in the federal district courts of the United States of America could face additional
litigation costs in pursuing any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_007"></A><B>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_008"></A><B>ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_009"></A><B>ITEM 4. MINE SAFETY DISCLOSURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_010"></A><B>ITEM 5. OTHER INFORMATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrant Modification</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 11, 2020,
the Company entered into an amendment to its warrant (the &ldquo; Amendment&rdquo;) to purchase an aggregate of 1,907 shares of
common stock at an exercise price of $15.61515 per share issued to Sandesh Seth, the Company&rsquo;s Chairman and Chief Executive
Officer, on March 14, 2017 (the &ldquo;Warrants&rdquo;). The Amendment modified Section 10 of the Warrant, removing the anti-dilution
provision thereto. Accordingly, pursuant to the Amendment, the exercise price of the Warrant will no longer be subject to a proportional
adjustment if and when the Company issues any shares of its common stock for a consideration less than the exercise price of the
Warrant. The Amendment is effective as of August 11, 2020. All other terms of the Warrant remained the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Agreements</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Employment Agreement with Sandesh Seth</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 12, 2020, the Company and Sandesh
Seth, the Company&rsquo;s Chairman and Chief Executive Officer, entered into an employment agreement, which replaces that certain
Employment Agreement, dated as of August 8, 2018, between the Company and Mr. Seth. Pursuant to the employment agreement, Mr. Seth
will serve as Chairman and Chief Executive Officer until February 24, 2020, unless terminated earlier as set forth in the employment
agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the employment agreement,
Mr. Seth will be entitled to (i) a base salary, which will be determined by the Board and adjusted to be competitively aligned
to a range between the 25<SUP>th</SUP> and 75<SUP>th</SUP> percentile of the relevant market data of chief executive officer positions
of similarly situated publicly companies, (ii) a performance bonus with a target of 50% of his annual base salary as well as other
multipliers as determined by the Board and (iii) options to purchase shares of common stock of the Company as the Board may grant.
When and if granted, the options will have an exercise price equal to the closing price of the Company&rsquo;s common stock on
the date of the approval, and 2% of the grant will vest each month from the grant date until fully vested, in accordance with the
Company&rsquo;s Amended and Restated 2013 Stock Plan and 2019 Stock Plan. The options will expire 10 years from the grant date,
subject to Mr. Seth&rsquo;s continuing service with the Company. Mr. Seth will also receive the standard benefits available to
other similarly situated employees.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Mr. Seth&rsquo;s employment as Chief
Executive Officer or Chairman are terminated due to death or disability, Mr. Seth will be entitled to earned, but unpaid, salary,
benefits and the Pro-Rated Bonus (as defined herein) for the year of termination. Upon termination of his employment for Cause
(as defined in the employment agreement), or his resignation without Good Reason (as defined in the employment agreement), Mr.
Seth will receive any accrued and unpaid base salary, the Pro-Rated Bonus and benefits through the date of termination.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Company terminates Mr. Seth&rsquo;s
employment without Cause, or if Mr. Seth resigns for Good Reason, Mr. Seth will be entitled to (i) a single lump sum payment equal
to the 24 months of his compensation, (ii) continued health benefits for 24 months, (iii) immediate vesting of all outstanding
equity awards granted to Mr. Seth, and (iv) a single lump sum payment equal to his annual bonus subject to the achievement of the
applicable goals, pro-rated based on the number of days in the Company&rsquo;s fiscal year through the date of termination (the
&ldquo;Pro-Rated Bonus&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, if the Company terminates Mr.
Seth&rsquo;s employment without Cause or if Mr. Seth resigns for Good Reason, or if the Company fails to renew his position as
Chief Executive Officer and Chairman on February 21, 2024, in any case, within the 12-month period beginning on the date of a Change
in Control (as defined in the Company&rsquo;s Amended and Restated 2013 Stock Plan and 2019 Stock Plan), Mr. Seth will be entitled
to (i) a single lump sum payment equal to 30 months of his compensation, (ii) continued health benefits for 30 months, (iii) immediate
vesting of all outstanding equity awards granted to Mr. Seth.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the employment agreement is filed
herewith as Exhibit 10.3 and is incorporated hereby reference. The above description is only a summary of the terms of the employment
agreement and does not purport to be complete description of such document and are qualified in their entirety by reference to
the employment agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Employment Agreement with Steve O&rsquo;Loughlin</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 12, 2020, the Company and Steve
O&rsquo;Loughlin, the Company&rsquo;s Chief Financial Officer, entered into an employment agreement, pursuant to which Mr. O&rsquo;Loughlin
will serve as Chief Financial Officer of the Company. Under the terms of the employment agreement, Mr. O&rsquo;Loughlin will be
entitled to (i) a base salary, which shall be determined by the Board, (ii) a performance bonus, which may be up to 30% of the
annual base salary based upon the achievement of certain objectives such as the Board shall determine and (iii) options to purchase
shares of common stock of the Company as the Board may grant. When and if granted, the options will have an exercise price equal
to the closing price of the Company&rsquo;s common stock on the date of the approval, and 2% of the grant will vest each month
from the grant date until fully vested, in accordance with the Company&rsquo;s Amended and Restated 2013 Stock Plan and 2019 Stock
Plan. The options will expire 10 years from the grant date, subject to Mr. O&rsquo;Loughlin&rsquo;s continuing service with the
Company. Mr. Loughlin will also receive the standard benefits available to other similarly situated employees.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, if the Company terminates Mr.
O&rsquo;Loughlin&rsquo;s employment without Cause (as defined in the employment agreement) or if Mr. O&rsquo;Loughlin resigns for
Good Reason (as defined in the employment agreement), in either case, within the 12-month period beginning on the date of a Change
in Control, Mr. O&rsquo;Loughlin will be entitled to (i) a single lump sum payment equal to his annual base salary, (ii) continued
health benefits for 12 months, (iii) immediate vesting of all outstanding equity awards granted to Mr. O&rsquo;Loughlin.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the employment agreement is filed
herewith as Exhibit 10.2 and is incorporated hereby reference. The above description is only a summary of the terms of the employment
agreement and does not purport to be complete description of such document and are qualified in their entirety by reference to
the employment agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Employment Agreement with Dale Ludwig</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 12, 2020, the Company and Dale
Ludwig, the Company&rsquo;s Chief Scientific and Technology Officer, entered into an employment agreement, pursuant to which Dr.
Ludwig will serve as Chief Scientific and Technology Officer of the Company. Under the terms of the employment agreement, Dr. Ludwig
will be entitled to (i) a base salary, which shall be determined by the Board, (ii) a performance bonus, which may be up to 30%
of the annual base salary based upon the achievement of certain objectives such as the Board shall determine and (iii) options
to purchase shares of common stock of the Company as the Board may grant. When and if granted, the options will have an exercise
price equal to the closing price of the Company&rsquo;s common stock on the date of the approval, and 2% of the grant will vest
each month from the grant date until fully vested, in accordance with the Company&rsquo;s Amended and Restated 2013 Stock Plan
and 2019 Stock Plan. The options will expire 10 years from the grant date, subject to Mr. Ludwig&rsquo;s continuing service with
the Company. Dr. Ludwig will also receive the standard benefits available to other similarly situated employees.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, if the Company terminates Dr.
Ludwig&rsquo;s employment without Cause (as defined in the employment agreement) within the 12-month period beginning on the date
of a Change in Control, Dr. Ludwig will be entitled to (i) a single lump sum payment equal to his annual base salary, (ii) continued
health benefits for 12 months, (iii) immediate vesting of all outstanding equity awards granted to Mr. Ludwig.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the employment agreement is filed
herewith as Exhibit 10.3 and is incorporated hereby reference. The above description is only a summary of the terms of the employment
agreement and does not purport to be complete description of such document and are qualified in their entirety by reference to
the employment agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Employment Agreement with Mark Berger</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 12, 2020, the Company and Mark
Berger, the Company&rsquo;s Chief Medical Officer, entered into an employment agreement, pursuant to which Dr. Berger will serve
as Chief Medical Officer of the Company. Under the terms of the employment agreement, Dr. Berger will be entitled to (i) a base
salary, which shall be determined by the Board, (ii) a performance bonus, which may be up to 30% of the annual base salary based
upon the achievement of certain objectives such as the Board shall determine and (iii) options to purchase shares of common stock
of the Company as the Board may grant. When and if granted, the options will have an exercise price equal to the closing price
of the Company&rsquo;s common stock on the date of the approval, and 2% of the grant will vest each month from the grant date until
fully vested, in accordance with the Company&rsquo;s Amended and Restated 2013 Stock Plan and 2019 Stock Plan. The options will
expire 10 years from the grant date, subject to Dr. Berger&rsquo;s continuing service with the Company. Mr. Berger will also receive
the standard benefits available to other similarly situated employees.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, if the Company terminates Dr.
Berger&rsquo;s employment without Cause (as defined in the employment agreement) within the 12-month period beginning on the date
of a Change in Control, Dr. Berger will be entitled to (i) a single lump sum payment equal to his annual base salary, (ii) continued
health benefits for 12 months, (iii) immediate vesting of all outstanding equity awards granted to Dr. Berger.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the employment agreement is filed
herewith as Exhibit 10.4 and is incorporated hereby reference. The above description is only a summary of the terms of the employment
agreement and does not purport to be complete description of such document and are qualified in their entirety by reference to
the employment agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_011"></A><B>ITEM 6. EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Copies of the following
documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 8%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 82%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of Document</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 8%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Location</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm">Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Form 8-K filed with the SEC on April 17, 2013).</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm">Certificate of Amendment to Certificate of Incorporation filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014).</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 7, 2014).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex3-7_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121ex3-1_actiniumpharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 4.1 to Form 8-K filed on June 16, 2020). </FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws, dated August 8, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342ex3-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to the Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020010060/ea120946ex4-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on April 24, 2020).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015271/ea123189ex4-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Common Stock Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on June 18, 2020).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015271/ea123189ex10-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on June 18, 2020).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10q0620ex10-2_actinium.htm" STYLE="-sec-extract: exhibit">Amendment to Warrant to Purchase Common Stock of Actinium Pharmaceuticals, Inc., dated March 14, 2017, issued to Sandesh Seth</A>.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Attached</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10q0620ex10-3_actinium.htm">Employment Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth.</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Attached</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10q0620ex10-4_actinium.htm">Employment Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc. and Steve O&rsquo;Loughlin.</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Attached</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10q0620ex10-5_actinium.htm">Employment Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc. and Dale Ludwig.</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Attached</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10q0620ex10-6_actinium.htm">Employment Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc. and Mark Berger.</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Attached</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10q0620ex31-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 82%; text-align: justify"><A HREF="f10q0620ex31-2_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10q0620ex32-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10q0620ex32-2_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Financial and Accounting Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance Document</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Schema Document</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Calculation Linkbase Document</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Label Linkbase Document</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Presentation Linkbase Document</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exhibit attached to this Form 10-Q shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange
Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to liability under that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">**</TD><TD STYLE="text-align: justify">Indicates a management contract or compensatory plan.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_012"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 14, 2020</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Sandesh Seth</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer<BR>
(Duly Authorized Officer and<BR>
Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Steve O&rsquo;Loughlin</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer and<BR>
Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">59</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>f10q0620ex10-2_actinium.htm
<DESCRIPTION>AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK OF ACTINIUM PHARMACEUTICALS, INC., DATED MARCH 14, 2017, ISSUED TO SANDESH SETH.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Amendment
to Warrant to purchase common stock of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Actinium
pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This <FONT STYLE="text-transform: uppercase"><B>amendment
to Warrant to purchase common stock oF Actinium pharmaceuticals, Inc.</B></FONT> (this &ldquo;<B><I>Amendment</I></B>&rdquo;) is
effective as of August 12, 2020 (the &ldquo;<B><I>Effective Date</I></B>&rdquo;), and is entered into by and between Sandesh Seth
(the &ldquo;<B><I>Holder</I></B>&rdquo;) and Actinium Pharmaceuticals, Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;). Capitalized
terms not otherwise defined herein shall have the meaning given to such terms in that certain Warrant to Purchase Common Stock
of Actinium Pharmaceuticals, Inc., dated March 14, 2017, by and between the Holder and the Company (the &ldquo;<B><I>Warrant</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, pursuant
to the Warrant, the Company previously granted the Holder the opportunity to acquire up to 57,212 shares (the &ldquo;<B><I>Covered
Shares</I></B>&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;<B><I>Common Stock</I></B>&rdquo;)
pursuant to the Warrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Section
9 of the Warrant provides that the Warrant may only be amended by a writing signed by the parties thereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Company
and the Holder mutually desire and agree to amend the Warrant to remove its anti-dilution provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>,
in accordance with Section 9 of the Warrant and in consideration of the mutual promises, conditions, and covenants contained herein
and in the Warrant, and other good and valuable consideration, the adequacy of which is hereby acknowledged, the parties hereby
agree to amend the Warrant, effective as of the Effective Date, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Warrant is amended by deleting Section 10(c) in its entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as expressly amended by this Amendment, the Warrant shall continue in full force and effect in accordance with the
provisions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Amendment may be executed in two or more counterparts (including by facsimile or portable document format (&ldquo;<B><I>.pdf</I></B>&rdquo;)
counterparts), all of which taken together shall constitute one instrument. The exchange of copies of this Amendment and of signature
pages by facsimile or .pdf transmission shall constitute effective execution and delivery of this Amendment as to the parties and
may be used in lieu of the original document for all purposes. Signatures of the parties transmitted by facsimile or .pdf shall
be deemed to be their original signatures for any purpose whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[Remainder of Page Intentionally Left Blank;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Signature Page Follows]</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS
WHEREOF</B>, the Company and the Holder have executed, or caused to be executed, this Amendment, to be effective as of the
Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>THE COMPANY</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 55%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 35%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium Pharmaceuticals, Inc.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Steve O&rsquo;Loughlin</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THE HOLDER</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Sandesh Seth</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandesh Seth</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 207pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 207pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 207pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 207pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 207pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 207pt; text-align: justify"></P>
<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>f10q0620ex10-3_actinium.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT, DATED AUGUST 12, 2020, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND SANDESH SETH
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">August 12, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sandesh Seth</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">275 Madison Avenue, Suite 702<BR>
New York, NY 10016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Mr. Seth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On behalf of Actinium
Pharmaceuticals, Inc. (the &ldquo;<U>Company</U>&rdquo;), I am pleased to provide you with this contract (the &ldquo;<U>Agreement</U>&rdquo;)
related to your position as Chief Executive Officer and Chairman of the Board of the Company. This Agreement replaces your employment
agreement with the Company dated August 8, 2018 (&ldquo;<U>Prior Agreement</U>&rdquo;). This Agreement sets forth the terms related
to your position as Chief Executive Officer and Chairman of the Board of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. &nbsp;<U>Position</U>.
The terms of your position with the Company are as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &nbsp;You shall serve
as Chief Executive Officer and Chairman of the Board of the Company with such responsibilities, duties and authority as are assigned
to you by the Board of Directors (the &ldquo;<U>Board</U>&rdquo;), or its designee. These responsibilities shall include implementation
of the overall direction of the Company as agreed to with the Board, including, strategic planning, corporate policies, research
and development, staffing, finance, commercial, business development and all aspects of company operations. You shall perform such
other duties and shall have authority consistent with your position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &nbsp;You agree to
devote your best efforts to advance the interests of the Company and to discharge adequately your duties hereunder. Nothing herein
shall prohibit you from being an investor in another company such as a member of a limited liability company, a general or limited
partner of a limited partnership or a stockholder of a corporation, or accepting or continuing in any advisory, or board position
with any other for-profit or non-profit entity, so long as such activities are not in direct competition with the Company&rsquo;s
business nor interfere with the duties of your position with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. &nbsp;<U>Compensation</U>.
The Board shall review the amount of your base salary and performance bonus, and shall determine the appropriate adjustments to
each component of your compensation each calendar year as specified below. As has been customary, the services of an independent
compensation consultant shall be utilized to determine the relevant benchmark companies and provide the market data which the Board
shall use as reference materials in setting compensation in addition to other parameters including overall company performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &nbsp;<U>Base Salary</U>.
Each calendar year the Board will review your base salary and make appropriate adjustments as needed and make its best efforts
to accomplish such review within the first calendar quarter. In doing so, the Board will seek to adjust your base fee is to be
competitively aligned to a range between the 25th (twenty-fifth) and 75th (seventy-fifth) percentile of the relevant market data
of Chief Executive Officer positions of similarly situated publicly traded Biotech companies provided however, that such adjustment
does not represent a reduction in base salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &nbsp;<U>Performance
Bonus</U>. You shall be entitled to participate in a Company annual bonus program for each calendar year of your employment period,
which shall be established by the Board pursuant to which the Board shall award bonuses to you, based upon the achievement of written
individual and corporate objectives such as the Board shall determine in consultation and agreement with you. Upon the attainment
of such performance objectives, in addition to your salary, you shall be entitled to a cash bonus in an amount to be determined
by the Board with a target of fifty percent (50%) of your annual base salary as well as any multiplier that may be deemed appropriate
taking into consideration individual contributions, overall company performance and other industry related benchmarks based on
relevant benchmark companies and market data. The Board shall make its best efforts to determine, award and have the Company pay
out such bonus, if applicable, in the first calendar quarter of the annual period for which the bonus is awarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;<U>Stock Option
Grant</U>. From time to time the Board may grant you an option to purchase common shares of the Company (the &ldquo;<U>Grant</U>&rdquo;).
Unless specified otherwise, the Grant shall be subject to the vesting schedule below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) &nbsp;<U>Stock
Options</U>. Such option will have an exercise price equal to the closing price of the Company&rsquo;s common stock on the date
of Board approval of the Grant, which is equal to fair market value as determined by the Board on the date of the grant (the &ldquo;<U>Grant
Date</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;<U>Vesting
Schedule of the Grant</U>. Two percent (2%) of the Grant shall vest each month from the Grant Date until fully vested in accordance
with the provisions of the Company&rsquo;s Amended and Restated 2013 Stock Plan and 2019 Stock Plan. The term of all option granted
under this Agreement will be for 10 years from the Grant Date, subject to your continuing service with the Company. The option
will be incentive stock options to the maximum extent allowed by the tax code and will be subject to the terms of the Company&rsquo;s
Amended and Restated 2013 Stock Plan and 2019 Stock Plan and corresponding Stock Option Agreement between you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. &nbsp;<U>Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &nbsp;<U>Benefit
Plans</U>. The Company will provide you with the opportunity to participate in the standard benefits plans currently available
to other senior executives, including health, disability and life insurance plans. The Company reserves the right to cancel and/or
change the benefits plans it offers to its participants at any time, subject to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<U>Vacation;
Sick Leave</U>. You will be entitled to 20 days paid vacation per year. Vacation may not be taken before it is accrued. You will
be entitled to 5 days paid sick leave per year. You may carry over a maximum of 5 days of paid vacation days and 5 days of paid
sick leave time vacation and sick leave policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;<U>Reimbursement
of Expenses</U>. You shall be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably
incurred by you on behalf of the Company provided such expenses are documented and submitted in accordance with the reimbursement
policies in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Confidential
Information and Invention Assignment Agreement</U>. You have already executed the Company&rsquo;s Confidential Information and
Invention Assignment Agreement, (the &ldquo;<U>Confidentiality Agreement</U>&rdquo;), which remains in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Term and
Severance</U>. The term of your Chief Executive Officer and Chairman of the Board positions shall be until February 21, 2024, unless
terminated earlier as provided herein. If your employment as Chief Executive Officer or Chairman positions are terminated because
of your death or Disability, the Company&rsquo;s only obligation to you shall be to pay your earned, but unpaid, salary (as of
the date of termination), benefits and the Pro-Rated Bonus for the year of termination (as defined below) and provide you, if eligible,
with the option to elect health coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&ldquo;<U>COBRA</U>&rdquo;);
provided that upon termination of your employment due to death, your estate also shall be entitled to receive a single lump sum
payment equal to three (3) months of your compensation at the rate in effect as of the date of termination, payable within 30 days
of your death. Upon termination of your employment for Cause (as defined below), or your resignation without Good Reason (as defined
below), you shall be paid any accrued and unpaid base salary, the Pro-Rated Bonus and benefits through the date of termination
and shall have no further rights to any compensation or any other benefits under the Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<U>Termination
of Service Other Than for Cause or Resignation for Good Reason (Not in Connection with a Change in Control)</U>. If the Company
terminates your employment or Chairman position other than for Cause or Disability or death, or if you resign for Good Reason,
in any case in circumstances other than those described in Section 5(b), you shall be entitled to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) &nbsp;Subject to
Section 6 hereof, a single lump sum payment equal to twenty-four (24) months of your compensation (at the rate in effect as of
the date of termination), payable on the first payroll date following the date the Release (as defined in Section 6 hereof) becomes
effective and irrevocable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;Subject to
Section 6 hereof, continued health benefits for the 24-month period beginning on the date of termination, with such period to run
concurrently with any period for which you are eligible to elect health coverage under COBRA. During this continuation period,
the Company will subsidize your premiums in an amount equal to what it would have paid toward health insurance premiums for an
active employee with similar coverage. Notwithstanding the foregoing, you shall be required to pay any and all service provider
premiums associated with COBRA coverage and, if you begin providing services to another service recipient and become covered by
such service recipient&rsquo;s health benefits plan or program, the continued health benefits and Company subsidy provided hereunder
shall cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;All outstanding
equity awards granted to you under the Company&rsquo;s equity compensation plans shall become immediately vested and exercisable
(as applicable) as of the date of such termination, the performance goals with respect to such outstanding performance awards,
if any, will deemed satisfied at &ldquo;target&rdquo;, and all outstanding and vested Company stock options (including those that
vest pursuant to the operation of this paragraph) will remain exercisable for the full duration of their term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;Subject to
Section 6 hereof, a single lump sum payment equal to your annual bonus for the year of termination, assuming that the applicable
goals were satisfied at the &ldquo;target&rdquo; level, pro-rated based on the number of days in the Company&rsquo;s fiscal year
through (and including) the date of termination (the &ldquo;<U>Pro-Rated Bonus</U>&rdquo;), payable on the first payroll date following
the date the Release (as defined in Section 6 hereof) becomes effective and irrevocable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<U>Change in
Control</U>. If the Company terminates your employment or Chairman position other than for Cause or Disability or death, or if
you resign for Good Reason, or if the Company fails to renew your position as Chief Executive Officer and Chairman of the Board
on February 21, 2024 under this Agreement and your employment with the Company terminates, in any case during the 12-month period
beginning on the date of a Change in Control (as defined in the Company&rsquo;s 2013 Amended and Restated Stock Plan and 2019 Stock
Plan), you shall be entitled to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;Subject to
Section 6 hereof, a single lump sum payment equal to thirty (30) months of your compensation (at the rate in effect as of the date
of termination), payable on the first payroll date following the date the Release (as defined in Section 6 hereof) becomes effective
and irrevocable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;Subject to
Section 6 hereof, continued health benefits for the 30-month period beginning on the date of termination, with such period to run
concurrently with any period for which you are eligible to elect health coverage under COBRA. During this continuation period,
the Company will subsidize your premiums in an amount equal to what it would have paid toward health insurance premiums for an
active employee with similar coverage. Notwithstanding the foregoing, you shall be required to pay any and all service provider
premiums associated with COBRA coverage and, if you begin providing services to another service recipient and become covered by
such service recipient&rsquo;s health benefits plan or program, the continued health benefits and Company subsidy provided hereunder
shall cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;All outstanding
equity awards granted to you under the Company&rsquo;s equity compensation plans shall become immediately vested and exercisable
(as applicable) as of the date of such termination, the performance goals with respect to such outstanding performance awards,
if any, will deemed satisfied at &ldquo;target&rdquo;, and all outstanding and vested Company stock options (including those that
vest pursuant to the operation of this paragraph) will remain exercisable for the full duration of their term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;Subject to
Section 6 hereof, a single lump sum payment equal to Pro-Rated Bonus, payable on the first payroll date following the date the
Release (as defined in Section 6 hereof) becomes effective and irrevocable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&ldquo;<U>Cause</U>&rdquo;
means: (i) your gross negligence and/or willful misconduct (as such terms are generally understood and applied to the performance
of an executive) in the performance of your material duties with respect to the Company as determined, in each case, by a court
of competent jurisdiction not subject to further appeal or a final arbitration award, as provided hereunder; (ii) the conviction
by you of a crime constituting a felony, or (iii) you shall have committed any material act of malfeasance, dishonesty or breach
of fiduciary duty against the Company, for which you shall have a thirty (30) day cure period following notice thereof from the
Company (except for a conviction pursuant to subsection (ii), for which there shall be no cure period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&ldquo;<U>Good
Reason</U>&rdquo; means: (i) the Company&rsquo;s material breach any of its obligations under this Agreement; (ii) a material reduction
of your base salary or target bonus opportunity; (iii) a material change to the title, scope of your work; (iv) an abandonment
of, or fundamental change in, the primary business or primary products of the Company; (v) the termination, elimination of your
duties as Chief Executive Officer or director or Chairman of the Board of the Company, other than for Cause or voluntary resignation;
(vi) the appointment of a new Chief Executive Officer or Chairman of the Board, or person performing similar duties; or (vii) the
Company&rsquo;s regular requirement that you perform services in or relocate to a location that is outside New York City. A termination
will not be deemed to be for Good Reason unless the Company does not cure within 30 days after receipt of written notice from you
specifying the Good Reason and referring to your right to resign for Good Reason. Any resignation for Good Reason will be effective
immediately upon your giving notice of your resignation for Good Reason to the Company, conditioned upon your having provided proper
notice of Good Reason and time to cure in accordance with this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&ldquo;<U>Disability</U>&rdquo;
means that (i) you have been unable, for a period of 180 consecutive business days, to perform your duties under this Agreement,
as a result of physical or mental illness or injury, and (ii) a physician selected or approved by the Company has determined that
it is either not possible to determine when such inability to perform will cease or that it appears probable that such inability
will be permanent during the remainder of your life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;<U>Mitigation</U>.
In the event that you are entitled to severance pursuant to this Agreement, you have no duty to mitigate and your severance will
not be reduced for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>Release</U>.
Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to provide any severance payment
or benefit under Sections 5(a)(i), 5(a)(ii), 5(a)(iv), 5(b)(i), 5(b)(ii), or 5(b)(iv) hereof unless: (a) you or your legal representative
first executes within 50 calendar days after the date of presentment a release of claims agreement in the form as to be provided
by the Company (the &ldquo;<U>Release</U>&rdquo;) and substantially similar to the form of Release attached hereto as <U>Exhibit
A</U>, (b) you do not revoke the Release, and (c) the Release becomes effective and irrevocable in accordance with its terms. The
Company shall provide the Release to you for your review within ten (10) days of the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>Non-Solicitation</U>.
You agree that during the term of your employment with the Company, and for a period of 24 months following the cessation of employment
with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage any of
the Company&rsquo;s employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing,
either for yourself or any other person or entity. For a period of 24 months following cessation of your employment with the Company
for any reason or no reason, you shall not attempt to negatively influence any of the Company&rsquo;s clients or customers from
purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person
either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution
or other entity in competition with the business of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>Arbitration</U>.
Any dispute or claim arising out of or in connection with your employment with the Company (except with regard to enforcement of
the Confidentiality Agreement) will be finally settled by arbitration in New York, New York in accordance with the Commercial Arbitration
Rules of the American Arbitration Association by one arbitrator appointed in accordance with said rules. Judgment on the award
rendered by the arbitrator may be entered in any court having jurisdiction thereof. The parties agree that this Agreement evidences
a transaction involving interstate commerce and that the operation, interpretation and enforcement of this arbitration provision,
the procedures to be used in conducting an arbitration pursuant to this arbitration provision, and the confirmation of any award
issued to either party by reason of such arbitration, is governed exclusively by the Federal Arbitration Act, 9 U.S.C. &sect; 21
et seq. Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim
equitable relief, or to compel arbitration in accordance with this paragraph, without breach of this arbitration provision. The
Company shall pay all fees and expenses for the arbitration itself; provided that the cost of the arbitrator will be equally divided
between the parties. The Company will pay your legal fees, provided that, if you substantially do not prevail, the Company shall
be reimbursed for your reasonable legal fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Indemnification</U>.
Effective August 7, 2015, you have entered into an Indemnification Agreement with the Company. This agreement shall still remain
in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Section
280G</U>. In the event it shall be determined that any payment or distribution by the Company to or for your benefit (whether paid
or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (the &ldquo;<U>Total Payments</U>&rdquo;),
is or will be subject to the excise tax (the &ldquo;<U>Excise Tax</U>&rdquo;) imposed by Section 4999 of the Internal Revenue Code
of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;), then the Total Payments shall be reduced to the maximum amount that could
be paid to you without giving rise to the Excise Tax (the &ldquo;<U>Safe Harbor Cap</U>&rdquo;), if the net after-tax benefit to
you after reducing your Total Payments to the Safe Harbor Cap is greater than the net after-tax (including the Excise Tax) benefit
to you without such reduction. The reduction of the amounts payable hereunder, if applicable, shall be made by reducing such payment
that trigger the Excise Tax in the following order: (i) reduction of cash payments, (ii) cancellation of accelerated vesting of
performance-based equity awards (based on the reverse order of the date of grant), (iii) cancellation of accelerated vesting of
other equity awards (based on the reverse order of the date of grant), and (iv) reduction of any other payments due to you (with
benefits or payments in any group having different payment terms being reduced on a pro-rata basis). All mathematical determinations,
and all determinations as to whether any of the Total Payments are &ldquo;parachute payments&rdquo; (within the meaning of Section
280G of the Code), that are required to be made under this paragraph, including determinations as to whether the Total Payments
to you shall be reduced to the Safe Harbor Cap and the assumptions to be utilized in arriving at such determinations, shall be
made at the Company&rsquo;s expense by the Company&rsquo;s then current independent auditors, or such other nationally recognized
accounting firm selected by the Committee prior to the relevant change in control transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11. &nbsp;<U>Section
409A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<U>In General</U>.
It is the Company&rsquo;s intent that this Agreement be exempt from the application of, or otherwise comply with, the requirements
of Section 409A of the Code (&ldquo;<U>Section 409A</U>&rdquo;). Specifically, any taxable benefits or payments provided under
this Agreement are intended to be separate payments that qualify for the &ldquo;short-term deferral&rdquo; exception to Section
409A to the maximum extent possible, and to the extent they do not so qualify, are intended to qualify for the involuntary separation
pay exceptions to Section 409A, to the maximum extent possible. If neither of these exceptions applies, and if you are a &ldquo;specified
employee&rdquo; within the meaning of Section 409A, then notwithstanding any provision in this Agreement to the contrary and to
the extent required to comply with Section 409A, all amounts that would otherwise be paid or provided to you during the first six
(6) months following your date of termination shall instead be accumulated through and paid or provided (without interest) on the
first business day following the six-month anniversary of the date of termination. If the period during which the Release must
become effective and irrevocable in accordance with its terms spans two calendar years, then, to the extent required to comply
with Section 409A, any payment to be made under this Agreement will commence on the first payroll date that occurs in the second
calendar year and after the Release has become effective and irrevocable in accordance with its terms. Further, to the extent required
to comply with Section 409A: (i) the amount of any expense reimbursement to which you may be entitled hereunder during a calendar
year will not affect the amount of reimbursements to be provided in any other calendar year; (ii) your right to receive reimbursement
of an eligible expense hereunder is not subject to liquidation or exchange for another benefit; and (iii) provided that the requisite
documentation is submitted, the Company will reimburse your eligible expenses on or before the last day of the calendar year following
the calendar year in which the expense was incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<U>Separation
from Service</U>. A termination of service shall not be deemed to have occurred for purposes of any provision of this Agreement
providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of service unless
such termination is also a &ldquo;separation from service&rdquo; within the meaning of Section 409A and you are no longer providing
services (at a level that would preclude the occurrence of a &ldquo;separation from service&rdquo; within the meaning of Section
409A) to the Company or its affiliates as an employee or consultant, and for purposes of any such provision of this Plan, references
to a &ldquo;termination,&rdquo; &ldquo;termination of employment&rdquo; or like terms shall mean &ldquo;separation from service&rdquo;
within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Attorneys&rsquo;
Fees</U>. Should either party hereto, or any heir, personal representative, successor or assign of either party hereto, resort
to legal proceedings in connection with this Agreement, the party or parties prevailing in such legal proceedings shall be entitled,
in addition to such other relief as may be granted, to recover its or their reasonable attorneys&rsquo; fees and costs in such
legal proceedings from the non-prevailing party or parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>Assistance
in Litigation</U>. You shall, during and after termination of employment, upon reasonable notice, furnish such information and
proper assistance to the Company as may reasonably be required by the Company in connection with any litigation in which it or
any of its subsidiaries or affiliates is, or may become a party; provided, however, that such assistance following termination
shall be furnished at mutually agreeable times and for mutually agreeable compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<U>Miscellaneous</U>.
This Agreement, together with the Confidentiality Agreement, and Indemnification Agreement sets forth the terms of your employment
with the Company and supersedes any prior representations or agreements, whether written or oral. This Agreement may not be modified
or amended except by a written agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement
will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is
held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity,
illegality or unenforceability will be lessened or reduced to the extent possible or will be severed and will not affect any other
provision and this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable
provision had never been contained herein. This Agreement will be governed by New York law without reference to rules of conflicts
of law. All notices, requests, demands and other communications called for hereunder shall be in writing and shall be deemed given
(i) on the date of delivery if delivered personally, (ii) one (1) day after being sent by a well established commercial overnight
service, (iii) three (3) days after being mailed by registered or certified mail, return receipt requested, prepaid and addressed
to the parties or their successors at the following addresses, or at such other addresses as the parties may later designate in
writing, (iv) upon confirmation of facsimile transfer, if sent by facsimile or (v) upon confirmation of delivery when directed
to the electronic mail address set forth below, if sent by electronic mail:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 1.5in"><FONT STYLE="font-size: 10pt">If to the Company:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">275 Madison Avenue, Suite 702</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">New York, NY 10016</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">If to you:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Sandesh Seth</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">275 Madison Avenue, Suite 702</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">New York, NY 10016</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<U>Withholding
of Taxes</U>. The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as
the Company may be required to withhold pursuant to any law or government regulation or ruling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To indicate your acceptance
of the Company&rsquo;s offer, please sign and date this letter in the space provided below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCEPTED AND AGREED:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SANDESH SETH</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman Compensation Committee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: August 12, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August 12, 2020</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>RELEASE OF CLAIMS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>FOR AND IN CONSIDERATION
OF</B> the payments and benefits (the &ldquo;<U>Separation Benefits</U>&rdquo;) to be provided to me in connection with the separation
of my relationship with the Company, in accordance with the Agreement between Actinium Pharmaceuticals, Inc. (the &ldquo;<U>Company</U>&rdquo;)
and me dated as August 12, 2020 (the &ldquo;<U>Agreement</U>&rdquo;), which Separation Benefits are conditioned on my signing this
Release of Claims (&ldquo;<U>Release</U>&rdquo;) and which I will forfeit unless I execute and do not revoke this Release of Claims,
I, on my own behalf and on behalf of my heirs and estate, voluntarily, knowingly and willingly release and forever discharge the
Company, its subsidiaries, affiliates, parents, and stockholders, together with each of those entities&rsquo; respective officers,
directors, stockholders, employees, agents, fiduciaries and administrators (collectively, the &ldquo;<U>Releasees</U>&rdquo;) from
any and all claims and rights of any nature whatsoever which I now have against them up to the date I execute this Release, whether
known or unknown, suspected or unsuspected. This Release includes, but is not limited to, any rights or claims relating in any
way to my employment or consulting relationship with the Company or any of the other Releasees or the termination thereof, any
contract claims (express or implied, written or oral), including, but not limited to, the Agreement, or any rights or claims under
any statute, including, without limitation, the Americans with Disabilities Act, the Age Discrimination in Employment Act, the
Older Workers&rsquo; Benefit Protection Act, the Rehabilitation Act of 1973 (including Section 504 thereof), Title VII of the 1964
Civil Rights Act, the Civil Rights Act of 1866 (42 U.S.C. &sect; 1981), the Civil Rights Act of 1991, the Equal Pay Act, the National
Labor Relations Act, the Worker Adjustment and Retraining Notification Act, the Family Medical Leave Act, the Lilly Ledbetter Fair
Pay Act, the Genetic Information Non-Discrimination Act, the New York State Human Rights Law, the New York City Human Rights Law,
and the Employee Retirement Income Security Act of 1974, all as amended, and any other federal, state or local law. This Release
specifically includes, but is not limited to, any claims based upon the right to the payment of wages, incentive and performance
compensation, bonuses, equity grants, vacation, pension benefits, 401(k) Plan benefits, stock benefits or any other employee benefits,
or any other rights arising under federal, state or local laws prohibiting discrimination and/or harassment on the basis of race,
color, age, religion, sexual orientation, religious creed, sex, national origin, ancestry, alienage, citizenship, nationality,
mental or physical disability, denial of family and medical care leave, medical condition (including cancer and genetic characteristics),
marital status, military status, gender identity, harassment or any other basis prohibited by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition of the
Company entering into this Release, I further represent that I have not filed against the Company or any of the other Releasees,
any complaints, claims or lawsuits with any arbitral tribunal, administrative agency, or court prior to the date hereof, and that
I have not transferred to any other person any such complaints, claims or lawsuits. I understand that by signing this Release,
I waive my right to any monetary recovery in connection with a local, state or federal governmental agency proceeding and I waive
my right to file a claim seeking monetary damages in any arbitral tribunal, administrative agency, or court. This Release does
not: (i) prohibit or restrict me from communicating, providing relevant information to or otherwise cooperating with the U.S. Equal
Employment Opportunity Commission or any other governmental authority with responsibility for the administration of fair employment
practices laws regarding a possible violation of such laws or responding to any inquiry from such authority, including an inquiry
about the existence of this Release or its underlying facts, or (ii) require me to notify the Company of such communications or
inquiry. Furthermore, notwithstanding the foregoing, this Release does not include and will not preclude: (a) rights or claims
to vested benefits under any applicable retirement and/or pension plans; (b) rights under the Consolidated Omnibus Budget Reconciliation
Act of 1985 (&ldquo;<U>COBRA</U>&rdquo;); (c) claims for unemployment compensation; (d) rights to defense and indemnification,
if any, from the Company for actions or inactions taken by me in the course and scope of my employment with the Company and its
parents, subsidiaries and/or affiliates; (e) any rights I may have to obtain contribution as permitted by law in the event of entry
of judgment against the Company as a result of any act or failure to act for which I and the Company are held jointly liable; (f)
the right to any equity awards that vested prior to or because of the termination of my employment, and/or (g) any actions to enforce
the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing herein shall
be construed to limit my right to (1) respond accurately and fully to any question, inquiry or request for information when required
by legal process; or (2) disclose information to regulatory bodies. I understand that I am not required to contact the Company
before engaging in such communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I acknowledge that,
in signing this Release, I have not relied on any promises or representations, express or implied, other than those that are set
forth expressly herein or in the Agreement and that are intended to survive separation from employment, in accordance with the
terms of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I further acknowledge
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;I first received
this Release on the date of the Agreement to which it is attached as Exhibit A;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;I understand
that, in order for this Release to be effective, I may not sign it prior to the date of my separation of employment with the Company
but that if I wish to receive the Separation Benefits, I must sign and return this Release within [21/45] days of its presentation
to me after my termination of employment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;I have carefully
read and understand this Release;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;The Company
advised me to consult with an attorney and/or any other advisors of my choice before signing this Release;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;I understand
that this Release is <B>LEGALLY BINDING</B> and by signing it I give up certain rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;I have voluntarily
chosen to enter into this Release and have not been forced or pressured in any way to sign it;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;I acknowledge
and agree that the Separation Benefits are contingent on execution of this Release, which releases all of my claims against the
Company and the Releasees, and <B>I KNOWINGLY AND VOLUNTARILY AGREE TO RELEASE</B> the Company and the Releasees from any and all
claims I may have, known or unknown, in exchange for the benefits I have obtained by signing, and that these benefits are in addition
to any benefit I would have otherwise received if I did not sign this Release;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;I have seven
(7) days after I sign this Release to revoke it by notifying the Company in writing. The Release will not become effective or enforceable
until the seven (7) day revocation period has expired;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;This Release
includes a <B>WAIVER OF ALL RIGHTS AND CLAIMS</B> I may have under the Age Discrimination in Employment Act of 1967 (29 U.S.C.
&sect;621 et seq.); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;This Release
does not waive any rights or claims that may arise after this Release becomes effective, which is seven (7) days after I sign it,
provided that I do not exercise my right to revoke this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intending to be legally bound, I have signed
this Release as of the date written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 10%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 30%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 20%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date Signed:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 30%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>f10q0620ex10-4_actinium.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT, DATED AUGUST 12, 2020, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND STEVE O'LOUGHLIN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="ex10-4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
12, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
O&rsquo;Loughlin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275
Madison Avenue, Suite 702</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Mr. O&rsquo;Loughlin,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of Actinium Pharmaceuticals, Inc. (the &ldquo;<U>Company</U>&rdquo;), I am pleased to provide you with this contract (the
&ldquo;<U>Agreement</U>&rdquo;) related to your position as Chief Financial Officer of the Company. This Agreement replaces and
supersedes the employment agreement between you and the Company dated August 8, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Position</U>.
The terms of your position with the Company are as set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) You
shall serve as Chief Financial Officer. You shall report to the Chief Executive Officer or appropriate company officer, as designated
by the CEO, the Board of Directors of the Company (the &ldquo;<U>Board</U>&rdquo;) or its representative, and shall perform your
duties for the Company at the Company&rsquo;s offices in New York City or at another location as directed by the Company in accordance
with its policies that may be in place from time to time, except for travel that may be necessary or appropriate in connection
with the performance of your duties hereunder. The offices of the Company are currently located in New York City at 275 Madison
Avenue, 7<SUP>th</SUP>&nbsp;Floor, New York, NY 10016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) You
agree to devote your best efforts and substantially all of your business time to advance the interests of the Company and to discharge
adequately your duties hereunder. You may perform certain consulting projects that do not interfere with your Company duties and
maintain whatever licenses required for performance of such consulting activities. Consulting activities must be non-competitive
with the Company&rsquo;s plans, disclosed and approved on a case by case basis by your direct supervisor or an authorized Company
representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;<U>Compensation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
 Base Salary. The Board shall review the amount of your base salary and performance bonus,
and shall determine the appropriate adjustments to each component of your compensation each calendar year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
 Performance Bonus. You shall be entitled to participate in an executive bonus program,
which shall be established by the Board pursuant to which the Board may award bonuses to you of up to 30% of your annual base
salary, based upon the achievement of written individual and corporate objectives such as the Board shall determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Stock Option Grant</U>. From time to time the Board may grant you an option to purchase common shares of the Company (the &ldquo;<U>Grant</U>&rdquo;).
Unless specified otherwise, the Grant shall be subject to the vesting schedule below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
 <U>Stock Options</U>. Such option will have an exercise price equal to the closing price
of the Company&rsquo;s common stock on the date of Board approval of the Grant, which is equal to fair market value as determined
by the Board on the date of the grant (the &ldquo;<U>Grant Date</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) <U>Vesting
Schedule of the Grant</U>. Two percent (2%) of the Grant shall vest each month from the Grant Date until fully vested in accordance
with the provisions of the Company&rsquo;s Amended and Restated 2013 Stock Plan and 2019 Stock Plan. The term of all option granted
under this Agreement will be for 10 years from the Grant Date, subject to your continuing service with the Company. The option
will be incentive stock options to the maximum extent allowed by the tax code and will be subject to the terms of the Company&rsquo;s
Amended and Restated 2013 Stock Plan or 2019 Stock Plan and corresponding Stock Option Agreement between you and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;<U>Benefits</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Benefit
Plans</U>. The Company will provide you with the opportunity to participate in the standard benefit plans currently available
to other similarly situated employees, including health, disability and life insurance plans. The Company reserves the right to
cancel and/or change the benefits plans it offers to its employees at any time, subject to applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Vacation;
Sick Leave</U>. You will be entitled to 20 days paid vacation per year. Vacation may not be taken before it is accrued. You will
be entitled to 5 days paid sick leave per year. You may carry over a maximum of 5 days of paid vacation days and 5 days of paid
sick leave time in accordance with the Company&rsquo;s vacation and sick leave policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Reimbursement
of Expenses.</U>&nbsp;You shall be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably
incurred by you on behalf of the Company provided such expenses are documented and submitted in accordance with the reimbursement
policies in effect from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Change in Control</U>. If the Company terminates your employment other than for death, Disability or Cause, or if you resign
for Good Reason, in any case during the 12-month period beginning on the date of a Change in Control (as defined in the Company&rsquo;s
Amended and Restated 2013 Stock Plan and 2019 Stock Plan), you shall be entitled to the following, subject to Section 5 hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
 A single lump sum payment equal to twelve (12) months of your annual base salary (at
the rate in effect as of the date of termination), payable within thirty (30) business days following the date the Release (as
defined in Section 5 hereof) becomes effective and irrevocable in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
 Continued health benefits for the 12-month period beginning on the date of termination,
with such period to run concurrently with any period for which you are eligible to elect health coverage under COBRA. During this
12-month continuation period, the Company will subsidize your COBRA premiums in an amount equal to what it would have paid toward
health insurance premiums for an active employee with similar coverage. Notwithstanding the foregoing, you shall be required to
pay any and all service provider premiums associated with COBRA coverage and, if you begin providing services to another service
recipient and become covered by such service recipient&rsquo;s health benefits plan or program, the continued health benefits
and Company subsidy provided hereunder shall cease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
 All outstanding equity awards granted to you under the Company&rsquo;s equity compensation
plans shall become immediately vested and exercisable (as applicable) as of the date of such termination, the performance goals
with respect to such outstanding performance awards, if any, will deemed satisfied at &ldquo;target&rdquo;, and all outstanding
and vested Company stock options (including those that vest pursuant to the operation of this paragraph) will remain exercisable
for the full duration of their term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
 &ldquo;<U>Cause</U>&rdquo; means: (i) your gross negligence and/or willful misconduct
(as such terms are generally understood and applied to the performance of an executive) in the performance of your material duties
with respect to the Company as determined, in each case, by a court of competent jurisdiction not subject to further appeal or
a final arbitration award, as provided hereunder; (ii) the conviction by you of a crime constituting a felony, or (iii) you shall
have committed any material act of malfeasance, dishonesty or breach of fiduciary duty against the Company, for which you shall
have a thirty (30) day cure period following notice thereof from the Company (except for a conviction pursuant to subsection (ii),
for which there shall be no cure period).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) &ldquo;<U>Good
Reason</U>&rdquo; means, during the 12-month period beginning on the date of a Change in Control: (i) the Company&rsquo;s material
breach of any of its obligations under this Agreement; (ii) a material reduction of your base salary or target bonus opportunity;
(iii) a material change to the scope of your work; or (iv) the Company&rsquo;s regular requirement that you perform services in
or relocate to a location that is more than twenty-five (25) miles from New York City. A termination will not be deemed to be
for Good Reason unless the Company does not cure within 30 days after receipt of written notice from you specifying the Good Reason
and referring to your right to resign for Good Reason. Any resignation for Good Reason will be effective immediately upon your
giving notice of your resignation for Good Reason to the Company, conditioned upon your having provided proper notice of Good
Reason and time to cure in accordance with this provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
 &ldquo;<U>Disability</U>&rdquo; means that (i) you have been unable, for a period of
180 consecutive business days, to perform your duties under this Agreement, as a result of physical or mental illness or injury,
and (ii) a physician selected or approved by the Company has determined that it is either not possible to determine when such
inability to perform will cease or that it appears probable that such inability will be permanent during the remainder of your
life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) <U>Mitigation. </U>In
the event that you are entitled to severance pursuant to this Agreement, you have no duty to mitigate and your severance will
not be reduced for any reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;<U>Release</U>.
Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to provide any severance payment
or benefit under Section 4(a), (b) or (c) hereof unless: (a) you or your legal representative first executes within fifty (50)
calendar days after the date of presentment a release of claims agreement in the form as to be provided by the Company (the &ldquo;<U>Release</U>&rdquo;)
and substantially similar to the form of Release attached hereto as Exhibit A, (b) you do not revoke the Release, and (c) the
Release becomes effective and irrevocable in accordance with its terms. The Company shall provide the Release to you for your
review within ten (10) days of the date of termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;<U>Confidential
Information and Invention Assignment Agreement</U>. You have already executed the Company&rsquo;s Confidential Information and
Invention Assignment Agreement (the &ldquo;<U>Confidentiality Agreement</U>&rdquo;), which remains in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;<U>At-Will
Employment</U>. Your employment with the Company will be on an &ldquo;at will&rdquo; basis, meaning that either you or the Company
may terminate your employment at any time for any reason or no reason, without further obligation or liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;<U>Non-Competition</U>.
During the term and for a period of three (3) years thereafter, you shall not, either directly or indirectly, engage (as principal,
partner, employee, consultant, owner, independent contractor, advisor or otherwise, with or without compensation) in any business
that directly or indirectly competes with the Company (the &ldquo;<U>Competing Business</U>&rdquo;). Notwithstanding the foregoing,
this does not prevent you from being engaged or employed with a business that has a Competing Business as part of its business,
so long as you are not engaged or involved in any way in the Competing Business at such business or enterprise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;<U>Non-Solicitation</U>.
You agree that during the term of your employment with the Company, and for a period of 24 months following the cessation of employment
with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage any of
the Company&rsquo;s employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing,
either for yourself or any other person or entity. For a period of 24 months following cessation of employment with the Company
for any reason or no reason, you shall not attempt to negatively influence any of the Company&rsquo;s clients or customers from
purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person
either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution
or other entity in competition with the business of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;<U>Arbitration</U>.
Any dispute or claim arising out of or in connection with your employment with the Company (except with regard to enforcement
of the Confidentiality Agreement) will be finally settled by arbitration in New York, New York in accordance with the Commercial
Arbitration Rules of the American Arbitration Association by one arbitrator appointed in accordance with said rules. Judgment
on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The parties agree that this Agreement
evidences a transaction involving interstate commerce and that the operation, interpretation and enforcement of this arbitration
provision, the procedures to be used in conducting an arbitration pursuant to this arbitration provision, and the confirmation
of any award issued to either party by reason of such arbitration, is governed exclusively by the Federal Arbitration Act, 9 U.S.C.
&sect; 21 et seq. Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for preliminary
or interim equitable relief, or to compel arbitration in accordance with this paragraph, without breach of this arbitration provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Section 280G</U>. In the event it shall be determined that any payment or distribution by the Company to or for your benefit
(whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (the &ldquo;<U>Total
Payments</U>&rdquo;), is or will be subject to the excise tax (the &ldquo;<U>Excise Tax</U>&rdquo;) imposed by Section 4999 of
the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;), then the Total Payments shall be reduced to the
maximum amount that could be paid to you without giving rise to the Excise Tax (the &ldquo;<U>Safe Harbor Cap</U>&rdquo;), if
the net after-tax benefit to you after reducing your Total Payments to the Safe Harbor Cap is greater than the net after-tax (including
the Excise Tax) benefit to you without such reduction. The reduction of the amounts payable hereunder, if applicable, shall be
made by reducing such payment that trigger the Excise Tax in the following order: (i) reduction of cash payments, (ii) cancellation
of accelerated vesting of performance-based equity awards (based on the reverse order of the date of grant), (iii) cancellation
of accelerated vesting of other equity awards (based on the reverse order of the date of grant), and (iv) reduction of any other
payments due to you (with benefits or payments in any group having different payment terms being reduced on a pro-rata basis).
All mathematical determinations, and all determinations as to whether any of the Total Payments are &ldquo;parachute payments&rdquo;
(within the meaning of Section 280G of the Code), that are required to be made under this paragraph, including determinations
as to whether the Total Payments to you shall be reduced to the Safe Harbor Cap and the assumptions to be utilized in arriving
at such determinations, shall be made at the Company&rsquo;s expense by the Company&rsquo;s then current independent auditors,
or such other nationally recognized accounting firm selected by the Committee prior to the relevant change in control transaction.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&nbsp;<U>Section
409A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>In
General</U>. It is the Company&rsquo;s intent that this Agreement be exempt from the application of, or otherwise comply
with, the requirements of Section 409A of the Code (&ldquo;<U>Section 409A</U>&rdquo;). Specifically, any taxable benefits or
payments provided under this Agreement are intended to be separate payments that qualify for the &ldquo;short-term
deferral&rdquo; exception to Section 409A to the maximum extent possible, and to the extent they do not so qualify, are
intended to qualify for the involuntary separation pay exceptions to Section 409A, to the maximum extent possible. If neither
of these exceptions applies, and if you are a &ldquo;specified employee&rdquo; within the meaning of Section 409A, then
notwithstanding any provision in this Agreement to the contrary and to the extent required to comply with Section 409A, all
amounts that would otherwise be paid or provided to you during the first six (6) months following your date of termination
shall instead be accumulated through and paid or provided (without interest) on the first business day following the
six-month anniversary of the date of termination. If the period during which the Release must become effective and
irrevocable in accordance with its terms spans two calendar years, then, to the extent required to comply with Section 409A,
any payment to be made under this Agreement will commence on the first payroll date that occurs in the second calendar year
and after the Release has become effective and irrevocable in accordance with its terms. Further, to the extent required to
comply with Section 409A: (i) the amount of any expense reimbursement to which you may be entitled hereunder during a
calendar year will not affect the amount of reimbursements to be provided in any other calendar year; (ii) your right to
receive reimbursement of an eligible expense hereunder is not subject to liquidation or exchange for another benefit; and
(iii) provided that the requisite documentation is submitted, the Company will reimburse your eligible expenses on or before
the last day of the calendar year following the calendar year in which the expense was incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Separation
from Service</U>. A termination of service shall not be deemed to have occurred for purposes of any provision of this
Agreement providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of
service unless such termination is also a &ldquo;separation from service&rdquo; within the meaning of Section 409A and you
are no longer providing services (at a level that would preclude the occurrence of a &ldquo;separation from service&rdquo;
within the meaning of Section 409A) to the Company or its affiliates as an employee or consultant, and for purposes of any
such provision of this Plan, references to a &ldquo;termination,&rdquo; &ldquo;termination of employment&rdquo; or like terms
shall mean &ldquo;separation from service&rdquo; within the meaning of Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&nbsp;<U>Miscellaneous.</U>&nbsp;This
Agreement, together with the Confidentiality Agreement, sets forth the terms of your employment with the Company and supersedes
any prior representations or agreements, whether written or oral. This Agreement may not be modified or amended except by a written
agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement will be interpreted in such manner
as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable
in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will be lessened
or reduced to the extent possible or will be severed and will not affect any other provision and this Agreement will be reformed,
construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.
This Agreement will be governed by New York law without reference to rules of conflicts of law. All notices, requests, demands
and other communications called for hereunder shall be in writing and shall be deemed given (i) on the date of delivery if delivered
personally, (ii) one (1) day after being sent by a well established commercial overnight service, (iii) three (3) days after being
mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at
the following addresses, or at such other addresses as the parties may later designate in writing, (iv) upon confirmation of facsimile
transfer, if sent by facsimile or (v) upon confirmation of delivery when directed to the electronic mail address set forth below,
if sent by electronic mail:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to the Company:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275 Madison Avenue,
    Suite 702</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10016</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to you:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
        O&rsquo;Loughlin</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275
        Madison Avenue, Suite 702</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
        York, NY 10016</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>Withholding of Taxes</U>. The Company may withhold from any amounts payable under this Agreement all federal, state, city or
other taxes as the Company may be required to withhold pursuant to any law or government regulation or ruling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
indicate your acceptance of the Company&rsquo;s offer, please sign and date this letter in the space provided below and return
it to me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM
    PHARMACEUTICALS, INC. &nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">Sandesh Seth</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; font-size: 10pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted and Agreed:</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Steve
    O&rsquo;Loughlin</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RELEASE
OF CLAIMS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
AND IN CONSIDERATION OF</B> the payments and benefits (the &ldquo;<U>Separation Benefits</U>&rdquo;) to be provided to me in connection
with the separation of my relationship with the Company, in accordance with the Agreement between Actinium Pharmaceuticals, Inc.
(the &ldquo;<U>Company</U>&rdquo;) and me dated as August 12, 2020 (the &ldquo;<U>Agreement</U>&rdquo;), which Separation Benefits
are conditioned on my signing this Release of Claims (&ldquo;<U>Release</U>&rdquo;) and which I will forfeit unless I execute
and do not revoke this Release of Claims, I, on my own behalf and on behalf of my heirs and estate, voluntarily, knowingly and
willingly release and forever discharge the Company, its subsidiaries, affiliates, parents, and stockholders, together with each
of those entities&rsquo; respective officers, directors, stockholders, employees, agents, fiduciaries and administrators (collectively,
the &ldquo;<U>Releasees</U>&rdquo;) from any and all claims and rights of any nature whatsoever which I now have against them
up to the date I execute this Release, whether known or unknown, suspected or unsuspected. This Release includes, but is not limited
to, any rights or claims relating in any way to my employment or consulting relationship with the Company or any of the other
Releasees or the termination thereof, any contract claims (express or implied, written or oral), including, but not limited to,
the Agreement, or any rights or claims under any statute, including, without limitation, the Americans with Disabilities Act,
the Age Discrimination in Employment Act, the Older Workers&rsquo; Benefit Protection Act, the Rehabilitation Act of 1973 (including
Section 504 thereof), Title VII of the 1964 Civil Rights Act, the Civil Rights Act of 1866 (42 U.S.C. &sect; 1981), the Civil
Rights Act of 1991, the Equal Pay Act, the National Labor Relations Act, the Worker Adjustment and Retraining Notification Act,
the Family Medical Leave Act, the Lilly Ledbetter Fair Pay Act, the Genetic Information Non-Discrimination Act, the New York State
Human Rights Law, the New York City Human Rights Law, and the Employee Retirement Income Security Act of 1974, all as amended,
and any other federal, state or local law. This Release specifically includes, but is not limited to, any claims based upon the
right to the payment of wages, incentive and performance compensation, bonuses, equity grants, vacation, pension benefits, 401(k)
Plan benefits, stock benefits or any other employee benefits, or any other rights arising under federal, state or local laws prohibiting
discrimination and/or harassment on the basis of race, color, age, religion, sexual orientation, religious creed, sex, national
origin, ancestry, alienage, citizenship, nationality, mental or physical disability, denial of family and medical care leave,
medical condition (including cancer and genetic characteristics), marital status, military status, gender identity, harassment
or any other basis prohibited by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition of the Company entering into this Release, I further represent that I have not filed against the Company or any of
the other Releasees, any complaints, claims or lawsuits with any arbitral tribunal, administrative agency, or court prior to the
date hereof, and that I have not transferred to any other person any such complaints, claims or lawsuits. I understand that by
signing this Release, I waive my right to any monetary recovery in connection with a local, state or federal governmental agency
proceeding and I waive my right to file a claim seeking monetary damages in any arbitral tribunal, administrative agency, or court.
This Release does not: (i) prohibit or restrict me from communicating, providing relevant information to or otherwise cooperating
with the U.S. Equal Employment Opportunity Commission or any other governmental authority with responsibility for the administration
of fair employment practices laws regarding a possible violation of such laws or responding to any inquiry from such authority,
including an inquiry about the existence of this Release or its underlying facts, or (ii) require me to notify the Company of
such communications or inquiry. Furthermore, notwithstanding the foregoing, this Release does not include and will not preclude:
(a) rights or claims to vested benefits under any applicable retirement and/or pension plans; (b) rights under the Consolidated
Omnibus Budget Reconciliation Act of 1985 (&ldquo;<U>COBRA</U>&rdquo;); (c) claims for unemployment compensation; (d) rights to
defense and indemnification, if any, from the Company for actions or inactions taken by me in the course and scope of my employment
with the Company and its parents, subsidiaries and/or affiliates; (e) any rights I may have to obtain contribution as permitted
by law in the event of entry of judgment against the Company as a result of any act or failure to act for which I and the Company
are held jointly liable; (f) the right to any equity awards that vested prior to or because of the termination of my employment,
and/or (g) any actions to enforce the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
herein shall be construed to limit my right to (1) respond accurately and fully to any question, inquiry or request for information
when required by legal process; or (2) disclose information to regulatory bodies. I understand that I am not required to contact
the Company before engaging in such communications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
acknowledge that, in signing this Release, I have not relied on any promises or representations, express or implied, other than
those that are set forth expressly herein or in the Agreement and that are intended to survive separation from employment, in
accordance with the terms of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
further acknowledge that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. I
first received this Release on the date of the Agreement to which it is attached as Exhibit A;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. I
understand that, in order for this Release to be effective, I may not sign it prior to the date of my separation of employment
with the Company but that if I wish to receive the Separation Benefits, I must sign and return this Release within [21/45] days
of its presentation to me after my termination of employment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. I
have carefully read and understand this Release;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. The
Company advised me to consult with an attorney and/or any other advisors of my choice before signing this Release;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. I
understand that this Release is <B>LEGALLY BINDING</B> and by signing it I give up certain rights;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. I
have voluntarily chosen to enter into this Release and have not been forced or pressured in any way to sign it;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. I
acknowledge and agree that the Separation Benefits are contingent on execution of this Release, which releases all of my claims
against the Company and the Releasees, and <B>I KNOWINGLY AND VOLUNTARILY AGREE TO RELEASE</B> the Company and the Releasees from
any and all claims I may have, known or unknown, in exchange for the benefits I have obtained by signing, and that these benefits
are in addition to any benefit I would have otherwise received if I did not sign this Release;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8. I
have seven (7) days after I sign this Release to revoke it by notifying the Company in writing. The Release will not become effective
or enforceable until the seven (7) day revocation period has expired;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9. This
Release includes a <B>WAIVER OF ALL RIGHTS AND CLAIMS</B> I may have under the Age Discrimination in Employment Act of 1967 (29
U.S.C. &sect;621 et seq.); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10. This
Release does not waive any rights or claims that may arise after this Release becomes effective, which is seven (7) days after
I sign it, provided that I do not exercise my right to revoke this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intending
to be legally bound, I have signed this Release as of the date written below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%">Signature:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 10%">Date&nbsp;Signed:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>f10q0620ex10-5_actinium.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT, DATED AUGUST 12, 2020, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND DALE LUDWIG
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.5</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-5_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">August 12, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Dale Ludwig</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">275 Madison Avenue, Suite 702</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Dr. Ludwig,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On behalf of Actinium
Pharmaceuticals, Inc. (the &ldquo;<U>Company</U>&rdquo;), I am pleased to provide you with this contract (the &ldquo;<U>Agreement</U>&rdquo;)
related to your position as Chief Scientific and Technology Officer of the Company. This Agreement replaces and supersedes the
employment agreement between you and the Company dated October 16, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.&nbsp;<U>Position</U>. The terms of your
position with the Company are as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;You
shall serve as Chief Scientific and Technology Officer. You shall report to the Chief Executive Officer or appropriate company
officer, as designated by the CEO, the Board of Directors of the Company (the &ldquo;<U>Board</U>&rdquo;) or its representative,
and shall perform your duties for the Company at the Company&rsquo;s offices in New York City, or at another location as directed
by the Company in accordance with its policies that may be in place from time to time, except for travel that may be necessary
or appropriate in connection with the performance of your duties hereunder. The offices of the Company are currently located in
New York City at 275 Madison Avenue, 7<SUP>th</SUP>&nbsp;Floor, New York, NY 10016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;You
agree to devote your best efforts and substantially all of your business time to advance the interests of the Company and to discharge
adequately your duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;<U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<U>Base
Salary</U>. The Board shall review the amount of your base salary and performance bonus, and shall determine the appropriate adjustments
to each component of your compensation each calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<U>Performance
Bonus</U>. You shall be entitled to participate in an executive bonus program, which shall be established by the Board pursuant
to which the Board may award bonuses to you of up to 30% of your annual base salary, based upon the achievement of written individual
and corporate objectives such as the Board shall determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Stock
Option Grant</U>. From time to time the Board may grant you an option to purchase common shares of the Company (the &ldquo;<U>Grant</U>&rdquo;).
Unless specified otherwise, the Grant shall be subject to the vesting schedule below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in">(i) &nbsp;<U>Stock
Options</U>. Such option will have an exercise price equal to the closing price of the Company&rsquo;s common stock on the date
of Board approval of the Grant, which is equal to fair market value as determined by the Board on the date of the grant (the &ldquo;<U>Grant
Date</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in">(ii)&nbsp;<U>Vesting
Schedule of the Grant</U>. Two percent (2%) of the Grant shall vest each month from the Grant Date until fully vested in accordance
with the provisions of the Company&rsquo;s Amended and Restated 2013 Stock Plan and 2019 Stock Plan. The term of all option granted
under this Agreement will be for 10 years from the Grant Date, subject to your continuing service with the Company. The option
will be incentive stock options to the maximum extent allowed by the tax code and will be subject to the terms of the Company&rsquo;s
Amended and Restated 2013 Stock Plan or 2019 Stock Plan and corresponding Stock Option Agreement between you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.&nbsp;<U>Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<U>Benefit
Plans</U>. The Company will provide you with the opportunity to participate in the standard benefit plans currently available to
other similarly situated employees, including health, disability and life insurance plans. The Company reserves the right to cancel
and/or change the benefits plans it offers to its employees at any time, subject to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<U>Vacation;
Sick Leave</U>. You will be entitled to 20 days paid vacation per year. Vacation may not be taken before it is accrued. You will
be entitled to 5 days paid sick leave per year. You may carry over a maximum of 5 days of paid vacation days and 5 days of paid
sick leave time in accordance with the Company&rsquo;s vacation and sick leave policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;<U>Reimbursement
of Expenses.</U>&nbsp;You shall be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably
incurred by you on behalf of the Company provided such expenses are documented and submitted in accordance with the reimbursement
policies in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. <U>Change in Control</U>.
If the Company terminates your employment other than for death, Disability or Cause during the 12-month period beginning on the
date of a Change in Control (as defined in the Company&rsquo;s Amended and Restated 2013 Stock Plan and 2019 Stock Plan), you shall
be entitled to the following, subject to Section 5 hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) &nbsp;A
single lump sum payment equal to twelve (12) months of your annual base salary (at the rate in effect as of the date of termination),
payable within thirty (30) business days following the date the Release (as defined in Section 5 hereof) becomes effective and
irrevocable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) &nbsp;Continued
health benefits for the 12-month period beginning on the date of termination, with such period to run concurrently with any period
for which you are eligible to elect health coverage under COBRA. During this 12-month continuation period, the Company will subsidize
your COBRA premiums in an amount equal to what it would have paid toward health insurance premiums for an active employee with
similar coverage. Notwithstanding the foregoing, you shall be required to pay any and all service provider premiums associated
with COBRA coverage and, if you begin providing services to another service recipient and become covered by such service recipient&rsquo;s
health benefits plan or program, the continued health benefits and Company subsidy provided hereunder shall cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c) &nbsp;All
outstanding equity awards granted to you under the Company&rsquo;s equity compensation plans shall become immediately vested and
exercisable (as applicable) as of the date of such termination, the performance goals with respect to such outstanding performance
awards, if any, will deemed satisfied at &ldquo;target&rdquo;, and all outstanding and vested Company stock options (including
those that vest pursuant to the operation of this paragraph) will remain exercisable for the full duration of their term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(d) &nbsp;&ldquo;<U>Cause</U>&rdquo;
means: (i) your gross negligence and/or willful misconduct (as such terms are generally understood and applied to the performance
of an executive) in the performance of your material duties with respect to the Company as determined, in each case, by a court
of competent jurisdiction not subject to further appeal or a final arbitration award, as provided hereunder; (ii) the conviction
by you of a crime constituting a felony, or (iii) you shall have committed any material act of malfeasance, dishonesty or breach
of fiduciary duty against the Company, for which you shall have a thirty (30) day cure period following notice thereof from the
Company (except for a conviction pursuant to subsection (ii), for which there shall be no cure period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(e) &ldquo;<U>Disability</U>&rdquo;
means that (i) you have been unable, for a period of 180 consecutive business days, to perform your duties under this Agreement,
as a result of physical or mental illness or injury, and (ii) a physician selected or approved by the Company has determined that
it is either not possible to determine when such inability to perform will cease or that it appears probable that such inability
will be permanent during the remainder of your life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(f)&nbsp;<U>Mitigation.</U>
In the event that you are entitled to severance pursuant to this Agreement, you have no duty to mitigate and your severance will
not be reduced for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Release</U>.
Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to provide any severance payment
or benefit under Section 4(a), (b) or (c) hereof unless: (a) you or your legal representative first executes within fifty (50)
calendar days after the date of presentment a release of claims agreement in the form as to be provided by the Company (the &ldquo;<U>Release</U>&rdquo;)
and substantially similar to the form of Release attached hereto as Exhibit A, (b) you do not revoke the Release, and (c) the Release
becomes effective and irrevocable in accordance with its terms. The Company shall provide the Release to you for your review within
ten (10) days of the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;6.&nbsp;<U>Confidential
Information and Invention Assignment Agreement</U>. By signing this Agreement, you hereby acknowledge and reaffirm your obligations
under the Company&rsquo;s Confidential Information and Invention Assignment Agreement, a copy of which you previously signed (the
&ldquo;<U>Confidentiality Agreement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>At-Will
Employment</U>. Your employment with the Company will be on an &ldquo;at will&rdquo; basis, meaning that either you or the Company
may terminate your employment at any time for any reason or no reason, without further obligation or liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>Non-Competition</U>.
During the term and for a period of three (3) years thereafter, you shall not, either directly or indirectly, engage (as principal,
partner, employee, consultant, owner, independent contractor, advisor or otherwise, with or without compensation) in any business
that directly or indirectly competes with the Company (the &ldquo;<U>Competing Business</U>&rdquo;). Notwithstanding the foregoing,
this does not prevent you from being engaged or employed with a business that has a Competing Business as part of its business,
so long as you are not engaged or involved in any way in the Competing Business at such business or enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Non-Solicitation</U>.
You agree that during the term of your employment with the Company, and for a period of 24 months following the cessation of employment
with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage any of
the Company&rsquo;s employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing,
either for yourself or any other person or entity. For a period of 24 months following cessation of employment with the Company
for any reason or no reason, you shall not attempt to negatively influence any of the Company&rsquo;s clients or customers from
purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person
either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution
or other entity in competition with the business of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Arbitration</U>.
Any dispute or claim arising out of or in connection with your employment with the Company (except with regard to enforcement of
the Confidentiality Agreement) will be finally settled by arbitration in New York, New York in accordance with the Commercial Arbitration
Rules of the American Arbitration Association by one arbitrator appointed in accordance with said rules. Judgment on the award
rendered by the arbitrator may be entered in any court having jurisdiction thereof. The parties agree that this Agreement evidences
a transaction involving interstate commerce and that the operation, interpretation and enforcement of this arbitration provision,
the procedures to be used in conducting an arbitration pursuant to this arbitration provision, and the confirmation of any award
issued to either party by reason of such arbitration, is governed exclusively by the Federal Arbitration Act, 9 U.S.C. &sect; 21
et seq. Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim
equitable relief, or to compel arbitration in accordance with this paragraph, without breach of this arbitration provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;<U>Section
280G</U>. In the event it shall be determined that any payment or distribution by the Company to or for your benefit (whether paid
or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (the &ldquo;<U>Total Payments</U>&rdquo;),
is or will be subject to the excise tax (the &ldquo;<U>Excise Tax</U>&rdquo;) imposed by Section 4999 of the Internal Revenue Code
of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;), then the Total Payments shall be reduced to the maximum amount that could
be paid to you without giving rise to the Excise Tax (the &ldquo;<U>Safe Harbor Cap</U>&rdquo;), if the net after-tax benefit to
you after reducing your Total Payments to the Safe Harbor Cap is greater than the net after-tax (including the Excise Tax) benefit
to you without such reduction. The reduction of the amounts payable hereunder, if applicable, shall be made by reducing such payment
that trigger the Excise Tax in the following order: (i) reduction of cash payments, (ii) cancellation of accelerated vesting of
performance-based equity awards (based on the reverse order of the date of grant), (iii) cancellation of accelerated vesting of
other equity awards (based on the reverse order of the date of grant), and (iv) reduction of any other payments due to you (with
benefits or payments in any group having different payment terms being reduced on a pro-rata basis). All mathematical determinations,
and all determinations as to whether any of the Total Payments are &ldquo;parachute payments&rdquo; (within the meaning of Section
280G of the Code), that are required to be made under this paragraph, including determinations as to whether the Total Payments
to you shall be reduced to the Safe Harbor Cap and the assumptions to be utilized in arriving at such determinations, shall be
made at the Company&rsquo;s expense by the Company&rsquo;s then current independent auditors, or such other nationally recognized
accounting firm selected by the Committee prior to the relevant change in control transaction.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Section
409A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<U>In General</U>.
It is the Company&rsquo;s intent that this Agreement be exempt from the application of, or otherwise comply with, the requirements
of Section 409A of the Code (&ldquo;<U>Section 409A</U>&rdquo;). Specifically, any taxable benefits or payments provided under
this Agreement are intended to be separate payments that qualify for the &ldquo;short-term deferral&rdquo; exception to Section
409A to the maximum extent possible, and to the extent they do not so qualify, are intended to qualify for the involuntary separation
pay exceptions to Section 409A, to the maximum extent possible. If neither of these exceptions applies, and if you are a &ldquo;specified
employee&rdquo; within the meaning of Section 409A, then notwithstanding any provision in this Agreement to the contrary and to
the extent required to comply with Section 409A, all amounts that would otherwise be paid or provided to you during the first six
(6) months following your date of termination shall instead be accumulated through and paid or provided (without interest) on the
first business day following the six-month anniversary of the date of termination. If the period during which the Release must
become effective and irrevocable in accordance with its terms spans two calendar years, then, to the extent required to comply
with Section 409A, any payment to be made under this Agreement will commence on the first payroll date that occurs in the second
calendar year and after the Release has become effective and irrevocable in accordance with its terms. Further, to the extent required
to comply with Section 409A: (i) the amount of any expense reimbursement to which you may be entitled hereunder during a calendar
year will not affect the amount of reimbursements to be provided in any other calendar year; (ii) your right to receive reimbursement
of an eligible expense hereunder is not subject to liquidation or exchange for another benefit; and (iii) provided that the requisite
documentation is submitted, the Company will reimburse your eligible expenses on or before the last day of the calendar year following
the calendar year in which the expense was incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<U>Separation
from Service</U>. A termination of service shall not be deemed to have occurred for purposes of any provision of this Agreement
providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of service unless
such termination is also a &ldquo;separation from service&rdquo; within the meaning of Section 409A and you are no longer providing
services (at a level that would preclude the occurrence of a &ldquo;separation from service&rdquo; within the meaning of Section
409A) to the Company or its affiliates as an employee or consultant, and for purposes of any such provision of this Plan, references
to a &ldquo;termination,&rdquo; &ldquo;termination of employment&rdquo; or like terms shall mean &ldquo;separation from service&rdquo;
within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>Miscellaneous.</U>&nbsp;This
Agreement, together with the Confidentiality Agreement, sets forth the terms of your employment with the Company and supersedes
any prior representations or agreements, whether written or oral. This Agreement may not be modified or amended except by a written
agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement will be interpreted in such manner
as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable
in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will be lessened
or reduced to the extent possible or will be severed and will not affect any other provision and this Agreement will be reformed,
construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.
This Agreement will be governed by New York law without reference to rules of conflicts of law. All notices, requests, demands
and other communications called for hereunder shall be in writing and shall be deemed given (i) on the date of delivery if delivered
personally, (ii) one (1) day after being sent by a well established commercial overnight service, (iii) three (3) days after being
mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at the
following addresses, or at such other addresses as the parties may later designate in writing, (iv) upon confirmation of facsimile
transfer, if sent by facsimile or (v) upon confirmation of delivery when directed to the electronic mail address set forth below,
if sent by electronic mail:</P>
<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275 Madison Avenue, Suite 702</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10016</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to you:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dale L. Ludwig, Ph.D.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275 Madison Avenue, Suite 702</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10016</FONT></TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14. <U>Withholding
of Taxes</U>. The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as
the Company may be required to withhold pursuant to any law or government regulation or ruling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To indicate your acceptance
of the Company&rsquo;s offer, please sign and date this letter in the space provided below and return it to me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted and Agreed:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Dale Ludwig</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>RELEASE OF CLAIMS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>FOR AND IN CONSIDERATION
OF</B> the payments and benefits (the &ldquo;<U>Separation Benefits</U>&rdquo;) to be provided to me in connection with the separation
of my relationship with the Company, in accordance with the Agreement between Actinium Pharmaceuticals, Inc. (the &ldquo;<U>Company</U>&rdquo;)
and me dated as August 12, 2020 (the &ldquo;<U>Agreement</U>&rdquo;), which Separation Benefits are conditioned on my signing this
Release of Claims (&ldquo;<U>Release</U>&rdquo;) and which I will forfeit unless I execute and do not revoke this Release of Claims,
I, on my own behalf and on behalf of my heirs and estate, voluntarily, knowingly and willingly release and forever discharge the
Company, its subsidiaries, affiliates, parents, and stockholders, together with each of those entities&rsquo; respective officers,
directors, stockholders, employees, agents, fiduciaries and administrators (collectively, the &ldquo;<U>Releasees</U>&rdquo;) from
any and all claims and rights of any nature whatsoever which I now have against them up to the date I execute this Release, whether
known or unknown, suspected or unsuspected. This Release includes, but is not limited to, any rights or claims relating in any
way to my employment or consulting relationship with the Company or any of the other Releasees or the termination thereof, any
contract claims (express or implied, written or oral), including, but not limited to, the Agreement, or any rights or claims under
any statute, including, without limitation, the Americans with Disabilities Act, the Age Discrimination in Employment Act, the
Older Workers&rsquo; Benefit Protection Act, the Rehabilitation Act of 1973 (including Section 504 thereof), Title VII of the 1964
Civil Rights Act, the Civil Rights Act of 1866 (42 U.S.C. &sect; 1981), the Civil Rights Act of 1991, the Equal Pay Act, the National
Labor Relations Act, the Worker Adjustment and Retraining Notification Act, the Family Medical Leave Act, the Lilly Ledbetter Fair
Pay Act, the Genetic Information Non-Discrimination Act, the New York State Human Rights Law, the New York City Human Rights Law,
and the Employee Retirement Income Security Act of 1974, all as amended, and any other federal, state or local law. This Release
specifically includes, but is not limited to, any claims based upon the right to the payment of wages, incentive and performance
compensation, bonuses, equity grants, vacation, pension benefits, 401(k) Plan benefits, stock benefits or any other employee benefits,
or any other rights arising under federal, state or local laws prohibiting discrimination and/or harassment on the basis of race,
color, age, religion, sexual orientation, religious creed, sex, national origin, ancestry, alienage, citizenship, nationality,
mental or physical disability, denial of family and medical care leave, medical condition (including cancer and genetic characteristics),
marital status, military status, gender identity, harassment or any other basis prohibited by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition of the
Company entering into this Release, I further represent that I have not filed against the Company or any of the other Releasees,
any complaints, claims or lawsuits with any arbitral tribunal, administrative agency, or court prior to the date hereof, and that
I have not transferred to any other person any such complaints, claims or lawsuits. I understand that by signing this Release,
I waive my right to any monetary recovery in connection with a local, state or federal governmental agency proceeding and I waive
my right to file a claim seeking monetary damages in any arbitral tribunal, administrative agency, or court. This Release does
not: (i) prohibit or restrict me from communicating, providing relevant information to or otherwise cooperating with the U.S. Equal
Employment Opportunity Commission or any other governmental authority with responsibility for the administration of fair employment
practices laws regarding a possible violation of such laws or responding to any inquiry from such authority, including an inquiry
about the existence of this Release or its underlying facts, or (ii) require me to notify the Company of such communications or
inquiry. Furthermore, notwithstanding the foregoing, this Release does not include and will not preclude: (a) rights or claims
to vested benefits under any applicable retirement and/or pension plans; (b) rights under the Consolidated Omnibus Budget Reconciliation
Act of 1985 (&ldquo;<U>COBRA</U>&rdquo;); (c) claims for unemployment compensation; (d) rights to defense and indemnification,
if any, from the Company for actions or inactions taken by me in the course and scope of my employment with the Company and its
parents, subsidiaries and/or affiliates; (e) any rights I may have to obtain contribution as permitted by law in the event of entry
of judgment against the Company as a result of any act or failure to act for which I and the Company are held jointly liable; (f)
the right to any equity awards that vested prior to or because of the termination of my employment, and/or (g) any actions to enforce
the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing herein shall
be construed to limit my right to (1) respond accurately and fully to any question, inquiry or request for information when required
by legal process; or (2) disclose information to regulatory bodies. I understand that I am not required to contact the Company
before engaging in such communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I acknowledge that,
in signing this Release, I have not relied on any promises or representations, express or implied, other than those that are set
forth expressly herein or in the Agreement and that are intended to survive separation from employment, in accordance with the
terms of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I further acknowledge
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;I
first received this Release on the date of the Agreement to which it is attached as Exhibit A;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;I
understand that, in order for this Release to be effective, I may not sign it prior to the date of my separation of employment
with the Company but that if I wish to receive the Separation Benefits, I must sign and return this Release within [21/45] days
of its presentation to me after my termination of employment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;I
have carefully read and understand this Release;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;The
Company advised me to consult with an attorney and/or any other advisors of my choice before signing this Release;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;I
understand that this Release is <B>LEGALLY BINDING</B> and by signing it I give up certain rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;I
have voluntarily chosen to enter into this Release and have not been forced or pressured in any way to sign it;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;I
acknowledge and agree that the Separation Benefits are contingent on execution of this Release, which releases all of my claims
against the Company and the Releasees, and <B>I KNOWINGLY AND VOLUNTARILY AGREE TO RELEASE</B> the Company and the Releasees from
any and all claims I may have, known or unknown, in exchange for the benefits I have obtained by signing, and that these benefits
are in addition to any benefit I would have otherwise received if I did not sign this Release;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;I
have seven (7) days after I sign this Release to revoke it by notifying the Company in writing. The Release will not become effective
or enforceable until the seven (7) day revocation period has expired;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;This
Release includes a <B>WAIVER OF ALL RIGHTS AND CLAIMS</B> I may have under the Age Discrimination in Employment Act of 1967 (29
U.S.C. &sect;621 et seq.); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;This
Release does not waive any rights or claims that may arise after this Release becomes effective, which is seven (7) days after
I sign it, provided that I do not exercise my right to revoke this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intending to be legally bound, I have signed
this Release as of the date written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 10%; font-size-adjust: none; font-stretch: normal">Signature:</TD>
    <TD STYLE="white-space: nowrap; width: 30%; border-bottom: black 1.5pt solid; font-size-adjust: none; font-stretch: normal">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 20%; font-size-adjust: none; font-stretch: normal">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; font-size-adjust: none; font-stretch: normal">Date&nbsp;Signed:&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 30%; border-bottom: black 1.5pt solid; font-size-adjust: none; font-stretch: normal">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>6
<FILENAME>f10q0620ex10-6_actinium.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT, DATED AUGUST 12, 2020, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND MARK BERGER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.6</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-6_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
12, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
S. Berger, M.D.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275
Madison Avenue, Suite 702</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Dr. Berger,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of Actinium Pharmaceuticals, Inc. (the &ldquo;<U>Company</U>&rdquo;), I am pleased to provide you with this contract (the
&ldquo;<U>Agreement</U>&rdquo;) related to your position as Chief Medical Officer of the Company. This Agreement replaces and
supersedes the employment agreement between you and the Company dated December 27, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;<U>Position</U>.
The terms of your position with the Company are as set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
You shall continue to serve as Chief Medical Officer. You shall report to the Chief Executive Officer or appropriate company officer,
as designated by the CEO, the Board of Directors of the Company (the &ldquo;<U>Board</U>&rdquo;) or its representative, and shall
perform your duties for the Company at the Company&rsquo;s offices in New York City, or at another location as directed by the
Company in accordance with its policies that may be in place from time to time, except for travel that may be necessary or appropriate
in connection with the performance of your duties hereunder. The offices of the Company are currently located in New York City
at 275 Madison Avenue, 7<SUP>th</SUP>&nbsp;Floor, New York, NY 10016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
You agree to devote your best efforts and substantially all of your business time to advance the interests of the Company and
to discharge adequately your duties hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;<U>Compensation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Base Salary</U>. The Board shall review the amount of your base salary and performance bonus, and shall determine the appropriate
adjustments to each component of your compensation each calendar year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Performance Bonus</U>. You shall be entitled to participate in an executive bonus program, which shall be established by the
Board pursuant to which the Board may award bonuses to you of up to 30% of your annual base salary, based upon the achievement
of written individual and corporate objectives such as the Board shall determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Stock Option Grant</U>. From time to time the Board may grant you an option to purchase common shares of the Company (the &ldquo;<U>Grant</U>&rdquo;).
Unless specified otherwise, the Grant shall be subject to the vesting schedule below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Stock Options</U>. Such option will have an exercise price equal to the closing price of the Company&rsquo;s common stock on
the date of Board approval of the Grant, which is equal to fair market value as determined by the Board on the date of the grant
(the &ldquo;<U>Grant Date</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Vesting Schedule of the Grant</U>. Two percent (2%) of the Grant shall vest each month from the Grant Date until fully vested
in accordance with the provisions of the Company&rsquo;s Amended and Restated 2013 Stock Plan and 2019 Stock Plan. The term of
all option granted under this Agreement will be for 10 years from the Grant Date, subject to your continuing service with the
Company. The option will be incentive stock options to the maximum extent allowed by the tax code and will be subject to the terms
of the Company&rsquo;s Amended and Restated 2013 Stock Plan or 2019 Stock Plan and corresponding Stock Option Agreement between
you and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;<U>Benefits</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Benefit Plans</U>. The Company will provide you with the opportunity to participate in the standard benefit plans currently
available to other similarly situated employees, including health, disability and life insurance plans. The Company reserves the
right to cancel and/or change the benefits plans it offers to its employees at any time, subject to applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Vacation; Sick Leave</U>. You will be entitled to 20 days paid vacation per year. Vacation may not be taken before it is accrued.
You will be entitled to 5 days paid sick leave per year. You may carry over a maximum of 5 days of paid vacation days and 5 days
of paid sick leave time in accordance with the Company&rsquo;s vacation and sick leave policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Reimbursement of Expenses.</U>&nbsp;You shall be reimbursed for all normal items of travel and entertainment and miscellaneous
expenses reasonably incurred by you on behalf of the Company provided such expenses are documented and submitted in accordance
with the reimbursement policies in effect from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Change in Control</U>. If the Company terminates your employment other than for death, Disability or Cause during the 12-month
period beginning on the date of a Change in Control (as defined in the Company&rsquo;s Amended and Restated 2013 Stock Plan and
2019 Stock Plan), you shall be entitled to the following, subject to Section 5 hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
A single lump sum payment equal to twelve (12) months of your annual base salary (at the rate in effect as of the date of termination),
payable within thirty (30) business days following the date the Release (as defined in Section 5 hereof) becomes effective and
irrevocable in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Continued health benefits for the 12-month period beginning on the date of termination, with such period to run concurrently with
any period for which you are eligible to elect health coverage under COBRA. During this 12-month continuation period, the Company
will subsidize your COBRA premiums in an amount equal to what it would have paid toward health insurance premiums for an active
employee with similar coverage. Notwithstanding the foregoing, you shall be required to pay any and all service provider premiums
associated with COBRA coverage and, if you begin providing services to another service recipient and become covered by such service
recipient&rsquo;s health benefits plan or program, the continued health benefits and Company subsidy provided hereunder shall
cease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
All outstanding equity awards granted to you under the Company&rsquo;s equity compensation plans shall become immediately vested
and exercisable (as applicable) as of the date of such termination, the performance goals with respect to such outstanding performance
awards, if any, will deemed satisfied at &ldquo;target&rdquo;, and all outstanding and vested Company stock options (including
those that vest pursuant to the operation of this paragraph) will remain exercisable for the full duration of their term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&ldquo;<U>Cause</U>&rdquo; means: (i) your gross negligence and/or willful misconduct (as such terms are generally understood
and applied to the performance of an executive) in the performance of your material duties with respect to the Company as determined,
in each case, by a court of competent jurisdiction not subject to further appeal or a final arbitration award, as provided hereunder;
(ii) the conviction by you of a crime constituting a felony, or (iii) you shall have committed any material act of malfeasance,
dishonesty or breach of fiduciary duty against the Company, for which you shall have a thirty (30) day cure period following notice
thereof from the Company (except for a conviction pursuant to subsection (ii), for which there shall be no cure period).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&ldquo;<U>Disability</U>&rdquo; means that (i) you have been unable, for a period of 180 consecutive business days, to perform
your duties under this Agreement, as a result of physical or mental illness or injury, and (ii) a physician selected or approved
by the Company has determined that it is either not possible to determine when such inability to perform will cease or that it
appears probable that such inability will be permanent during the remainder of your life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Mitigation.</U> In the event that you are entitled to severance pursuant to this Agreement, you have no duty to mitigate and
your severance will not be reduced for any reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;<U>Release</U>.
Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to provide any severance payment
or benefit under Section 4(a), (b) or (c) hereof unless: (a) you or your legal representative first executes within fifty (50)
calendar days after the date of presentment a release of claims agreement in the form as to be provided by the Company (the &ldquo;<U>Release</U>&rdquo;)
and substantially similar to the form of Release attached hereto as Exhibit A, (b) you do not revoke the Release, and (c) the
Release becomes effective and irrevocable in accordance with its terms. The Company shall provide the Release to you for your
review within ten (10) days of the date of termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;6.&nbsp;<U>Confidential
Information and Invention Assignment Agreement</U>. By signing this Agreement, you hereby acknowledge and reaffirm your obligations
under the Company&rsquo;s Confidential Information and Invention Assignment Agreement, a copy of which you previously signed (the
&ldquo;<U>Confidentiality Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;<U>At-Will
Employment</U>. Your employment with the Company will be on an &ldquo;at will&rdquo; basis, meaning that either you or the Company
may terminate your employment at any time for any reason or no reason, without further obligation or liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;<U>Non-Competition</U>.
During the term and for a period of three (3) years thereafter, you shall not, either directly or indirectly, engage (as principal,
partner, employee, consultant, owner, independent contractor, advisor or otherwise, with or without compensation) in any business
that directly or indirectly is developing, or plans to develop, radioimmunotherapy for cancer or any therapy related to bone marrow
transplant (the &ldquo;<U>Competing Business</U>&rdquo;). Notwithstanding the foregoing, this does not prevent you from being
engaged or employed with a business that has a Competing Business as part of its business, so long as you are not engaged or involved
in any way in the Competing Business at such business or enterprise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;<U>Non-Solicitation</U>.
You agree that during the term of your employment with the Company, and for a period of 24 months following the cessation of employment
with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage any of
the Company&rsquo;s employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing,
either for yourself or any other person or entity. For a period of 24 months following cessation of employment with the Company
for any reason or no reason, you shall not attempt to negatively influence any of the Company&rsquo;s clients or customers from
purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person
either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution
or other entity in competition with the business of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;<U>Arbitration</U>.
Any dispute or claim arising out of or in connection with your employment with the Company (except with regard to enforcement
of the Confidentiality Agreement) will be finally settled by arbitration in New York, New York in accordance with the Commercial
Arbitration Rules of the American Arbitration Association by one arbitrator appointed in accordance with said rules. Judgment
on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The parties agree that this Agreement
evidences a transaction involving interstate commerce and that the operation, interpretation and enforcement of this arbitration
provision, the procedures to be used in conducting an arbitration pursuant to this arbitration provision, and the confirmation
of any award issued to either party by reason of such arbitration, is governed exclusively by the Federal Arbitration Act, 9 U.S.C.
&sect; 21 et seq. Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for preliminary
or interim equitable relief, or to compel arbitration in accordance with this paragraph, without breach of this arbitration provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;<U>Section
409A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>In General</U>. It is the Company&rsquo;s intent that this Agreement be exempt from the application of, or otherwise comply
with, the requirements of Section 409A of the Code (&ldquo;<U>Section 409A</U>&rdquo;). Specifically, any taxable benefits or
payments provided under this Agreement are intended to be separate payments that qualify for the &ldquo;short-term deferral&rdquo;
exception to Section 409A to the maximum extent possible, and to the extent they do not so qualify, are intended to qualify for
the involuntary separation pay exceptions to Section 409A, to the maximum extent possible. If neither of these exceptions applies,
and if you are a &ldquo;specified employee&rdquo; within the meaning of Section 409A, then notwithstanding any provision in this
Agreement to the contrary and to the extent required to comply with Section 409A, all amounts that would otherwise be paid or
provided to you during the first six (6) months following your date of termination shall instead be accumulated through and paid
or provided (without interest) on the first business day following the six-month anniversary of the date of termination. If the
period during which the Release must become effective and irrevocable in accordance with its terms spans two calendar years, then,
to the extent required to comply with Section 409A, any payment to be made under this Agreement will commence on the first payroll
date that occurs in the second calendar year and after the Release has become effective and irrevocable in accordance with its
terms. Further, to the extent required to comply with Section 409A: (i) the amount of any expense reimbursement to which you may
be entitled hereunder during a calendar year will not affect the amount of reimbursements to be provided in any other calendar
year; (ii) your right to receive reimbursement of an eligible expense hereunder is not subject to liquidation or exchange for
another benefit; and (iii) provided that the requisite documentation is submitted, the Company will reimburse your eligible expenses
on or before the last day of the calendar year following the calendar year in which the expense was incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Separation from Service</U>. A termination of service shall not be deemed to have occurred for purposes of any provision of
this Agreement providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of
service unless such termination is also a &ldquo;separation from service&rdquo; within the meaning of Section 409A and you are
no longer providing services (at a level that would preclude the occurrence of a &ldquo;separation from service&rdquo; within
the meaning of Section 409A) to the Company or its affiliates as an employee or consultant, and for purposes of any such provision
of this Plan, references to a &ldquo;termination,&rdquo; &ldquo;termination of employment&rdquo; or like terms shall mean &ldquo;separation
from service&rdquo; within the meaning of Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&nbsp;<U>Miscellaneous.</U>&nbsp;This
Agreement, together with the Confidentiality Agreement, sets forth the terms of your employment with the Company and supersedes
any prior representations or agreements, whether written or oral. This Agreement may not be modified or amended except by a written
agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement will be interpreted in such manner
as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable
in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will be lessened
or reduced to the extent possible or will be severed and will not affect any other provision and this Agreement will be reformed,
construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.
This Agreement will be governed by New York law without reference to rules of conflicts of law. All notices, requests, demands
and other communications called for hereunder shall be in writing and shall be deemed given (i) on the date of delivery if delivered
personally, (ii) one (1) day after being sent by a well established commercial overnight service, (iii) three (3) days after being
mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at
the following addresses, or at such other addresses as the parties may later designate in writing, (iv) upon confirmation of facsimile
transfer, if sent by facsimile or (v) upon confirmation of delivery when directed to the electronic mail address set forth below,
if sent by electronic mail:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to
    the Company:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275
    Madison Avenue, Suite 702</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10016</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to you:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark S. Berger, M.D.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275 Madison Avenue, Suite 702</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10016</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Withholding of Taxes</U>. The Company may withhold from any amounts payable under this Agreement all federal, state, city or
other taxes as the Company may be required to withhold pursuant to any law or government regulation or ruling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
indicate your acceptance of the Company&rsquo;s offer, please sign and date this letter in the space provided below and return
it to me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted and Agreed:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Mark S. Berger </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RELEASE
OF CLAIMS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
AND IN CONSIDERATION OF</B> the payments and benefits (the &ldquo;<U>Separation Benefits</U>&rdquo;) to be provided to me in connection
with the separation of my relationship with the Company, in accordance with the Agreement between Actinium Pharmaceuticals, Inc.
(the &ldquo;<U>Company</U>&rdquo;) and me dated as August 12, 2020 (the &ldquo;<U>Agreement</U>&rdquo;), which Separation Benefits
are conditioned on my signing this Release of Claims (&ldquo;<U>Release</U>&rdquo;) and which I will forfeit unless I execute
and do not revoke this Release of Claims, I, on my own behalf and on behalf of my heirs and estate, voluntarily, knowingly and
willingly release and forever discharge the Company, its subsidiaries, affiliates, parents, and stockholders, together with each
of those entities&rsquo; respective officers, directors, stockholders, employees, agents, fiduciaries and administrators (collectively,
the &ldquo;<U>Releasees</U>&rdquo;) from any and all claims and rights of any nature whatsoever which I now have against them
up to the date I execute this Release, whether known or unknown, suspected or unsuspected. This Release includes, but is not limited
to, any rights or claims relating in any way to my employment or consulting relationship with the Company or any of the other
Releasees or the termination thereof, any contract claims (express or implied, written or oral), including, but not limited to,
the Agreement, or any rights or claims under any statute, including, without limitation, the Americans with Disabilities Act,
the Age Discrimination in Employment Act, the Older Workers&rsquo; Benefit Protection Act, the Rehabilitation Act of 1973 (including
Section 504 thereof), Title VII of the 1964 Civil Rights Act, the Civil Rights Act of 1866 (42 U.S.C. &sect; 1981), the Civil
Rights Act of 1991, the Equal Pay Act, the National Labor Relations Act, the Worker Adjustment and Retraining Notification Act,
the Family Medical Leave Act, the Lilly Ledbetter Fair Pay Act, the Genetic Information Non-Discrimination Act, the New York State
Human Rights Law, the New York City Human Rights Law, and the Employee Retirement Income Security Act of 1974, all as amended,
and any other federal, state or local law. This Release specifically includes, but is not limited to, any claims based upon the
right to the payment of wages, incentive and performance compensation, bonuses, equity grants, vacation, pension benefits, 401(k)
Plan benefits, stock benefits or any other employee benefits, or any other rights arising under federal, state or local laws prohibiting
discrimination and/or harassment on the basis of race, color, age, religion, sexual orientation, religious creed, sex, national
origin, ancestry, alienage, citizenship, nationality, mental or physical disability, denial of family and medical care leave,
medical condition (including cancer and genetic characteristics), marital status, military status, gender identity, harassment
or any other basis prohibited by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition of the Company entering into this Release, I further represent that I have not filed against the Company or any of
the other Releasees, any complaints, claims or lawsuits with any arbitral tribunal, administrative agency, or court prior to the
date hereof, and that I have not transferred to any other person any such complaints, claims or lawsuits. I understand that by
signing this Release, I waive my right to any monetary recovery in connection with a local, state or federal governmental agency
proceeding and I waive my right to file a claim seeking monetary damages in any arbitral tribunal, administrative agency, or court.
This Release does not: (i) prohibit or restrict me from communicating, providing relevant information to or otherwise cooperating
with the U.S. Equal Employment Opportunity Commission or any other governmental authority with responsibility for the administration
of fair employment practices laws regarding a possible violation of such laws or responding to any inquiry from such authority,
including an inquiry about the existence of this Release or its underlying facts, or (ii) require me to notify the Company of
such communications or inquiry. Furthermore, notwithstanding the foregoing, this Release does not include and will not preclude:
(a) rights or claims to vested benefits under any applicable retirement and/or pension plans; (b) rights under the Consolidated
Omnibus Budget Reconciliation Act of 1985 (&ldquo;<U>COBRA</U>&rdquo;); (c) claims for unemployment compensation; (d) rights to
defense and indemnification, if any, from the Company for actions or inactions taken by me in the course and scope of my employment
with the Company and its parents, subsidiaries and/or affiliates; (e) any rights I may have to obtain contribution as permitted
by law in the event of entry of judgment against the Company as a result of any act or failure to act for which I and the Company
are held jointly liable; (f) the right to any equity awards that vested prior to or because of the termination of my employment,
and/or (g) any actions to enforce the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
herein shall be construed to limit my right to (1) respond accurately and fully to any question, inquiry or request for information
when required by legal process; or (2) disclose information to regulatory bodies. I understand that I am not required to contact
the Company before engaging in such communications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
acknowledge that, in signing this Release, I have not relied on any promises or representations, express or implied, other than
those that are set forth expressly herein or in the Agreement and that are intended to survive separation from employment, in
accordance with the terms of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
further acknowledge that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I first received this Release on the date of the Agreement to which it is attached as Exhibit A;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
I understand that, in order for this Release to be effective, I may not sign it prior to the date of my separation of employment
with the Company but that if I wish to receive the Separation Benefits, I must sign and return this Release within [21/45] days
of its presentation to me after my termination of employment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
I have carefully read and understand this Release;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The Company advised me to consult with an attorney and/or any other advisors of my choice before signing this Release;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I understand that this Release is <B>LEGALLY BINDING</B> and by signing it I give up certain rights;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
I have voluntarily chosen to enter into this Release and have not been forced or pressured in any way to sign it;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
I acknowledge and agree that the Separation Benefits are contingent on execution of this Release, which releases all of my claims
against the Company and the Releasees, and <B>I KNOWINGLY AND VOLUNTARILY AGREE TO RELEASE</B> the Company and the Releasees from
any and all claims I may have, known or unknown, in exchange for the benefits I have obtained by signing, and that these benefits
are in addition to any benefit I would have otherwise received if I did not sign this Release;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
I have seven (7) days after I sign this Release to revoke it by notifying the Company in writing. The Release will not become
effective or enforceable until the seven (7) day revocation period has expired;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
This Release includes a <B>WAIVER OF ALL RIGHTS AND CLAIMS</B> I may have under the Age Discrimination in Employment Act of 1967
(29 U.S.C. &sect;621 et seq.); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
This Release does not waive any rights or claims that may arise after this Release becomes effective, which is seven (7) days
after I sign it, provided that I do not exercise my right to revoke this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intending
to be legally bound, I have signed this Release as of the date written below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 10%"><FONT STYLE="font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 30%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 20%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 10%"><FONT STYLE="font-size: 10pt">Date&nbsp;Signed:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 30%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>f10q0620ex31-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 302 OF</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Sandesh Seth, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Form 10-Q of Actinium Pharmaceuticals, Inc.;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
present in this report;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the
registrant and have:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financing reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that
has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 14, 2020</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Sandesh Seth</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh
    Seth</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    &amp; CEO</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly
    Authorized Officer and <BR>
Principal Executive Officer)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>f10q0620ex31-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 302 OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Steve O&rsquo;Loughlin, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
I have reviewed this Form 10-Q of Actinium Pharmaceuticals, Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
present in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the
registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financing reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that
has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)
Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: August 14, 2020</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 4%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 36%">&nbsp;</TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Steve O&rsquo;Loughlin</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steve
    O&rsquo;Loughlin</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Duly
    Authorized Officer and <BR>
Principal Financial and Accounting Officer)</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>f10q0620ex32-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with the Quarterly Report of Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period
ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Sandesh
Seth, Chairman &amp; CEO of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and result
of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: August 14, 2020</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 4%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 36%">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Sandesh Seth</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandesh
    Seth</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman
    &amp; CEO</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Duly
    Authorized Officer and <BR>
Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>f10q0620ex32-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with the Quarterly Report of Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period
ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Steve
O&rsquo;Loughlin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and result
of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: August 14, 2020&#9;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 4%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 36%">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Steve O&rsquo;Loughlin</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steve
    O&rsquo;Loughlin</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Duly
    Authorized Officer and <BR>
Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex10-3_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "3 E # 2(  A$! Q$!_\0
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ML2<#CUXK\<?C)_P6$^$_PI^/WA7P1=^&YM6^#DLM[X?\>?$BR:6XO_"VKM+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>))=-MO'>FP>#M&\.Z_X4M-1=$EU[PS)X?2V9I].+23MHVM_:8I[*UEQ<3W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUX-.@5A#!+>JHCE<*K(CR[#@XK][+;1[&TC"VMK!$H4+&H3A%10J*"1DA0
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M7M,D6YTI[JYEBCADMM/NA'?%(B2]U;VXQL#5_3MX)\5:AX:N[2#S'22W$>Z
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M=[%?>+_"%LO@/QB4?%R^J>'HHX;'4+B%W>1)=9T-M/U9RSD-/<3JIPHK\H_
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M1UFU/4KR0^7;6EN#([AL[45G'Y)^'KS]MS]GO]M/PK\*!XI^*_QK^ OC;7K
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MWZM4445^:'] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MONMK6MN>'B>+\7AU*'U#!M[K][4>_?==/\C^]B;_ (*@_L(0$"7]J#X00Y'
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M7/#$$%S<QW,LEGX<OI7TRRNDDC++<V\*&19ITD4^8Q/D_P 4?^"8O[+?Q/\
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M_ O]EL/<?\%:?B)AUVVOBO\ :#7A@0[-]J50@/ 16N8CL& -V0.<U^KG@/\
MX)Y_ GX>>#O$OA+0[CXB"Z\5VNEZ7JWC:7Q]JZ>//[!T6[6^TWPWIOB*T6TD
MT;PY#<!R^CZ5!:V\HED+L3@#D-,_X)<_LT:)K$?B+17^*&D^(D>:7^WM-^)W
MB&PUH3W)S<S'4[,P7DTMR?\ CXEN)I'N,GS_ #%X/K<'<4>'G#%#Q5P53.<_
MK4>->&,YX7RBM3X6C&=#^UZ_UO\ M#%)9_&4%23^KQIN5:K&2=;VD&XTX^!X
MB^'/C!QYCO #-7PGP9@ZGA1QCEW&.<8>?&M6O4Q+P638#)'E>%<N&^6MB>7
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M [YQ_JQ#]GGX(;MS?";X>9[M_P (3X9W?KI9 ]^!0?V=?@0V=WPA^'+YZ[_
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MVS1J8K>:!'$:D+MQO4EFSG)S^M8?Q*^#%EX25VT?2X(;,*WF16UNL. 03N)
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MJQU&SN9;*\B/B&TGCM+V!6>:SN+FU:>VBNH@K"2%I0R,K*0&!%>_:-XI\/\
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M485N *_+3]A6(#_@I9\5D1WW+>?'<IC</,D;Q>#"KA.3"23YV.=@& 2:^_X
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M'/XQ5:-.C*JE3P.;8B'O5:55.TZ,59Q<>64E92<9P_F[Z8$I0^C5XP27O?\
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MGB\-45XUJ5NWM(;=_BV9M87)&>G)'/8<<]>,^IJ.1XXE+.X R!V')XP,\G/
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M3-#%A3_47X7\*67A[3XK>&)%;R=C8&"-P"D#;R.,\]@<]:_(3_@J_P#\$O\
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MZNL1"E-S4DH7YHK66S>ZLKNS]#^VR1&9_OGAE8$ 9&UCE>G1@2/P[CK^4O\
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M-820RW\44A:/;Y6YR1]X?T>V4GVM5FB=)(7MT>WE"RJ[I,%EB9UD6-EW(5<
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M8PT=ND3E!P'0<D?>ZGG&< YZDDUKZ=HNDZ3%]GTVQMK.($MY=O$D0!< ,0$
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M%_VE/'O[(?Q"@,CWJ^&[R]@M?%GA6=F(C5Y%CEN([<LR13;(_-C8(S20AQN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5&RL00.Y)XZ\]/R]JDI" >M)ZZ633WOTMM96UU
M]!-.ZDMXWMV=^YGS6J[<DX)9>57<Q 4+A@<AC@<G&#GH2,U-%N ^?+8& Q 5
MFP .  %7G!& ,?SLE%/;'T)IJQ(I+#.3URQ/Y ]/PQVJV^91YI2ER.\5LOG;
M]6_)$QA:_P %--N3A3I03J2?Q<]5*,W%[VUM\QR'*J<8XZ4ZCI14E_AY=O+Y
M!1110 4444 %%%% !1110 4444 %%%% !1110 4'Z9]O_P!=%%)JZ:O:_5=
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@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex10-4_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-4_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "7 G # 2(  A$! Q$!_\0
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MEHIJON__ %TI;!Z4ABT4A;% .10 M%%% !39!E#3JAO[R.QM7EE<1H@R68X
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M=)B8D1HC@O*ZJ>-S.<$_[(KZG).&Y8RHG7NH_B>'C<YITVX4G=G[8>"_V^/
M_P 8H;D>$-<MM4FL\?:+?8T%S "< M#(%<#/ )&*74_VA+B4$IGN0*_"3]B7
MXZ>*_&'[>'@*]LFF^TZK>_8;J.+.V>U:-]Z,!_"/O ]BM?M?I?PGO-0&X0L0
M>?FSD_6OK,1P]E^ ER5/Q/F<3F./G+]WJCP[_@HK_P %3KW]CWX>:>=.6VNO
M%/B:=K;2TN,F"W5!F6=P#SMRN%R 2W6OG'PA_P %T?&7PW\6^'KOQ-KUMXJ\
M/:DT::I"NGQV]Q8JW66(QXY7D[7SD \DUL?\%TOV"/&7Q3^'OA?Q1X:L9]3N
M/"<LXN+&!?WMS!*%W.H[L&0''I7Y]_L^_L0_$'X[>*M-T:'0=2MH;BX5+FXN
M(6B6&//SL01P0/UKT,#0RB="?,H^KW''ZW&%Y.5_(_H7\/\ [1CWEO%,KB6&
M9%D1P>&4C(-=OX9^.-KJNU9,*6]^E>":'\(+[PQX4L+8P2_Z-;1PJP/+!5"@
M_I7YV_\ !9#]L37/A3\2?#7PUTZ^O[#3)[+^UM8$+F%[Y3(4BBWCG8-CLP'4
MD=J\C^P<!B_=I$X;-\=3J\D]C]P=$\16FO0^9;3PSIG;NC<,,^F16B*_G2_9
MJ_X*6:W\!OVE?"6J^&+B[MM O+VVL=:TT2MY&H0R.J,3&20'7.0PYR/>OW_\
M _$VS\56BX?#-R,]Z^8S[AJKE\_=?-'N?5X'-H5O<J:2.OHIC')R#232K"A9
MCC'))[5\NG?0]@)[A+:)G=E15&22<8K\^O\ @H]_P4>@L9KOP/X2O UQS'>7
M,<G"=<J,=ZYO_@KI_P %=;'X5B\^&_@6^2?Q!(C1ZC>Q-D6(Z&,8_C([_P -
M? '[-GA#4?CCXJ2\O6N9+,R;II6)+7#9S@>H]:]:AE]10]K)>ARU,3!>Z>Z?
ML\_ ^]^-.OI?7D<K:<7#X.=UT<]CZ?SK[G^%'P@FUN^7PWH1\B.W54U/48QA
M;1"/]5&?^>I'_?-<U^S;\.+K6Y(?#GAN,1RQJHO[]1F+2HR. OK*>P[=>U?:
M/P]\ :7\*/"4.G:?$(((02S,VYY6/+.Q[LQY)KO6=UZ%)T8O4^5Q7!^!QE;V
MU=7CU7?_ (!'X=T#1/A'X($,9MM+TC2H2\DLD@CBB11EI'8G Z$DGWKS3PA_
MP4?^"WCKQG#H&F?$#2)[^ZF^SVS/%-#:W<F<!(KAT$,C$X "N<FOC[_@XW_:
M,UOPA^QI'HWA^:YAM-?URUL]6>'J;;#OL)'16=4!^F.]?CI<_'[5_$7PZ@T.
M0^5;6I8JZG:4XR"#VQC(]P*];).$HXZBZ^)G*,GMU^\]/$YJL/*-.C%66GRZ
M']7=J^]3_ABI:\/_ .";GC_6?B=^PO\ "W6O$<DDVO7GARS:^ED^_+((P"S>
MYQDU[>WW37Q%6FZ<Y0?1M'OPDI14D+1FL/Q-XOTCP59)<:QJ5EID$CB%);JX
M6%&;LH+$#)]*U+%E==R_=(!!SG-)Q:2;ZDQK0E-TTUS*UUU5RQ1114F@4444
M %%0/\HSS@=L]:Q[?X@Z+>Z[+I46L:5+JL(S+9I=(T\8_P!I =PZ]Q51A*7P
MHSG5A#XVE?17=KF_142?=_\ KU(OW:DT%HIDHROXUD^)O&NC^#+>.;6-4T_2
MHII!'')=W"0+(YZ*"Q&3[4).3Y8J[(J5(4X\\W9+J]$;-%1VDRW%LCHP='&Y
M6!R&'KFI*"D[JX4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH CN+A;=06[G ^M>'_%O]IWPY;Z_)X?M/$FAMK$;F-K-+Z,SJW]W9NSN
M_P!GK7!_\%G?VI=9_94_8(\:^(?#4YM-?>**PM+I5RUH;B18FE'NJL2#V.#V
MK\"]$_::FG^',FF?9W?49)Q<M?$G[2TO5I#*?G+D\[LY-?;\(\/PQG-B*LK<
MNRMN?.9[C)PC[&GI?J?N[J.HW.O7C\[LG:QSW]![UX/^V!_P2<L?VQYK'5G@
MNH-2L%*0W=N0LNP_P'/4?6O1_P#@CKKVK_M*_LA>$?$GB%S-J<*264\[+@W/
ME2%%D/J2H&3W.:^ZM(T>+2+=(XU4;5P2*[,ZSQ827L,/\2/*R7)95)O$5F?!
M?_!.W_@CQH'[+OC-/$MU:R3ZO%"88[FX.6A!^]M'0$_XU][6VCP6D>(HD4=
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MZ3+D8CZLQ7G!X_?#]EW]E_PY^RG\,+7P_H$19U_?7EY,<W&H3D?-+(W=C^0
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M']!7RE^S_P#$OQ__ ,% =?US6O\ A(]3\ _#_2;@6MK9Z+MCOKUR WS3D$C
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M:KN\D2@[G8*/O,,$]JW/^"87[6NO?M(>#=7T[Q3(EWK/AUXBMV  UU#)G:7
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M)8YKU.3]M?X;0#YO$VGI]9,5^?.J?\%!; 0A?](_"T-<CKO_  4!L-S<7/\
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M=OC^TM^P%K&J>&0]RVL:1'J,44.6:3:RR218]1M88]J\1_X(^_'C1='T+6_
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MC^&S>Q@N?_CE7OV(O^"]'CO]HK]K&^^'NLV'A*XT_3]-:[DOM)CF4B<2*OE
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MR?FSVQ5'X;_M!^"OB^+C_A&/$NDZV]KS-':7"O)$.F2O4#WQ7R)_P35_9_\
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M]B\4:=NQ!?6ER@=<@2Q3*>0>X(-?G9_P3]B%O_P4>\60QHD<,!U8*B+@(HG
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MBIQ1#B-5TN2#I\CA]EZOWN?>_E8_+;]J3XF:-\0OV]M-\56']HWGAJRNM/\
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M5FA>1!--<?NK=$526)#,2>V.:\9_90^,VD?#+]MO7O&FMPZW8>']4;43#/\
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MM5^!7B#0_$/@2XN]+N+9XVU6".5A#JL8/[R.9,X?(W8;[P)R#FOU"_X*U?\
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' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex10-5_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "1 D\# 2(  A$! Q$!_\0
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ML2<#CUXK\<?C)_P6$^$_PI^/WA7P1=^&YM6^#DLM[X?\>?$BR:6XO_"VKM+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>))=-MO'>FP>#M&\.Z_X4M-1=$EU[PS)X?2V9I].+23MHVM_:8I[*UEQ<3W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH KW%Q';JC29.^0(@ '+D,5'/ W$;5)(!<J
MN<LH/P_\6_VG?AQ;Z_<?#_2?B1X'E\8V]Q-9S>&K;Q3HDNO17*LZ-:/IJWWV
ML7ZE"K:>8A>(RR*\2O$RCP?_ (+._M2^,OV4_P!@CXU_$+X:W[Z1X^GL-$\(
M^']=AB$USX=D\:ZS:>'[S7[52KHEUIEA>W$UK<2*1:79@NU#20H*_@6T/]IJ
M\G^'-SX8.G3S>([C5(]:F\5222-XCFU=]D]WK4WB&5SK,VJS7B+<3:I+>->7
M,H+SS2%FS^W^$?A_AN)GB\XQ^-="G@JU&G@L*\*JRQ52]JJ4I-)I.T;6<N9O
M6*23_...\ZQ6'H2RS!J=&=:,?:XA=8S5U&#?PM+1M.]_,_N\U'4=2UZ\F&_S
M2SM#*V]SB5R=T43 ',NUL@%5P2%.#FO@_P#; _X).:'^V1-H7BR>PU6P\2:#
M%+;Z9XAT=HK?5183 LVGW1EC>.\M5DVL(INK*NUAC!^C?^".NO>+OVE?V0OA
M%\2?B%-)>^)[.TU;PMJNK30A)=;_ .$;UB?2[/6)CD+/<7EC:PFZNW\Q[F?S
MISAI,#]U-(T>TTBWAM[>*-!'$%9U"\GCV['CI7L<;<<QX=Q$\HR:4:6+PDYJ
MI4@HQ4'3<H-N+2UNOA:?*WR[QN_E>"^"JN+Q-3.,RK.49^[[-W_>Q2:LM[-W
M3<MV[OK8_!C_ ()V_P#!'CP#^R[XSA^)>JZ5<WWB^TTU]-L=9U=UFN-.BN!&
MUX-.@5A#!+>JHCE<*K(CR[#@XK][+;1[&TC"VMK!$H4+&H3A%10J*"1DA0
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M7M,D6YTI[JYEBCADMM/NA'?%(B2]U;VXQL#5_3MX)\5:AX:N[2#S'22W$>Z
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M=[%?>+_"%LO@/QB4?%R^J>'HHX;'4+B%W>1)=9T-M/U9RSD-/<3JIPHK\H_
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M1UFU/4KR0^7;6EN#([AL[45G'Y)^'KS]MS]GO]M/PK\*!XI^*_QK^ OC;7K
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MWZM4445^:'] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MONMK6MN>'B>+\7AU*'U#!M[K][4>_?==/\C^]B;_ (*@_L(0$"7]J#X00Y'
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M7/#$$%S<QW,LEGX<OI7TRRNDDC++<V\*&19ITD4^8Q/D_P 4?^"8O[+?Q/\
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M_ O]EL/<?\%:?B)AUVVOBO\ :#7A@0[-]J50@/ 16N8CL& -V0.<U^KG@/\
MX)Y_ GX>>#O$OA+0[CXB"Z\5VNEZ7JWC:7Q]JZ>//[!T6[6^TWPWIOB*T6TD
MT;PY#<!R^CZ5!:V\HED+L3@#D-,_X)<_LT:)K$?B+17^*&D^(D>:7^WM-^)W
MB&PUH3W)S<S'4[,P7DTMR?\ CXEN)I'N,GS_ #%X/K<'<4>'G#%#Q5P53.<_
MK4>->&,YX7RBM3X6C&=#^UZ_UO\ M#%)9_&4%23^KQIN5:K&2=;VD&XTX^!X
MB^'/C!QYCO #-7PGP9@ZGA1QCEW&.<8>?&M6O4Q+P638#)'E>%<N&^6MB>7
MQQ2Q\94L)33C3PV'G*5:;^:_^"TYC3X/?!J,2 /'\1]4EW@\ICP[<2,^_KNC
M56DW Y"J3GBOT:_9#-L_[+W[.^R1&$?P=^'2X#!@LL/ANQ25-HSL>.0,KIU1
MQA@#T\S^*G_!/OX&?&?6+36OB'=_$C7Y[*TT^UM;*?X@ZVVD6C:?I\.FBZM-
M)E\VQMKR[@AWW]S##'+=W%Q=3.P:4BNN\$?L:_##X=_#;Q3\*O">M?$K3/"G
MBN2V>X6/XB^(O[5T5;9E)A\+:F9O-\.P7>T_;(M/6-;@.^X9:O,SSBK@_,_"
M7@G@6CFF;K-,@XHS?.<76J\-6PD,+Q!*A#$PI2_MIRG5P:H>W7[FC[6I*RE"
M5JA[W#'A]XG9+](7Q'\6<1D7##R'C/@OAOAS"8&AQ9+Z]A<;PK]8J8:M4A_J
M_&FL/F$L0\/4:E*6&@E5Y:G*X/\ '']@#(_X*7_&)$8@!/C\D8((!7_A.M/Y
M9L <R@;L\LX'\5>K?\%LX5.D_ 2-V6%EU'XA/&78A3C3O#X4[CWD9C''GDG*
MKDU]O>&?^"97[./@_P 36WC7PT_Q+T;Q9:7AOH]<L/B3KUMJ%Q</<"ZG;4;J
M 12ZE'?S@G48+YIX[L,3(&;!&G\1O^"</[/OQ9\1:GXJ\>M\1]=U75-0O-1:
M*\^)'B&[TO3&OKAIYK31--O6N;/2K.-B!!!9Q1"-(XDW'8"/TE>+G G_ !%O
M@OQ'AC<\H8;AGA/*,DQ6$APW>MB<=E&1YAD$JM.#S]0='%T,7'%<TIITYQE3
M5.7,IO\ %(?1T\7X?1P\0/!997P?1SKC/Q$SGBW"9G3XKJULNRG*<YXHPG$M
M;#/FX>]MB<3AZF$6#IX?>O\ 6YXOV]-85TY^S^!(\_LO>#T"E[A?@+IBH(D)
M,KCX>)&L0QR)5W !=H8E@.I&?QK_ ."*E]I]EXU^/&AW-Y#!JNH^%_!%S9VM
MQ,BW5ZNBZMXAAOY+:%V$LXLFN4^V^4C&W#[YBO!'[7_!3]GCP=\!?#^I^&/!
M.I^,+_1-1EB=+#Q?XJU7Q5%IL4,!MUL]*_M::=]/T]HB%DLK=D@?  C0 @_*
M/BC_ ()7?LQ>)/'=[X^LXOB#X+U#4;^YU*]TSP/XUN/#NCM>7[M)J$EG':V1
MU'2TOY'=[N/3-1M Y=@GEYR?@N&.-.#L#D/B[P=FN-SNEEG'G]DXC*,]P>4T
ML1.EB,GSC'9SAL+CLDJ8VG6HT*U3%1P]7$4L?.5'V?M(*HI6/U?C;PR\4\QX
MI^CMXD\.Y)P[6SOPIP>=Y;Q1PCC^,/J5/&T<WR' Y!];RSB..2XC#U_J]+!*
MO##U\MAS*482@YK3\W?^"OOCSPEXH^+_ ,'_  ]H6L:?J=WX1\.:Z-?-A=0W
MMO8WFKZ[I(L].N)86>./4HX--:XNK5V$T$5Q;NX"RIN_9W]H$>5^R-\468&)
MA\"]9'!( +>%#F(XQA8\L!GA5!!&!BO-/&G_  3=_9B\=77@LZMX1U*TT7P)
MHL^AZ3X7T7Q#?Z3HU_%>7:WM[J>O26FS6=6UJ[F16O=2GU<7%\5#W32/R/0O
M&O[%WP:\;> ]+^&4UKXN\.>"--O;N[ET3PKX\\3Z3#K)O;>&UN4\0.UY=2:[
M&]O:PQK#J;W$*"2?:HWC%YSQQP/CN'_!S(L!BN(J,/#[%8RMF<\7DD)^UA7S
MRGF,I85PSOWJE58:C[BA2BH5>65:K*A.<^+AKPD\6,KXO^D=Q9FV X/Q4O&#
M)LJRS)L#EW$>*PN$P%;+\DQV34:LJ=?):^*BZ,,VK?6,37Q%)XEX:I/#X*E2
MK04/SR_X(J"+_A5OQE5O*+'QQX?)9P"%#>&;<,6R.6 5$ST( 7.!BO%?^"P:
M/_PT%^SUY82.(>"KM4!79^Y'C?3ED0 \;MY^4<<8*C&*_5SX)_L)_!7]G[Q2
MOBOX9GQSI-R8+BWO=+NO'>MWWA[55FA\F.34M#D9+&ZELT.VSDD1I(2JNL@.
M,<AXZ_X)N?L^?$[Q!<^)?B%<?$_Q9JLTUVT%QJWQ,\0W0TZWO;HWTMCI23,[
M:;I\=U([V]E;.J0>7$4?@;?J,/XJ\&8?QWS?Q4EB,TGE&,P6.A0PL>'N?'JO
MF&0_V)4IO#SS:M1]E0Y8XF-252I[24Y1=.,KS?QF.^C_ .+F-^B=P[X"K <'
MQXHRW.<MQ&,S.IQ--9%/"99Q3/BKVSIT^'U/$2Q4<3++EAZ5.C*A6H.NZTX.
M,%]5^,E5_A1XHC12LJ^ =8"C;\[1+X?F4O[HZL3D\$D@9R,_B1_P1+LT36OC
MO? O)*NE^!+3DD(JBZU@^6!T^59-^!C&[=CFOUK@_90\#0_":[^#;^*?BI<>
M%+W4A?RWL_Q*\1R>*$AQ&C:1#XC:7^T(]"DC0I/I(<P3J[J^%=E' ?"'_@G[
M\"/@7XNTSQE\-)?B%X>U&QN;:XN+*#Q]K9T;5X[3S/(M-<TK<+35;*,RL5MK
MA"F<?-QS\1PWQ=PGD?AWXI\'?VCF<L7QOC,JGEV)I\/M0EALDQL\?1^NSGF,
MIX.6.J2C1J1A&HL.H\SE6B^4_4^,O#?Q#XG\8? 'Q(HY-D.'RWPVR_.,-Q/E
M5;B=UJL:V>Y=2RV4LGDLCC'&?V;R/$1E*6%^LQ4:7[N:<S[CHHHK\8/ZH"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#\=OVL/^"7=M^TI\=]?^//_"PFTG4M6\+^$O#5GX;;25DATV'PY;3V
MYNEU#S29GNDERJB(A I!!)W+\U-_P1BUCYB_Q @+,Q8F/3FW-Q@,Y8-G(P!M
M Z9/7CZ;^*_[?WB?PU^U3\2_V8+.;P7X6O/".G^#-3\+ZIXAM=2N[CQ+#XA\
M-V^O7\"R1:A9VT&J:=)<K#]D8A+F(/)"'= !OP_M,?&YEP_CSX<QL#@[O#NH
M;A@XV,1K?WD&>-Q()Y K^FL@S7QVP/"F0Y;E.991#)*>7TZV4PGA<MG4IX*K
MK"A5JPP=24YJ3G*:;J<LXM2<6TE_F[Q_Q%]"=^)_&$>-<IXLJ>(%'/L;1XCJ
MRP_%BPL<;@^6A5Q.$K8?,I8.=*JJD8TU2A)N#NXPLK?(?_#E_5CT^(40YYW6
M#?IA0">I'8 \^T=Q_P $8]9@B,D?Q#M]ZCY?^)=_$3A 6"@@LY"ENP.21S7V
M6/VC_C4RAC\0_AMDL<_\4]?@=QT.N<<#@YYQSZU6OOVA?C1/;3QK\1OALIDA
M=/\ D7=0'S,IV$E=:<X#E2<(<C(QQFO.Q>*\:J[D\=C<NJP<XPF\)3PU*5.,
MYQ4Y5'1PE"Z<5[JG)ZWY5N?:\-9S]$R2C'A_"YS0KUJ3CAUCL/Q!6A4DDW!0
MECZM:G2Y9-.3ARMIVFVDK?R2?$3QIX?\,_M!?$[X8OJ%U?>$?ASXOU;P7'+;
MS3:<^K:EX?<66K7[O;O%<+$=4BOK6"-70*EH7<,SJU>X_L0^#;/]K#]H76/V
M>X]6ETEK_P +:IXL\&ZI<1?;-DN@W=G'J>DW%PX:9UELKZ*YM7=LK]FNQ([[
MT">3_M5_LN^-=(^/GC_QQHUQH^OZ?\1?%>K^,M3.F!K*/2M<UN99]45(;B1R
M;6]NDFO8Q&S&-YI P#2'/US_ ,$VO@YXP^#WQDG^,]KXE\-Z-XGA\.:CX7TE
M=2L;S4;2UL=::!KZY>*WO+7-S(L2PY0[D08)((K^C>-,1@9>#^(P]25*KFM/
M*,/%27LY55BE17M9.<%9QE.[BHOF4;J2YB^"H9='Q P-3+N2. EBVX<JFE*E
MS^ZK3U4DDD^:R3VTL?IG=_\ !$G6+SD?$F *<'Y=,<8#9).TAB ,D@9SV]JY
M'4?^"$&LWS,R_%:VC#9QNT=VP3GJ"R#H?PQR.1C[NO\ ]J#X[68<0_$;X7-M
MW;E?PUK0Y4'()_M@G&1SAB?0G@UQ%_\ ME_M V!9E\=?"-T&5&/#NMAB>3SN
MU?IP<]SQWK_/W"T\Q=O9T^>K=<JE)14I^;=DDW=WEYG]ONIAU%N4+02U>EN7
M373RL?!]_P#\&^/B"\#C_A<EBA8G;G06< >Y\T;>!C&3T'<@UQ.H?\&X&O7X
M_P"2Y6<;')8?\(Z^U22?NXF&0.O3)P0*^X]5_;\_:,LQ(T7B[X//L!P&\/:]
M\V#U8)K(7IW//&/05YUJG_!2O]IZP4M%KOP,E/',WA_Q4&X&03MUQ54C'8 #
M ^M?69?AN,U:6%5.GS))*G6I<R5UOS.UK]M;GCUZ^2J4OK4Y1C]GD@Y^]U34
M$VM.^GS1\4W_ /P;)^)+MBZ_M 6,:D8)/A><GKDX N 1D_7 SQG(''7O_!K/
MXDOPX'[1MG&6W=?"MSMR<]Q<YX_F<#&<U]?:M_P5@_:OLBRQ:K\ 9% RIDT/
MQ=S@<'CQ 3S^.37G6H_\%D?VP;-9 D_[/$GE@A=VB^-%&/<)XA4''<D9QTQ7
MV>"P7BQ*T<'4@T[/GEB<+&S:6EI-3=M-5H[Z;,\.O7X0<6ZE2NY7?_+FIMTM
M=+:_ZGRAJ'_!IQXGO3Q^TUIL;;=A5O!MTR8/(RRW(+$Y)SGC)'K7T1^Q-_P;
M8^(/V3/VA=(^-UW\?K#QE:6'ASQ#X=D\.6_A>;3IIGU=]-:*[-U)=S)'%926
M,Z2J8G:5FA,90$M6+J?_  7!_;/T]1Y=O^S9*>?EDTGQP&QR3Q_PD97G'!)Q
MZ\9K<_8B_P""]/QW_:*_:QUS]GOQEH'PDU#P_P"'O!5SXBO/%/P]L_$=J\?B
M2'6M/T\:%#+K6LWT6H6Z66HM+J5Q#;JD-["L,)V@FM>),)XNX;(,VK9QC,N6
M43P6'K8NE'-,#*M/#SKO!5H*C&\W5=I2=.+YFFX+WS'+*W!5;-<)3PN&Y<PD
MY3P]:5.JOWN'E[K=M%*4E=?83W/ZP_!VA'PSX<TO1"XD-A:Q0%U&%8H@7@;C
MC[O/3J*Z>L/PWJ)U?1--U,KM-[:Q7!4]C(H;'.,8)(_#CC%;9(Y&<8Z^OK_*
MOP?\NODNY^B-V]7HEW?8;(@=75OF5E(*G&",?3/ZU\R?&;X>VEY93:C;QQQL
M(][,@4R# )98U(^=W8K$!_"7WME585]*S31P1232OB.)2S%C\N ,]P 3GH,Y
M/6OC[XS_ !0BD@N-'LI2JLKK(8L8V>7)$<-G<K2&4!9%&4VNW P1]=P50S2M
MG6'GE4JGNS@JKCS*GRW3?,EO*U]>B^1\EQAB,MI937AF<:2C*$G34W!SYK-+
ME;Z-]._H?QC?MY?\%!=:F_;$\7_ Y-?UGP[\'/@WKMIX8UC1=!UJ_P!&7QEX
MPM;.UO\ 7-8\17.EW%K?7MKI]Y<G1-.TOSXK%8K6XGN(;F:2*5/5?^":7[<?
MB;Q?^U)8_LXZGK6M>(_AA\0=.UZ7P*GB'4;K7+WP9XNTBU?6&CLM4OY)K]-%
MUK2+348FTVYEN+6"_2&YLS:RLY?Q'_@I+_P3H^(?C+]HOQ-\=/A-:66I6OQ'
MO(+_ ,7:))(+21/$=O!'9S:]I#F(PRVVH101R7T%PP(G@>:+>TQS[C_P3%_8
M<\6?"#XT67QJ\=/&^J:-IMSI_AFUCC/DV%UJT$D-[J-Q(ZJKL+%;BRM1D/"]
MR[ #SC7]D?6\/4R"6&Q$<*LSI4W348)*NZW))*<I:2<N>4;N]WLW;1?@U1Y3
M# 4ZL9)X>\9-*.[4FUJU;=+?YG]EOPA\"V&DZ;#?-'&9'C1UV[3ND*J0S<9Q
M@GOGMGI7O<:A5 ' QP/3KT]O;IQQUS7RK\%OB;#=VT&FWTH$BB.W![AMHQUZ
M@XXQUQCG@U]4Q2+)&KJZN",[@1CGI]*_C#BZCF5'.\4LQ]I*3G+V<GS<B@F[
M)7ZVMZN_D?OW"&(R_$9+A7@(PBE"/M4N7F<K;M1^>Y)1117S!]2%%5I&82C:
M&)\HD8;"D[L %<<GJ00<^U?!O[0/[>/AS]G77M3TWQ[\%OCK_P (Y87MII]K
M\0M*\-:')X(UJXO8XGB33-:N_$MN#OD=K94O;:RF>XBD2-)  S>OD>09SQ-C
MX95P_E];-LSJW]E@<//"TZ]:2M>G26+QF"A5J6=U3A5E.2ORPDTTOF.+.,^%
M^!<HJ\0<6YO1R3),--PQ69XG#XZMAL)RQYI5,2\#@<?4H8>$;<^*JTZ>'@VE
M*K%GWW17Y6>&/^"J_P +?&L=_+X,^"'[2?BZ+2A&^IR>&O ^CZU'I_GQM)#'
M=2:=XGN1#)+&K20QRD221@R(K*,UV'PQ_P""GW[-GQ+\86O@;4+CQI\+O$-]
MJ2:';VOQ*T!= A;6&=HO[*N[RWO[ZWT:^6;;$(]7:R$DTB1HS2%E'U.,\*/$
MK K'_6>".((SRNC/$YE1IX6C7Q.!PE.$:E7%8O"X?'XG%4*-*C.-:I*>%7+3
M:E9H_/<O^D7X'9K6RVC@/$WABM_;.*HX+*:U3$8W!X7,<77JNC2PV#QV891E
M^78BO4JJ5.%.EF51SJ1]G%\[2/TCHKY4^/'[7'P/_9J.DV?Q5\:3Z5K.N6=S
M?:)X?T[3=2UK6]3M+:3RI[FVMK"&>/RXI76(2SS"#>5&UB<%G[+/[3OA[]J?
MP;XA\?\ A31->T#1=&\7ZKX2M;?Q ]J+_4$L(+2\35I+2TFG&GI=)<8AM9Y)
M+B)5!;:'"CYQ<,<0_P!A2XHGDN9T.'%6I8:&<XG!U</@JU>M4JTZ5.A4JV]M
MSSHU4I03BG"2=K'VE/Q&X&K<9_\ $/:/%.35^-%A<3C9\-T,;1Q&:T<)A:-"
MO.OBL-1E4>%C*GB(2IJK.\U>4;H^KJ*C0GD$YZGG\./I4E>%JM_^'71_,^T3
MND[6OT^;73T"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M15:X;&U=SIG&"AY!R?T/(R.GKUJ!)(V\QOM#88]R 5*#+!03SA2>@S[=*GF7
M=6OR1:DGS5;V]E9:J=M=;7VW:)YFY)1BY6FHU7M[)35Z<W?XU4?NQ4+RO>ZL
MC0HKYF_:;_:1\.?LO_"R[^)GBG1]:\0VZZIIFA:9H^B-%'<ZCJNL.4LHI;RY
MQ;V%HI4_:+R42>5D!89781G2_9B_:$\-_M-_"^T^*/A?3-:T.SN=2O\ 1+[1
M==%LUYINL:0ZQ:A!'<VDTUM>VH>1/(NXB@G4;C%$V4'NKAO/O]7UQ6\IQD.'
M99C+*8YM.$(X9YE"*E+"?Q74511=[^SY&_=4^;0^57'7",N,WX>QS[ OC6.2
MRXCEPY*56&8K(HXGZF\R4)4?92HK$M4G"-?VT4_:.G[/WG]#T445XA]8%%%%
M !17F/Q(^)7@WX4^$M;\=_$/Q+!X6\)Z'%$-1UB<7$T-L)Y52 F*WAGNI)I9
M"(U2-6))Q@"OD?X-_M__  C_ &@_C9_PIWX61^)]8B3POK?B2;QM?V7]C:+(
M^D36<;Z?86%[MU6Z,HN-Z7CVD-N55P&,@P?=RSA?B+.,KS3.LLR3,\5E62X:
MKC,UQ\,)4CA,!0I<B<\1B)/V4.:=6C",>9R;JP]VS=OC,\\0^"N&\_R'A;.^
M),HR_B+B;&8# 9#D>(Q<(YQF6(QU:O1B\/EJC/%/#45AZE2KC)1AA.7EBJW/
M*,9?H-15.%G=(SEP<#()/)8 ]SR.>#T[#&*MCH._ KP(RNVFN62C3;BVFTZD
M.>SMI>.S\]M#[&,E.,91VE'F3VMM9-/6[33]!:***HH**I7&Y8Y%1V4NK#S!
MDE">C?[JX.X@$CGKP#^=7Q7_ ."B?A'X%ZW<Z3\2O@C^T1H=@NOZGH>D^)YO
M"GAQ/#GB22QDFVW>@WD_BV&2\M;BW@>ZMQ/#:S&U*RR6R+G;[G#_  UGG%6+
MEE_#N6XC-\P47..!PCP_UJI"*DY2HT<1C,)4KN/)*\*$:U6R<E2E!.2^0XQX
M]X0X P%/->,<]PG#^5SJ5*<\SS"&+A@,.X0H24L7BZ.!Q>'PE*;KJ$:V*JX:
MDIQ:=2\HQ/TBHKX.^ ?[<?A[]HW7K#3_  '\(OCG9>'[N2\@G\>>(/"^AVW@
M;3Y;2-V=+[6K/Q)>R-+*Z&WBAT^"XDBNP5N!%&I:ONJW<R0HQZG.??D_TZ^]
M<^<9)G'#^-EEN>9=7RS'TZ=.I6PM>>'G4HRG?]S5^KXK$JG6A;WJ<W3FDTW"
M.QT\)<9<+<=Y1#/^#L[PG$&259QA1S3 0Q:P==R@ZB="IB\#@77@XIVJT(5J
M+:?+6D]">BBBO+/I@HHHH **** /XU/^"FVAZUJO_!1;XUZAI$6H!+#2OA5-
M_:EE%./LMPG@32Y$:"=%&Z>-N456 )1E)P,'QE/BS\:@BQC7-:<(JHK3:= 9
M=L2+&I9S ZN7 $C$!6#D[RW;^U75? ?@G6Y'?6?#/A_4[J81^=<7VCZ=<W4Q
MC01QF6[FMGN)#&@"1^9*Y2(>6N$X&&OP:^& W#_A!?#3<YXT/2^>O( M3ZX)
M/M[U_5W#?TE<'D7"G#W#%;@NMB*V1Y/# RQT,RPD'7KJI%N49+*J=2,.12T5
M9RT5YR3:/\\^,OH.YSQ=X@<4\:5O$;*<%@\^SW&YI@LDEPOCZ[P]/&M5:REC
MJ>8TJJDJD8N,E*SBG'E7,DOXQ6^+?QK! _M[65/!P--@/3KC_1/3!*_IZQ?\
M+8^-S'#>(-;*G.?^);$Q.>W$?0C R!GV&<5_9Z?@S\,"23X$\,^F#H>F\8'I
M]DQD]O3G/'-2?\*4^%I&5\#^&>A_Y@FF=<>GV3G/&<$=\5\_G/CW1S12C/AO
M$PISG?DEF:K*-VOBM2A:VCOKV5FM?M^&OHGYCPY*ER<:8+$1A'E<:63XN@FD
MEO\ 7<5BU)/9>R=-QU<G).*C_$YJ/BCQ_J[>=J]YJ$\C+D&2PC5NH&3^ZX8]
MATR<YJQ8^-OB/I$8_LK4[^QV$1-LLX6*NX8\X3*EE 4L<(/E&[CC^IC]J#X8
M?"7P#X.\0^/-7\.Z#HWA[PGHFI>(->U :78QQ6>C:397%]J,[ 1*CR+;6[K!
M;[E>>5@J.A#,/Y9O#W_!3RX\42^*O'/@'PM\)/"OA'0KXS>#O"?C/PK_ &UK
M6NZ,TIBMY?$6K6U_9C1I[^=%63[%:SFPBN(AF282&OT7(LSEXA<)8K!9=EU/
M#5HPJ))XE);Z*7->]UKHUIOV?HQX"QW"/$N#J_7*6)H8>K&<YPI>RDW/WI67
M-=*ZT=K/IIJ8VK?%CXV'/_$_UK!!;<VFVV,8/)(M'&1G&0[@XR&8<UY%KWQ8
M^->^0_V_J[ Y'S:9;XSST)L<9]:_K0_X)X?';]G#]NKX :/\5O#7P]\+Z1KE
MCJ5SX6\=^#KO2]*N;GPEXOT86ZWUGYYM7:XTV^@N+75=&N)F,MQ8W<,4[&Y6
M2OOO_A1OPCD&7^'G@YLC(+>'-'((_P"!61'?.<9K^3\PEBLES',<#C:%6G6P
M>+E35*6\U&<E--JR=VFX2BW%QY91;C),_JO"N./P-*IAZM-J<(*:?O:<D+K1
MJSO>]_,_SR->^+/QK"RYUS501T!TZV!/. 1FS!QQ^)_$5XOK_P 6_C5A@==U
M7!SR=/MN/4'_ $(\=3STZ\#FO])S_A0GP:;A_AKX';/4'POH+9].6T\GVP./
MS-0-^S[\%6R&^%?@%QVW>#_#S=^O_(-YY&3D'/TKU<!QAAL-&/\ PG5JE1):
M?6'122MK=M\VNG+TWO:QSULBG5^"O3IR?Q/DNFMK*_7KZ:'^8%KOQ:^,N^0#
MQ!JA&.HT^VQTX&39=>1CN< >AKQ;7OBU\90)L^(-5! ; .GVW/T_T$\<G)Z#
M [YQ_JQ#]GGX(;MS?";X>9[M_P (3X9W?KI9 ]^!0?V=?@0V=WPA^'+YZ[_
MWA9LYY(^;22>>O&/6OJL%XI8;"Q7/D4ZE1/1_7I6Y;*R:4HJZUOU/*K\(U*K
MUS/DNEI'#J?SYFNO:VA_D7^)_BK\8;FVN;>77-6:.YC,,Y2Q5)G@(&8HW6-#
M&Y/'FJBG##C)S7Z'_P#!"/1]5O/VY=?6*PN'N1\*-2N&A2&=I&A_X2G0))YI
MMZLS2K(</)(8Y&;< I -?Z7+_LV? !P=WP;^&+ #[K> ?"1[CH?[')X/O]*T
MM$^ OP9\.7YU/P[\,? ?A_4VC\HZAH7A'P]HU^8=X<V[7NEZ=:7,EL[*KO;R
MRO&SHCD%@#7;G_B]2S?AK&9 LC</KF'6&=:56A-T:<:SQ$)0E['VG[NJ[M\\
MI2@N7FN^8YL!P96P.9X;,(YO&I##S=J4L(DYJ<[U(.5]&]8QE;W;]3L_ :/'
MX1T!'4HXTVU#*PPRGR4X([&NGDD6,.[G:@!)8XP JD$]>^>/7!_%N([2)(XU
M"1QJ%50  JC@ <@8'/TZU\N?M&_%V^\$^ ?%]WX7*3>)K/0-8FT.$M&3+KD&
ME7SZ2IWG88A>F)I%/5DVG@G'Y#E>58O-\91P>%AS>WG&G*;7NTH2DE*I-](J
MZNW:V_9/ZW,,SPF74I5<144.36/-LYN,G%;J][/3K8^7/VG_ /@I3^SG\(O&
M6K?"6X\9ZCK_ (YT;R5\5:#X%T'4?%DW@I;J/?;'QA-IX6WT6XF7)CT^26;5
M6Q_QXX*Y\4\)_$KPQ\;]&M/&/P^\5Z?XO\+:M+-&FM:1<BXA>XMY2MUI<R.(
M[FPO[20K'>V5Y!;W,!91)$*_@A\'_M(?%32_%'CS5M3U&]N?%GC+6_%DWC&]
MU0M)J-QXAU"^G;5KB^+[)GN8+D P;V: 0HJ"'8H!_I/_ .#<^X\8>,];_:=A
M\122S_#FTU7P5X@@N+MY5M[#QC>V^L?VG;01^:((_M6B1V%Q=".(E'MX0LJ*
MYAK^LZ/#.1>'_"5/-*-3VN,IP5/%57*$X5J[IQGS48J"<%&\5'WIZKWFV[K\
M'SJEF?&&9JE[9JG/$)T:;NHRPZDDFES-.-^9;:NY_23\.O@9IWB:T,^OZ7!=
MVS1J8K>:!'$:D+MQO4EFSG)S^M8?Q*^#%EX25VT?2X(;,*WF16UNL. 03N)
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MJQU&SN9;*\B/B&TGCM+V!6>:SN+FU:>VBNH@K"2%I0R,K*0&!%>_:-XI\/\
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M485N *_+3]A6(#_@I9\5D1WW+>?'<IC</,D;Q>#"KA.3"23YV.=@& 2:^_X
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M'/XQ5:-.C*JE3P.;8B'O5:55.TZ,59Q<>64E92<9P_F[Z8$I0^C5XP27O?\
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MGB\-45XUJ5NWM(;=_BV9M87)&>G)'/8<<]>,^IJ.1XXE+.X R!V')XP,\G/
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M3-#%A3_47X7\*67A[3XK>&)%;R=C8&"-P"D#;R.,\]@<]:_(3_@J_P#\$O\
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MZNL1"E-S4DH7YHK66S>ZLKNS]#^VR1&9_OGAE8$ 9&UCE>G1@2/P[CK^4O\
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M-820RW\44A:/;Y6YR1]X?T>V4GVM5FB=)(7MT>WE"RJ[I,%EB9UD6-EW(5<
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M[+1-OI]_\27_  3P_P""*WQ:\6_'CP'XV^-UI8:=\./A[KNE^*QX=B$MU?\
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M77:E6Q6(KXFJTK+VE>K4JR22Z)U'%>23ZGV%"DJ%&E13NJ<(P3[J*L@HHHK
MU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ J-E8@@=R3QUYZ?E[5)2$ ]:3UTLFGO?I;
M:RMKKZ":=U);QO;L[]S/FM5VY)P2R\JNYB H7# Y#' Y.,'/0D9J:+<!\^6P
M,!B K-@ <  *O.", 8_G9**>V/H335B126&<GKEB?R!Z?ACM5M\RCS2E+D=X
MK9?.WZM^2)C"U_@IIMR<*=*"=23^+GJI1FXO>VMOF.0Y53C''2G4=**DO\/+
MMY?(**** "BBB@ HHHH **** "BBB@ HHHH **** "@_3/M_^NBBDU=-7M?J
MN@"9_P!EOT[_ (__ *N]1D9)^1L?48Y]N3]1SSQ4M%)1M?WF_6SM^ .[M9N/
M>W7R=[Z$+H'4JZ%E88VMAE(/&"#V]1SCO5.#3+&T<FUL;: L<O)%'&CL<$ G
M R>IZGOVR:TJ*3BW9J;C)/645&[7\KTUCN"NNOY?Y#%!&!@^YR/Y=/RP?SQ3
M\#(/IT_&BBKLM;*U]7;J_P#@BMW?-K=72T]+!1110,**** "J-]:07MM+:W$
M"SQ2)(K+(JO&RR!E96#[@5*D@@J1CM5ZFN"58#KBFKIIIM--6:W3OHUYIZKT
M"R>CV>C]'H_P9^6?QX^#<?PKNM1U&QLA<?!_7KF:XU33T$DMQX"U.ZE0R:MI
MNQ7BB\-WLQ<7MB8A%I%QMUD2J+BX$?X+?MS_  YT?X6:OH/B[388T;Q3J5[9
MSR6[QP:;<Q06XO([Q/+_ '7V@PLHDG#;9@J3N5>< _V.:QHMCKFGW6F:C;0W
M=E>0R0W%M.@D29)49'CD1@0R$,3AE(^Z<$]/RH^-?_!+SP=\;?B;\,K?Q/XJ
MO/\ AG_P->:QXFU+X<6K3VNO:YJEZD-I:^#T\0++YMAX&ES+J%_:P@W;6\+Z
M-;3P6\Z7-K^_^$_BK@N&N:/$,JD:671K5L'*C3<ZN)E2IWI48RGS4X8BM4<:
M4)SC&CRRG*33BD_XA^D=X <9\89UD6<>&KI*.<8^AE?%N Q%>%'"X7"UIRA#
M-X6=.K'"8:,9ULRY*CQ,X2IPP[ASU.;YB_X(M^./VAO&>F^)?M_A6:/]G*Q,
ML.D^--=OKJVGU#Q= R(NG^#+&: ?VWI=J4E77-1CGCTJV(M(+?[3>K<;/Z#Z
MY'PQX7T+PAH.C^%O"VCZ5X;\.>'[*TTS1M%T.PATW2]*TZS58[;3[&TME2"&
MWB11'Y:*0R_,S-)ESUU?E'&G$\.,.)LUSZGE>$R6&.KNI#+,(I-487G&->O-
MSG&IB<7R^WK2IJG3YVU&$4DC^FO"K@/_ (AKP-DW"$L\QO$57+8UO;YGC'93
MK59QJ5,/@::BEA\LPLG*C@</>?LZ2;E-SJ3"BBBOEC]$"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FO]T_A_,444GL_1_D)[
M/T?Y,B'1OI_45GS_ .O;_KV'_HUJ***O^ZU_^P>7Y40?Q8K_ + JGY1)X/\
M6I_UQB_I6A110_C7_7FC^4RO^7=#_L'H_P#IN(4444Q!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex10-6_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-6_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "7 G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BF%\$C&<>__P!:D\S'48'8DX!^GT[\<]J.C>]NBU;]%NWY),:3
M>W]?Y_(DHIH8$<<G&<#/3ZXIK2*HR2@XS@N ?Y?G0M;63N^EG?YJUU\T)Z;M
M+U:7YV)**JBZB+;0\9/. '4'C'7)Q^O/:E^U0YQYD><XQYB]?\_T]15.$UO&
M6U_A>W?;R9/-'I)/SBU)?>FU?RO?R+-%,5PWW2I'J&!_3K2EB#@+D=SG 'YC
MU]ZBZZNWKI^=K_(=T]M?34=132P'N?2E!R ?7_(I^8Q:*** "F2 %&!&X$<C
MUI]4[^\M[&TGNKN:.V@A1GDFE8(B* 3DL2%&2" &(]R*3?DW?2R3;?EIU>R]
M1.R3;2:2=T]FK.Z?DUH_4R]3O['2+>]U+4'M[.SMH'EFN99!&@C1<GS'<[$7
ML2<#CUXK\<?C)_P6$^$_PI^/WA7P1=^&YM6^#DLM[X?\>?$BR:6XO_"VKM+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7E]>W=KI^F6-A9QM<WNK:IJ%U+%#!&K1SWNHWUY*0TS3NSX8 ?-/A#_@H_\
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M"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]Q<1VZHTF3O
MD"( !RY#%1SP-Q&U22 7*KG+*#\/_%O]IWX<6^OW'P_TGXD>!Y?&-O<36<WA
MJV\4Z)+KT5RK.C6CZ:M]]K%^I0JVGF(7B,LBO$KQ,H\'_P""SO[4OC+]E/\
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M;9?L%H("@VV\;XCB)'JGPB^!_P"T%HWPFDL$_:PUS6+_ %_X>>#;+P!=:O\
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MVR_:D*BYN[=GD5\QL 0/K.$?#7C+A/QCR?AO*.+^'LCXIA0IYQD6>QPV-S3
M9I@\?E.8XC"5L!AI8+$N,\1EE'%R]AFE'#QBY4Y5)PE&+?YYX@^/'AKX@_1I
MS_Q S[@'C7BC@3$8W&\/\3<,QJ8#)LRRK.,@SC!X6>%S;%TLVHRPV'CGZPN$
MCF>25,>\1#G_ -@C"\9?NG\*_!=E\*_AKX&^'=CJ&H:Q9>#/#.E^'8=6U.1Y
MKV^72K5+<W5R[&5@TS(75&=A$C)$'8)N/?"\B(!'.5++\RC<0,E%!(8L!U!
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M,*6%M7EEV8-5Z3E&E7Y9WM^K5%%%?FA_0 4444 %%%% !1110 4444 %%%%
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M_?==/\C^]B;_ (*@_L(0$"7]J#X00Y' D\::2N?4C,HR,^PYR.<9K?\ !/\
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M?YH@"-X<;LI%&,,S$>6N0"X9@IR/B9\0[OQ!=E6+A 6"Q,2KLQ7>J%"<$LK
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M)I'N,GS_ #%X/K<'<4>'G#%#Q5P53.<_K4>->&,YX7RBM3X6C&=#^UZ_UO\
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MC/@OAOAS"8&AQ9+Z]A<;PK]8J8:M4A_J_&FL/F$L0\/4:E*6&@E5Y:G*X/\
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M/_'&C7&CZ_I_Q%\5ZOXRU,Z8&LH]*US6YEGU14AN)')M;VZ2:]C$;,8WFD#
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MQE':4>9/:VUDT];M-/T%HHHJB@HJE<;ECD5'92ZL/,&24)Z-_NK@[B 2.>O
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MFD@TEC"(I(;""%3;*EI&D4!=:_L'&\0<$< ?2(\2>/>)N,\-@H9?0J99+A3
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M>&/"/A^Y\G['JNO:S86%I?\ VF-9+8:>\LX-\;E&!MUM5E:;!V!@,UA_#?\
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MB&A7JX.O@XT\54H0PRKU)-4_91;?1F?TF?$'*N#_  L\7L?P3PG0\+?$7/\
MA7(*V78;.\\QO'64QXKKT\NP6<\\\NPO#^)HQS.ECX/+(4H8I8.C2JSQ$IU7
M*C_3)/JEK;0O<2EDBC4O)(^Q$CC #-)([NJ(B*=S,S *OS$XYKYQU?\ ;2_9
M6T'4;O2M7^.OPZLKZRO9=.NHF\0V<Z0WUN"9[-[BU>>V%S%M;?!YQD&UL*<'
M'A?[=7P7_:0^/.B^$?A/\&?%&A>!OA]KK:M)\5O%%_JES9WKV-O'9IH>@10:
M=')K&H65X\MY=7EGITEDEW]EB@O=0AMV,4OR3^W%K/[,G@#]D75/V??!%UX'
MU'Q[X1L/""66E>$-"@U2XTB_\/ZGIL5]K/B'6-&M[B'PY<:E+'?[)-:U**YN
MYKIK9DN'WJWR' _ >0\1U.%L-B\RS3-,TXHSV67U<HX3PCQ5?A;)W6P>&IYY
MQ%C<5@J^"IJMB:V(AA\!AW&K5H485ZE>G.M2P\_T?Q2\8N,.#(<?8[ </Y+D
M?#_ ?#6(S3"9[Q_6Q>64?$/B*.!EF'^K7!N'P6.C5J87+<,\.LQSRKA\0Y8W
M%1PE' JEA\3BJ?[4Z/XHT+Q!I-AKNAZE:ZOHVJP0W6F:GIL\-Y8W]K.N^&YM
M+BWDDBFAD&0KHQ!*L.U8/CCXI?#SX::))XC^(7C'P_X,T*,[3J?B/4[32[:1
MSC9% ;F5'N9I,G9#;I+*V"-F1BOS9_X)9>*WL_V+;G5]=NII-)\&^+OB%+ L
MKF7[#H6G,NKS:?9*=ODP6Z^>ME"I"PF4QIM0XKY(_8EN5_;G_:U^)/QH^,TT
M'B[3OAOH%EJ_PZ\%:O MYX8\*?VWK&HV/AT6VAS,; 3:3IUA<7+7#0/<S:G>
M32SSND<*)V5O"BG@<Y\4H9GFU?#\.^%>+J8;,L=0P,ZN.S?%5\8L/D^68)3C
M]1PF(Q].I3JXS%XRI##Y="-5J-:HZ=!^5#Z1F(S'(? 6AD>0X2?'WCW@J&-R
MC(\WQ&-H9-PU@L#E]7&<3YOGF/RW#XG&5,%@9T*E/**&%IT:V:SE1A*K07M:
MB_8GPK^V#^S)XVUVT\,>%OC7X"U;Q#?SBUL-'CUNWMK^^NG56AMK2"^-J;B>
MXWHMO%$6:5VV*-P('T%<ZI96<3SW<R6T$<;S2S7$D4$44,8)DEEDFD1(XT4%
MF=F"@ G/%?E_^VC_ ,$](/VE?$G@;QQ\/?$>@_#;Q9X;2#3->O(=&EBMM5T6
MTO1J&GWUB=&-C)!XAT:Y>Z_L^:59(U^U*Q0^1$A^3_\ @K=\:_%7A6W^%_[-
MVAZ_J,>E:IX/M]<\?:IY[VE]XG%M/;Z%H-GJ4MNRRK9W4T%YJFJJI2">1568
M&&-LKASP[X:X^S?@C)N#>)<5''\0T\TJ\3X+,<%'$UN$\/E<9UYXF&)P\<-A
M<WCB\)3G/#0IQH6J."J3C#GDCB[QPX_\).&O%+B7Q3X(RNKE7"6.X?PG &:\
M*8[$T,'XA5N)(_5\+@H83.:F88[*J^68_F_M:I-3Y<+3J_5(5ZWL5+]83^VI
M^R@-6_L,_'WX:C4OM\FF>4?$=H(/M\<AA>W^W$BPW"563=]I\O<CC?\ (V/<
M==\?>"_"_AR\\8>)/%&AZ#X3TZVAO+[Q-JVJ65EH-K9W)B6WNY]7FG6PCMIV
MGA6*=[@1N9%VL00:_)7Q+\,_BCXB_9VG^ NC_L!>'-+T";P,=&\/:K;?%_X:
M#4-'UB2Q$>G>,K:2"QAOI]1COS'JTJI>1W$CB>WN#-$Q1_4/^">_P@^//P]^
M%/C'X._M+>%+6Z\)6.J6[>!K/7=7T;Q=')HFH6P_MGP]=6D,]_"FF6.JI%>V
M-O<MMC6[N&CBA\PJ>+.^"^$L-D.-SK+>(*L,5E&?4\#BN'\5G?!F8YEG.18F
M<J%+.,G>48R?U?&8>M2E+$Y5CJ4^6-:FEB)JC6;]3A;Q7\2<PXPRWA7..#L-
MB,%Q#PAB,VR_B_*N%_$3*.'N'N*,#R*OD/%-7B;#49/ 9BZT/[&S#+ZM#%UG
MAL1'$X.DL1@JC^XO!G[1/P)^(NN)X8\ _%SX>^,_$4MI<7\6A^&?%FBZSJDM
ME:J7N+N*SL+R>:2VA49>=5,0&/GY&:/B7]IS]GGP9KNH>%_%_P :OAAX7\2Z
M24&K>']?\;>'M*UG3#+"L\8O]-N]0CN[8O"ZRKYL2AHV#C(.:_"S]@O2]*TG
M_@I5\6]+TG2K;3=*TJ3XX6.DV-G!]FM++3[3Q*L%M;V5M&WE0101?Z.D,:JJ
MQ@*H4 5]+?\ !8[PKX9MO@]X \30:#I$'B6\^)EI8WVMVVF6D&N7UA)X<U7S
M8+R^BCCN+J!Q%"CBZDG \I=JY1,?78KP?X=PGBWPCX<1SKB'&8+B[(.%LSPV
M/IX;A^CF6 Q7$6 J9A-8W"RKUL$\/A8TW0G&GBH5N9>T2T=-_G^ ^DIQSCOH
M[<?^-,.&>$*>=>'_ !3QADN,R&>,X@GDV:9?PMGE#)98G+\SHU7B_K=>I5E6
MAS.KA)*+IM*<9L_6V]^)7@"'P?'\19?&?AJ+P&UBFJ)XPEUK3X_#DFF<M]OA
MU=[A;*:W*D,CQ3.TN<1*[86OS.\#_P#!1OP!X\_:MU[P>OC+PAX4_9[\.^!M
M7CL/&GBVYLO#Y\5>-;?4=-<SV.I:M<VS1Z3)9RW']GVJPA]3BBENIC$(HXJ^
MAOV9OAYX,^(?[#GP4\*^/_"^D>,?#=]\*?#<]]HFOV-OJ.E74EC%->6#3VUP
MIC+V<X62%U4%9 'ZXV_C)_P35^$?PO\ BK^T?\7/"WQ)\ >%_&GAK2_#WB*^
MTS0O$6DVVI:78W%OXQ^S0/:6MT)%BDMK61K:)U8%+=RB@ !1? _ / BR3QQQ
MW$*XAS#&<"PQ>!P=7 _V-#"PH4\[K993S&A2K2BZF=-82:E5Q:I97"C5E[.3
MKRIS7/XK^+'BNN*?HMY=PE+A?)LN\5\PR3.L?0QU3.:F*Q./I<.4LZEDN.J8
M2K!4^'8?VG*4YX"-?-,36P]&-6,(+]Y^\/QK^(W[+.I_#6>Q^-_C+X8W_P .
M_%6CP:O!I^O:WIE[;:]ILB+<6.HZ';6\TFI7<D\4B7&E76E1_:79DELI2P+B
M_P#LI>,?@EXN^#.@:U^S[H3>'_A/'/K&E^'+(:(V@B3^P-3N])U&]^P3227;
MB[O+.61+V_<WEY&$EN CL5'Y^_\ !4SX#?!G1/V;+OX@Z%\.O#6C>./"5[\-
M_ ^@>(-+TZ.SOM+\)6VHKIUIX<AEAV@Z78Z:7L[*W966TC>00>66W5ZE_P $
MW-?L_!__  3^T/Q5?(W]F>&S\6]=N8XUC,KVNE>*/$5_);Q)A(VDF,3Q+NQO
MDE0R-G)KYR?!F3?\05P?%V4YKQ34J8SQ#H\/4\@QE7"4\HAB)X/%XC%XF&#P
MV-Q+JXZK"KE=.EBI4X.+EBH\JC[,^QP7B/G^'^D[FG W%'#_  -@<+E/@Y6X
MQJ\59)A*V*XAQ.6+&8*NL!FN<YWA\%C,ERRC5PV>8RAEN&GBL+B(TL/6Q.*H
MUJ4X/] _'OQ=^&GPLT8>(?B3XU\.^!M%>86\&H^)]5LM*@NYV("Q60N9EEO)
M&+ ".UCE<Y'RUYYX/_:W_9J\?^(8/"?@_P"-/@'7/$EW))#9Z+;Z[;0:A>3Q
M0Q7$D%I;WAMGN)U@FCF\F,-(T;!D5N:_'/\ 8!4?MJ?M)?%GX^_&U&\6:EX(
ML- F\!^%=91;WPYX1&N76K+HYT_2)S)IT+Z-I=A);1)+;R)-J%W<W]PCW"QD
M?7_[77_!.VW_ &A/B+X%^)WPZ\4Z-\,O$N@/I=EXID&B3"/5K#2M134-/UK2
M;C1_LSV_C#3L2VUM>WBS6\T;0><F;6+.^9>'?!G"?%TN!>..*<RRO-Z64QQ&
M:9S@L!2Q&39!GF,R=YQ@,GQ&']AB,=F-"-.>$PM?,J$J$)XO%.%&E[.C[27/
MD?C/XO>(? <?%'PLX X>SWAVMQ3/+LHX3S?'YC@^,.(.%L#G7]B9EQ"LVH8J
MAPGD^*=:.*QF#REO,YRP&$C5GBI5:TZ4?U'N-4LK1)9;J9+:&&&2>:>X>.&"
M**)=TKRS2.L421#'F/*R(F1N8 BOF^Z_;4_90LM3?2;KX^?#2*\2<VQ8>);*
M:R-RKM%) NIP/+IKR0R(R3!;HB,JQ9@JLP^9/VT_V?\ ]H_]H^Y^'WPK\">+
M](\%?!"WTP:G\3_$5_J4T6L^(-5L[VTAM].GTZV5+G4K1=,BFOVB-Y::9/?7
M)%[.5B5*^3_^"D'BK]F[3OV;--^#OPHN?!EWXL\!^,?!2+;^!]$CO(/"]C8V
M.H6EQ:ZMXCT:S?1].U"_@D0&QU'4DGU%&F586/S+P\!\ \-<48SA#+L3G^.S
M#'\5YA]0Q6&X;H4ITN#Z$L=5P6$S+B;%9CERIPJYC*$:U+*Z%2A/#X22KU:\
MZDZ=,]'Q:\;.-> LL\0\[PG#G#^0Y-P'D\<=E^-\0L9C<#6\0\\_LVCF&+X;
MX.P.48N%>IA\L52I1JYY4CC)8_%4*U+!Y=3P]#$8P_<"/^Q/%&G";98:[I&I
M6\%Q!YBVVIZ5J-M<H)K>5 R3V=U;S( 8Y5WHT9# C(-?SL_\$_8EM_\ @H]\
M6+.UA@MK.Q;XX)!:V\4<4-K;Q>*XH$AC4!0L,(C*I&BB)%(*JNZOU(_X)CZS
M?:O^QI\(Q>O,XT<^)M$M99FEDDDL=.\5:O': M*781Q6Y2VC0.R)'%&%;@"O
MRT_85B _X*6?%9$=]RWGQW*8W#S)&\7@PJX3DPDD^=CG8!@$FOO^ ,EK<-Y5
M]*#A:KC:DO\ 5[A/$Y9.I"M5>&Q%>AQ-1PL:BHJM*D^>A2C4:M:#E+WN2+BO
MQ[QAXFP?&N?_ $%>/*66TL)+BSQ$RS./JLUAX5</]?X4PF.J*6.KX2KBU3PV
M+J5HTKU7&5&Z^K^VK1JP_H$\?_%?X<?"?1AX@^)/C7P]X*T9[F.UM[[7]1M[
M".[GERL-K9I(XEO+ERCA8;:.5_E;( !-<7X%_:M_9R^).NV_A;P5\8_ NO>)
M;MF2TT"WUNVAUB\9%+LMII]TT%S=,J*7*01R.$PY7:RD_CW^WI\4]7^"'[>/
MPE^*_P 0_ Q^(GPP\/>!+5/!_AV^4+H4EW?Q:O9^)=0TA[F"XLK?Q3I5[=6M
MZ'FMYGFMDMH8S;&1Y8NAB^*'['7[8_QA^!WBWPAJLGP"^.O@+Q_X<U_38/%?
MA"UTJV\>Z9I=]'?S^$!K.C7J:3>7=UMQH\]Y=K?QW:I"+*Y@8P'P,)X*5*?"
M61\68W!\68S),\X8Q>>XGBK(,'EF;9+D&.H0S>G@\JSG+\/7KYS"G"KEN'H9
MIF,*,?JCQT*SPJI4JLC[[,_I+XO_ (B%Q1P)E-?@/+.(.&N-L'PMA>!^-,=F
M?#O$_&&62KY-'$\1<-YMBL3@^&I4J^"Q^+Q.28+VE:68O+W2JSI5\31HR_>)
M9E9@@5@2&/( 'RG![YZGCC!]:EK*M03=,RY*,A9\J5*R$(I#@Y^8[,C:P7'&
MW/-:M?S]'JN=S:=FY4_9N[C&5N6[35I)QDMTU=)J27]APFIQYO=O>2DHMRC&
M46TXJ;4>?ELN:23CS\\8N2@I.E/'(S-MVD, I5B<%"^7/8 E,@=QVYK\9_\
M@L^K)\%/A&!*8@GQ5G1%5=V%_P"$2U@,^X$990609Z@YS@U^T+_>_P" G^35
M^+'_  6H8CX-?!T+T/Q5O@1GK_Q2>KCCWR<^U?K7@#>7C1X:SC+DJQS^,56C
M3HRJI4\#FV(A[U6E53M.C%6<7'EE)64G&</YN^F!*4/HU>,$E[W_ !B5HPG[
MU*+CFF2T^;V+_=2O&M)S52,XSE&#<?=L>Z_\$HSC]C;P@N69%\7^.R&/38VO
M2YRI."6*EMN.YP#DU]D?%_\ :#^$_P !/"<OBSXE^*K/1K%)H+.TL(3%<Z[J
M^H74J0VVG:/HL4OVR^O9I' 2*- JJKO)(D:%A\;_ /!)P?\ &&WA%B<!?%/C
M8]%(/_$^N>N[(QGKC#'&-PS7Y8?\%3_@-X2^$'QI\'>*O"VI^(99/BN?$GB'
M5['6=6N-6M=#U^+6K W%QX>>],EWIMI>-J+3SVT=R887CC2VV0GRU^^7 >3^
M(?TB>/>%\US7%Y+1Q/$_%>*HRRS+(XVOC*N =3%SPL;2A1P?-0ISG&O5IU:4
M5&5&%*-2<)P_)JWBUQ7X,?0V\*^.N&.'\MXEQ%#@C@G*ZT<WS-8&CETL?2AE
MN S!86$(U<UOC:U+"U<!AJV#G&%18R=6='#U*4_Z#/'/[3WP!^&,NF6OQ#^*
MW@SP=J&L6-OJ5CI.N:U9VVK/8W,<4D-S+IRRR75O$PF10\T:*7RJEL9/I?A+
MQYX0\>Z#8^*/!/B'2O%GA[4HUFL=8T"^MM3L+B)^CK<6TKHI'(DBD*31$$2Q
MH:_/ZX_8+_9HF^#NN1ZGX 3Q-XRUCX?W>NWGQ.\3WE_K'C^XU>?09-1BU3_A
M)Y)TN+&>"_5/LME:(FGVUI$+2.W$3R[_ (G_ ."+&JZI'?\ Q\\+/?2SZ/:V
M?@_5!IX=Q96^J2WFNZ=>7L-ODPP374%O!)>31*INI+99'&[FOCGX>\,9OP#Q
MMQ5POG/$%;,. L?@</FM+,LKR^C@<?AL?F$\#2J8-4<94Q&"J>TC[-4L=4K5
M927/+V<:D51_1(>,_B3D/C!X:>'W&O#7!"R3Q9P6:SR+&\+9UGF,SKAO&Y!D
MF%S;,X<0K-<!@\GQU"?MI>SK93.%*DJD:2]M.C4G4_>'Q!XQ\,^$],OM;\4:
MSI_AW1--@DNM0UG6KRUTW2K.WB7>\US?7<T5O"@' ,CKN;Y5!-?/UG^VY^R;
M?ZC:Z7:_'OX<O>WLD45FCZ[#!#=//-]FB^SW=PL5I,DEP1"LL<S1>80I<&OQ
M\\4>.C^VM_P49T7X/^-+R^NO@5\/?%/B6TL?!0E9=&\1R>!=(O[K4KK5;1&*
M:A)K.LP)"R2[HUT:!;=+?S0\[_I'^V%^Q#X6_:3^&.D>$?",/ACP!XJ\(ZBM
MWX0U5?#ULND6UF]H+"_\/ZA;:9'9W3Z1=VNR58TD:2*ZC2>,E]ZM6(\/^$^%
M,QX.RCQ SK/,!B^*LIP.=YEB<GPN6U\+P=@,VHXFKE3S2CB9RQ695ZJIX>KC
M:."]E+ TJKC%8FLN6.&$\;/$KQ#RCQ&XD\&.%>%<[RC@+/<SX6RC <09AF,L
M[\1L\R'%X59Y_8M;*<1A<FX?RZEA,7;+:V:U<;BL=7PU6=7#X6$U%??4.H6M
MS$D]O()X955X9H2)(IHWQLFAD0E)86!!61&9&!R":M)(LFXKGY6*'(QRO7'J
M/>O#/V=_A;JGP5^#/PZ^%^L^([GQ;J7@GPU:Z+=Z_(KHFHSQ9;,*29D%K;JP
MM[82;I$MXXE=R^XGW*,$+R,$DDC&*_(<=3PV'Q^-PV$Q$<;@Z.,Q%' 8^"E"
M.882E4J1I8OV$DY8?VU.,*GLIR<H^TY;WBT?TYDN+Q^.RO+,7FN7/*<SQ>5Y
M?BLQRCV\,5_9&85L-2J8S 2Q<%&&+]C7G4I0JPC%-4N:WO$E%%%<QZ@4444
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MJD-M:78^QS3A/[*OAS\+[_Q!<PRO S0&03R2,H'G[V)+8R0A4$1O$N CHZJ
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MQJGB>'PEXO2S\KPU?0G6YS = &H&&PE?RY_)L)ED:',<@4DC]$/^"H'QN^(
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MGGO"^58/"472P7"N;YGCGEV29=C\SP\\3F\:.45<?FD<36IU9855(XF'X?\
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M%3B+%^RP^89IAZ^#Q->GBH92J\Z<:>)DZ5!0B^:*J5*E6,;'YOQ#]'?.^(_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %(0""#WHHH ;L7GKSQU-126L4A).\,4";E8@[0V['IG/4XSC([T44/6+
MB]8R3BXO9Q:2:?E9+3R7832?-=?%!TY;^]!VO%ZJZ=EI^(Y8$1PXW9"A0"Q(
MPH ''KQGZ_4U-111V\DHKR2T2OO9=+M^I5V[>245Y12LDO)+1!1110(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>15
<FILENAME>atnm-20200630.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: atnm%2D20200630.xfr; Date: 2020%2D08%2D13T15:50:50Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:atnm="http://actiniumpharmaceuticals.com/20200630">
    <link:schemaRef xlink:href="atnm-20200630.xsd" xlink:type="simple" />
    <xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-01to2012-06-15_custom_LicenseAndSponsoredResearchAgreementMember_custom_FredHutchinsonCancerResearchCenterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-01</xbrli:startDate>
        <xbrli:endDate>2012-06-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember173911536">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-03to2018-10-31_custom_LincolnParkCapitalFundLlcMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-03</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_OakRidgeNationalLaboratoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_custom_OakRidgeNationalLaboratoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_CapitalLeaseObligationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_us-gaap_CapitalLeaseObligationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_OperatingLeaseLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:OperatingLeaseLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_FinanceLeaseLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:FinanceLeaseLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_WarrantMember545104671">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_LincolnParkCapitalFundLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-04to2020-04-24_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-04</xbrli:startDate>
        <xbrli:endDate>2020-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-04to2019-11-30_custom_OakRidgeNationalLaboratoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-04</xbrli:startDate>
        <xbrli:endDate>2019-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-19_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-19_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_CapitalLeaseObligationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_CapitalLeaseObligationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atnm:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atnm:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atnm:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-15to2020-07-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-15</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-30_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-30_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-30_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-30_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-03to2020-06-19_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-03</xbrli:startDate>
        <xbrli:endDate>2020-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-15to2020-08-20_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-15</xbrli:startDate>
        <xbrli:endDate>2020-08-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_EmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">atnm:EmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_NonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">atnm:NonEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USD_per_Share">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-06-30" unitRef="shares" decimals="INF">3236</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-06-30" unitRef="shares" decimals="INF">3142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-06-30_us-gaap_OptionMember" unitRef="shares" decimals="INF">365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-06-30_us-gaap_OptionMember" unitRef="shares" decimals="INF">264</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember" unitRef="shares" decimals="INF">2871</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-06-30_us-gaap_WarrantMember" unitRef="shares" decimals="INF">2878</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <dei:EntityRegistrantName contextRef="From2020-01-01to2020-06-30">Actinium Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-06-30">0001388320</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="From2020-01-01to2020-06-30">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-06-30">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityFilerCategory contextRef="From2020-01-01to2020-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2020-01-01to2020-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityShellCompany contextRef="From2020-01-01to2020-06-30">false</dei:EntityShellCompany>
    <dei:EntityFileNumber contextRef="From2020-01-01to2020-06-30">001-36374</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-01-01to2020-06-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-06-30">2020</dei:DocumentFiscalYearFocus>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-06-30">P2Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-06-30">P2Y2M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="-3">8813000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">195666000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-186857000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" decimals="-3">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">213251000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-197555000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">15701000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">197866000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-192527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" unitRef="USD" decimals="-3">5343000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">50774000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">5644000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">214397000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">269815000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-208758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-214428000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">217442000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-214428000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3">3020000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember173911536" unitRef="shares" decimals="INF">3856768</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">5401117</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">3971201</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">5490038</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">13171824</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">5827982</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">277000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">277000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">210000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">372000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">316000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">210000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3">372000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3">316000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">74</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">5240</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ProfitLoss contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-5027000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">-5027000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">-4625000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-5670000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-5670000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-4625000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3">-5670000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3">-5670000</us-gaap:ProfitLoss>
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2019-04-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">1504000</atnm:StockIssuedDuringPeriodValueWarrantsExercised>
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3">1504000</atnm:StockIssuedDuringPeriodValueWarrantsExercised>
    <atnm:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">1249</atnm:StockIssuedDuringPeriodSharesWarrantsExercised>
    <atnm:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">83542</atnm:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Basis of Presentation&#13;- Unaudited Interim Financial Information -&lt;/b&gt; The accompanying unaudited interim consolidated financial statements and related&#13;notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S.&#13;GAAP") for interim financial information, and in accordance with the rules and regulations of the United States Securities&#13;and Exchange Commission (the "SEC") with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do&#13;not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim&#13;consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in&#13;the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are&#13;not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be&#13;read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's annual&#13;report on Form 10-K for the year ended December 31, 2019.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:LessorLeasesPolicyTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&amp;#8211; The&#13;Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporate office&#13;space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is&#13;recognized on a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Fair Value of Financial&#13;Instruments&lt;/b&gt; - Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,&#13;in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives&#13;the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable&#13;inputs.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development&#13;Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product,&#13;the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities&#13;and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments&#13;-&lt;/b&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing&#13;model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee&#13;is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt;&#13;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt;&#13;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt;&#13;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt;&#13;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt; width: 52%; text-align: left"&gt;Operating lease expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;93&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;93&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;186&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;186&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;50&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <atnm:ScheduleOrDescriptionOfWeightedAverageTerm contextRef="From2020-01-01to2020-06-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average remaining lease term:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 89%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.2 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finance Leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.2 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</atnm:ScheduleOrDescriptionOfWeightedAverageTerm>
    <atnm:ScheduleOfWeightedAverageDiscountRate contextRef="From2020-01-01to2020-06-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average discount rates:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 89%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finance Leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</atnm:ScheduleOfWeightedAverageDiscountRate>
    <atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in&#13;    thousands)&lt;br /&gt;&#13;    Year ending December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Operating&#13;    Leases&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Finance&#13;    Leases&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 78%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020 (excluding six months&#13;    ended June 30, 2020)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;187&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;47&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;94&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;252&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;816&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;209&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less imputed interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Present value of lease liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;747&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;191&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="From2020-01-01to2020-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">50000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="From2019-01-01to2019-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">52000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="From2020-04-01to2020-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">25000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="From2019-04-01to2019-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">26000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseInterestExpense contextRef="From2020-01-01to2020-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">9000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="From2019-01-01to2019-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">11000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="From2020-04-01to2020-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">4000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="From2019-04-01to2019-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">6000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="From2020-01-01to2020-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">41000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="From2019-01-01to2019-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">41000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="From2020-04-01to2020-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">21000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="From2019-04-01to2019-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">20000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:OperatingLeaseExpense contextRef="From2020-01-01to2020-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">186000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="From2019-01-01to2019-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">186000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="From2020-04-01to2020-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">93000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="From2019-04-01to2019-06-30_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3">93000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2020-06-30" unitRef="pure" decimals="INF">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2020-06-30" unitRef="pure" decimals="INF">0.08</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OtherRestrictedAssetsCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">391000</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:OtherRestrictedAssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">391000</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2020-01-01to2020-06-30_custom_LincolnParkCapitalFundLlcMember" unitRef="USD" decimals="-3">200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2019-01-01to2019-06-30_custom_SeriesAWarrantsMember" unitRef="USD" decimals="-3">1500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2020-01-01to2020-06-30" unitRef="shares" decimals="INF">300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2020-01-01to2020-06-30_custom_LincolnParkCapitalFundLlcMember" unitRef="shares" decimals="INF">27000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">2500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <atnm:ShareCancelledDueToTerminationOfEmployees contextRef="From2020-01-01to2020-06-30" unitRef="shares" decimals="INF">400</atnm:ShareCancelledDueToTerminationOfEmployees>
    <atnm:WarrantsExercisedByWarrantHolders contextRef="From2019-01-01to2019-06-30_custom_SeriesAWarrantsMember" unitRef="shares" decimals="INF">83000</atnm:WarrantsExercisedByWarrantHolders>
    <atnm:WarrantsExercisedByWarrantHolders contextRef="From2020-06-03to2020-06-19_us-gaap_WarrantMember" unitRef="shares" decimals="INF">0.003</atnm:WarrantsExercisedByWarrantHolders>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">1500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SubsequentEventDescription contextRef="From2020-01-01to2020-06-30">The Company issued 5 thousand shares of restricted common stock, valued at $30 thousand, for consulting services.</us-gaap:SubsequentEventDescription>
    <us-gaap:SubsequentEventDescription contextRef="From2020-04-04to2020-04-24_us-gaap_SubsequentEventMember">The Company issued and sold 4.3 million shares of common stock and 2.8 million pre-funded warrants to purchase shares of common stock. The price to the public in this offering for each share of common stock was $4.50 and for each pre-funded warrant was $4.497. Each pre-funded warrant has an exercise price of $0.003 per share and is exercisable immediately upon issuance. The pre-funded warrants are subject to certain limitations on beneficial ownership. Gross proceeds from this offering to Actinium were $31.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this offering were $29.1 million.</us-gaap:SubsequentEventDescription>
    <us-gaap:SubsequentEventDescription contextRef="From2020-08-15to2020-08-20_us-gaap_SubsequentEventMember">The Company filed a registration statement including a base prospectus which covers the offering, issuance and sale of up to $500 million of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus covering the offering, issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued and sold under the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC.</us-gaap:SubsequentEventDescription>
    <atnm:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="From2012-06-01to2012-06-15_custom_LicenseAndSponsoredResearchAgreementMember_custom_FredHutchinsonCancerResearchCenterMember">Royalty payments of 2% of net sales will be due to FHCRC.</atnm:DescriptionOfRoyaltyPaymentToRelatedParty>
    <atnm:PurchaseOfMaterials contextRef="From2020-01-01to2020-06-30_custom_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="-3">100000</atnm:PurchaseOfMaterials>
    <atnm:PurchaseOfMaterials contextRef="From2019-01-01to2019-06-30_custom_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="-3">100000</atnm:PurchaseOfMaterials>
    <atnm:PurchaseOfMaterials contextRef="From2019-11-04to2019-11-30_custom_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="-3">300000</atnm:PurchaseOfMaterials>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">260000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">237000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-06-30" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-06-30" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-06-30" unitRef="shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31" unitRef="shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-06-30" unitRef="shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="shares" xsi:nil="true" />
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-06-30" unitRef="shares" decimals="INF">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="shares" decimals="INF">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-06-30" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-06-30" unitRef="shares" decimals="INF">13171824</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" unitRef="shares" decimals="INF">5490038</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-06-30" unitRef="shares" decimals="INF">13171824</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="shares" decimals="INF">5490038</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">337944</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">30817</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">2673000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">380000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3">2674000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3">380000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <atnm:MilestonePayment contextRef="From2012-06-01to2012-06-15_custom_LicenseAndSponsoredResearchAgreementMember_custom_FredHutchinsonCancerResearchCenterMember" unitRef="USD" decimals="-3">1000000</atnm:MilestonePayment>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-06-30">P2Y9M18D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-06-30_us-gaap_WarrantMember" unitRef="shares" decimals="INF">2871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-06-30_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_us-gaap_WarrantMember" unitRef="shares" decimals="INF">2871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-06-30_custom_PrefundedWarrantsMember" unitRef="shares" decimals="INF">2259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_PrefundedWarrantsMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-06-30_us-gaap_StockOptionMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember545104671" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-06-30_custom_PrefundedWarrantsMember" unitRef="shares" decimals="INF">3459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember545104671" unitRef="shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-06-30_custom_PrefundedWarrantsMember" unitRef="shares" decimals="INF">1200</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2020-01-01to2020-06-30_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember545104671" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-06-30_us-gaap_WarrantMember" unitRef="shares" decimals="INF">2865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-06-30_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-06-30_custom_PrefundedWarrantsMember" unitRef="shares" decimals="INF">2259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-06-30_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">20.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-06-30_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">36.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">35.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">20.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-06-30_custom_PrefundedWarrantsMember" unitRef="USD_per_Share" decimals="INF">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_PrefundedWarrantsMember" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember545104671" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-06-30_custom_PrefundedWarrantsMember" unitRef="USD_per_Share" decimals="INF">0.003</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember545104671" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-06-30_custom_PrefundedWarrantsMember" unitRef="USD_per_Share" decimals="INF">0.003</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-06-30_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">15.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember545104671" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-06-30_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">20.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-06-30_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">56.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-06-30_custom_PrefundedWarrantsMember" unitRef="USD_per_Share" decimals="INF">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-06-30_us-gaap_StockOptionMember">P7Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember545104671">P2Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2020-01-01to2020-06-30_us-gaap_StockOptionMember">P7Y5M27D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember545104671">P2Y5M12D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-06-30_us-gaap_StockOptionMember">P6Y5M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember545104671">P2Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="-3">497000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-06-30_us-gaap_StockOptionMember" unitRef="USD" decimals="-3">519000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-12-31_us-gaap_StockOptionMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="-3">301000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-06-30_custom_PrefundedWarrantsMember" unitRef="USD" decimals="-3">23814000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-12-31_custom_PrefundedWarrantsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2020-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="-3">496000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2020-06-30_us-gaap_StockOptionMember" unitRef="USD" decimals="-3">112000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2020-06-30_custom_PrefundedWarrantsMember" unitRef="USD" decimals="-3">23814000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <atnm:AggregateValueOfCommonStock contextRef="From2018-10-03to2018-10-31_custom_LincolnParkCapitalFundLlcMember_custom_PurchaseAgreementMember" unitRef="USD" decimals="-3">32500000</atnm:AggregateValueOfCommonStock>
    <atnm:DescriptionOfWarrants contextRef="From2020-01-01to2020-06-30">Holders of 1.2 million pre-funded April 2020 warrants exercised their warrants at $0.003 per share and received 1.2 million shares of common stock.</atnm:DescriptionOfWarrants>
    <atnm:DescriptionOfWarrants contextRef="From2020-07-15to2020-07-31_us-gaap_SubsequentEventMember">Holders of 0.4 million pre-funded April 2020 and June 2020 warrants exercised their warrants at $0.003 per share and received 0.4 million shares of common stock. Holders of 2 thousand April 2019 warrants exercised their warrants at $15.00 per share and received 2 thousand shares.</atnm:DescriptionOfWarrants>
    <atnm:WarrantToPurchaseOfCommonStock contextRef="From2020-01-01to2020-06-30" unitRef="shares" decimals="INF">1907</atnm:WarrantToPurchaseOfCommonStock>
    <atnm:WarrantToPurchaseOfCommonStock contextRef="From2020-06-03to2020-06-19_us-gaap_WarrantMember" unitRef="shares" decimals="INF">700000</atnm:WarrantToPurchaseOfCommonStock>
    <us-gaap:SharePrice contextRef="AsOf2020-06-19_us-gaap_CommonStockMember" unitRef="USD_per_Share" decimals="INF">9.75</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2020-06-19_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">9.747</us-gaap:SharePrice>
    <atnm:PotentialReverseStockSplitPolicyTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Reverse Stock Split&#13;- &lt;/b&gt;On April 29, 2020, the Company received a deficiency letter from the NYSE American LLC, or NYSE American, indicating that&#13;the Company was not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE&#13;American Company Guide because its shares of common stock had been selling for a substantial period of time at a low price per&#13;share. Pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the NYSE American staff determined that the Company's&#13;continued listing is predicated on the Company effecting a reverse stock split of its common stock or otherwise demonstrating sustained&#13;price improvement within a reasonable period of time, which the staff determined to be no later than October 29, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On October 18, 2019, the&#13;Company's board of directors, or the Board, unanimously approved, subject to stockholder approval, an amendment to the Company's&#13;certificate of incorporation to effect a reverse stock split of its outstanding common stock by combining outstanding shares of&#13;common stock into a lesser number of outstanding shares of common stock by a ratio of not more than 1-for-75 prior to December&#13;18, 2020, with the exact ratio to be set within this range by the Board at its sole discretion. At its Annual Meeting of Stockholders&#13;held on December 18, 2019, the Company's stockholders approved such amendment to its certificate of incorporation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 7, 2020, the Board unanimously approved a reverse&#13;stock split of its outstanding common stock by combining outstanding shares of common stock into a lesser number of outstanding&#13;shares of common stock by a ratio of 1-for-30, and on August 10, 2020, the Company filed with the Secretary of State of Delaware&#13;a certificate of amendment to its certificate of incorporation to effect the reverse stock split. The reverse stock split became&#13;effective as of 5:00 p.m. Eastern Time on August 10, 2020, and the Company's common stock began trading on a split-adjusted&#13;basis when the market opened on August 11, 2020. Accordingly, all common share and per common share data in these consolidated&#13;financial statements and related notes hereto have been retroactively adjusted to account for the effect of this reverse stock&#13;split for all periods presented. In addition, at the effective time of the reverse stock split, the number of shares of our common&#13;stock reserved for issuance upon exercise of all options and warrants to acquire common stock have been proportionally decreased,&#13;and the exercise price of all options and warrants to acquire common stock have been proportionally increased.&lt;/p&gt;</atnm:PotentialReverseStockSplitPolicyTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, &lt;br /&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;br /&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53,466&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,254&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify"&gt;Restricted cash &amp;#8211; current&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &amp;#8211; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;391&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;391&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;53,905&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,693&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 1 - Description of Business and Summary&#13;of Significant Accounting Policies&lt;/b&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business -&lt;/b&gt;&#13;Actinium Pharmaceuticals, Inc. (the "Company", "Actinium", or "We") is a clinical-stage, biopharmaceutical&#13;company applying its proprietary platform technology and deep understanding of radioimmunobiology to the development of novel targeted&#13;therapies known as ARCs or Antibody Radiation-Conjugates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Basis of Presentation&#13;- Unaudited Interim Financial Information -&lt;/b&gt; The accompanying unaudited interim consolidated financial statements and related&#13;notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S.&#13;GAAP") for interim financial information, and in accordance with the rules and regulations of the United States Securities&#13;and Exchange Commission (the "SEC") with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do&#13;not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim&#13;consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in&#13;the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are&#13;not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be&#13;read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's annual&#13;report on Form 10-K for the year ended December 31, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Reverse Stock Split&#13;- &lt;/b&gt;On April 29, 2020, the Company received a deficiency letter from the NYSE American LLC, or NYSE American, indicating that&#13;the Company was not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE&#13;American Company Guide because its shares of common stock had been selling for a substantial period of time at a low price per&#13;share. Pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the NYSE American staff determined that the Company's&#13;continued listing is predicated on the Company effecting a reverse stock split of its common stock or otherwise demonstrating sustained&#13;price improvement within a reasonable period of time, which the staff determined to be no later than October 29, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On October 18, 2019, the&#13;Company's board of directors, or the Board, unanimously approved, subject to stockholder approval, an amendment to the Company's&#13;certificate of incorporation to effect a reverse stock split of its outstanding common stock by combining outstanding shares of&#13;common stock into a lesser number of outstanding shares of common stock by a ratio of not more than 1-for-75 prior to December&#13;18, 2020, with the exact ratio to be set within this range by the Board at its sole discretion. At its Annual Meeting of Stockholders&#13;held on December 18, 2019, the Company's stockholders approved such amendment to its certificate of incorporation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 7, 2020, the Board unanimously approved a reverse&#13;stock split of its outstanding common stock by combining outstanding shares of common stock into a lesser number of outstanding&#13;shares of common stock by a ratio of 1-for-30, and on August 10, 2020, the Company filed with the Secretary of State of Delaware&#13;a certificate of amendment to its certificate of incorporation to effect the reverse stock split. The reverse stock split became&#13;effective as of 5:00 p.m. Eastern Time on August 10, 2020, and the Company's common stock began trading on a split-adjusted&#13;basis when the market opened on August 11, 2020. Accordingly, all common share and per common share data in these consolidated&#13;financial statements and related notes hereto have been retroactively adjusted to account for the effect of this reverse stock&#13;split for all periods presented. In addition, at the effective time of the reverse stock split, the number of shares of our common&#13;stock reserved for issuance upon exercise of all options and warrants to acquire common stock have been proportionally decreased,&#13;and the exercise price of all options and warrants to acquire common stock have been proportionally increased.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation&#13;-&lt;/b&gt; The consolidated financial statements include the Company's accounts and those of the Company's wholly owned&#13;subsidiary.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates in&#13;Financial Statement Presentation&lt;/b&gt; - The preparation of these consolidated financial statements in conformity with U.S. GAAP&#13;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of&#13;the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ&#13;from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Impact of COVID&amp;#8211;19&#13;Pandemic on Financial Statements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In December 2019, a novel&#13;strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China to other&#13;countries has resulted in the World Health Organization ("WHO") declaring the outbreak of COVID-19 as a "pandemic,"&#13;or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictions&#13;on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses, and many local jurisdictions&#13;continue to have such restrictions in place.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As local jurisdictions&#13;continue to put restrictions in place, the Company's ability to continue to operate its business may also be limited. Such&#13;events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of&#13;which could materially affect the Company's business, financial condition and results of operations. In response to COVID-19,&#13;the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations as&#13;it relates to the clinical development or drug production of our drug candidates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The spread of COVID-19,&#13;which has caused a broad impact globally, may materially affect the Company economically. While the ultimate economic impact brought&#13;by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, including new information which may emerge&#13;concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others, the pandemic has resulted&#13;significant disruptions in the general commercial activity and the global economy and caused financial market volatility and uncertainty&#13;in significant and unforeseen ways in the recent months. A continuation or worsening of the levels of market disruption and volatility&#13;seen in the recent past could have an adverse effect on the Company's ability to access capital, which could in the future&#13;negatively affect the Company's liquidity. In addition, a recession or market correction resulting from the spread of COVID-19&#13;could materially affect the Company's business and the value of the Company's common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Additionally, COVID-19&#13;may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions&#13;with IRB's or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and&#13;contractors due to limitations in employee resources or forced furlough of government employees.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;To date, COVID-19 has not&#13;had a financial impact on the Company. However, COVID-19 has caused severe disruptions in transportation and limited access to&#13;the Company's facility, resulting in limited support from its staff and professional advisors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash, Cash Equivalents&#13;and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to&#13;be cash equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary&#13;of cash, cash equivalents and restricted cash at June 30, 2020 and December 31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, &lt;br /&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;br /&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53,466&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,254&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify"&gt;Restricted cash &amp;#8211; current&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &amp;#8211; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;391&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;391&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;53,905&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,693&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Current restricted cash&#13;relates to credit card accounts, while long-term restricted cash relates to a certificate of deposit held as collateral for a letter&#13;of credit issued in connection with the Company's lease for corporate office space.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&amp;#8211; The&#13;Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporate office&#13;space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is&#13;recognized on a straight-line basis over the lease term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Fair Value of Financial&#13;Instruments&lt;/b&gt; - Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,&#13;in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives&#13;the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable&#13;inputs.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development&#13;Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product,&#13;the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities&#13;and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments&#13;-&lt;/b&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing&#13;model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee&#13;is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common&#13;Share&lt;/b&gt; - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted&#13;average number of common shares outstanding during the reporting period. For periods of net income, and when the effects are not&#13;anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average&#13;number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common shares underlying&#13;common stock options and warrants using the treasury stock method. The Company issued pre-funded warrants in April 2020 and June&#13;2020 that are considered outstanding shares for the purposes of calculating net loss per common share, see Note 4 for additional&#13;information. Since the shares underlying the outstanding 2.3 million pre-funded warrants are issuable for negligible consideration&#13;and are fully vested and exercisable, they are considered outstanding for the calculations of both basic and diluted loss per&#13;share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;For periods of net loss,&#13;diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares&#13;is anti-dilutive. For the six months ended June 30, 2020 and 2019, the Company's potentially dilutive shares, which include&#13;outstanding common stock options and warrants have not been included in the computation of diluted net loss per share as the result&#13;would have been anti-dilutive.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;365&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,871&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,878&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,236&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,142&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Accounting Standards&#13;Recently Adopted&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In August 2018, FASB issued&#13;ASU 2018-13, &lt;i&gt;Fair Value Measurement - Disclosure Framework (Topic 820).&lt;/i&gt; The updated guidance improves the disclosure requirements&#13;on fair value measurements, primarily associated with Level 3 fair value measurements and is effective for fiscal years, and interim&#13;periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the standard&#13;for disclosures modified or removed with a delay of adoption of the additional disclosures until their effective date. The Company&#13;adopted this standard effective January 1, 2020 and the standard did not have a significant impact to the Company's financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In November 2018, FASB&#13;issued ASU 2018-18, C&lt;i&gt;ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, &lt;/i&gt;which,&#13;among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted&#13;for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years,&#13;beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard effective January&amp;#160;1, 2020&#13;and the standard did not have a significant impact to the Company's financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 2 - Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Agreements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company has entered&#13;into agreements with third parties for the rights to certain intellectual property, manufacturing and clinical trial services under&#13;which the Company may incur obligations to make payments including upfront payments as well as milestone and royalty payments.&#13;Notable inclusions in this category are:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Oak Ridge National Laboratory ("ORNL") &amp;#8211; The Company is contracted to purchase radioactive material to be used for research and development, with a renewal option at the contract end. During the six months ended June 30, 2020 and 2019, the Company purchased material from ORNL of $0.1 million in each period. In November 2019, the Company signed a contract with ORNL to purchase $0.3 million of radioactive material during calendar year 2020.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center ("FHCRC") to build upon previous and ongoing clinical trials with BC8 (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial with BC8. The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC. A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed BC 8 antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Collaborative Agreement&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In March 2018, the&#13;Company entered into a research and option agreement with Astellas Pharma Inc. ("Astellas") to develop ARCs using the&#13;Company's AWE Technology Platform. Under this collaboration, the Company will utilize its AWE Platform to conjugate and label&#13;selected Astellas targeting agents with an Actinium-225 payload. The Company is also responsible for conducting preclinical validation&#13;studies on any ARCs generated. Payments from Astellas under this agreement are accounted for as a reduction to research and development&#13;expense.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <atnm:NatureOfBusinessPolicyTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business -&lt;/b&gt;&#13;Actinium Pharmaceuticals, Inc. (the "Company", "Actinium", or "We") is a clinical-stage, biopharmaceutical&#13;company applying its proprietary platform technology and deep understanding of radioimmunobiology to the development of novel targeted&#13;therapies known as ARCs or Antibody Radiation-Conjugates.&lt;/p&gt;</atnm:NatureOfBusinessPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation&#13;-&lt;/b&gt; The consolidated financial statements include the Company's accounts and those of the Company's wholly owned&#13;subsidiary.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates in&#13;Financial Statement Presentation&lt;/b&gt; - The preparation of these consolidated financial statements in conformity with U.S. GAAP&#13;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of&#13;the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ&#13;from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <atnm:PandemicOnFinancialStatements contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Impact of COVID&amp;#8211;19&#13;Pandemic on Financial Statements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In December 2019, a novel&#13;strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China to other&#13;countries has resulted in the World Health Organization ("WHO") declaring the outbreak of COVID-19 as a "pandemic,"&#13;or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictions&#13;on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses, and many local jurisdictions&#13;continue to have such restrictions in place.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As local jurisdictions&#13;continue to put restrictions in place, the Company's ability to continue to operate its business may also be limited. Such&#13;events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of&#13;which could materially affect the Company's business, financial condition and results of operations. In response to COVID-19,&#13;the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations as&#13;it relates to the clinical development or drug production of our drug candidates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The spread of COVID-19,&#13;which has caused a broad impact globally, may materially affect the Company economically. While the ultimate economic impact brought&#13;by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, including new information which may emerge&#13;concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others, the pandemic has resulted&#13;significant disruptions in the general commercial activity and the global economy and caused financial market volatility and uncertainty&#13;in significant and unforeseen ways in the recent months. A continuation or worsening of the levels of market disruption and volatility&#13;seen in the recent past could have an adverse effect on the Company's ability to access capital, which could in the future&#13;negatively affect the Company's liquidity. In addition, a recession or market correction resulting from the spread of COVID-19&#13;could materially affect the Company's business and the value of the Company's common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Additionally, COVID-19&#13;may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions&#13;with IRB's or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and&#13;contractors due to limitations in employee resources or forced furlough of government employees.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;To date, COVID-19 has not&#13;had a financial impact on the Company. However, COVID-19 has caused severe disruptions in transportation and limited access to&#13;the Company's facility, resulting in limited support from its staff and professional advisors.&lt;/p&gt;</atnm:PandemicOnFinancialStatements>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash, Cash Equivalents&#13;and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to&#13;be cash equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary&#13;of cash, cash equivalents and restricted cash at June 30, 2020 and December 31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, &lt;br /&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;br /&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53,466&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,254&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify"&gt;Restricted cash &amp;#8211; current&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &amp;#8211; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;391&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;391&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;53,905&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,693&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Current restricted cash&#13;relates to credit card accounts, while long-term restricted cash relates to a certificate of deposit held as collateral for a letter&#13;of credit issued in connection with the Company's lease for corporate office space.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <atnm:AccountingPronouncementsRecentlyAdopted contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Accounting Standards&#13;Recently Adopted&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In August 2018, FASB issued&#13;ASU 2018-13, &lt;i&gt;Fair Value Measurement - Disclosure Framework (Topic 820).&lt;/i&gt; The updated guidance improves the disclosure requirements&#13;on fair value measurements, primarily associated with Level 3 fair value measurements and is effective for fiscal years, and interim&#13;periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the standard&#13;for disclosures modified or removed with a delay of adoption of the additional disclosures until their effective date. The Company&#13;adopted this standard effective January 1, 2020 and the standard did not have a significant impact to the Company's financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In November 2018, FASB&#13;issued ASU 2018-18, C&lt;i&gt;ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, &lt;/i&gt;which,&#13;among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted&#13;for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years,&#13;beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard effective January&amp;#160;1, 2020&#13;and the standard did not have a significant impact to the Company's financial statements.&lt;/p&gt;</atnm:AccountingPronouncementsRecentlyAdopted>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-06-30" unitRef="shares" decimals="INF">2300000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="From2020-01-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">302000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">83000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">1177000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">39000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">36000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">9000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">12000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:OperatingLeasePayments contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">188000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">172000</us-gaap:OperatingLeasePayments>
    <atnm:MaturitiesOfLeaseLiabilities contextRef="AsOf2020-06-30_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" decimals="-3">747000</atnm:MaturitiesOfLeaseLiabilities>
    <atnm:MaturitiesOfLeaseLiabilities contextRef="AsOf2020-06-30_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3">191000</atnm:MaturitiesOfLeaseLiabilities>
    <atnm:PaymentWithImputedInterestPremium contextRef="AsOf2020-06-30_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" decimals="-3">69000</atnm:PaymentWithImputedInterestPremium>
    <atnm:PaymentWithImputedInterestPremium contextRef="AsOf2020-06-30_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3">18000</atnm:PaymentWithImputedInterestPremium>
    <atnm:LeaseLiabilityPaymentsDue contextRef="AsOf2020-06-30_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" decimals="-3">816000</atnm:LeaseLiabilityPaymentsDue>
    <atnm:LeaseLiabilityPaymentsDue contextRef="AsOf2020-06-30_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3">209000</atnm:LeaseLiabilityPaymentsDue>
    <atnm:MaturitiesLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-06-30_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" xsi:nil="true" />
    <atnm:MaturitiesLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-06-30_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3">4000</atnm:MaturitiesLeaseLiabilityPaymentsDueYearFour>
    <atnm:MaturitiesLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-06-30_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" decimals="-3">252000</atnm:MaturitiesLeaseLiabilityPaymentsDueYearThree>
    <atnm:MaturitiesLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-06-30_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3">64000</atnm:MaturitiesLeaseLiabilityPaymentsDueYearThree>
    <atnm:MaturitiesLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-06-30_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" decimals="-3">377000</atnm:MaturitiesLeaseLiabilityPaymentsDueYearTwo>
    <atnm:MaturitiesLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-06-30_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3">94000</atnm:MaturitiesLeaseLiabilityPaymentsDueYearTwo>
    <atnm:MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-06-30_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" decimals="-3">187000</atnm:MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths>
    <atnm:MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-06-30_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3">47000</atnm:MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember545104671">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Contractual &lt;br /&gt; Term &lt;br /&gt; (in&amp;#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate &lt;br /&gt; Intrinsic &lt;br /&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 52%"&gt;Outstanding, December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,871&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;301&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,871&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;20.71&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.45&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;497&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,865&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;20.37&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.45&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;496&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2020-01-01to2020-06-30_custom_PrefundedWarrantsMember">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate &lt;br /&gt; Intrinsic &lt;br /&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;Outstanding, December 31, 2019&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 64%"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,459&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.003&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.003&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 10pt"&gt;Outstanding, June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,259&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;0.003&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;23,814&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,259&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;0.003&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;23,814&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2019-04-30_custom_WarrantsMember_srt_MinimumMember" unitRef="USD_per_Share" decimals="INF">26.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2019-04-30_custom_WarrantsMember_srt_MaximumMember" unitRef="USD_per_Share" decimals="INF">37.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-04-30_custom_WarrantsMember_srt_MinimumMember" unitRef="USD_per_Share" decimals="INF">15.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-06-30_custom_WarrantsMember_srt_MinimumMember" unitRef="USD_per_Share" decimals="INF">15.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-04-30_custom_WarrantsMember_srt_MaximumMember" unitRef="USD_per_Share" decimals="INF">26.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-06-30_custom_WarrantsMember_srt_MaximumMember" unitRef="USD_per_Share" decimals="INF">26.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">1000</us-gaap:ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan>
    <us-gaap:ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">1000</us-gaap:ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2020-06-03to2020-06-19_us-gaap_WarrantMember" unitRef="USD" decimals="-3">23000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <atnm:GrossProceedsFromWarrantExercises contextRef="From2020-06-03to2020-06-19_us-gaap_WarrantMember" unitRef="USD" decimals="-3">25000000</atnm:GrossProceedsFromWarrantExercises>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">55958000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">11670000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">-219054000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">-208758000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">269815000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">214397000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">13000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">5000</us-gaap:CommonStockValue>
    <us-gaap:Liabilities contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">5184000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">6026000</us-gaap:Liabilities>
    <atnm:LongtermFinanceLeaseObligationsNoncurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">109000</atnm:LongtermFinanceLeaseObligationsNoncurrent>
    <atnm:LongtermFinanceLeaseObligationsNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">151000</atnm:LongtermFinanceLeaseObligationsNoncurrent>
    <atnm:LongtermOperatingLeaseObligationsNoncurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">419000</atnm:LongtermOperatingLeaseObligationsNoncurrent>
    <atnm:LongtermOperatingLeaseObligationsNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">531000</atnm:LongtermOperatingLeaseObligationsNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">4656000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">5344000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">82000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">79000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">328000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">286000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">154000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">381000</us-gaap:NotesPayableCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">4092000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">4598000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:Assets contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">55958000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">11670000</us-gaap:Assets>
    <us-gaap:RestrictedCash contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">391000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">391000</us-gaap:RestrictedCash>
    <us-gaap:SecurityDeposit contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">50000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">50000</us-gaap:SecurityDeposit>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">181000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">221000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">738000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">807000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">90000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">113000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">54508000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">10088000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">994000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">786000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">48000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">48000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">53466000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">9254000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-01-01to2020-06-30" unitRef="shares" decimals="INF">8559385</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-01-01to2019-06-30" unitRef="shares" decimals="INF">4476215</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-04-01to2019-06-30" unitRef="shares" decimals="INF">5051471</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-04-01to2020-06-30" unitRef="shares" decimals="INF">11379345</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-01to2020-06-30" unitRef="USD_per_Share" decimals="INF">-1.20</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-01-01to2019-06-30" unitRef="USD_per_Share" decimals="INF">-2.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-04-01to2019-06-30" unitRef="USD_per_Share" decimals="INF">-1.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-04-01to2020-06-30" unitRef="USD_per_Share" decimals="INF">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">-10296000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-10698000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">-5028000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">-4626000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <atnm:ProvisionOfDeemedDividendForWarrantDownroundProtection contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">-1000</atnm:ProvisionOfDeemedDividendForWarrantDownroundProtection>
    <atnm:ProvisionOfDeemedDividendForWarrantDownroundProtection contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-1000</atnm:ProvisionOfDeemedDividendForWarrantDownroundProtection>
    <atnm:ProvisionOfDeemedDividendForWarrantDownroundProtection contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">-1000</atnm:ProvisionOfDeemedDividendForWarrantDownroundProtection>
    <atnm:ProvisionOfDeemedDividendForWarrantDownroundProtection contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">-1000</atnm:ProvisionOfDeemedDividendForWarrantDownroundProtection>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">-10295000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-10697000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">-5027000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">-4625000</us-gaap:NetIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">50000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">88000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">59000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">37000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">50000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">88000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">59000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">37000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">-10345000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-10785000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">-5086000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">-4662000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">10345000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">10785000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">5086000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">4662000</us-gaap:OperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">2686000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">2440000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">1076000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">1154000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">7659000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">8345000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">4010000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">3508000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:Revenues contextRef="From2020-01-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2019-01-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2019-04-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2020-04-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">1428667</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">15107000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">15108000</us-gaap:StockIssuedDuringPeriodValueOther>
    <atnm:DeemedDividendForWarrantDownroundProtectionProvision contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <atnm:DeemedDividendForWarrantDownroundProtectionProvision contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">1000</atnm:DeemedDividendForWarrantDownroundProtectionProvision>
    <atnm:DeemedDividendForWarrantDownroundProtectionProvision contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-1000</atnm:DeemedDividendForWarrantDownroundProtectionProvision>
    <atnm:DeemedDividendForWarrantDownroundProtectionProvision contextRef="From2019-04-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <atnm:DeemedDividendForWarrantDownroundProtectionProvision contextRef="From2020-04-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <atnm:DeemedDividendForWarrantDownroundProtectionProvision contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <atnm:DeemedDividendForWarrantDownroundProtectionProvision contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">1000</atnm:DeemedDividendForWarrantDownroundProtectionProvision>
    <atnm:DeemedDividendForWarrantDownroundProtectionProvision contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-1000</atnm:DeemedDividendForWarrantDownroundProtectionProvision>
    <atnm:IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">1200000</atnm:IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares>
    <atnm:IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">4000</atnm:IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue>
    <atnm:IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">1000</atnm:IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue>
    <atnm:IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">3000</atnm:IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue>
    <atnm:IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <atnm:SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">6138602</atnm:SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares>
    <atnm:SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="-3">52165000</atnm:SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue>
    <atnm:SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">6000</atnm:SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue>
    <atnm:SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">52159000</atnm:SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue>
    <atnm:SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <atnm:DeemedDividendForWarrantsDownroundProtectionProvision contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">1000</atnm:DeemedDividendForWarrantsDownroundProtectionProvision>
    <atnm:DeemedDividendForWarrantsDownroundProtectionProvision contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">1000</atnm:DeemedDividendForWarrantsDownroundProtectionProvision>
    <us-gaap:InterestPaidNet contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">6000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">4000</us-gaap:InterestPaidNet>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="-3">14104000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">20000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">53905000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">9693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">44212000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">5896000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">54577000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">16808000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2020-01-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">1504000</us-gaap:ProceedsFromWarrantExercises>
    <atnm:ProceedsFromExerciseOfPrefundedWarrants contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">4000</atnm:ProceedsFromExerciseOfPrefundedWarrants>
    <atnm:ProceedsFromExerciseOfPrefundedWarrants contextRef="From2019-01-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <atnm:ProceedsFromIssuanceOfCommonStockAndWarrantNet contextRef="From2020-01-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <atnm:ProceedsFromIssuanceOfCommonStockAndWarrantNet contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">15488000</atnm:ProceedsFromIssuanceOfCommonStockAndWarrantNet>
    <atnm:SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">54839000</atnm:SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts>
    <atnm:SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts contextRef="From2019-01-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">227000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">148000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-59000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2020-01-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">59000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">-10365000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-10853000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <atnm:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">-154000</atnm:IncreaseDecreaseInOperatingLeaseLiabilities>
    <atnm:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-127000</atnm:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">-506000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-1111000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">208000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-280000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:DepreciationAndAmortization contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">216000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">209000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">582000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">593000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeTaxesPaid contextRef="From2020-01-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaid contextRef="From2019-01-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-08-13" unitRef="shares" decimals="INF">13585222</dei:EntityCommonStockSharesOutstanding>
    <atnm:CompensationExpenseRelatedToStockOptions contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="-3">500000</atnm:CompensationExpenseRelatedToStockOptions>
    <atnm:CompensationExpenseRelatedToStockOptions contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">300000</atnm:CompensationExpenseRelatedToStockOptions>
    <atnm:IssuanceOfCommonStockShares contextRef="From2020-06-03to2020-06-19_us-gaap_WarrantMember" unitRef="shares" decimals="INF">1900000</atnm:IssuanceOfCommonStockShares>
    <atnm:IssuanceOfCommonStockShares contextRef="From2020-01-01to2020-06-30_custom_EmployeeMember" unitRef="shares" decimals="INF">357189</atnm:IssuanceOfCommonStockShares>
    <atnm:IssuanceOfCommonStockShares contextRef="From2020-01-01to2020-06-30_custom_NonEmployeeMember" unitRef="shares" decimals="INF">33332</atnm:IssuanceOfCommonStockShares>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 3 - Leases &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company adopted ASC&#13;842 as of January 1, 2019, using a modified retrospective approach and applying the standard's transition provisions at January&#13;1, 2019, the effective date. The Company made an accounting policy election to exclude from balance sheet reporting those leases&#13;with initial terms of 12 months or less.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company determines&#13;if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company&#13;the right to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset&#13;is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic&#13;benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which&#13;the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable&#13;lease components are recognized when the obligation is probable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Right-of-use assets and&#13;liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires&#13;a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily&#13;determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company's leases,&#13;the incremental borrowing rate is used based on the information available at commencement date in determining the present value&#13;of lease payments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The lease term for all&#13;of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a&#13;Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend&#13;(or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and&#13;lease liability) for the majority of the Company's leases as the reasonably certain threshold is not met.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;At June 30, 2020, the Company&#13;has an operating lease for corporate office space and two finance leases for office equipment and furniture located in the corporate&#13;office space. In addition, the Company has auxiliary corporate office space that it rents on a month-to-month basis; this rental&#13;is accounted for as an operating lease with the same term as the Company's main office in the same building.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The components of lease expense are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt;&#13;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt;&#13;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt;&#13;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt;&#13;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt; width: 52%; text-align: left"&gt;Operating lease expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;93&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;93&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;186&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;186&lt;/td&gt;&lt;td style="padding-bottom: 4pt; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;50&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Supplemental cash flow information related to&#13;leases are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cash flow information:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Six months ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30,&lt;br /&gt;&#13;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30,&lt;br /&gt;&#13;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 71%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating cash flow use from operating leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;188&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;172&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating cash flow use from finance leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Financing cash flow use from finance leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;36&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Non-cash activity:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,177&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finance Leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;302&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Weighted average remaining lease terms are as&#13;follows at June 30, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average remaining lease term:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 89%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.2 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finance Leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.2 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;As the Company's&#13;leases do not provide an implicit rate, the Company used its incremental borrowing rate based on the information available at adoption&#13;date in determining the present value of lease payments. Below is information on the weighted average discount rates used:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average discount rates:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 89%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finance Leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Maturities of lease liabilities&#13;are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;b&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in&#13;    thousands)&lt;br /&gt;&#13;    Year ending December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Operating&#13;    Leases&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Finance&#13;    Leases&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 78%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020 (excluding six months&#13;    ended June 30, 2020)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;187&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;47&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;94&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;252&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;816&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;209&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less imputed interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Present value of lease liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;747&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;191&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <atnm:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cash flow information:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Six months ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30,&lt;br /&gt;&#13;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30,&lt;br /&gt;&#13;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 71%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating cash flow use from operating leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;188&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;172&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating cash flow use from finance leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Financing cash flow use from finance leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;36&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Non-cash activity:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,177&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finance Leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;302&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</atnm:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;365&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,871&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,878&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,236&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,142&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common&#13;Share&lt;/b&gt; - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted&#13;average number of common shares outstanding during the reporting period. For periods of net income, and when the effects are not&#13;anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average&#13;number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common shares underlying&#13;common stock options and warrants using the treasury stock method. The Company issued pre-funded warrants in April 2020 and June&#13;2020 that are considered outstanding shares for the purposes of calculating net loss per common share, see Note 4 for additional&#13;information. Since the shares underlying the outstanding 2.3 million pre-funded warrants are issuable for negligible consideration&#13;and are fully vested and exercisable, they are considered outstanding for the calculations of both basic and diluted loss per&#13;share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;For periods of net loss,&#13;diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares&#13;is anti-dilutive. For the six months ended June 30, 2020 and 2019, the Company's potentially dilutive shares, which include&#13;outstanding common stock options and warrants have not been included in the computation of diluted net loss per share as the result&#13;would have been anti-dilutive.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br /&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;365&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,871&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,878&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,236&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,142&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 4 - Equity&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 7, 2020,&#13;the Board unanimously approved a reverse stock split of its outstanding common stock by combining outstanding shares of common&#13;stock into a lesser number of outstanding shares of common stock by a ratio of 1-for-30, and on August 10, 2020, the Company filed&#13;with the Secretary of State of Delaware a certificate of amendment to its certificate of incorporation to effect the reverse stock&#13;split. Accordingly, all common share and per common share data in these consolidated financial statements and related notes hereto&#13;have been retroactively adjusted to account for the effect of this reverse stock split for all periods presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 24, 2020,&#13;the Company issued and sold 4.3 million shares of common stock and 2.8 million pre-funded warrants to purchase shares of common&#13;stock. The price to the public in this offering for each share of common stock was $4.50 and for each pre-funded warrant was $4.497.&#13;Each pre-funded warrant has an exercise price of $0.003 per share and is exercisable immediately upon issuance. The pre-funded&#13;warrants are subject to certain limitations on beneficial ownership. Gross proceeds from this offering to Actinium were $31.6 million,&#13;before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this&#13;offering were $29.1 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In June 2020, holders&#13;of 1.2 million pre-funded April 2020 warrants exercised their warrants at $0.003 per share and received 1.2 million shares of common&#13;stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 19, 2020, the&#13;Company issued and sold 1.9 million shares of common stock and 0.7 million pre-funded warrants to purchase shares of common stock.&#13;The price to the public in this offering for each share of common stock was $9.75 and for each pre-funded warrant was $9.747. Each&#13;pre-funded warrant has an exercise price of $0.003 per share and is exercisable immediately upon issuance. The pre-funded warrants&#13;are subject to certain limitations on beneficial ownership. Gross proceeds from this offering to Actinium were $25.0 million, before&#13;deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this offering&#13;were $23.0 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2018, the&#13;Company entered into the Amended and Restated At Market Issuance Sales Agreement with B. Riley FBR, Inc. and JonesTrading Institutional&#13;Services LLC, pursuant to which the Company conducted its at-the market program. During the six months ended June 30, 2020, the&#13;Company sold 0.3 million common shares through its at-the-market program, resulting in net proceeds of $2.5 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In October 2018, the&#13;Company and Lincoln Park Capital Fund, LLC (&amp;#8220;Lincoln Park&amp;#8221;) entered into a purchase agreement and a registration rights&#13;agreement, pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&amp;#8217;s common stock having&#13;an aggregate value of up to $32.5 million, subject to certain limitations and conditions set forth in the agreement. During the&#13;six months ended June 30, 2020, the Company elected to sell to Lincoln Park 27 thousand shares and received $0.2 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In June 2020, the Company&#13;issued 5 thousand shares of restricted common stock, valued at $30 thousand, for consulting services.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For the six months&#13;ended June 30, 2019, holders of March 2018 series A warrants exercised 83 thousand shares, resulting in the Company receiving $1.5&#13;million. The remaining March 2018 series A warrants expired in March 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has outstanding&#13;warrants to purchase 1,907 shares of common stock that include down-round protection. For warrants with down-round protection,&#13;a deemed dividend is recorded for the change in fair value of the warrants when the down-round provision is triggered. As result&#13;of the April 2019 offering, the exercise price of the warrant was reset from $37.50 per share to $26.40 per share. As a result&#13;of the April 2020 offering and June 2020 offering, the exercise price of the warrant was reset from $26.40 per share to $15.60&#13;per share. The down-round protection provision in the above warrants created a deemed dividend to common stockholders of $1 thousand&#13;in the six months ended June 30, 2020 and 2019, which are reflected in the accompanying consolidated statement of operations and&#13;consolidated statement of changes in stockholders&amp;#8217; equity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary&#13;of stock option activity for the six months ended June 30, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Contractual &lt;br /&gt; Term &lt;br /&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate &lt;br /&gt; Intrinsic &lt;br /&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 52%"&gt;Outstanding, December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;380&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.88&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(15&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;15.86&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;365&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;36.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.49&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;519&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;194&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;56.43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.47&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;112&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the six months&#13;ended June 30, 2020, options to purchase 15 thousand shares were cancelled upon the termination of employment for several employees.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of all&#13;options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense&#13;at June 30, 2020 was $1.5 million related to unvested options, which is expected to be expensed over a weighted average of 2.8&#13;years. During the six months ended June 30, 2020 and 2019, the Company recorded compensation expense related to stock options of&#13;$0.5 million and $0.3 million, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Pre-funded Warrants&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As part of the April&#13;2020 offering and the June 2020 offering, the Company issued pre-funded warrants. Each pre-funded warrant has an exercise price&#13;of $0.003 per share and is exercisable immediately upon issuance. The pre-funded warrants are subject to certain limitations on&#13;beneficial ownership. The pre-funded warrants do not have an expiration date. Management determined that the pre-funded warrants&#13;are freestanding instruments and that the pre-funded warrants should be classified as permanent equity in accordance with authoritative&#13;guidance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary&#13;of pre-funded warrant activity for the six months ended June 30, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate &lt;br /&gt; Intrinsic &lt;br /&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;Outstanding, December 31, 2019&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 64%"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,459&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.003&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.003&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 10pt"&gt;Outstanding, June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,259&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;0.003&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;23,814&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,259&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;0.003&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;23,814&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary&#13;of warrant activity for the six months ended June 30, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Contractual &lt;br /&gt; Term &lt;br /&gt; (in&amp;#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate &lt;br /&gt; Intrinsic &lt;br /&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 52%"&gt;Outstanding, December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,871&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;301&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,871&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;20.71&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.45&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;497&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,865&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;20.37&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.45&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;496&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In July 2020, holders&#13;of 0.4 million pre-funded April 2020 and June 2020 warrants exercised their warrants at $0.003 per share and received 0.4 million&#13;shares of common stock. Holders of 2 thousand April 2019 warrants exercised their warrants at $15.00 per share and received 2 thousand&#13;shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2020, the&#13;Company filed a registration statement including a base prospectus which covers the offering, issuance and sale of up to $500 million&#13;of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus covering the offering,&#13;issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued and sold under&#13;the Capital on Demand&amp;#8482; Sales Agreement with JonesTrading Institutional Services LLC.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Since June 30, 2020, the&#13;Company has issued stock options for 357,189 shares to employees and 33,332 shares to non-employee directors.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Contractual &lt;br /&gt; Term &lt;br /&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate &lt;br /&gt; Intrinsic &lt;br /&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 52%"&gt;Outstanding, December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;380&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.88&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(15&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;15.86&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;365&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;36.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.49&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;519&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;194&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;56.43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.47&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;112&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>atnm-20200630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: atnm%2D20200630.xfr; Date: 2020%2D08%2D13T15:50:50Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +a8pw7xRiXhun8uCa3NMOa6HecOdypp0aZkxsGd1fbl6Hy4kAGstuixjNaVWAW0A -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:atnm="http://actiniumpharmaceuticals.com/20200630" elementFormDefault="qualified" targetNamespace="http://actiniumpharmaceuticals.com/20200630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" id="StatementOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000008 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Leases" id="Leases">
	  <link:definition>00000009 - Disclosure - Leases</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Equity" id="Equity">
	  <link:definition>00000010 - Disclosure - Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000011 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000012 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000013 - Disclosure - Leases (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" id="EquityTables">
	  <link:definition>00000014 - Disclosure - Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1">
	  <link:definition>00000016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
	  <link:definition>00000017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000018 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails" id="LeasesDetails">
	  <link:definition>00000019 - Disclosure - Leases  (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails1" id="LeasesDetails1">
	  <link:definition>00000020 - Disclosure - Leases (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails2" id="LeasesDetails2">
	  <link:definition>00000021 - Disclosure - Leases (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails3" id="LeasesDetails3">
	  <link:definition>00000022 - Disclosure - Leases (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails4" id="LeasesDetails4">
	  <link:definition>00000023 - Disclosure - Leases (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" id="EquityDetails">
	  <link:definition>00000024 - Disclosure - Equity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" id="EquityDetailsTextual">
	  <link:definition>00000025 - Disclosure - Equity (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="atnm_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" name="ScheduleOrDescriptionOfWeightedAverageTerm" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ScheduleOfWeightedAverageDiscountRate" name="ScheduleOfWeightedAverageDiscountRate" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" name="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ShareCancelledDueToTerminationOfEmployees" name="ShareCancelledDueToTerminationOfEmployees" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_WarrantsExercisedByWarrantHolders" name="WarrantsExercisedByWarrantHolders" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" name="DescriptionOfRoyaltyPaymentToRelatedParty" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PurchaseOfMaterials" name="PurchaseOfMaterials" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_MilestonePayment" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_AggregateValueOfCommonStock" name="AggregateValueOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_DescriptionOfWarrants" name="DescriptionOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_WarrantToPurchaseOfCommonStock" name="WarrantToPurchaseOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PotentialReverseStockSplitPolicyTextBlock" name="PotentialReverseStockSplitPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_NatureOfBusinessPolicyTextBlock" name="NatureOfBusinessPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PandemicOnFinancialStatements" name="PandemicOnFinancialStatements" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_AccountingPronouncementsRecentlyAdopted" name="AccountingPronouncementsRecentlyAdopted" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_MaturitiesOfLeaseLiabilities" name="MaturitiesOfLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PaymentWithImputedInterestPremium" name="PaymentWithImputedInterestPremium" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LeaseLiabilityPaymentsDue" name="LeaseLiabilityPaymentsDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour" name="MaturitiesLeaseLiabilityPaymentsDueYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree" name="MaturitiesLeaseLiabilityPaymentsDueYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo" name="MaturitiesLeaseLiabilityPaymentsDueYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" name="MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_GrossProceedsFromWarrantExercises" name="GrossProceedsFromWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LongtermFinanceLeaseObligationsNoncurrent" name="LongtermFinanceLeaseObligationsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LongtermOperatingLeaseObligationsNoncurrent" name="LongtermOperatingLeaseObligationsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ProvisionOfDeemedDividendForWarrantDownroundProtection" name="ProvisionOfDeemedDividendForWarrantDownroundProtection" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_DeemedDividendForWarrantDownroundProtectionProvision" name="DeemedDividendForWarrantDownroundProtectionProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares" name="IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue" name="IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares" name="SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue" name="SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_DeemedDividendForWarrantsDownroundProtectionProvision" name="DeemedDividendForWarrantsDownroundProtectionProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ProceedsFromExerciseOfPrefundedWarrants" name="ProceedsFromExerciseOfPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet" name="ProceedsFromIssuanceOfCommonStockAndWarrantNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts" name="SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CompensationExpenseRelatedToStockOptions" name="CompensationExpenseRelatedToStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_IssuanceOfCommonStockShares" name="IssuanceOfCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LicenseAndSponsoredResearchAgreementMember" name="LicenseAndSponsoredResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_FredHutchinsonCancerResearchCenterMember" name="FredHutchinsonCancerResearchCenterMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_GeorgeClinicalMember" name="GeorgeClinicalMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_MedpaceIncMember" name="MedpaceIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_GoodwinMember" name="GoodwinMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_OakRidgeNationalLaboratoryMember" name="OakRidgeNationalLaboratoryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_TotalstockholdersequityMember" name="TotalstockholdersequityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LabEquipmentMember" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LincolnParkCapitalFundLlcMember" name="LincolnParkCapitalFundLlcMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ConsultantsMember" name="ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_TwoThousandThirteenStockPlanMember" name="TwoThousandThirteenStockPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_EmployeesDirectorsAndConsultantsMember" name="EmployeesDirectorsAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_TwoThousandThirteenEquityIncentivePlanMember" name="TwoThousandThirteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_MrSandeshSethMember" name="MrSandeshSethMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_OrphanDrugCreditsMember" name="OrphanDrugCreditsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_OperatingLeaseLiabilitiesMember" name="OperatingLeaseLiabilitiesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_FinanceLeaseLiabilitiesMember" name="FinanceLeaseLiabilitiesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_EmployeeMember" name="EmployeeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_NonEmployeeMember" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SupplementalDisclosureOfNoncashFlowInformationAbstract" name="SupplementalDisclosureOfNoncashFlowInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CommitmentsAndContingenciesDetailsAbstract" name="CommitmentsAndContingenciesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_AgreementAxis" name="AgreementAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="atnm_AgreementDomain" name="AgreementDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CommitmentsAndContingenciesTextualAbstract" name="CommitmentsAndContingenciesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_FirstCommercialSalePeriod" name="FirstCommercialSalePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ProjectEstimatedCost" name="ProjectEstimatedCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ServicesFees" name="ServicesFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LeaseTerm" name="LeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" name="CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CapitalleaseOfOfficeEquipment" name="CapitalleaseOfOfficeEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CapitalLeaseAgreement" name="CapitalLeaseAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_OfficeEquipmentServices" name="OfficeEquipmentServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_FinanceLeasesCosAbstractt" name="FinanceLeasesCosAbstractt" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CashFlowInformationAbstract" name="CashFlowInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_NoncashActivityAbstract" name="NoncashActivityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LeasesDetails21Abstract" name="LeasesDetails21Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_WeightedAverageRemainingLeaseTermAbstract" name="WeightedAverageRemainingLeaseTermAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LeasesDetails3Abstract" name="LeasesDetails3Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_WeightedAverageDiscountRateAbstract" name="WeightedAverageDiscountRateAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LeaseAxis" name="LeaseAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="atnm_LeaseDomain" name="LeaseDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_MaturitiesLeaseLiabilitiesPaymentsDueAbstract" name="MaturitiesLeaseLiabilitiesPaymentsDueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_EquityTextualsAbstract" name="EquityTextualsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>atnm-20200630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: atnm%2D20200630.xfr; Date: 2020%2D08%2D13T15:50:50Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:href="atnm-20200630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:href="atnm-20200630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="atnm-20200630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:href="atnm-20200630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="atnm-20200630.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="atnm-20200630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="atnm-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/Leases" xlink:href="atnm-20200630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/Equity" xlink:href="atnm-20200630.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables" xlink:href="atnm-20200630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:href="atnm-20200630.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" xlink:href="atnm-20200630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails" xlink:href="atnm-20200630.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails1" xlink:href="atnm-20200630.xsd#LeasesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails2" xlink:href="atnm-20200630.xsd#LeasesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails3" xlink:href="atnm-20200630.xsd#LeasesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails4" xlink:href="atnm-20200630.xsd#LeasesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:href="atnm-20200630.xsd#EquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:href="atnm-20200630.xsd#EquityDetailsTextual" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:label="loc_atnmLongtermOperatingLeaseObligationsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_atnmLongtermOperatingLeaseObligationsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LongtermFinanceLeaseObligationsNoncurrent" xlink:label="loc_atnmLongtermFinanceLeaseObligationsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_atnmLongtermFinanceLeaseObligationsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_atnmIncreaseDecreaseInOperatingLeaseLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_atnmIncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts" xlink:label="loc_atnmSalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_atnmSalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet" xlink:label="loc_atnmProceedsFromIssuanceOfCommonStockAndWarrantNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_atnmProceedsFromIssuanceOfCommonStockAndWarrantNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ProceedsFromExerciseOfPrefundedWarrants" xlink:label="loc_atnmProceedsFromExerciseOfPrefundedWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_atnmProceedsFromExerciseOfPrefundedWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Description of Business and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000008 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Leases" xlink:title="00000009 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity" xlink:title="00000010 - Disclosure - Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000011 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000012 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesTables" xlink:title="00000013 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:title="00000014 - Disclosure - Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails" xlink:title="00000019 - Disclosure - Leases  (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails1" xlink:title="00000020 - Disclosure - Leases (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails2" xlink:title="00000021 - Disclosure - Leases (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails3" xlink:title="00000022 - Disclosure - Leases (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails4" xlink:title="00000023 - Disclosure - Leases (Details 4)">
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseLiabilityPaymentsDue" xlink:label="loc_atnmLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmLeaseLiabilityPaymentsDue" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmLeaseLiabilityPaymentsDue" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmLeaseLiabilityPaymentsDue" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmLeaseLiabilityPaymentsDue" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesOfLeaseLiabilities" xlink:label="loc_atnmMaturitiesOfLeaseLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmMaturitiesOfLeaseLiabilities" xlink:to="loc_atnmLeaseLiabilityPaymentsDue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PaymentWithImputedInterestPremium" xlink:label="loc_atnmPaymentWithImputedInterestPremium" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmMaturitiesOfLeaseLiabilities" xlink:to="loc_atnmPaymentWithImputedInterestPremium" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:title="00000024 - Disclosure - Equity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:title="00000025 - Disclosure - Equity (Details Textual)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>atnm-20200630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: atnm%2D20200630.xfr; Date: 2020%2D08%2D13T15:50:50Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:href="atnm-20200630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:href="atnm-20200630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="atnm-20200630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:href="atnm-20200630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="atnm-20200630.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="atnm-20200630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="atnm-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/Leases" xlink:href="atnm-20200630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/Equity" xlink:href="atnm-20200630.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables" xlink:href="atnm-20200630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:href="atnm-20200630.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" xlink:href="atnm-20200630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails" xlink:href="atnm-20200630.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails1" xlink:href="atnm-20200630.xsd#LeasesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails2" xlink:href="atnm-20200630.xsd#LeasesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails3" xlink:href="atnm-20200630.xsd#LeasesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails4" xlink:href="atnm-20200630.xsd#LeasesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:href="atnm-20200630.xsd#EquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:href="atnm-20200630.xsd#EquityDetailsTextual" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue" xlink:label="loc_atnmIssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmIssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares" xlink:label="loc_atnmIssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmIssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue" xlink:label="loc_atnmSaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmSaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares" xlink:label="loc_atnmSaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmSaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_atnmStockIssuedDuringPeriodValueWarrantsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmStockIssuedDuringPeriodValueWarrantsExercised_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_atnmStockIssuedDuringPeriodSharesWarrantsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmStockIssuedDuringPeriodSharesWarrantsExercised_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DeemedDividendForWarrantDownroundProtectionProvision" xlink:label="loc_atnmDeemedDividendForWarrantDownroundProtectionProvision_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmDeemedDividendForWarrantDownroundProtectionProvision_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_50" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Description of Business and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000008 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Leases" xlink:title="00000009 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity" xlink:title="00000010 - Disclosure - Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000011 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000012 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesTables" xlink:title="00000013 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:title="00000014 - Disclosure - Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PrefundedWarrantsMember" xlink:label="loc_atnmPrefundedWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_atnmPrefundedWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AgreementAxis" xlink:label="loc_atnmAgreementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_atnmAgreementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AgreementDomain" xlink:label="loc_atnmAgreementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnmAgreementAxis" xlink:to="loc_atnmAgreementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AgreementDomain" xlink:label="loc_atnmAgreementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_atnmAgreementAxis" xlink:to="loc_atnmAgreementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_atnmLicenseAndSponsoredResearchAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmAgreementDomain" xlink:to="loc_atnmLicenseAndSponsoredResearchAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_atnmFredHutchinsonCancerResearchCenterMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmFredHutchinsonCancerResearchCenterMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_atnmOakRidgeNationalLaboratoryMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmOakRidgeNationalLaboratoryMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_atnmDescriptionOfRoyaltyPaymentToRelatedParty_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_atnmDescriptionOfRoyaltyPaymentToRelatedParty_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_atnmFirstCommercialSalePeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_atnmFirstCommercialSalePeriod_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_atnmProjectEstimatedCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_atnmProjectEstimatedCost_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="loc_us-gaapDevelopmentInProcess_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_us-gaapDevelopmentInProcess_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaapResearchAndDevelopmentInProcess_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_us-gaapResearchAndDevelopmentInProcess_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:label="loc_us-gaapPaymentsForLeasingCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_us-gaapPaymentsForLeasingCosts_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ServicesFees" xlink:label="loc_atnmServicesFees_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_atnmServicesFees_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseTerm" xlink:label="loc_atnmLeaseTerm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_atnmLeaseTerm_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PurchaseOfMaterials" xlink:label="loc_atnmPurchaseOfMaterials_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_atnmPurchaseOfMaterials_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_us-gaapLineOfCredit_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_us-gaapDeposits_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_us-gaapPaymentsForRent_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" xlink:label="loc_atnmCapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_atnmCapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CapitalleaseOfOfficeEquipment" xlink:label="loc_atnmCapitalleaseOfOfficeEquipment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_atnmCapitalleaseOfOfficeEquipment_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CapitalLeaseAgreement" xlink:label="loc_atnmCapitalLeaseAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_atnmCapitalLeaseAgreement_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_OfficeEquipmentServices" xlink:label="loc_atnmOfficeEquipmentServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_atnmOfficeEquipmentServices_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MilestonePayment" xlink:label="loc_atnmMilestonePayment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_50" xlink:to="loc_atnmMilestonePayment_50" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails" xlink:title="00000019 - Disclosure - Leases  (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="loc_us-gaapCapitalLeaseObligationsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapCapitalLeaseObligationsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_FinanceLeasesCosAbstractt" xlink:label="loc_atnmFinanceLeasesCosAbstractt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmFinanceLeasesCosAbstractt_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmFinanceLeasesCosAbstractt_50" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmFinanceLeasesCosAbstractt_50" xlink:to="loc_us-gaapFinanceLeaseInterestExpense_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmFinanceLeasesCosAbstractt_50" xlink:to="loc_us-gaapOperatingLeaseCost_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails1" xlink:title="00000020 - Disclosure - Leases (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails2" xlink:title="00000021 - Disclosure - Leases (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails3" xlink:title="00000022 - Disclosure - Leases (Details 3)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails4" xlink:title="00000023 - Disclosure - Leases (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseAxis" xlink:label="loc_atnmLeaseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_atnmLeaseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseDomain" xlink:label="loc_atnmLeaseDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnmLeaseAxis" xlink:to="loc_atnmLeaseDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseDomain" xlink:label="loc_atnmLeaseDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_atnmLeaseAxis" xlink:to="loc_atnmLeaseDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_OperatingLeaseLiabilitiesMember" xlink:label="loc_atnmOperatingLeaseLiabilitiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmLeaseDomain" xlink:to="loc_atnmOperatingLeaseLiabilitiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_FinanceLeaseLiabilitiesMember" xlink:label="loc_atnmFinanceLeaseLiabilitiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmLeaseDomain" xlink:to="loc_atnmFinanceLeaseLiabilitiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract_30" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearTwo_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract_30" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearTwo_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearThree_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract_30" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearThree_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearFour_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract_30" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearFour_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseLiabilityPaymentsDue" xlink:label="loc_atnmLeaseLiabilityPaymentsDue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract_30" xlink:to="loc_atnmLeaseLiabilityPaymentsDue_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PaymentWithImputedInterestPremium" xlink:label="loc_atnmPaymentWithImputedInterestPremium_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract_30" xlink:to="loc_atnmPaymentWithImputedInterestPremium_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesOfLeaseLiabilities" xlink:label="loc_atnmMaturitiesOfLeaseLiabilities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract_30" xlink:to="loc_atnmMaturitiesOfLeaseLiabilities_30" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:title="00000024 - Disclosure - Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PrefundedWarrantsMember" xlink:label="loc_atnmPrefundedWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_atnmPrefundedWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_atnmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_atnmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AggregateIntrinsicValueAbstract" xlink:label="loc_atnmAggregateIntrinsicValueAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_atnmAggregateIntrinsicValueAbstract_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmAggregateIntrinsicValueAbstract_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmAggregateIntrinsicValueAbstract_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_70" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:title="00000025 - Disclosure - Equity (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LincolnParkCapitalFundLlcMember" xlink:label="loc_atnmLincolnParkCapitalFundLlcMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmLincolnParkCapitalFundLlcMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AgreementAxis" xlink:label="loc_atnmAgreementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_atnmAgreementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AgreementDomain" xlink:label="loc_atnmAgreementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnmAgreementAxis" xlink:to="loc_atnmAgreementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AgreementDomain" xlink:label="loc_atnmAgreementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_atnmAgreementAxis" xlink:to="loc_atnmAgreementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PurchaseAgreementMember" xlink:label="loc_atnmPurchaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmAgreementDomain" xlink:to="loc_atnmPurchaseAgreementMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SeriesAWarrantsMember" xlink:label="loc_atnmSeriesAWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_atnmSeriesAWarrantsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WarrantsMember" xlink:label="loc_atnmWarrantsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_atnmWarrantsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_EmployeeMember" xlink:label="loc_atnmEmployeeMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_atnmEmployeeMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_NonEmployeeMember" xlink:label="loc_atnmNonEmployeeMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_atnmNonEmployeeMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_EquityTextualsAbstract" xlink:label="loc_atnmEquityTextualsAbstract_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_atnmEquityTextualsAbstract_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_IssuanceOfCommonStockShares" xlink:label="loc_atnmIssuanceOfCommonStockShares_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_atnmIssuanceOfCommonStockShares_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_us-gaapSharePrice_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WarrantToPurchaseOfCommonStock" xlink:label="loc_atnmWarrantToPurchaseOfCommonStock_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_atnmWarrantToPurchaseOfCommonStock_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ShareCancelledDueToTerminationOfEmployees" xlink:label="loc_atnmShareCancelledDueToTerminationOfEmployees_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_atnmShareCancelledDueToTerminationOfEmployees_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CompensationExpenseRelatedToStockOptions" xlink:label="loc_atnmCompensationExpenseRelatedToStockOptions_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_atnmCompensationExpenseRelatedToStockOptions_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_atnmWarrantsExercisedByWarrantHolders_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_atnmWarrantsExercisedByWarrantHolders_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_GrossProceedsFromWarrantExercises" xlink:label="loc_atnmGrossProceedsFromWarrantExercises_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_atnmGrossProceedsFromWarrantExercises_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DescriptionOfWarrants" xlink:label="loc_atnmDescriptionOfWarrants_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_atnmDescriptionOfWarrants_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_210" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_us-gaapSubsequentEventDescription_210" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AggregateValueOfCommonStock" xlink:label="loc_atnmAggregateValueOfCommonStock_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_atnmAggregateValueOfCommonStock_210" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_210" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan_210" xlink:type="arc" order="18" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>atnm-20200630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: atnm%2D20200630.xfr; Date: 2020%2D08%2D13T15:50:50Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AgreementAxis" xlink:label="atnm_AgreementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="atnm_LicenseAndSponsoredResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseAndSponsoredResearchAgreementMember" xlink:to="atnm_LicenseAndSponsoredResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LicenseAndSponsoredResearchAgreementMember_lbl" xml:lang="en-US">License and Sponsored Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="atnm_FredHutchinsonCancerResearchCenterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FredHutchinsonCancerResearchCenterMember" xlink:to="atnm_FredHutchinsonCancerResearchCenterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FredHutchinsonCancerResearchCenterMember_lbl" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LincolnParkCapitalFundLlcMember" xlink:label="atnm_LincolnParkCapitalFundLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LincolnParkCapitalFundLlcMember" xlink:to="atnm_LincolnParkCapitalFundLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LincolnParkCapitalFundLlcMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PurchaseAgreementMember" xlink:label="atnm_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PurchaseAgreementMember" xlink:to="atnm_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options Held [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="atnm_OakRidgeNationalLaboratoryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OakRidgeNationalLaboratoryMember" xlink:to="atnm_OakRidgeNationalLaboratoryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OakRidgeNationalLaboratoryMember_lbl" xml:lang="en-US">Oak Ridge National Laboratory [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="us-gaap_CapitalLeaseObligationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsMember" xlink:to="us-gaap_CapitalLeaseObligationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsMember_lbl" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseAxis" xlink:label="atnm_LeaseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeaseAxis_lbl" xml:lang="en-US">Lease [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_OperatingLeaseLiabilitiesMember" xlink:label="atnm_OperatingLeaseLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeaseLiabilitiesMember" xlink:to="atnm_OperatingLeaseLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OperatingLeaseLiabilitiesMember_lbl" xml:lang="en-US">Operating Lease Liabilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_FinanceLeaseLiabilitiesMember" xlink:label="atnm_FinanceLeaseLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseLiabilitiesMember" xlink:to="atnm_FinanceLeaseLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FinanceLeaseLiabilitiesMember_lbl" xml:lang="en-US">Finance Lease Liabilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SeriesAWarrantsMember" xlink:label="atnm_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SeriesAWarrantsMember" xlink:to="atnm_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PrefundedWarrantsMember" xlink:label="atnm_PrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PrefundedWarrantsMember" xlink:to="atnm_PrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WarrantsMember" xlink:label="atnm_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantsMember" xlink:to="atnm_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_EmployeeMember" xlink:label="atnm_EmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EmployeeMember" xlink:to="atnm_EmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_NonEmployeeMember" xlink:label="atnm_NonEmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonEmployeeMember" xlink:to="atnm_NonEmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonEmployeeMember_lbl" xml:lang="en-US">Non Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DocumentAndEntityInformationAbstract" xlink:label="atnm_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DocumentAndEntityInformationAbstract" xlink:to="atnm_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash - current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $260 and $237, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating leases right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance leases right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating leases current liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance leases current liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Long-term operating leases obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LongtermFinanceLeaseObligationsNoncurrent" xlink:label="atnm_LongtermFinanceLeaseObligationsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermFinanceLeaseObligationsNoncurrent" xlink:to="atnm_LongtermFinanceLeaseObligationsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LongtermFinanceLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Long-term finance leases obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 13,171,824 and 5,490,038 shares issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of reimbursements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income - net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ProvisionOfDeemedDividendForWarrantDownroundProtection" xlink:label="atnm_ProvisionOfDeemedDividendForWarrantDownroundProtection" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProvisionOfDeemedDividendForWarrantDownroundProtection" xlink:to="atnm_ProvisionOfDeemedDividendForWarrantDownroundProtection_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ProvisionOfDeemedDividendForWarrantDownroundProtection_lbl" xml:lang="en-US">Deemed dividend for warrant down-round protection provision</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss applicable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share of common stock - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average shares of common stock outstanding, including outstanding pre-funded warrants- basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_2_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsMember_2_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue" xlink:label="atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue" xlink:to="atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue_lbl" xml:lang="en-US">Issuance of common stock from exercise of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares" xlink:label="atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares" xlink:to="atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares_lbl" xml:lang="en-US">Issuance of common stock from exercise of pre-funded warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue" xlink:label="atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue" xlink:to="atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue_lbl" xml:lang="en-US">Sale of common stock and pre-funded warrants, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares" xlink:label="atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares" xlink:to="atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares_lbl" xml:lang="en-US">Sale of common stock and pre-funded warrants, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="atnm_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="atnm_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="atnm_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="atnm_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Sale of common stock and warrants, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Sale of common stock and warrants, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DeemedDividendForWarrantDownroundProtectionProvision" xlink:label="atnm_DeemedDividendForWarrantDownroundProtectionProvision" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DeemedDividendForWarrantDownroundProtectionProvision" xlink:to="atnm_DeemedDividendForWarrantDownroundProtectionProvision_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_DeemedDividendForWarrantDownroundProtectionProvision_lbl" xml:lang="en-US">Deemed dividend for warrant down-round protection provision</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation &amp; amortization expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used In Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows Used In Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used In Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payments on note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts" xlink:label="atnm_SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts" xlink:to="atnm_SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts_lbl" xml:lang="en-US">Sales of shares of common stock and pre-funded warrants, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet" xlink:label="atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet" xlink:to="atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet_lbl" xml:lang="en-US">Sales of shares of common stock and warrants, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ProceedsFromExerciseOfPrefundedWarrants" xlink:label="atnm_ProceedsFromExerciseOfPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProceedsFromExerciseOfPrefundedWarrants" xlink:to="atnm_ProceedsFromExerciseOfPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ProceedsFromExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Proceeds from exercise of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents, and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest on note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SupplementalDisclosureOfNoncashFlowInformationAbstract" xlink:label="atnm_SupplementalDisclosureOfNoncashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SupplementalDisclosureOfNoncashFlowInformationAbstract" xlink:to="atnm_SupplementalDisclosureOfNoncashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SupplementalDisclosureOfNoncashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DeemedDividendForWarrantsDownroundProtectionProvision" xlink:label="atnm_DeemedDividendForWarrantsDownroundProtectionProvision" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DeemedDividendForWarrantsDownroundProtectionProvision" xlink:to="atnm_DeemedDividendForWarrantsDownroundProtectionProvision_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_DeemedDividendForWarrantsDownroundProtectionProvision_lbl" xml:lang="en-US">Deemed dividend for warrant down-round protection provision</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_NatureOfBusinessPolicyTextBlock" xlink:label="atnm_NatureOfBusinessPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NatureOfBusinessPolicyTextBlock_lbl" xml:lang="en-US">Nature of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation - Unaudited Interim Financial Information</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PotentialReverseStockSplitPolicyTextBlock" xlink:label="atnm_PotentialReverseStockSplitPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PotentialReverseStockSplitPolicyTextBlock" xlink:to="atnm_PotentialReverseStockSplitPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PotentialReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates in Financial Statement Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PandemicOnFinancialStatements" xlink:label="atnm_PandemicOnFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PandemicOnFinancialStatements" xlink:to="atnm_PandemicOnFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PandemicOnFinancialStatements_lbl" xml:lang="en-US">Impact of COVID-19 Pandemic on Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Share-Based Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AccountingPronouncementsRecentlyAdopted" xlink:label="atnm_AccountingPronouncementsRecentlyAdopted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AccountingPronouncementsRecentlyAdopted" xlink:to="atnm_AccountingPronouncementsRecentlyAdopted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AccountingPronouncementsRecentlyAdopted_lbl" xml:lang="en-US">Accounting Standards Recently Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of cash and cash equivalent and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule components of lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:label="atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:to="atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to leases</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl" xml:lang="en-US">Schedule of weighted average remaining lease terms</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ScheduleOfWeightedAverageDiscountRate" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate_lbl" xml:lang="en-US">Schedule of weighted average discount rates</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_2_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrant activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestrictedAssetsCurrent" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsCurrent" xlink:to="us-gaap_OtherRestrictedAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherRestrictedAssetsCurrent_lbl" xml:lang="en-US">Restricted cash - long-term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OptionMember_2_lbl" xml:lang="en-US">Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding pre-funded warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_AgreementAxis_2_lbl" xml:lang="en-US">Agreements [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="atnm_CommitmentsAndContingenciesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CommitmentsAndContingenciesTextualAbstract" xlink:to="atnm_CommitmentsAndContingenciesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CommitmentsAndContingenciesTextualAbstract_lbl" xml:lang="en-US">Commitments and Contingencies (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">License fee payment</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl" xml:lang="en-US">Description of royalty payment</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_FirstCommercialSalePeriod" xlink:label="atnm_FirstCommercialSalePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FirstCommercialSalePeriod" xlink:to="atnm_FirstCommercialSalePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FirstCommercialSalePeriod_lbl" xml:lang="en-US">First commercial sale period</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ProjectEstimatedCost" xlink:label="atnm_ProjectEstimatedCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProjectEstimatedCost" xlink:to="atnm_ProjectEstimatedCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ProjectEstimatedCost_lbl" xml:lang="en-US">Project estimated cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="us-gaap_DevelopmentInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentInProcess" xlink:to="us-gaap_DevelopmentInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentInProcess_lbl" xml:lang="en-US">Total project estimated to cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:label="us-gaap_PaymentsForLeasingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLeasingCosts" xlink:to="us-gaap_PaymentsForLeasingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLeasingCosts_lbl" xml:lang="en-US">Cost of lease agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ServicesFees" xlink:label="atnm_ServicesFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ServicesFees" xlink:to="atnm_ServicesFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ServicesFees_lbl" xml:lang="en-US">Services fees</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseTerm" xlink:label="atnm_LeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseTerm" xlink:to="atnm_LeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeaseTerm_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PurchaseOfMaterials" xlink:label="atnm_PurchaseOfMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PurchaseOfMaterials" xlink:to="atnm_PurchaseOfMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PurchaseOfMaterials_lbl" xml:lang="en-US">Purchase of materials</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Lines of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Deposits" xlink:label="us-gaap_Deposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Certified deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent for office</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" xlink:label="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" xlink:to="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Capitalized lease financial by accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CapitalleaseOfOfficeEquipment" xlink:label="atnm_CapitalleaseOfOfficeEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalleaseOfOfficeEquipment" xlink:to="atnm_CapitalleaseOfOfficeEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalleaseOfOfficeEquipment_lbl" xml:lang="en-US">Capital lease of office equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CapitalLeaseAgreement" xlink:label="atnm_CapitalLeaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalLeaseAgreement" xlink:to="atnm_CapitalLeaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalLeaseAgreement_lbl" xml:lang="en-US">Capital lease agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_OfficeEquipmentServices" xlink:label="atnm_OfficeEquipmentServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OfficeEquipmentServices" xlink:to="atnm_OfficeEquipmentServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OfficeEquipmentServices_lbl" xml:lang="en-US">Office equipment services</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MilestonePayment" xlink:label="atnm_MilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsMember" xlink:to="us-gaap_CapitalLeaseObligationsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsMember_2_lbl" xml:lang="en-US">Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_FinanceLeasesCosAbstractt" xlink:label="atnm_FinanceLeasesCosAbstractt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeasesCosAbstractt" xlink:to="atnm_FinanceLeasesCosAbstractt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FinanceLeasesCosAbstractt_lbl" xml:lang="en-US">Finance lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-to-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CashFlowInformationAbstract" xlink:label="atnm_CashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashFlowInformationAbstract" xlink:to="atnm_CashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CashFlowInformationAbstract_lbl" xml:lang="en-US">Cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="atnm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow use from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash flow use from finance leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Financing cash flow use from finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_NoncashActivityAbstract" xlink:label="atnm_NoncashActivityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NoncashActivityAbstract" xlink:to="atnm_NoncashActivityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NoncashActivityAbstract_lbl" xml:lang="en-US">Non-cash activity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeasesDetails21Abstract" xlink:label="atnm_LeasesDetails21Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetails21Abstract" xlink:to="atnm_LeasesDetails21Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_LeasesDetails21Abstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted average remaining lease term:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeasesDetails3Abstract" xlink:label="atnm_LeasesDetails3Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetails3Abstract" xlink:to="atnm_LeasesDetails3Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_LeasesDetails3Abstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WeightedAverageDiscountRateAbstract" xlink:label="atnm_WeightedAverageDiscountRateAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRateAbstract" xlink:to="atnm_WeightedAverageDiscountRateAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US">Weighted average discount rates:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance Leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_LeaseAxis_2_lbl" xml:lang="en-US">LeaseAxis [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeaseLiabilitiesMember" xlink:to="atnm_OperatingLeaseLiabilitiesMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_OperatingLeaseLiabilitiesMember_2_lbl" xml:lang="en-US">Operating Leases [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseLiabilitiesMember" xlink:to="atnm_FinanceLeaseLiabilitiesMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_FinanceLeaseLiabilitiesMember_2_lbl" xml:lang="en-US">Finance Leases [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilitiesPaymentsDueAbstract" xlink:label="atnm_MaturitiesLeaseLiabilitiesPaymentsDueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesLeaseLiabilitiesPaymentsDueAbstract" xlink:to="atnm_MaturitiesLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MaturitiesLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Year ending December 31,</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2020 (excluding six months ended June 30, 2020)</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo" xlink:label="atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo" xlink:to="atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree" xlink:label="atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree" xlink:to="atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour" xlink:label="atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour" xlink:to="atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseLiabilityPaymentsDue" xlink:label="atnm_LeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseLiabilityPaymentsDue" xlink:to="atnm_LeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="atnm_LeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PaymentWithImputedInterestPremium" xlink:label="atnm_PaymentWithImputedInterestPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="atnm_PaymentWithImputedInterestPremium_lbl" xml:lang="en-US">Less imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesOfLeaseLiabilities" xlink:label="atnm_MaturitiesOfLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="atnm_MaturitiesOfLeaseLiabilities_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Cancelled/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AggregateIntrinsicValueAbstract" xlink:label="atnm_AggregateIntrinsicValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateIntrinsicValueAbstract" xlink:to="atnm_AggregateIntrinsicValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Outstanding, Beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SeriesAWarrantsMember" xlink:to="atnm_SeriesAWarrantsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_SeriesAWarrantsMember_2_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_RangeAxis_2_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EmployeeMember" xlink:to="atnm_EmployeeMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_EmployeeMember_2_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_EquityTextualsAbstract" xlink:label="atnm_EquityTextualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityTextualsAbstract" xlink:to="atnm_EquityTextualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityTextualsAbstract_lbl" xml:lang="en-US">Equity (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Received amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_IssuanceOfCommonStockShares" xlink:label="atnm_IssuanceOfCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IssuanceOfCommonStockShares" xlink:to="atnm_IssuanceOfCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IssuanceOfCommonStockShares_lbl" xml:lang="en-US">Issuance of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net proceeds on sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WarrantToPurchaseOfCommonStock" xlink:label="atnm_WarrantToPurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantToPurchaseOfCommonStock" xlink:to="atnm_WarrantToPurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WarrantToPurchaseOfCommonStock_lbl" xml:lang="en-US">Warrant to purchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ShareCancelledDueToTerminationOfEmployees" xlink:label="atnm_ShareCancelledDueToTerminationOfEmployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareCancelledDueToTerminationOfEmployees" xlink:to="atnm_ShareCancelledDueToTerminationOfEmployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareCancelledDueToTerminationOfEmployees_lbl" xml:lang="en-US">Share cancelled due to termination of employees</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CompensationExpenseRelatedToStockOptions" xlink:label="atnm_CompensationExpenseRelatedToStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToStockOptions" xlink:to="atnm_CompensationExpenseRelatedToStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CompensationExpenseRelatedToStockOptions_lbl" xml:lang="en-US">Compensation expense related to stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="atnm_WarrantsExercisedByWarrantHolders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantsExercisedByWarrantHolders" xlink:to="atnm_WarrantsExercisedByWarrantHolders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WarrantsExercisedByWarrantHolders_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds of public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_GrossProceedsFromWarrantExercises" xlink:label="atnm_GrossProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrossProceedsFromWarrantExercises" xlink:to="atnm_GrossProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GrossProceedsFromWarrantExercises_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DescriptionOfWarrants" xlink:label="atnm_DescriptionOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfWarrants" xlink:to="atnm_DescriptionOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionOfWarrants_lbl" xml:lang="en-US">Description of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="us-gaap_SubsequentEventDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent event, description</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AggregateValueOfCommonStock" xlink:label="atnm_AggregateValueOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateValueOfCommonStock" xlink:to="atnm_AggregateValueOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AggregateValueOfCommonStock_lbl" xml:lang="en-US">Aggregate value of common stock, shares over life of agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan_lbl" xml:lang="en-US">Dividend to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AccountingPronouncementsRecentlyAdopted" xlink:to="atnm_AccountingPronouncementsRecentlyAdopted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AccountingPronouncementsRecentlyAdopted_doc" xml:lang="en-US">Disclosure of accounting policy for accounting pronouncements recently adopted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateValueOfCommonStock" xlink:to="atnm_AggregateValueOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AggregateValueOfCommonStock_doc" xml:lang="en-US">Aggregate value of common stock, can sell up to shares over life of agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AgreementAxis_doc" xml:lang="en-US">Agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AgreementDomain" xlink:label="atnm_AgreementDomain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementDomain" xlink:to="atnm_AgreementDomain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AgreementDomain_doc" xml:lang="en-US">Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalLeaseAgreement" xlink:to="atnm_CapitalLeaseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_CapitalLeaseAgreement_doc" xml:lang="en-US">Capital lease agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" xlink:to="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses_doc" xml:lang="en-US">Capitalized lease financial by accounts payable and accrued expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalleaseOfOfficeEquipment" xlink:to="atnm_CapitalleaseOfOfficeEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_CapitalleaseOfOfficeEquipment_doc" xml:lang="en-US">Capitallease of office equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_doc" xml:lang="en-US">Description of royalty payment to related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfWarrants" xlink:to="atnm_DescriptionOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_DescriptionOfWarrants_doc" xml:lang="en-US">Description of pre-funded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DocumentAndEntityInformationAbstract" xlink:to="atnm_DocumentAndEntityInformationAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_DocumentAndEntityInformationAbstract_doc" xml:lang="en-US">Document and Entity Information.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityTextualsAbstract" xlink:to="atnm_EquityTextualsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_EquityTextualsAbstract_doc" xml:lang="en-US">Equity textual abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeasesCosAbstractt" xlink:to="atnm_FinanceLeasesCosAbstractt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_FinanceLeasesCosAbstractt_doc" xml:lang="en-US">Finance lease cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FirstCommercialSalePeriod" xlink:to="atnm_FirstCommercialSalePeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_FirstCommercialSalePeriod_doc" xml:lang="en-US">First commercial sale period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FredHutchinsonCancerResearchCenterMember" xlink:to="atnm_FredHutchinsonCancerResearchCenterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_FredHutchinsonCancerResearchCenterMember_doc" xml:lang="en-US">Fred hutchinson cancer research center.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrossProceedsFromWarrantExercises" xlink:to="atnm_GrossProceedsFromWarrantExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_GrossProceedsFromWarrantExercises_doc" xml:lang="en-US">Gross proceeds from warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseTerm" xlink:to="atnm_LeaseTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LeaseTerm_doc" xml:lang="en-US">Lease term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseAndSponsoredResearchAgreementMember" xlink:to="atnm_LicenseAndSponsoredResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LicenseAndSponsoredResearchAgreementMember_doc" xml:lang="en-US">License and sponsored research agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermFinanceLeaseObligationsNoncurrent" xlink:to="atnm_LongtermFinanceLeaseObligationsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LongtermFinanceLeaseObligationsNoncurrent_doc" xml:lang="en-US">Long-term finance lease obligations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent_doc" xml:lang="en-US">Long-term operating lease obligations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_MilestonePayment_doc" xml:lang="en-US">The amount of milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NatureOfBusinessPolicyTextBlock_doc" xml:lang="en-US">Nature of Business policy text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OakRidgeNationalLaboratoryMember" xlink:to="atnm_OakRidgeNationalLaboratoryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OakRidgeNationalLaboratoryMember_doc" xml:lang="en-US">Oak ridge national laboratory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OfficeEquipmentServices" xlink:to="atnm_OfficeEquipmentServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OfficeEquipmentServices_doc" xml:lang="en-US">Office equipment and services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of maturities of lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PandemicOnFinancialStatements" xlink:to="atnm_PandemicOnFinancialStatements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_PandemicOnFinancialStatements_doc" xml:lang="en-US">Impact of COVID&amp;#8211;19 Pandemic on Financial Statements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet" xlink:to="atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet_doc" xml:lang="en-US">Sales of shares of common stock and warrants, net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProjectEstimatedCost" xlink:to="atnm_ProjectEstimatedCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ProjectEstimatedCost_doc" xml:lang="en-US">Project estimated cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PurchaseOfMaterials" xlink:to="atnm_PurchaseOfMaterials_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_PurchaseOfMaterials_doc" xml:lang="en-US">Purchase of materials.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:to="atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of supplemental information related to leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ServicesFees" xlink:to="atnm_ServicesFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ServicesFees_doc" xml:lang="en-US">Amount paid for services fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options outstanding and currently granted or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="atnm_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Number of warrants exercised during the current period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="atnm_StockIssuedDuringPeriodValueWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockIssuedDuringPeriodValueWarrantsExercised_doc" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantToPurchaseOfCommonStock" xlink:to="atnm_WarrantToPurchaseOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WarrantToPurchaseOfCommonStock_doc" xml:lang="en-US">Warrant to purchase of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantsExercisedByWarrantHolders" xlink:to="atnm_WarrantsExercisedByWarrantHolders_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WarrantsExercisedByWarrantHolders_doc" xml:lang="en-US">Warrants exercised by warrant holders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DeemedDividendForWarrantDownroundProtectionProvision" xlink:to="atnm_DeemedDividendForWarrantDownroundProtectionProvision_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DeemedDividendForWarrantDownroundProtectionProvision_2_lbl" xml:lang="en-US">DeemedDividendForWarrantDownroundProtectionProvision</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DeemedDividendForWarrantsDownroundProtectionProvision" xlink:to="atnm_DeemedDividendForWarrantsDownroundProtectionProvision_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DeemedDividendForWarrantsDownroundProtectionProvision_2_lbl" xml:lang="en-US">DeemedDividendForWarrantsDownroundProtectionProvision</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessor, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_2_lbl" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree" xlink:to="atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">MaturitiesLeaseLiabilityPaymentsDueYearThree</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseLiabilityPaymentsDue" xlink:to="atnm_LeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PaymentWithImputedInterestPremium_2_lbl" xml:lang="en-US">Orphan Drug Credits [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MaturitiesOfLeaseLiabilities_2_lbl" xml:lang="en-US">MaturitiesOfLeaseLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_3_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>atnm-20200630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: atnm%2D20200630.xfr; Date: 2020%2D08%2D13T15:50:50Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:href="atnm-20200630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:href="atnm-20200630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="atnm-20200630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:href="atnm-20200630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="atnm-20200630.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="atnm-20200630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="atnm-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/Leases" xlink:href="atnm-20200630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/Equity" xlink:href="atnm-20200630.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables" xlink:href="atnm-20200630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:href="atnm-20200630.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="atnm-20200630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" xlink:href="atnm-20200630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails" xlink:href="atnm-20200630.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails1" xlink:href="atnm-20200630.xsd#LeasesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails2" xlink:href="atnm-20200630.xsd#LeasesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails3" xlink:href="atnm-20200630.xsd#LeasesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails4" xlink:href="atnm-20200630.xsd#LeasesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:href="atnm-20200630.xsd#EquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:href="atnm-20200630.xsd#EquityDetailsTextual" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DocumentAndEntityInformationAbstract" xlink:label="loc_atnmDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:label="loc_atnmLongtermOperatingLeaseObligationsNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_atnmLongtermOperatingLeaseObligationsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LongtermFinanceLeaseObligationsNoncurrent" xlink:label="loc_atnmLongtermFinanceLeaseObligationsNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_atnmLongtermFinanceLeaseObligationsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ProvisionOfDeemedDividendForWarrantDownroundProtection" xlink:label="loc_atnmProvisionOfDeemedDividendForWarrantDownroundProtection" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_atnmProvisionOfDeemedDividendForWarrantDownroundProtection" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue" xlink:label="loc_atnmIssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmIssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares" xlink:label="loc_atnmIssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmIssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue" xlink:label="loc_atnmSaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmSaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares" xlink:label="loc_atnmSaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmSaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_atnmStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_atnmStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DeemedDividendForWarrantDownroundProtectionProvision" xlink:label="loc_atnmDeemedDividendForWarrantDownroundProtectionProvision" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmDeemedDividendForWarrantDownroundProtectionProvision" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_atnmIncreaseDecreaseInOperatingLeaseLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_atnmIncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts" xlink:label="loc_atnmSalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_atnmSalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet" xlink:label="loc_atnmProceedsFromIssuanceOfCommonStockAndWarrantNet" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_atnmProceedsFromIssuanceOfCommonStockAndWarrantNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ProceedsFromExerciseOfPrefundedWarrants" xlink:label="loc_atnmProceedsFromExerciseOfPrefundedWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_atnmProceedsFromExerciseOfPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SupplementalDisclosureOfNoncashFlowInformationAbstract" xlink:label="loc_atnmSupplementalDisclosureOfNoncashFlowInformationAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_atnmSupplementalDisclosureOfNoncashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DeemedDividendForWarrantsDownroundProtectionProvision" xlink:label="loc_atnmDeemedDividendForWarrantsDownroundProtectionProvision" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmSupplementalDisclosureOfNoncashFlowInformationAbstract" xlink:to="loc_atnmDeemedDividendForWarrantsDownroundProtectionProvision" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Description of Business and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000008 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Leases" xlink:title="00000009 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity" xlink:title="00000010 - Disclosure - Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000011 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_NatureOfBusinessPolicyTextBlock" xlink:label="loc_atnmNatureOfBusinessPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_atnmNatureOfBusinessPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PotentialReverseStockSplitPolicyTextBlock" xlink:label="loc_atnmPotentialReverseStockSplitPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_atnmPotentialReverseStockSplitPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PandemicOnFinancialStatements" xlink:label="loc_atnmPandemicOnFinancialStatements" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_atnmPandemicOnFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="loc_us-gaapLessorLeasesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapLessorLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AccountingPronouncementsRecentlyAdopted" xlink:label="loc_atnmAccountingPronouncementsRecentlyAdopted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_atnmAccountingPronouncementsRecentlyAdopted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000012 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesTables" xlink:title="00000013 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:label="loc_atnmScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_atnmScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:label="loc_atnmScheduleOrDescriptionOfWeightedAverageTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_atnmScheduleOrDescriptionOfWeightedAverageTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ScheduleOfWeightedAverageDiscountRate" xlink:label="loc_atnmScheduleOfWeightedAverageDiscountRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_atnmScheduleOfWeightedAverageDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_atnmOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_atnmOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:title="00000014 - Disclosure - Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PrefundedWarrantsMember" xlink:label="loc_atnmPrefundedWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_atnmPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestrictedAssetsCurrent" xlink:label="loc_us-gaapOtherRestrictedAssetsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOtherRestrictedAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CommitmentsAndContingenciesDetailsAbstract" xlink:label="loc_atnmCommitmentsAndContingenciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AgreementAxis" xlink:label="loc_atnmAgreementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_atnmAgreementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AgreementDomain" xlink:label="loc_atnmAgreementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAgreementAxis" xlink:to="loc_atnmAgreementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_atnmLicenseAndSponsoredResearchAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAgreementDomain" xlink:to="loc_atnmLicenseAndSponsoredResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_atnmFredHutchinsonCancerResearchCenterMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmFredHutchinsonCancerResearchCenterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_atnmOakRidgeNationalLaboratoryMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmOakRidgeNationalLaboratoryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_atnmCommitmentsAndContingenciesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_atnmDescriptionOfRoyaltyPaymentToRelatedParty" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmDescriptionOfRoyaltyPaymentToRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_atnmFirstCommercialSalePeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmFirstCommercialSalePeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_atnmProjectEstimatedCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmProjectEstimatedCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="loc_us-gaapDevelopmentInProcess" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapDevelopmentInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaapResearchAndDevelopmentInProcess" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:label="loc_us-gaapPaymentsForLeasingCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapPaymentsForLeasingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ServicesFees" xlink:label="loc_atnmServicesFees" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmServicesFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseTerm" xlink:label="loc_atnmLeaseTerm" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PurchaseOfMaterials" xlink:label="loc_atnmPurchaseOfMaterials" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmPurchaseOfMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" xlink:label="loc_atnmCapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmCapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CapitalleaseOfOfficeEquipment" xlink:label="loc_atnmCapitalleaseOfOfficeEquipment" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmCapitalleaseOfOfficeEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CapitalLeaseAgreement" xlink:label="loc_atnmCapitalLeaseAgreement" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmCapitalLeaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_OfficeEquipmentServices" xlink:label="loc_atnmOfficeEquipmentServices" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmOfficeEquipmentServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MilestonePayment" xlink:label="loc_atnmMilestonePayment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmMilestonePayment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails" xlink:title="00000019 - Disclosure - Leases  (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="loc_us-gaapCapitalLeaseObligationsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapCapitalLeaseObligationsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_FinanceLeasesCosAbstractt" xlink:label="loc_atnmFinanceLeasesCosAbstractt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmFinanceLeasesCosAbstractt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmFinanceLeasesCosAbstractt" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmFinanceLeasesCosAbstractt" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmFinanceLeasesCosAbstractt" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails1" xlink:title="00000020 - Disclosure - Leases (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CashFlowInformationAbstract" xlink:label="loc_atnmCashFlowInformationAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_atnmCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="loc_atnmCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCashFlowInformationAbstract" xlink:to="loc_atnmCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_NoncashActivityAbstract" xlink:label="loc_atnmNoncashActivityAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="loc_atnmNoncashActivityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaapLeaseCostAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCostAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseCostAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseCostAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails2" xlink:title="00000021 - Disclosure - Leases (Details 2)">
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeasesDetails21Abstract" xlink:label="loc_atnmLeasesDetails21Abstract" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:label="loc_atnmWeightedAverageRemainingLeaseTermAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmLeasesDetails21Abstract" xlink:to="loc_atnmWeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmWeightedAverageRemainingLeaseTermAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmWeightedAverageRemainingLeaseTermAbstract" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails3" xlink:title="00000022 - Disclosure - Leases (Details 3)">
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeasesDetails3Abstract" xlink:label="loc_atnmLeasesDetails3Abstract" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WeightedAverageDiscountRateAbstract" xlink:label="loc_atnmWeightedAverageDiscountRateAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmLeasesDetails3Abstract" xlink:to="loc_atnmWeightedAverageDiscountRateAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmWeightedAverageDiscountRateAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmWeightedAverageDiscountRateAbstract" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails4" xlink:title="00000023 - Disclosure - Leases (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseAxis" xlink:label="loc_atnmLeaseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_atnmLeaseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseDomain" xlink:label="loc_atnmLeaseDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmLeaseAxis" xlink:to="loc_atnmLeaseDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_OperatingLeaseLiabilitiesMember" xlink:label="loc_atnmOperatingLeaseLiabilitiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmLeaseDomain" xlink:to="loc_atnmOperatingLeaseLiabilitiesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_FinanceLeaseLiabilitiesMember" xlink:label="loc_atnmFinanceLeaseLiabilitiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmLeaseDomain" xlink:to="loc_atnmFinanceLeaseLiabilitiesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LeaseLiabilityPaymentsDue" xlink:label="loc_atnmLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_atnmLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PaymentWithImputedInterestPremium" xlink:label="loc_atnmPaymentWithImputedInterestPremium" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_atnmPaymentWithImputedInterestPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_MaturitiesOfLeaseLiabilities" xlink:label="loc_atnmMaturitiesOfLeaseLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmMaturitiesLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_atnmMaturitiesOfLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:title="00000024 - Disclosure - Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PrefundedWarrantsMember" xlink:label="loc_atnmPrefundedWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_atnmPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_atnmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_atnmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AggregateIntrinsicValueAbstract" xlink:label="loc_atnmAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_atnmAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:title="00000025 - Disclosure - Equity (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_LincolnParkCapitalFundLlcMember" xlink:label="loc_atnmLincolnParkCapitalFundLlcMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmLincolnParkCapitalFundLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AgreementAxis" xlink:label="loc_atnmAgreementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_atnmAgreementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AgreementDomain" xlink:label="loc_atnmAgreementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAgreementAxis" xlink:to="loc_atnmAgreementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_PurchaseAgreementMember" xlink:label="loc_atnmPurchaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAgreementDomain" xlink:to="loc_atnmPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SeriesAWarrantsMember" xlink:label="loc_atnmSeriesAWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_atnmSeriesAWarrantsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WarrantsMember" xlink:label="loc_atnmWarrantsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_atnmWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_EmployeeMember" xlink:label="loc_atnmEmployeeMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_atnmEmployeeMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_NonEmployeeMember" xlink:label="loc_atnmNonEmployeeMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_atnmNonEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_EquityTextualsAbstract" xlink:label="loc_atnmEquityTextualsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_atnmEquityTextualsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_IssuanceOfCommonStockShares" xlink:label="loc_atnmIssuanceOfCommonStockShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmIssuanceOfCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WarrantToPurchaseOfCommonStock" xlink:label="loc_atnmWarrantToPurchaseOfCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmWarrantToPurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_ShareCancelledDueToTerminationOfEmployees" xlink:label="loc_atnmShareCancelledDueToTerminationOfEmployees" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmShareCancelledDueToTerminationOfEmployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_CompensationExpenseRelatedToStockOptions" xlink:label="loc_atnmCompensationExpenseRelatedToStockOptions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmCompensationExpenseRelatedToStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_atnmWarrantsExercisedByWarrantHolders" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmWarrantsExercisedByWarrantHolders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_GrossProceedsFromWarrantExercises" xlink:label="loc_atnmGrossProceedsFromWarrantExercises" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmGrossProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_DescriptionOfWarrants" xlink:label="loc_atnmDescriptionOfWarrants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmDescriptionOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSubsequentEventDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20200630.xsd#atnm_AggregateValueOfCommonStock" xlink:label="loc_atnmAggregateValueOfCommonStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmAggregateValueOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505558628248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 13, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Actinium Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001388320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,585,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505555416152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 53,466<span></span>
</td>
<td class="nump">$ 9,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - current</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">994<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">54,508<span></span>
</td>
<td class="nump">10,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $260 and $237, respectively</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases right-of-use assets</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance leases right-of-use assets</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">55,958<span></span>
</td>
<td class="nump">11,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">4,092<span></span>
</td>
<td class="nump">4,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating leases current liability</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases current liability</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">4,656<span></span>
</td>
<td class="nump">5,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongtermOperatingLeaseObligationsNoncurrent', window );">Long-term operating leases obligations</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongtermFinanceLeaseObligationsNoncurrent', window );">Long-term finance leases obligations</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">5,184<span></span>
</td>
<td class="nump">6,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 13,171,824 and 5,490,038 shares issued and outstanding, respectively</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">269,815<span></span>
</td>
<td class="nump">214,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(219,054)<span></span>
</td>
<td class="num">(208,758)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">50,774<span></span>
</td>
<td class="nump">5,644<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 55,958<span></span>
</td>
<td class="nump">$ 11,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongtermFinanceLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term finance lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LongtermFinanceLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongtermOperatingLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term operating lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LongtermOperatingLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505555964344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">13,171,824<span></span>
</td>
<td class="nump">5,490,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">13,171,824<span></span>
</td>
<td class="nump">5,490,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505555303672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
<td class="nump">3,508<span></span>
</td>
<td class="nump">4,010<span></span>
</td>
<td class="nump">7,659<span></span>
</td>
<td class="nump">8,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,154<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">2,686<span></span>
</td>
<td class="nump">2,440<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,662<span></span>
</td>
<td class="nump">5,086<span></span>
</td>
<td class="nump">10,345<span></span>
</td>
<td class="nump">10,785<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,662)<span></span>
</td>
<td class="num">(5,086)<span></span>
</td>
<td class="num">(10,345)<span></span>
</td>
<td class="num">(10,785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income - net</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,625)<span></span>
</td>
<td class="num">(5,027)<span></span>
</td>
<td class="num">(10,295)<span></span>
</td>
<td class="num">(10,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProvisionOfDeemedDividendForWarrantDownroundProtection', window );">Deemed dividend for warrant down-round protection provision</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common stockholders</a></td>
<td class="num">$ (4,626)<span></span>
</td>
<td class="num">$ (5,028)<span></span>
</td>
<td class="num">$ (10,296)<span></span>
</td>
<td class="num">$ (10,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock - basic and diluted</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
<td class="num">$ (2.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock outstanding, including outstanding pre-funded warrants- basic and diluted</a></td>
<td class="nump">11,379,345<span></span>
</td>
<td class="nump">5,051,471<span></span>
</td>
<td class="nump">8,559,385<span></span>
</td>
<td class="nump">4,476,215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ProvisionOfDeemedDividendForWarrantDownroundProtection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ProvisionOfDeemedDividendForWarrantDownroundProtection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505553569272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 195,666<span></span>
</td>
<td class="num">$ (186,857)<span></span>
</td>
<td class="nump">$ 8,813<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="nump">3,856,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,504<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock from exercise of warrants, shares</a></td>
<td class="nump">83,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of offering costs, shares</a></td>
<td class="nump">30,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,670)<span></span>
</td>
<td class="num">(5,670)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">197,866<span></span>
</td>
<td class="num">(192,527)<span></span>
</td>
<td class="nump">5,343<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2019</a></td>
<td class="nump">3,971,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock from exercise of warrants, shares</a></td>
<td class="nump">1,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock and warrants, net of offering costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">15,107<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock and warrants, net of offering costs, shares</a></td>
<td class="nump">1,428,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DeemedDividendForWarrantDownroundProtectionProvision', window );">Deemed dividend for warrant down-round protection provision</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,027)<span></span>
</td>
<td class="num">(5,027)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">213,251<span></span>
</td>
<td class="num">(197,555)<span></span>
</td>
<td class="nump">15,701<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2019</a></td>
<td class="nump">5,401,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">214,397<span></span>
</td>
<td class="num">(208,758)<span></span>
</td>
<td class="nump">5,644<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">5,490,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of offering costs, shares</a></td>
<td class="nump">337,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,670)<span></span>
</td>
<td class="num">(5,670)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">217,442<span></span>
</td>
<td class="num">(214,428)<span></span>
</td>
<td class="nump">3,020<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="nump">5,827,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">5,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue', window );">Issuance of common stock from exercise of pre-funded warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares', window );">Issuance of common stock from exercise of pre-funded warrants, shares</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue', window );">Sale of common stock and pre-funded warrants, net of offering costs</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">52,159<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">52,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares', window );">Sale of common stock and pre-funded warrants, net of offering costs, shares</a></td>
<td class="nump">6,138,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DeemedDividendForWarrantDownroundProtectionProvision', window );">Deemed dividend for warrant down-round protection provision</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,625)<span></span>
</td>
<td class="num">(4,625)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 269,815<span></span>
</td>
<td class="num">$ (214,428)<span></span>
</td>
<td class="nump">$ 50,774<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2020</a></td>
<td class="nump">13,171,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DeemedDividendForWarrantDownroundProtectionProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DeemedDividendForWarrantDownroundProtectionProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IssuanceOfCommonStockFromExerciseOfPrefundedWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SaleOfCommonStockAndPrefundedWarrantsNetOfOfferingCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505555929096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,295)<span></span>
</td>
<td class="num">$ (10,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation &amp; amortization expenses</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(208)<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(506)<span></span>
</td>
<td class="num">(1,111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(154)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="num">(10,365)<span></span>
</td>
<td class="num">(10,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Used In Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on note payable</a></td>
<td class="num">(227)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance leases</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts', window );">Sales of shares of common stock and pre-funded warrants, net of costs</a></td>
<td class="nump">54,839<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet', window );">Sales of shares of common stock and warrants, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProceedsFromExerciseOfPrefundedWarrants', window );">Proceeds from exercise of pre-funded warrants</a></td>
<td class="nump">4<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,504<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="nump">54,577<span></span>
</td>
<td class="nump">16,808<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">44,212<span></span>
</td>
<td class="nump">5,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">9,693<span></span>
</td>
<td class="nump">14,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">53,905<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest on note payable</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SupplementalDisclosureOfNoncashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DeemedDividendForWarrantsDownroundProtectionProvision', window );">Deemed dividend for warrant down-round protection provision</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DeemedDividendForWarrantsDownroundProtectionProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DeemedDividendForWarrantsDownroundProtectionProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ProceedsFromExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ProceedsFromExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales of shares of common stock and warrants, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SalesOfSharesOfCommonStockAndPrefundedWarrantsNetOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SupplementalDisclosureOfNoncashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SupplementalDisclosureOfNoncashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505642134328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business -</b>
Actinium Pharmaceuticals, Inc. (the "Company", "Actinium", or "We") is a clinical-stage, biopharmaceutical
company applying its proprietary platform technology and deep understanding of radioimmunobiology to the development of novel targeted
therapies known as ARCs or Antibody Radiation-Conjugates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation
- Unaudited Interim Financial Information -</b> The accompanying unaudited interim consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S.
GAAP") for interim financial information, and in accordance with the rules and regulations of the United States Securities
and Exchange Commission (the "SEC") with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do
not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim
consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in
the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are
not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be
read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's annual
report on Form 10-K for the year ended December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Reverse Stock Split
- </b>On April 29, 2020, the Company received a deficiency letter from the NYSE American LLC, or NYSE American, indicating that
the Company was not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE
American Company Guide because its shares of common stock had been selling for a substantial period of time at a low price per
share. Pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the NYSE American staff determined that the Company's
continued listing is predicated on the Company effecting a reverse stock split of its common stock or otherwise demonstrating sustained
price improvement within a reasonable period of time, which the staff determined to be no later than October 29, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 18, 2019, the
Company's board of directors, or the Board, unanimously approved, subject to stockholder approval, an amendment to the Company's
certificate of incorporation to effect a reverse stock split of its outstanding common stock by combining outstanding shares of
common stock into a lesser number of outstanding shares of common stock by a ratio of not more than 1-for-75 prior to December
18, 2020, with the exact ratio to be set within this range by the Board at its sole discretion. At its Annual Meeting of Stockholders
held on December 18, 2019, the Company's stockholders approved such amendment to its certificate of incorporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 7, 2020, the Board unanimously approved a reverse
stock split of its outstanding common stock by combining outstanding shares of common stock into a lesser number of outstanding
shares of common stock by a ratio of 1-for-30, and on August 10, 2020, the Company filed with the Secretary of State of Delaware
a certificate of amendment to its certificate of incorporation to effect the reverse stock split. The reverse stock split became
effective as of 5:00 p.m. Eastern Time on August 10, 2020, and the Company's common stock began trading on a split-adjusted
basis when the market opened on August 11, 2020. Accordingly, all common share and per common share data in these consolidated
financial statements and related notes hereto have been retroactively adjusted to account for the effect of this reverse stock
split for all periods presented. In addition, at the effective time of the reverse stock split, the number of shares of our common
stock reserved for issuance upon exercise of all options and warrants to acquire common stock have been proportionally decreased,
and the exercise price of all options and warrants to acquire common stock have been proportionally increased.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The consolidated financial statements include the Company's accounts and those of the Company's wholly owned
subsidiary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates in
Financial Statement Presentation</b> - The preparation of these consolidated financial statements in conformity with U.S. GAAP
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of
the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ
from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Impact of COVID&#8211;19
Pandemic on Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In December 2019, a novel
strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China to other
countries has resulted in the World Health Organization ("WHO") declaring the outbreak of COVID-19 as a "pandemic,"
or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictions
on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses, and many local jurisdictions
continue to have such restrictions in place.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As local jurisdictions
continue to put restrictions in place, the Company's ability to continue to operate its business may also be limited. Such
events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of
which could materially affect the Company's business, financial condition and results of operations. In response to COVID-19,
the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations as
it relates to the clinical development or drug production of our drug candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The spread of COVID-19,
which has caused a broad impact globally, may materially affect the Company economically. While the ultimate economic impact brought
by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, including new information which may emerge
concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others, the pandemic has resulted
significant disruptions in the general commercial activity and the global economy and caused financial market volatility and uncertainty
in significant and unforeseen ways in the recent months. A continuation or worsening of the levels of market disruption and volatility
seen in the recent past could have an adverse effect on the Company's ability to access capital, which could in the future
negatively affect the Company's liquidity. In addition, a recession or market correction resulting from the spread of COVID-19
could materially affect the Company's business and the value of the Company's common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, COVID-19
may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with IRB's or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To date, COVID-19 has not
had a financial impact on the Company. However, COVID-19 has caused severe disruptions in transportation and limited access to
the Company's facility, resulting in limited support from its staff and professional advisors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to
be cash equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2020 and December 31, 2019:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53,466</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,254</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Restricted cash &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">391</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">391</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">53,905</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,693</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Current restricted cash
relates to credit card accounts, while long-term restricted cash relates to a certificate of deposit held as collateral for a letter
of credit issued in connection with the Company's lease for corporate office space.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporate office
space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is
recognized on a straight-line basis over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Fair Value of Financial
Instruments</b> - Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,
in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives
the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable
inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product,
the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities
and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments
-</b> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common
Share</b> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted
average number of common shares outstanding during the reporting period. For periods of net income, and when the effects are not
anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average
number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common shares underlying
common stock options and warrants using the treasury stock method. The Company issued pre-funded warrants in April 2020 and June
2020 that are considered outstanding shares for the purposes of calculating net loss per common share, see Note 4 for additional
information. Since the shares underlying the outstanding 2.3 million pre-funded warrants are issuable for negligible consideration
and are fully vested and exercisable, they are considered outstanding for the calculations of both basic and diluted loss per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For periods of net loss,
diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares
is anti-dilutive. For the six months ended June 30, 2020 and 2019, the Company's potentially dilutive shares, which include
outstanding common stock options and warrants have not been included in the computation of diluted net loss per share as the result
would have been anti-dilutive.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">365</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">264</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,871</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,878</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,236</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,142</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Accounting Standards
Recently Adopted</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2018, FASB issued
ASU 2018-13, <i>Fair Value Measurement - Disclosure Framework (Topic 820).</i> The updated guidance improves the disclosure requirements
on fair value measurements, primarily associated with Level 3 fair value measurements and is effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the standard
for disclosures modified or removed with a delay of adoption of the additional disclosures until their effective date. The Company
adopted this standard effective January 1, 2020 and the standard did not have a significant impact to the Company's financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November 2018, FASB
issued ASU 2018-18, C<i>ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, </i>which,
among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted
for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years,
beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard effective January&#160;1, 2020
and the standard did not have a significant impact to the Company's financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505560431688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 - Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has entered
into agreements with third parties for the rights to certain intellectual property, manufacturing and clinical trial services under
which the Company may incur obligations to make payments including upfront payments as well as milestone and royalty payments.
Notable inclusions in this category are:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Oak Ridge National Laboratory ("ORNL") &#8211; The Company is contracted to purchase radioactive material to be used for research and development, with a renewal option at the contract end. During the six months ended June 30, 2020 and 2019, the Company purchased material from ORNL of $0.1 million in each period. In November 2019, the Company signed a contract with ORNL to purchase $0.3 million of radioactive material during calendar year 2020.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center ("FHCRC") to build upon previous and ongoing clinical trials with BC8 (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial with BC8. The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC. A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed BC 8 antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC. </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Collaborative Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2018, the
Company entered into a research and option agreement with Astellas Pharma Inc. ("Astellas") to develop ARCs using the
Company's AWE Technology Platform. Under this collaboration, the Company will utilize its AWE Platform to conjugate and label
selected Astellas targeting agents with an Actinium-225 payload. The Company is also responsible for conducting preclinical validation
studies on any ARCs generated. Payments from Astellas under this agreement are accounted for as a reduction to research and development
expense.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505634356552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3 - Leases </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company adopted ASC
842 as of January 1, 2019, using a modified retrospective approach and applying the standard's transition provisions at January
1, 2019, the effective date. The Company made an accounting policy election to exclude from balance sheet reporting those leases
with initial terms of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company determines
if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company
the right to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset
is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic
benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which
the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable
lease components are recognized when the obligation is probable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and
liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires
a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily
determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company's leases,
the incremental borrowing rate is used based on the information available at commencement date in determining the present value
of lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The lease term for all
of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a
Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend
(or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and
lease liability) for the majority of the Company's leases as the reasonably certain threshold is not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2020, the Company
has an operating lease for corporate office space and two finance leases for office equipment and furniture located in the corporate
office space. In addition, the Company has auxiliary corporate office space that it rents on a month-to-month basis; this rental
is accounted for as an operating lease with the same term as the Company's main office in the same building.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The components of lease expense are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three months ended</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">(in thousands)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br />
2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br />
2019</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br />
2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br />
2019</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; width: 52%; text-align: left">Operating lease expense</td><td style="padding-bottom: 4pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">93</td><td style="padding-bottom: 4pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 4pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">93</td><td style="padding-bottom: 4pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 4pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">186</td><td style="padding-bottom: 4pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 4pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">186</td><td style="padding-bottom: 4pt; width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">26</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">50</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">52</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Supplemental cash flow information related to
leases are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Cash flow information:</b></font></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Six months ended</b></font></td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30,<br />
2020</b></font></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30,<br />
2019</b></font></td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 71%"><font style="font: 10pt Times New Roman, Times, Serif">Operating cash flow use from operating leases</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">188</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">172</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Operating cash flow use from finance leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Financing cash flow use from finance leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">39</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">36</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-cash activity:</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Right-of-use assets obtained in exchange for lease obligations:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Operating leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">83</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,177</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Finance Leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-&#160;&#160;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">302</font></td>
    <td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Weighted average remaining lease terms are as
follows at June 30, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Weighted average remaining lease term:</font></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 89%"><font style="font: 10pt Times New Roman, Times, Serif">Operating leases</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.2 years</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Finance Leases</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.2 years</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As the Company's
leases do not provide an implicit rate, the Company used its incremental borrowing rate based on the information available at adoption
date in determining the present value of lease payments. Below is information on the weighted average discount rates used:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Weighted average discount rates:</font></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 89%"><font style="font: 10pt Times New Roman, Times, Serif">Operating leases</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Finance Leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><b>&#160;&#160;&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>(in
    thousands)<br />
    Year ending December 31,</b></font></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Operating
    Leases</b></font></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Finance
    Leases</b></font></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman, Times, Serif; width: 78%"><font style="font: 10pt Times New Roman, Times, Serif">2020 (excluding six months
    ended June 30, 2020)</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">187</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">47</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">377</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">94</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">252</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">64</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Total lease payments</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">816</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">209</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Less imputed interest</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(69</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(18</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Present value of lease liabilities</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">747</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">191</font></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505634358168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 - Equity&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 7, 2020,
the Board unanimously approved a reverse stock split of its outstanding common stock by combining outstanding shares of common
stock into a lesser number of outstanding shares of common stock by a ratio of 1-for-30, and on August 10, 2020, the Company filed
with the Secretary of State of Delaware a certificate of amendment to its certificate of incorporation to effect the reverse stock
split. Accordingly, all common share and per common share data in these consolidated financial statements and related notes hereto
have been retroactively adjusted to account for the effect of this reverse stock split for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 24, 2020,
the Company issued and sold 4.3 million shares of common stock and 2.8 million pre-funded warrants to purchase shares of common
stock. The price to the public in this offering for each share of common stock was $4.50 and for each pre-funded warrant was $4.497.
Each pre-funded warrant has an exercise price of $0.003 per share and is exercisable immediately upon issuance. The pre-funded
warrants are subject to certain limitations on beneficial ownership. Gross proceeds from this offering to Actinium were $31.6 million,
before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this
offering were $29.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2020, holders
of 1.2 million pre-funded April 2020 warrants exercised their warrants at $0.003 per share and received 1.2 million shares of common
stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 19, 2020, the
Company issued and sold 1.9 million shares of common stock and 0.7 million pre-funded warrants to purchase shares of common stock.
The price to the public in this offering for each share of common stock was $9.75 and for each pre-funded warrant was $9.747. Each
pre-funded warrant has an exercise price of $0.003 per share and is exercisable immediately upon issuance. The pre-funded warrants
are subject to certain limitations on beneficial ownership. Gross proceeds from this offering to Actinium were $25.0 million, before
deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this offering
were $23.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018, the
Company entered into the Amended and Restated At Market Issuance Sales Agreement with B. Riley FBR, Inc. and JonesTrading Institutional
Services LLC, pursuant to which the Company conducted its at-the market program. During the six months ended June 30, 2020, the
Company sold 0.3 million common shares through its at-the-market program, resulting in net proceeds of $2.5 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2018, the
Company and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a purchase agreement and a registration rights
agreement, pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s common stock having
an aggregate value of up to $32.5 million, subject to certain limitations and conditions set forth in the agreement. During the
six months ended June 30, 2020, the Company elected to sell to Lincoln Park 27 thousand shares and received $0.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2020, the Company
issued 5 thousand shares of restricted common stock, valued at $30 thousand, for consulting services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the six months
ended June 30, 2019, holders of March 2018 series A warrants exercised 83 thousand shares, resulting in the Company receiving $1.5
million. The remaining March 2018 series A warrants expired in March 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has outstanding
warrants to purchase 1,907 shares of common stock that include down-round protection. For warrants with down-round protection,
a deemed dividend is recorded for the change in fair value of the warrants when the down-round provision is triggered. As result
of the April 2019 offering, the exercise price of the warrant was reset from $37.50 per share to $26.40 per share. As a result
of the April 2020 offering and June 2020 offering, the exercise price of the warrant was reset from $26.40 per share to $15.60
per share. The down-round protection provision in the above warrants created a deemed dividend to common stockholders of $1 thousand
in the six months ended June 30, 2020 and 2019, which are reflected in the accompanying consolidated statement of operations and
consolidated statement of changes in stockholders&#8217; equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the six months ended June 30, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Term <br /> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br /> Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">380</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.88</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">15.86</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">365</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">36.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">7.49</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">519</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">194</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">56.43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.47</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">112</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months
ended June 30, 2020, options to purchase 15 thousand shares were cancelled upon the termination of employment for several employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair values of all
options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense
at June 30, 2020 was $1.5 million related to unvested options, which is expected to be expensed over a weighted average of 2.8
years. During the six months ended June 30, 2020 and 2019, the Company recorded compensation expense related to stock options of
$0.5 million and $0.3 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Pre-funded Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the April
2020 offering and the June 2020 offering, the Company issued pre-funded warrants. Each pre-funded warrant has an exercise price
of $0.003 per share and is exercisable immediately upon issuance. The pre-funded warrants are subject to certain limitations on
beneficial ownership. The pre-funded warrants do not have an expiration date. Management determined that the pre-funded warrants
are freestanding instruments and that the pre-funded warrants should be classified as permanent equity in accordance with authoritative
guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following is a summary
of pre-funded warrant activity for the six months ended June 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br /> Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,459</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.003</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,200</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.003</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 10pt">Outstanding, June 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,259</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.003</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">23,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,259</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.003</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">23,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following is a summary
of warrant activity for the six months ended June 30, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Term <br /> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br /> Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,871</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20.71</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">301</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Cancelled/Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,871</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">20.71</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.45</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">497</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,865</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">20.37</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.45</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">496</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Subsequent Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2020, holders
of 0.4 million pre-funded April 2020 and June 2020 warrants exercised their warrants at $0.003 per share and received 0.4 million
shares of common stock. Holders of 2 thousand April 2019 warrants exercised their warrants at $15.00 per share and received 2 thousand
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the
Company filed a registration statement including a base prospectus which covers the offering, issuance and sale of up to $500 million
of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus covering the offering,
issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued and sold under
the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since June 30, 2020, the
Company has issued stock options for 357,189 shares to employees and 33,332 shares to non-employee directors.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505555962200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NatureOfBusinessPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business -</b>
Actinium Pharmaceuticals, Inc. (the "Company", "Actinium", or "We") is a clinical-stage, biopharmaceutical
company applying its proprietary platform technology and deep understanding of radioimmunobiology to the development of novel targeted
therapies known as ARCs or Antibody Radiation-Conjugates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation - Unaudited Interim Financial Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation
- Unaudited Interim Financial Information -</b> The accompanying unaudited interim consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S.
GAAP") for interim financial information, and in accordance with the rules and regulations of the United States Securities
and Exchange Commission (the "SEC") with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do
not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim
consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in
the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are
not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be
read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's annual
report on Form 10-K for the year ended December 31, 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PotentialReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Reverse Stock Split
- </b>On April 29, 2020, the Company received a deficiency letter from the NYSE American LLC, or NYSE American, indicating that
the Company was not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE
American Company Guide because its shares of common stock had been selling for a substantial period of time at a low price per
share. Pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the NYSE American staff determined that the Company's
continued listing is predicated on the Company effecting a reverse stock split of its common stock or otherwise demonstrating sustained
price improvement within a reasonable period of time, which the staff determined to be no later than October 29, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 18, 2019, the
Company's board of directors, or the Board, unanimously approved, subject to stockholder approval, an amendment to the Company's
certificate of incorporation to effect a reverse stock split of its outstanding common stock by combining outstanding shares of
common stock into a lesser number of outstanding shares of common stock by a ratio of not more than 1-for-75 prior to December
18, 2020, with the exact ratio to be set within this range by the Board at its sole discretion. At its Annual Meeting of Stockholders
held on December 18, 2019, the Company's stockholders approved such amendment to its certificate of incorporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 7, 2020, the Board unanimously approved a reverse
stock split of its outstanding common stock by combining outstanding shares of common stock into a lesser number of outstanding
shares of common stock by a ratio of 1-for-30, and on August 10, 2020, the Company filed with the Secretary of State of Delaware
a certificate of amendment to its certificate of incorporation to effect the reverse stock split. The reverse stock split became
effective as of 5:00 p.m. Eastern Time on August 10, 2020, and the Company's common stock began trading on a split-adjusted
basis when the market opened on August 11, 2020. Accordingly, all common share and per common share data in these consolidated
financial statements and related notes hereto have been retroactively adjusted to account for the effect of this reverse stock
split for all periods presented. In addition, at the effective time of the reverse stock split, the number of shares of our common
stock reserved for issuance upon exercise of all options and warrants to acquire common stock have been proportionally decreased,
and the exercise price of all options and warrants to acquire common stock have been proportionally increased.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The consolidated financial statements include the Company's accounts and those of the Company's wholly owned
subsidiary.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in Financial Statement Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates in
Financial Statement Presentation</b> - The preparation of these consolidated financial statements in conformity with U.S. GAAP
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of
the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ
from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PandemicOnFinancialStatements', window );">Impact of COVID-19 Pandemic on Financial Statements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Impact of COVID&#8211;19
Pandemic on Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In December 2019, a novel
strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China to other
countries has resulted in the World Health Organization ("WHO") declaring the outbreak of COVID-19 as a "pandemic,"
or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictions
on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses, and many local jurisdictions
continue to have such restrictions in place.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As local jurisdictions
continue to put restrictions in place, the Company's ability to continue to operate its business may also be limited. Such
events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of
which could materially affect the Company's business, financial condition and results of operations. In response to COVID-19,
the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations as
it relates to the clinical development or drug production of our drug candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The spread of COVID-19,
which has caused a broad impact globally, may materially affect the Company economically. While the ultimate economic impact brought
by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, including new information which may emerge
concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others, the pandemic has resulted
significant disruptions in the general commercial activity and the global economy and caused financial market volatility and uncertainty
in significant and unforeseen ways in the recent months. A continuation or worsening of the levels of market disruption and volatility
seen in the recent past could have an adverse effect on the Company's ability to access capital, which could in the future
negatively affect the Company's liquidity. In addition, a recession or market correction resulting from the spread of COVID-19
could materially affect the Company's business and the value of the Company's common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, COVID-19
may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with IRB's or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To date, COVID-19 has not
had a financial impact on the Company. However, COVID-19 has caused severe disruptions in transportation and limited access to
the Company's facility, resulting in limited support from its staff and professional advisors.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to
be cash equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2020 and December 31, 2019:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53,466</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,254</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Restricted cash &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">391</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">391</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">53,905</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,693</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Current restricted cash
relates to credit card accounts, while long-term restricted cash relates to a certificate of deposit held as collateral for a letter
of credit issued in connection with the Company's lease for corporate office space.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporate office
space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is
recognized on a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Fair Value of Financial
Instruments</b> - Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,
in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives
the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable
inputs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product,
the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities
and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments
-</b> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common
Share</b> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted
average number of common shares outstanding during the reporting period. For periods of net income, and when the effects are not
anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average
number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common shares underlying
common stock options and warrants using the treasury stock method. The Company issued pre-funded warrants in April 2020 and June
2020 that are considered outstanding shares for the purposes of calculating net loss per common share, see Note 4 for additional
information. Since the shares underlying the outstanding 2.3 million pre-funded warrants are issuable for negligible consideration
and are fully vested and exercisable, they are considered outstanding for the calculations of both basic and diluted loss per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For periods of net loss,
diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares
is anti-dilutive. For the six months ended June 30, 2020 and 2019, the Company's potentially dilutive shares, which include
outstanding common stock options and warrants have not been included in the computation of diluted net loss per share as the result
would have been anti-dilutive.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">365</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">264</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,871</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,878</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,236</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,142</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AccountingPronouncementsRecentlyAdopted', window );">Accounting Standards Recently Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Accounting Standards
Recently Adopted</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2018, FASB issued
ASU 2018-13, <i>Fair Value Measurement - Disclosure Framework (Topic 820).</i> The updated guidance improves the disclosure requirements
on fair value measurements, primarily associated with Level 3 fair value measurements and is effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the standard
for disclosures modified or removed with a delay of adoption of the additional disclosures until their effective date. The Company
adopted this standard effective January 1, 2020 and the standard did not have a significant impact to the Company's financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November 2018, FASB
issued ASU 2018-18, C<i>ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, </i>which,
among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted
for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years,
beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard effective January&#160;1, 2020
and the standard did not have a significant impact to the Company's financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AccountingPronouncementsRecentlyAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounting pronouncements recently adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AccountingPronouncementsRecentlyAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NatureOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature of Business policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NatureOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PandemicOnFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impact of COVID&amp;#8211;19 Pandemic on Financial Statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PandemicOnFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PotentialReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PotentialReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL117410129-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Subparagraph 14<br> -URI http://asc.fasb.org/section&amp;trid=77888298<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919352-209981<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL117410129-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505634131704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of cash and cash equivalent and restricted cash</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53,466</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,254</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Restricted cash &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">391</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">391</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">53,905</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,693</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">365</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">264</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,871</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,878</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,236</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,142</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505558560920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule components of lease expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three months ended</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">(in thousands)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br />
2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br />
2019</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br />
2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br />
2019</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; width: 52%; text-align: left">Operating lease expense</td><td style="padding-bottom: 4pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">93</td><td style="padding-bottom: 4pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 4pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">93</td><td style="padding-bottom: 4pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 4pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">186</td><td style="padding-bottom: 4pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 4pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">186</td><td style="padding-bottom: 4pt; width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">26</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">50</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">52</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock', window );">Schedule of supplemental cash flow information related to leases</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Cash flow information:</b></font></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Six months ended</b></font></td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30,<br />
2020</b></font></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30,<br />
2019</b></font></td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 71%"><font style="font: 10pt Times New Roman, Times, Serif">Operating cash flow use from operating leases</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font: 10pt Times New Roman, Times, Serif">188</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font: 10pt Times New Roman, Times, Serif">172</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Operating cash flow use from finance leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Financing cash flow use from finance leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">39</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">36</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-cash activity:</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Right-of-use assets obtained in exchange for lease obligations:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Operating leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">83</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,177</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Finance Leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-&#160;&#160;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">302</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOrDescriptionOfWeightedAverageTerm', window );">Schedule of weighted average remaining lease terms</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Weighted average remaining lease term:</font></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 89%"><font style="font: 10pt Times New Roman, Times, Serif">Operating leases</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.2 years</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Finance Leases</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.2 years</font></td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOfWeightedAverageDiscountRate', window );">Schedule of weighted average discount rates</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Weighted average discount rates:</font></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 89%"><font style="font: 10pt Times New Roman, Times, Serif">Operating leases</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Finance Leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>(in
    thousands)<br />
    Year ending December 31,</b></font></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Operating
    Leases</b></font></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Finance
    Leases</b></font></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman, Times, Serif; width: 78%"><font style="font: 10pt Times New Roman, Times, Serif">2020 (excluding six months
    ended June 30, 2020)</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">187</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">47</font></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">377</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">94</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">252</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">64</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Total lease payments</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">816</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">209</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Less imputed interest</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(69</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(18</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Present value of lease liabilities</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">747</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 4.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">191</font></td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOrDescriptionOfWeightedAverageTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOrDescriptionOfWeightedAverageTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505558520120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Term <br /> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br /> Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">380</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.88</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">15.86</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">365</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">36.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">7.49</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">519</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">194</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">56.43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.47</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">112</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=atnm_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activities</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br /> Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,459</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.003</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,200</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.003</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 10pt">Outstanding, June 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,259</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.003</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">23,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,259</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.003</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">23,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Term <br /> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br /> Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,871</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20.71</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">301</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Cancelled/Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,871</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">20.71</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.45</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">497</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,865</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">20.37</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.45</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">496</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=atnm_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=atnm_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505554592264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 53,466<span></span>
</td>
<td class="nump">$ 9,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - current</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssetsCurrent', window );">Restricted cash - long-term</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 53,905<span></span>
</td>
<td class="nump">$ 9,693<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 14,104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505554590744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,236<span></span>
</td>
<td class="nump">3,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,871<span></span>
</td>
<td class="nump">2,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505634450968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding pre-funded warrants</a></td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505555350472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Jun. 15, 2012</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_OakRidgeNationalLaboratoryMember', window );">Oak Ridge National Laboratory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PurchaseOfMaterials', window );">Purchase of materials</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AgreementAxis=atnm_LicenseAndSponsoredResearchAgreementMember', window );">License and Sponsored Research Agreement [Member] | Fred Hutchinson Cancer Research Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty', window );">Description of royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Royalty payments of 2% of net sales will be due to FHCRC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of royalty payment to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DescriptionOfRoyaltyPaymentToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PurchaseOfMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of materials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PurchaseOfMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_OakRidgeNationalLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_OakRidgeNationalLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AgreementAxis=atnm_LicenseAndSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AgreementAxis=atnm_LicenseAndSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_FredHutchinsonCancerResearchCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_FredHutchinsonCancerResearchCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505556547880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases  (Details) - Lease [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FinanceLeasesCosAbstractt', window );"><strong>Finance lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-to-use assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FinanceLeasesCosAbstractt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_FinanceLeasesCosAbstractt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505554623016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow use from operating leases</a></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flow use from finance leases</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow use from finance leases</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance Leases</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505634416888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details 2)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Leases</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505634512088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details 3)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted average discount rates:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance Leases</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505555315736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details 4)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember', window );">Operating Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Year ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020 (excluding six months ended June 30, 2020)</a></td>
<td class="nump">$ 187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PaymentWithImputedInterestPremium', window );">Less imputed interest</a></td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesOfLeaseLiabilities', window );">Present value of lease liabilities</a></td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Year ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020 (excluding six months ended June 30, 2020)</a></td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PaymentWithImputedInterestPremium', window );">Less imputed interest</a></td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesOfLeaseLiabilities', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaturitiesLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MaturitiesLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaturitiesOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MaturitiesOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PaymentWithImputedInterestPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PaymentWithImputedInterestPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505553582376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=atnm_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">3,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(1,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending</a></td>
<td class="nump">2,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="nump">2,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">0.003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised | $ / shares</a></td>
<td class="nump">0.003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending | $ / shares</a></td>
<td class="nump">0.003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable | $ / shares</a></td>
<td class="nump">$ 0.003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Beginning | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Ending | $</a></td>
<td class="nump">23,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable | $</a></td>
<td class="nump">$ 23,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning</a></td>
<td class="nump">2,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/Expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending</a></td>
<td class="nump">2,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="nump">2,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning | $ / shares</a></td>
<td class="nump">$ 20.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending | $ / shares</a></td>
<td class="nump">20.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable | $ / shares</a></td>
<td class="nump">$ 20.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Beginning</a></td>
<td class="text">2 years 11 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding, Ending</a></td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Beginning | $</a></td>
<td class="nump">$ 301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Ending | $</a></td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable | $</a></td>
<td class="nump">$ 496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning</a></td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/Expired</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending</a></td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning | $ / shares</a></td>
<td class="nump">$ 35.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled | $ / shares</a></td>
<td class="nump">15.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending | $ / shares</a></td>
<td class="nump">36.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable | $ / shares</a></td>
<td class="nump">$ 56.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Beginning</a></td>
<td class="text">7 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding, Ending</a></td>
<td class="text">7 years 5 months 27 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">6 years 5 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Beginning | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Ending | $</a></td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable | $</a></td>
<td class="nump">$ 112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=atnm_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=atnm_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140505549902328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 20, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jun. 19, 2020</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds on sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ShareCancelledDueToTerminationOfEmployees', window );">Share cancelled due to termination of employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CompensationExpenseRelatedToStockOptions', window );">Compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfWarrants', window );">Description of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Holders of 1.2 million pre-funded April 2020 warrants exercised their warrants at $0.003 per share and received 1.2 million shares of common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company issued and sold 4.3 million shares of common stock and 2.8 million pre-funded warrants to purchase shares of common stock. The price to the public in this offering for each share of common stock was $4.50 and for each pre-funded warrant was $4.497. Each pre-funded warrant has an exercise price of $0.003 per share and is exercisable immediately upon issuance. The pre-funded warrants are subject to certain limitations on beneficial ownership. Gross proceeds from this offering to Actinium were $31.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this offering were $29.1 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company issued 5 thousand shares of restricted common stock, valued at $30 thousand, for consulting services.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan', window );">Dividend to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=atnm_EmployeeMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_IssuanceOfCommonStockShares', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=atnm_NonEmployeeMember', window );">Non Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_IssuanceOfCommonStockShares', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfWarrants', window );">Description of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Holders of 0.4 million pre-funded April 2020 and June 2020 warrants exercised their warrants at $0.003 per share and received 0.4 million shares of common stock. Holders of 2 thousand April 2019 warrants exercised their warrants at $15.00 per share and received 2 thousand shares.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, description</a></td>
<td class="text">The Company filed a registration statement including a base prospectus which covers the offering, issuance and sale of up to $500 million of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus covering the offering, issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued and sold under the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Received amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsExercisedByWarrantHolders', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember', window );">Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.60<span></span>
</td>
<td class="nump">$ 26.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember', window );">Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.40<span></span>
</td>
<td class="nump">$ 37.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_LincolnParkCapitalFundLlcMember', window );">Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Received amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_LincolnParkCapitalFundLlcMember', window );">Lincoln Park Capital Fund, LLC [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AggregateValueOfCommonStock', window );">Aggregate value of common stock, shares over life of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_IssuanceOfCommonStockShares', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsExercisedByWarrantHolders', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_GrossProceedsFromWarrantExercises', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AggregateValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of common stock, can sell up to shares over life of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AggregateValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CompensationExpenseRelatedToStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CompensationExpenseRelatedToStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DescriptionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EquityTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity textual abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EquityTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GrossProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_GrossProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IssuanceOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IssuanceOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareCancelledDueToTerminationOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareCancelledDueToTerminationOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantToPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant to purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WarrantToPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsExercisedByWarrantHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised by warrant holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WarrantsExercisedByWarrantHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=atnm_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=atnm_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=atnm_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=atnm_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atnm_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_LincolnParkCapitalFundLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_LincolnParkCapitalFundLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AgreementAxis=atnm_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AgreementAxis=atnm_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>46
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MG"NMPL2:%X<GOML_$8\\\;>V.0<1G (,,?2X7X?=W]-"NR/CCO)3][D>>Y<
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MH+,X@JX"&A@LCJ@K@@:F%D=W)]3C@O&E.#@60?9P%=2* 7L#$@GF1)4^IUI
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M<$I.<568+=M'051H@NS,0;YP)?=*S% S3:B9)E3%L0?BW-*8I@$#M!!:@O<
MPW< 6=#3%?@2R:DBE7WB:6.O5T_=(JH6T">.X_3-MJK9$GJ.1]R^W4ZU\SR(
M&Z/>@'$S8'S-@-^!_$ SL0JO&?@E(NGHP!YQ7,?32[$;*;912K46EV4W"D'
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M0!1=B^POENKMQ6@Q0BG=D#+37\3^(ZT-BHV^1&3*_HOVE>Q\-D))J;3(Z\6
M(&>\^B1/M2,.%H >]P)<+\#=!=.!!5&](+*&5LBL6==$D]6Y%'LDC31H,P_6
M-W8U6,.X">.=EO K@W5ZM19<B8RE1-,4W6GX@!AIA<0&K8G:HAN(LT)O[SDI
M4P8R[] 8W=]=H[=OWJ$WB''TQU:4BO!4G4\TX#%:)TF]]U6U-Q[8>X8^"ZZW
M"OW"4YJ^7C\!.QIC\(LQ5]BK\->2?T!1\![A  <./.NCEX=+#YRH\6UD]45#
MOFT=>"-%CGXOJ"2:\4=T:9*7:4;5F6>?:;//U.XS'=CG-ZCV3"AG!*J5,[O2
ME/1N-0X#O(S/)[M#QSC%9LMY(_8*6-P B[T.N$S_A@RN$DH+J/I$\(1E%/$:
ML7EKGA/CJ5)!"D)&B<9-Y"@WS1HT,Z^;[K1(OHY-S:<H$3DT0D5L*Z%/YIFZ
MW%=IC _\$B]PQW<.F67D=MR\@3KW0KVFT),35L'[B>3%SXCD0FKVSRO$SHC/
M>W!P..M =L@$2S?D10-YX4_V+>&/5'4"J!2%V$-[0!DC#RS[;C"7S79+KX=N
M)2T(2QM/V#V$WE()75-*2+EZ<Y>+ECWSQSA8='S4%\*+P.VC,&B[;>"%?9DD
MHC3E4)!G\@"58&"3))$E3;U1K?6^PAP'W;BZI$+X&X!]0!*A%W;;N3(*]7,8
M3"?8T $CGG;!NJ3P0,L)<8L5?[<;VLY[;PK]$W>V72=J[, 31+-NKW3++>*!
MF@];N@B/YHL7[)_XCJH3*"-L.2/TD\9M*9.MB24P?2%-R>IGFXWT6\D*T[.=
M/O(J-3/GF2I(0B]&T, 4E3LZ6B$7$]>*7N?S0 L*6[X)X]-B[_*?TRZOWE/L
MBD^PJV6N<';2)''#. $F/3XM6N()_<QS2Y[K 9 C+C1]:51.I_5I9(P/"KCV
MB$,JG"X&7-+23;@X&NC&NH-6S<D=WT4?1+3L(G4)S0: MD05^IGJCF34SM-J
M2V3U!--'#K"5&4ALS4%2C3>EF8+1GDA)P*[W=C"RPLK-8F&?H>+IHF^5%]Y1
MJ?UZ&&_)#OO)[AC+CS?7O]D))8K[) GDM!C(2-R2)/:3Y*T4":6I0AM3HO2)
MRH2]]-=>>)T6]@FQRYE^"#\0S)96L9]6AZWSFN15>DK0^J0;QL%T(&8MY>+H
M.,( \W;,!.CJV=E=G<9%C@*,Y]T&Z! +9XM@*-]:!L??/_8E=NHV0[<Y0KVO
M#E*&P7=0>[:L3)&!:[5DB3GB&P&G+7T^GDYQV#WK.,3BQ7*@1^*6M[&?M]?'
M@T=$HP?ZR#@W 3+%1243J=.F/A<O9P='L]JDOE0X#0=3J^5L[#]NGF@3-><7
MKS6.<V:T#+K3J4,,!_ W8$X[&."Y=P2Y*XLBLY=#)$,I4PF<WTMI&X U80/3
M">1A=;$(9U3?.();EL=^EK>U:0]ZH!C4:VI<=\QP@OMDWCTM.42&HMZR/?:S
M_6O FCP-M([_3LJU#?\SNT<MNT?!CR8$%WQ\<E)$+=%&?J*]IK!M"GN:CLTK
M3]<DA%*QYV,)9VPS5$&*5)?%A>GNYN;9%8MZM\/+K["3*5Z1RHK)P1UL3N6C
MO9I6R![WJQO,YFUS_7UI+WT[[Z_"LW5UB=VJJ>[4/Q,)?4_!F+L!E<&'.62N
MK*ZIJR]:%/:F]T%H+7+[N*4DI=((P.\; 1ZIOY@-FO\L6/T+4$L#!!0    (
M  >*#E'D)$%/.@P  *,>   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
MO5EM;QLW$OZ^OX+0'>X:0)(E^25V+C%@*PGBHDF,.&T^'.X#M4MIV>PNMR37
MBN[7WS-#[HM<V4V!XH#6T2[)>9]G9K@OM\9^=;E27GPKB\J]&N7>UR^.CER:
MJU*ZJ:E5A96UL:7T>+2;(U=;)3,^5!9'B]GL[*B4NAI=ON1WM_;RI6E\H2MU
M:X5KRE+:W;4JS/;5:#YJ7WS2F]S3BZ/+E[7<J#OE?ZYO+9Z..BJ9+E7EM*F$
M5>M7HZOYB^L3VL\;?M%JZP:_!6FR,N8K/=QDKT8S$D@5*O5$0>*?>[5414&$
M(,9OD>:H8TD'A[];ZF]9=^BRDDXM3?%%9SY_-3H?B4RM95/X3V;[3D5]3HE>
M:@K'?\4V[IV-1-HX;\IX&!*4N@K_RF_1#M]S8!$/+%CNP(BE?"V]O'QIS598
MV@UJ](-5Y=,03E?DE#MOL:IQSE^^5BZUNF8+F;6X;APV."=DE8F[X"AZ?Z<W
ME5[K5%9>7*6I:2JOJXVX-85.M7(OCSQD(8I':>1['?@N'N%[)MZ;RN=.O*DR
ME>V?/X(.G2*+5I'KQ9,$?VRJJ3B>C<5BMI@]0>^X,\PQTSM^A-Y'NY&5_J\D
MRXS%TE0.NF8RA!*,<VN54Y67K>7>ZDI6J9:%N,-+A;CU3OS[:N6\1>3]YPF)
M3CJ)3EBBD_^[JY[D2[#PPM4R5:]&-2EM[]7H\H/Q2LS%1'R'5,D?2R4^2-]8
MM4=A(JZETX[>#8V=3,3/E6PR[54F;BJOK"X'UK^I E*1/!/Q2=TKZQ1\8M*O
MXJXNM,?YCY7XF'JS4E;,SREBYA=CX7.5+$U9RVKW3R=61MJ,6&?: D",=6-A
M+&T2U[0T%@TXZM(TKM@)6=?6W"N\=<WJ5^P7W@A'/'-39& 3-LAB#+L(B>#(
M*$!H%U'LV":ILI[-Y-D6NDJ-K8T-ZF"W6J^)N@0>!L68B7"D&!] T %ZG8?Y
MR;ZI*4N<#+M6.WI>Z8I6AKM<+F%@G$_V]NL*'*4HX RH4#4E&0Q,#A[]'2O(
M2&+34F6\* W<ZW.H/Y_ 0Y/GIZ*VFDQJ$$.I(N))\,8"6;S5/F?;J&](GT@*
M6U=0&:6*EC4LDB,^K*PVBCAVSA'2LR60L@H.1( J,N!47(7W5U75(%3> S39
M%.L0'\%7+LE5 ==7G5C[0=)[:^AAU\4 0B#-]WU,/)_R[)0B\JK9 .[%\]8"
MO3:'(JT/@>2O#0'Q9T,@^:X0"$XG?"9@,)VZ\]E0WVA:L=8%5.QBX$Z1!UM\
M\]&$KU4AMV"=R(?&_5/&'Z05\3J06%/Q^? "HC$%KR0<1W<A)-OA],5L)NII
M.15OI - 5>(S&IF#6I,U]H-JWX@*54B@A+"3J/0$SA.9_0I"*DM6C)';7%5,
M!WC[%?E!39O:L_,\<)PR^EHB5^S OB@ZAN1&EJ>&C_=>HNQ)P>D&&,926PO!
M?MT!K^O+'A&Q\ XA-'(?P9$K.-"(7,)&*Z6HG_/6A):,HCIJ0[Z0H3J(=83;
MZ!N8-63[T U)< -M)4T@N#:9$W4H%RJ;HAR .&H%5W'I!Q3)79[=LG[,\2$H
M^ZCO(]TTK8EB^L7"F+$LVKD&5E&BJ6%#]4W95+L0F9#2<+$,5D+\ KY@,E;\
MMP;%9C\ >HLA[Q&R=!1$=N@\D1-H1[-QTL90QPC FO[%[) R@=T4Q1@/NBZ"
M)?8Z(ZK-0=$W#K:5Y'I=)0=ZH_W^Z0;!'WR\_/C+S>M__.U\,9__:WZ1W$)J
M5>J4(OE@AW4S@.D T1(AAZ!*J/'254=S,K^ ^A0_I!8<A;4E:HB<HC<A7\&"
MU.BU>W/L#7..V!1F148(.!!?#NFNK2D#,3*L 26;<!!;:FURYNHP)@2NY*HO
MQJ+&O%.R ,0-6TWQP^C+NX^C9^3?0EK*>MH/O%V![=<]MJ KQ:B.)AJ/$DH#
MFH**#$/$4%+8!/,1*B&Y<$S&?"\MJE2/"N\)=GN9I<7/$%5,+P2&+FN#$!"_
M-9+"B-JTF.LPMN8QRR6&\0H>X"5,D$YL))D$NG#@.0R"3+F7CY[NM6T".>:5
M%LRJ,M6$B@^XP?&KV!LJ-X[4(75A4BS]VECMLE8(8!3$:Y1H08>+\E!.\D1=
MH*L%(KH_I%$W_O#IARV!7&D QX[.#,\#CRT5'RI&K1*0'LA7.&YJ"EUJ!JP[
M")H BBBX:4.('.(G([Z1P5H:U'#6-2$HK)'99D-YFS7()9BF62.I&HXAN-XV
M=43!BL/0*NRC&L&BD5*T1"4VV>8:UD(T%&1BZK 9 V1?)0>-<B=)7PJ@>8#<
M-CJ@08#-CA<C,U8 D(XMU$;U.!DV HBX@C-=$9V2A@Z:\DFE@'H(F;6T8TXR
M:C/5-S*2JE)ND=Q@ZNA-0(U\AO)$J!;:I4XLY%2B?2Q>KNW/4XQ$F@(D@V,*
M4S. $9&!P>/\0X6!7Z?4'5&-=(_!QCC:F41/9>-8XA6J8D9J$QZVP#/F2'C2
M$T+!Z*8D*0FHON3HH'@=IF<@[C:TQ,&IV>0^6>WZ+B1K;#O0QL!NL:9%&99D
M15WU&G:ER*120AGIR")0DO)G3/6B:+AI(>31@Z$L*$UDX%B[491GZ,^J%NH<
MU6%*H3VHBP+*F'XQO0C@NSW4+\#&H<4/2D(SU+9-@&075.HT&>)R<CA27(O7
M&[135H9>B8HL?G+S0G*VL@5O13N'U]&M?6;$]NS>(+X"4-"VA@Q ROA= H9#
M6<(RK(=JB:J\E;M.)LRE%(<EWZ, Q5K D6V,(U, G''"H1,%A2\G8I1CD!/$
MJ!<K86[[C&KTLA$4&%)IDLU"S]3V:-7C:(BVCF(DE;7V- </,2;R63=T!Y!4
MZ'G;OO 0XA0:C0OP9?>PNV-!G8O:1Q71[-IX QB<3?;@@NT/9F7RYV"O\SZ&
M^Z;K)0]W\_!1%#8D=<=R'^<9FER Z%0AQ@CLXOV!"Z*'<D6L*3(0+MBZ:> \
M@QE)-CXWR"!-5;(G5K%Q:(C2=&D2,RGA(>OFT_4_.7]O*O1MO@DRTNT)W:OR
M% I:3W#%JD)[G@:%M?<JM@:<>=PX(, IGI%)?.&#1:ZP) C. WJX#' =E%WN
M*>"_V2F*00=H315+"?:$[^O&%H1A9/4->CY;,3"W9PAX#<TNZD%;ASJ1Y)+0
MMD_,"(K[$3P5[\R6X.@!@9C6C%3J=W"!ULBQNEU>Q>+>YH WR7Z0H$YSGHP'
M(0I*[3$J\: 77,_W&AXQ&48U:]8AY,DSV;UVL.54+*7+Q_Q7O$&R('"HG^!!
MX5/L8D"7UR=<G=:F0%?&?*FI=/W%7<JDZ*]0/:F]MD]E81W0^V-3J>X6EC=U
MW?GQ/%RBO$A^X'PWC<.Z>]:?&6Y-6+B H0]8_UV<'H]/SL[PXV*\.#U)/CV0
M(XX/(FV0^@B(DW/\]^BN @5B@H0HQ?'%G/Y/EM^O,LMR,3ME6<XNCL4R\GRP
M,1ET%"G52  37U2%8=<Q'J)B]\(\Y#0@\+O[C@PSC0-)OKBB^(0W";\0$SP:
M _B1D9;=&9C3A!JF$>1@%?&QNV\98"T-#$RDO3$AAFL:+_E*>"I^HAU.O)7:
MBE]:#.Q&M80 Q39A5H,'%(\=(2ZZ5BI9&N?IOO>.YNO)-8V9XE;N^!1&R@^
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MV'2KN%,5GX-GN4:@5(.'X*$&J9DA55 J/F;J63@E5EJR0VQ0.1!CB-#:J#\
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M'0K \]+:T-Z@@>Y#Y/W_ 5!+ P04    "  'B@Y19:[M4T8+  #Y(0  &0
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M#YL,C;@URV#RI)GL3CO(<J@!FTW;*XKI8$U^)=T:?.-3O('#P?B:SOUCK(1
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M6O;7=M_0HNFNRK70=/%VU8)>.BB- 8UOA-"'AIE@>#NM_@-02P,$%     @
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MZF9[0^2*FL^%868H@[.^D23K_E5/M"A="U@*;1J*&^:FYZ.T 68_$T)O)_:
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M' U2IX5A2U<;K$^@]=H8O 2^W9:?1?$/4$L#!!0    (  >*#E&["](0*P,
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M.@2Z*M)5QZJMKT(K9:FF^69.[QK4SH#FUTK9YXX3:%Y*\Q]02P,$%     @
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MON!(W'C*JX&QZAGB#./'WD[8+/_ 1"[R?^6<[(R>Q.A))-[L#.\I72743+Z
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MVC;.R=XB35U<UO2:@PL)='ZP%D]!&+WIPU'\!5!+ P04    "  'B@Y1H[&
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M/VC-@M;Q@S8L:!,_:,N"MO&#,A:4Q0_:L:!=_* ]"]K'#SJPH$/\($BYC*F
MI 76 K0&SC4(\!HXV"! ;.!D@P"S@:,- M0&SC8(<!LXW"! ;N!T@P"[@>,-
M O1&KC<*T!NYWBA ;UQ\; O0&[G>*$!OY'JC +V1ZXWOU-N'1TM^[GFN^?GO
MI#J,S])\_+1\;BY>J EGS7[13[]02P,$%     @ !XH.42O0<HYR 0  GQ
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M<' N>&UL4$L! A0#%     @ !XH.4;TPWPOO    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ !XH.49E<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  'B@Y1V:Q#0^,#  !:#@  &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ !XH.44/QH]VC
M!0  BA8  !@              ("!)PP  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    (  >*#E$IV:*X*P,  +T*   8              "
M@0 2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  'B@Y1
MG&588/$$  #D$@  &               @(%A%0  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ !XH.41 H,^O"!@  K"<  !@
M     ("!B!H  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M  >*#E&Z5;F8^P4  #@8   8              " @8 A  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    "  'B@Y1Y"1!3SH,  "C'@  &
M            @(&Q)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ !XH.40-F*OU[!0  5@P  !@              ("!(30  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (  >*#E$9G!AI\P<  )04
M   8              " @=(Y  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    "  'B@Y19:[M4T8+  #Y(0  &0              @('[00
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (  >*#E%;E__
M$ T  ',E   9              " @7A-  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ !XH.4>/)M147 P  !0<  !D
M ("!OUH  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  '
MB@Y1/:-E%C($  "G"P  &0              @($-7@  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  >*#E'=GK8>/0,  $<)   9
M          " @79B  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#
M%     @ !XH.48L+/??8 @  ^P<  !D              ("!ZF4  'AL+W=O
M<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  'B@Y1:>8V!L,"  !1
M"   &0              @('Y:   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM
M;%!+ 0(4 Q0    (  >*#E$U"D?S^ $  #@$   9              " @?-K
M  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ !XH.4;L+
MTA K P  -0D  !D              ("!(FX  'AL+W=O<FMS:&5E=',O<VAE
M970Q."YX;6Q02P$"% ,4    "  'B@Y18\R,<.P"  !#"0  &0
M    @(&$<0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M  >*#E&Z$:S_]@(  '\(   9              " @:=T  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ !XH.4=_'5*OJ 0  < 0  !D
M             ("!U'<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    "  'B@Y1P8AJFMT!  !$!   &0              @('U>0  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  >*#E&CL8"6+0,
M #L+   9              " @0E\  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ !XH.44&CZQG-!0  "R(  !D              ("!
M;7\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  'B@Y1
M!#7GHYH(   2)0  &0              @(%QA0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    (  >*#E$/8D<50P(  &(+   -
M      "  4*.  !X;"]S='EL97,N>&UL4$L! A0#%     @ !XH.49>*NQS
M    $P(   L              ( !L)   %]R96QS+RYR96QS4$L! A0#%
M  @ !XH.473_K4R> @  *!$   \              ( !F9$  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    (  >*#E%^V5 B/ $  +(/   :
M  "  624  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M  >*#E$KT'*.<@$  )\0   3              "  =B5  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     A "$ W@@  'N7      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>83</ContextCount>
  <ElementCount>263</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>11</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/Leases</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/Equity</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Leases  (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesDetails</Role>
      <ShortName>Leases  (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Leases (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesDetails1</Role>
      <ShortName>Leases (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Leases (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesDetails2</Role>
      <ShortName>Leases (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Leases (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesDetails3</Role>
      <ShortName>Leases (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Leases (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesDetails4</Role>
      <ShortName>Leases (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="atnm-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnm-20200630.xml</File>
    <File>atnm-20200630.xsd</File>
    <File>atnm-20200630_cal.xml</File>
    <File>atnm-20200630_def.xml</File>
    <File>atnm-20200630_lab.xml</File>
    <File>atnm-20200630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>51
<FILENAME>0001213900-20-022334-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-20-022334-xbrl.zip
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M.S'T&5'VA83=/UOFS&7VXII-W,?5DB4. #>A7NNJHNY7S4FGQTDGJ)/B$=;
MTBVQ" 1XL$3#S[HRT0UR6,^;?7C<'U&*&K'-N!XO7^<04>/DPG_23;P,^PJ6
M?2.F+W71<W@@E('SDF*3UT"I)P7WW3= 2]O#H>YUY\^XS5A#N_8X]HHP]GM]
MN=T;#(]W'E42^^3,%3F9V,T)\D["U+S( .$YL,F17(O:LAS7LAPG#Z%>]I-9
M]FHS*S*6O=;N+W2]MY_$;,FL.W=F.'RFX:OR%K>?PSS N,RY%-)VYL&)(&AI
M* YH4H'4K7VOS^;1A-%4I.M@9H9JZL&_OFKJ-3N]T!OQ)@[[EX>J_(D=W3R5
M(\"(;&$!1JI4N=U;<PCJBVVG<">\<D=P_4BS7O=CK_M1]GWU;<03NXUX9#U0
M\\/)\L-1]$-]M?3H5TN/K!%J#C@A#CC$P3-RF2QV9OQSG5QYKLF5M)!%]_ZT
MXM4?,LKC>O=Q:KL/>5R];8FL>WW\\$+7.Q;CJY.HSR7UU5^PDSQHR"[&57/2
MR7'2R=9F2=-)YW^R<'H2N^GH^<YF4\_4F/:R#@>W. "\HDPZZL=6^B=VNIR>
M]EZSS;'9YDC!R'K]3V[]#Y6]-&S*?=^$#&,)BR>5(E 6*\216O?W4K$^MO$8
M1EK9Y38>PXK+D7$'-#0><<'YYMCNMR^ZJ2^\Q<M@G6V924451YZY@8CO[A5S
M)I@4_XS1]*CJB5:_8O.TE<.4[S6'E<UA49J^; [CF[M:A[U.'>:O_D%.>VL.
M>Z4<=H@+9K65?*U6\E1T6,UA+YG##E&*82#JN==GV,<^PTZ&'P9%JZ$GC[X/
M<?Q1-]X[A7274HX]NI5%KM(OU=6L<VJLL_.ENJI99W/"3<TZQV>=$SRO#[WH
M6M.< KO$?=NJVQQN=%3JVT G=AOH_!V8FJ5.F*7.T[&I6>J$6>I\')Z:C4Z,
MC4[($:HO01[]$N3YNSXU$YT4$YVGLU,ST4DQT?FX-S7C')UQCN_0G/E-I[.Q
M^6=,YQ,TBW&-=F:T/930AT0:->7N61,)$:A:,XXB%TM&S4Z[OEAR>A=+1KM<
M+,'%/&1F1S3U[.-B:5@KQLZ;:3"[ZU%W#78[O3$U_4G7/,6())C%L3PVDYS8
MU=7M3/+5,E\'GZPA6K/*.\_4.9\XV''865OZ!5,<SV:_"B#I(7] _[?X-#AB
MQAR_/UQG3J [5J\C#]_!,_N,_PU0_T;=D]=F(HY((2^^_M5;,"J3M<YR!4!,
M@IDV:F32:V9:"]W<-NUVTB?G31O8_SU&A1PT77HII(R#AH_D7[.2FF-?+BS/
M="7!U/=LNDG574@( 3TD^%S2F*HO%,/YY>+FZZ>+7[N=[N#GMZ7"=BB$TXK>
MYT!8[G7.%.&-_<1B/6.V4V'0/U,B;&SC6HP(G4'O3(F0O[-<#BJ,AO*9DF$C
M+Q0GPZ@B,FA,?_>1'*9[-M,=%\'ZJBQ87B7^ZZ7JZJ;N+:0[&'RAJ S@4@'T
MAG1CJJV?WV9-L [ %3ANMF* F\B^_S=;Y88@ZL9FCA:=[A+<1@U=QT^&,LL]
MS1208GR&V #1D:\\V\:O=0=(\ ^FV!^Y,YA[DJ9?,6/3:-$9KRV5VE;A;CWW
M+'*[^3]\BNCK:</>D=-:%(NH4YPY6MIT'%7^V"?XSLD]Y?]TXE.MC;3.;Y]T
M@]E7 ,G,LO-S&VQ8FHJJ,@.]2*9)-$J4\6+#KL_Z ')M?/ <W61.?O1<VV/1
M26*CK$_R$7S<&0C];[;U[,Y1'2AF?A0CG+YAN!0!YOQZSY:6C6V8\=REP!+^
M UWI;:.E$'3.#&-O%*.CI+,*;!QP;YM?*\G-[J [["5Y@X^S/@>H2\M>8F%@
M'5.+@8&N4%';JRM+RR]ZUQ^C\VT<,PT$%[A:1<,"$JJ(%=AU =-'RQ9[U'#%
MA!X_IXE],%+2V,<[A/_!\%8DTRZ?X-L9NV<+13?]'Q^9O9!CD,1ODE[\>M?Y
M1^>+W+D.+7/1X9/@13M9EPY<L<&3H%&N^]PR-&8[_!@U-OT5__SMTOEV._T&
MGLX#6WX#QV?XV&Y_X_\^WJ9^'_%^,!01<7V:W8M?1R.Y"_8]Q&(=CH*0BKHL
MHT(]3C;"*(_[@\'@(%!FG,]O!*\ICP:C_O @\*W=BY"'W;$L][N#S3#V*H%N
MK0;LVFV5C4#U#P+4'HS7D;N=OGP0*'=CO/&PWZ^4BEL$$[B^,O)LN0=U''8O
MD*N\1:4-1Q6IM)P)C]LXJ]/O5*/2_.2,S:JAVZO$+*7$1E,5TW!8%0N1/M\R
M_:!7Z>PGI:]SW)#=+$G5N"_%6K1ML2*][K@262IX"6<SE(/Q2*[*EI3@9'7:
MHV%_=! J[@:?W.MU*H-O'V-8B9DI>'%GBX ,@78'@?)$EW8S -TV$J?8[!3G
MOO5<S-O2 -/2-A=99TJC_F XB 31UR#8"<0B.XP,R/J]MBS+PPH@RRV4630;
M#^5.6RX?LOQ6/I-FXW:[6_9J%C+U&9#)77DHCSJ]"D#;=SG[H\YP/.H4@0R'
MOW$<CVG7G@T/\'#ZWQ7#8_3R!\5A&@9-F>E0B#'C'"R[*\LV4_'=T=^9NO'+
M!0; +Z2WAP=Q'\,Q3'&K"@%[>'3S6:"C+<M9$CRUG<P6ER/%HIX&(@4*EAV+
M:0H4QCH&B 4+,!T+Q!T+OFQV%8<I?O3Q^7J/8B2;T953-C?'1W>/0ADO3FN=
MF+TK>B_\5)3#BQ'[$Q%H[IM7;_4R]@K#WE8<-T%8#9([V\VL#5&GMWTIBZ!Y
M9UM3W?ULI>;U5+L/VGWJ0OJ^.C!VBGSUVXE#H'#^O2$[T-3%]P;-WJ#3+VOJ
MZKSYPE@?<.IR7-OJ*'!8,/;TC9*",1BVRY+)/;VABB#;I?3*\23ZB,NU_]1T
M17"3D^7W,?CXG=FJ#O;Y8):W>M!*T0+5@[G?SJ0R^ X.0/E1I^I!VR=%J-_F
M62#%H3P<?B?"F\448\64Y3N:2A5GUN%8IS?>C%4&;.6C5>9F>=3MX[7-/?#R
M#2#L,'7G=GJIJIBECV];AJZN^'\? 8L/!@R?.SW^OPSW_5)RW)7!?KF8PDOO
M)+F]=*5'?<$<Z2M[ENZMA6(V^!<-Z0%@G;Z7%@I>]G@GM=]+.$U3,?09_/E/
MSW'UZ4I\J9M8*@ >:O5U\^*_9NY[G&V"'P@+R9I*=X S/$1[Y?_Z3[G[OBG]
M;BH>J!Q8%[H=H"\DGI:N*P9\,[7L!=_]-W&TMS2<]#AGD@(DH;L9>#[J!8/H
M8A"@B -$TNA&SC08T?$+?SF28FJ2S0Q\@$ Q+1=H,%>>F#1AS)26-EO"&N&0
M-)FM8;*\]*R[<_J;KP<\IL/02P/>G3&3V8IAK/!WMN3@2"X ^[M)P-%]"R+$
MY0*@5!7IS<7OK8<6S?_;Y>7=Q4\28!P@$<*MAY1H$.0I0.%$MH> <-1FGD$O
MT(3K4(07!6EZ?.?C=W6.[9HDY'G=P7H-TAM\\^+AXQ7 1M/ $BZ9ZDJN)7T"
MF"2\.D8S7MJNKAH,OL )[X/YI8?F_[:D2X(6*&:L&@C-2M(LG^Z #5U5E(!X
M/K 1C&GTJ66Y?(EL]B]/QX69K"2DGH24([HA1QC,9:D+WB*V6>,4@F$[MTP]
ML!?.G"%AIP;BC[ J&LH ?^(-#J([Q!2 @XG0&_ T4!G%/OHL4'*NJ\!&-FL
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M^7V1;H\O7>T?1KMK@O02WEMT2M?K*1EA171\@8/LVA84MP4[OSFJQHB,]J/
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M%5\)F-5D2O3KY:_!/'4N'=26YOQW--US7\-<YW632L[KS@V12K1 \V4RT)F
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MWGIHT?R_75[>@<10/%X@$<*MAY3@9S(I0-'!@$>=;@FU&;9!I#"Z.#6(0_'
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M.(A?T!L/X58H:8>FI_&X3Z OEA;65/B7IZ '@4>XL5P;5#8<$')A\8P3?UZ
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MB:)#"3F17$)[(ZE/06N?(C]3:[$FM:*41"]*)_6F4I @&%PRH;RJ4 <B,RE
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M@7SKE.4@< VOO9+'8//*72M2N(RK9!8V-18%VC80RZ=20!E19FYBP?YQ0CJ
M;+^0 9]@?,=)A8;.5(%FY_8<8(J#*O\458C+R%W:Y,)&%)O@",Q-U(%M%=K*
M68(I$L_[]:V*JR/?!8@I7:Z_2:KT[W[ @M=K6T]>2JL)$\R*=_K]>7W]Q]T0
ML0/@P;6LJA^IBH[2Z3%D,N%9]S1.D!;/#4)P2]DG<$S=B H13J04'T]@#M/U
M:>PX4:KEUCH[J\[.VC<[B_S,.CEK#Y*]RGRL6ZYE,S&O+@TI?PY4=CY2=Y!]
M]GG2.5AE(-\9O*!4K$TZ0S2=SV;2EYK>T6F,AG6.3 E$S,XS.YDLF=+3S_ST
MC$?+A=WSZ25U[+KDV[,[ND#$[-S<%Y(34R7YY%[GZ,DQ:_LJOEMJNM:2=DSB
M3Q^,$P[\1AJJ/(C:UGSK?4^WQ6&;?*E9V.G@I Z]3XB2-T$!2'#21PWIT^7#
M!Q'%)&@N'WZG7YIREU]2T1.G]5\H)LJKBS6EL+^/],E6%@SKBDAO'JVEKDJC
M3OLGOMG7@Z,B;\G+@LT\G7>*$/6L>0A!"T<31RGAH9-E1@]X%B$40)(P_!LY
MI:34D<]XV"=ULU[USW["PH]T[ )@*+R-@.-7? E[,_@QJ*!R,!89B[\R8; T
M5 9!F6)I[;#V;U\4YY<^4AQ*T<21EDX!%;JEK?'"D$&92'&IWR_E3C @E"&Q
M'&EA:?I4QYBH315>GGS\%5&C!:-8_EQBP# <'!L*I<O !X!@(5EPU6*1;QZ[
MY;+&:W &M>;#M_ZFF![><)<C8:XH+C QU0(5E1UB92A$^"U9Y#J\"LUCMV$[
MC>/+UHG)^5>L$R_JH E)%U%*.K,()1U^O I$'<-0$[I;"TMR:5--;-%01(AU
M>_33.^D*BY!-@_.!F["&@?1!Y,8$C].Z\[\&[0%7*UPG4 A3U"@-RZ<@/YDS
MDFLZ0W5"=0'#S[$Z6% -YGG.Z!51TH2'T0+XE1#^:/I.I,6'?^#*0L&BHX\0
M7L[V025A40P%&!X)2%D:^92'M%UQ$ A;E8>H:<[B&B10'XGSY'PB&K*ND-7@
M;*8T>952937L7'?H/G/)/G?48XCWPX$QKJBRC:B,$8X>O'UR7>HZ8(TC*!#G
MQ9 XB$=T\%RMA'LXL]D!:U*>>&9:5 ]@\B%%;86BXW7= W+YB=<Z"#DE,T9.
MGFDWPU/'A9)%C69@TRFLP8IUH.%[*B$6S3NCBZFQY#(_%T:<+O.CHJ _B0_I
M@DK*J9XM61/ 4PG*<%$AVZ5(1(J4_O*64]NB2E'B)T#UF;(]'3RG9HYKF;R.
MN6VM%,-=!4_R1F<@/G3&0R,Z81TN.CQTV8R*^-CLW2DM;9%SJ^@Y5?(<JS"\
M.QQ.P2XS1V2]-UI^WS4TW.GY[\*OB$M1O.AEA9LE?"?<7>>]P)E4S#M#<:O\
M*=WKVHQ)7Q7AGG_F#@WRX9N+V_NOGR]^BEU[C">D2'[Y)I&'YMGJ'!/4J0%E
MD"',ZXN)1BB\;!SM'=(3)1O^;L)F)GM6C""'ST_DYS/BV79+N@X3FG8Y]@X@
M#LN@\6I"B#EN7GYHM^0@ 073ZC"UT$^82OB]B:'18:$BB '$A!>-'*453!'F
MN/C-.Y.T$XE;*MZ: ^^(=V,+FR:E\5&.@$VM1LY<C4Q.0XV87-;$IJ$3EP/A
M"03=7< HXW48E$<J*&O9E#GK*P/?3>#2\@E__*OGJK"+<4 ^KG!G9H>IVU<T
M.JBJ3W^]NL<VG:AD/-T0@8VES9YT2Y1RACV?14(4ST+G$WVX&DEO!&P:)9%@
MI]N?6A(-S"N<B0Z;&L_T4K WL(,MFW%P_KF3]$+\L>,;I>!V!J4B8Y[D=W('
MGJ(.$*4D7XT"6&)-31;4WH5D0YHHYI^^ N5)E00SW@T)71+AAI!."S7:LX[O
M,[_R'L>5*/?I^C*H/.A'<::Z[;@\Q]_#0IK_]E5O0+</5U((<$OZ?4E9^4%A
M40?4ES\8#M-8\Y+PU\Z/?LX5/N^D MF2CJCWZ/_D5B?GC;UFFQX]@,N.]7SC
MFY2K>(C%%ZYJ=RSG7^;XQB],S\-9;N+>8D*EQ3P9WUN)Z[%+!W<Q(/:\G[CH
M(G[A?\T5EY!AWF\[2 V.SOP71[K\XZ/T&#8!OQ.-P4'8*)3$MQ+AJF/)V*@V
M)F'BTLL+G>-X_B"B #'OZ,VK-"H3OYT!PTT8QO)\5'C;<-I^S<)]G6)*?C/T
M9J?31\DV+&4ME9G75!<UQ74_>Q=KD7NJ2+-F@2X%'13M7N.XL!G#[&23ZJ 3
MN7@98PI)^?='N"<7@.N%] D7AW(*_:@<SUR.W^AQK4Q'E6 1UZ92HTS%HCQ^
MC$AQS<4[WJ+^=NHWJ*>(TNK4(D(G<E#'B85&PR=7]/(;/VH2+"GD3V4>^7L
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M[;U NV>\@/I'Q<:22,ZEJGH+#YM.:==LJJO8WVI'NC4[\KC=[\7+MV^=KA0
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M&KH_&J]?2ST>!<$LX)!D)<%O^K#ZW6$P'J^< "-<@A%]6B_$MG-R8*\_7,O
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MR9,K6\XS$9@S ;,28>[FSDI[L72MP3QY+AWWSIVLY[[1*L72%+W0?G*K^$K
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MN#$:RD65TJY OF0BCJHEXJ$5>R[YZ8G5HZ(JN?'OE;7FO<B]G5*7/&O@B%4
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MC+0BB.*%/7:\7#;Z%4E%.9E6(!+(!0!02P,$%     @ !XH.46[]UFLA#@
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M6TL1<SZ]1LF7Y;TVRAC\L(5]XF6ZG&-J;B--E#/\:5=Y\,*<E9<EY-)?N\I
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M[QXQB#S$O_DEV;1+;/")F]+;%[N&A*;!WZ@=;PW. 'N*]P<CUIX#L.R(H.A
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MGID6JD."@R09V_ K<7'^<. (1]5_O*.AW+\AH _/Y'#PM@*,[2O6@5G&+?9
MQ86H4D,U$<9V+FN#:]\UU@!V0R)Z'%YK"<;.O^N":]\Q3:(UGFG6Z1:S&!VA
M=*Q)/?&R%+_Z*PW6C?Z.PL4H6$:A."!8WU4\H3#@DS95C4$YG]&!IRH4VGXH
MJ=@R>D8B?Z=E:AJMW!1K?B%8^([+E-*Y3:Z,TIGMA T&XK\GCCR_\B=02P,$
M%     @ !XH.4:HJBV7$%@  4VD! !4   !A=&YM+3(P,C P-C,P7V1E9BYX
M;6SM75MSX[BQ?C]5^0^*4R>U>?#8\F5W9G;GI.3;QE4>RV5[9Y.\N& 1DGF&
M(AR"]&5_?0"*E$D*#8 42( SFMKRVA(N7_?7N#6;C5_^_C(/!D\XHCX)/VT-
MW^UN#7 X(9X?SCYM_7:S/;HY/C_?&M 8A1X*2(@_;85DZ^__]Z?_&;!_O_QY
M>WMPYN/ ^S@X(9/M\W!*?AY<HCG^./@5ASA",8E^'GQ!0<(_(?\\NKY@?RZZ
M^S@X?'> !MO;&HU]P:%'HM^NSY>-/<3QX\>=G>?GYW<A>4+/)/I*WTV(7G,W
M)(DF>-D6BL/Y_^Z=[.WN[>[^N+_[[F7*0)^@F'W%/V-?[;YG/X;[M\/#CX>[
M[+]_:_83HSBARWYV7][O[@YWV;]%]5\"/_SZD?^X1Q0/&!4A_?A"_4];!>F>
M]]^1:+;#H UW_OGYXF;R@.=HVP\Y)1.\E=?BK8CJ#3]\^+"3?IL772GY<A\%
M>1_[.SF<9<OL6R]>5B@6/MQ9?%DLZDN:+H"F_D>:2G)!)BA.C4^): "6X']M
MY\6V^4?;P[WM_>&[%^IMY3RERHY(@*_Q=,#_S\QIV2N:Q'[H)_/'!Q3-T00G
ML3]! ;>H^0XON\.H3>8XC$>A=QK&?OS*>69%.78F3]KX0X2GG[:X-6V_V1+U
M_J)3-WY]9&.+^O/'@.EGQPSH(Q1P?=\\8!Q3%4IAX?9A7:&(J>8!IX5J8136
M; 4P'\>8,TC'T_$CG]88<TJ%RFNU"W0\/7Y X0S3\_ F)I.O#R3PV+1[^I^$
MF9\V<*U66M?X,:(/9P%YKJ7PE4JMP#S!=!+YCYS8\?0HH7Z(*67#_":9SU'T
M.I[>^+/0G[):;/1/)B1APS^<79' G_A8*8^9UEL1_)C,YWZ<ZIH!.B9ISVSG
MH"&51M56(%]@MC@HT95+M0)$;Q!V,,C6LZ]NK+@3:UX/XBVZ#]I60[F/%L>'
MGC"BLBV.%3U0HK(.FLL)CI$?M&POE4[<5<.P$ST,W5?$+7Z)$_4.N(V^NMXA
M:(X _19:G \UL0H+MP]+.7K$I=L'ME<+V%YWP/9K =OO#MA!+6 '':RZFJ8O
M+-P^+,WY4E9'!A)%DQRGJ'"Q4\ ME7O'N#_J,,7RP)J()LD]WO9\-JW1U/V3
M=514Q+(5/XQW6-&=K,R.L('V<2\[V_;('/DU0:_6[@!QVM/V',_O<503;KEJ
M^UA1$-1#F%9H'U=(XE%=:'F=3FT23U$2Q(V-,J]>QLP^9I,1WV9=L#]+N-DD
M@D,/>SERWJ!91S+[F#>YN_@W'&P/\EK%7U'H#19-#$IM="2(V%]<0K['X"Z=
M<NQWMH>C;"?JL4^\059_L&A@\,-O(4H\GWWS-SLBB-W))7GVF\DS^*'4=G?R
M*3S0)=D.9+*]-30@T\%;4U98J^F>+DEYJ"4E%S)K>N"'@V+C?T6/A/X\6/11
M$C\3/A<_().2S %_T$4BX7273E-31._3N2JAVS.$'G?X/F8'!S'-/TEW-MN[
MP^S)UE^RC^^6N)FB\3G[=4EQ@.YQD/9]EQ46E=UQ 'KJMM& G96K0GXSME&4
M@\_F>LT%=;' ?)RP8R8SS],@[8TM4GC&?\F132,R5^HSTQV12E!4, .R-2 1
MLZ]/6\/=-RP!H=C[M!5'B4!D&RPMS)X=S!])F)[+7WP=6Q-7,\JA<&NLXJQ,
M!<"73&8!?5:)JF ]R3;<$$% <:/$K&[_5:Q(%4YT!(#(V=OM/3MW0X$,I@C*
MM\+KSH7K,I@*"9&X;Y=$[I4DB_W&Y^R,"!&X4O3..'?EPRK BWR4$#5F-R>[
MD>>E>D/!%?*]\_ 8/?HQ"E2L2*NU,+R,4Z06 .3++F'7W L78N\41:$?SJB*
M*7'Y.]$L[AA%$N3@VF27&_@ )=K75<O>'=KAI,;N6PC9S8GMAIU\,1TG<1IV
MR^Q'0D6UJ/M,"!&#H\+^H#BG-,'>21+QYZ@X\HF7AO.F<APA=D#C4P+;094\
M>,"@J=66^U0V$PG<V+G(]<)<#9$M:ZRO;"ME@N@^:$CWZC,^_LD=1\;]K^-I
M80M[QJ0]?<'1Q*?LBRM6/^%^Q]]1%"%V+DDM5< B;[!Q>^X2N;Y8$)>']KE<
MV*%!,A<-?GML%N2"Z/S1+)TW*"@C'(7>"JQ+'(^GX^D4\ZGEF%#YZ%RG2;<I
M75LRB-2?G"!5.DS7:O.;I%5CL+XWS*MD4Y?CS&<7#^*Q3AN.\U9;%(BG#YWP
MM#"8-8D"&NDE4S)99,_@W#N*I#9WB9_3;Z2/W32JN\ME;2D<]79*[;$YC97Z
M?>51) 9(I+M>H''\(/-@*ZOVE;Z*!"!S#OMTFE%7J-M7[JHB@.09]M"<8(;:
M._&?? ^'WAF)LD7YA#R'$4GX?IC$>,)UQWY[\JG8Q<;;:M*4NW2M)1'(7E.?
MC)FAQT!._?B"4,D*]U;&76[$4$&E%SPGO^Q4I&!]?.T^[G/U1?A20.2/^F&?
MO*5!VI25L$]#;\.7I/^)QU/[E ?:)1'F?[QUPD7.NTECK;..^.>%K@9O?0W>
M.NM()SKOTI<$?E\5N-!"*F2EC8[DJ+QU7X+\H0HY+]P1-DDX\7"WBBTOW(LQ
M(1T;PV$[8V/P0_Y;7Z:.RAOE)27MM:6D1:?=J4CX1G])U'WQ..P>JO ]_Q+4
M _&P?(/J0"CURHYC$ZN_B=7?Q.IO8O4!@C:Q^KUC9Q.KWSA6'W AK3PQ!4.(
M>7&@M,M1^ K8;LYD&4Y5.'>I6!\"[5<!N_JH:?* O80'&(CC\%)'\#@]E- 1
MVUX_Y?MGGA#CB '[*MD8K-WVW8'CSCU#(D+&8?EA\IMP*S'PER1>!C&,HVM_
M]A#3>B91K\D^64(#R31F9XM.8;,)Y4KG[<.VO"!9KWWQ%*WDV2IIZ<>6M308
MVG1LC!@JSP^81I_P#9XD$:,'T].729 P-GA,*I]2DQ@M=)N_&76%HW32U7"'
MF.O!B>EX37%43AC#_3CCQ#%M9^ *8)*??KB.UI3XZ%7<@-SQU&JG]MQ6[9@1
MZ4YU;AXUQ8CY;1LJ#XVZIAU76A<DZIC-J@Z=\\FU1[[+GCKW#,3E]!R+8[K*
M%54L9<D=J#T*B12YF]-TGSR"#8GHC7-PS?EC-.<'SM;V;XOF[WYRB7MCAPES
MNM'P+?;=M51-SESRG;04J/?F.\EZ[\[35".[?4D3]2+X"BXT!T(2-)P\FYB7
M[RKF!7C..YI%. 4#^ YXH4H91R-4!$A-;]E4.@0/1R5LED[!L'Y$"FSM@&I2
MATX>)IOHN=/0C@M_PF3$?-?PR-]!B+!WC2EF73XL84FC/?0;Z/K$)S-ATE0
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MS"_\:)3!,' H8C4Y9]H8N0E*ML-3S:'9Y'BK(Y:=BK/-#DOP];9&C[QWQ@P
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M1>V0*O\MVDT]=K8\U:\X %$\9*<AF?+GF" FZ,HMS2S.\F2I$B$.UP94OR-
M2P?$A0D:(0LCJ+)RA)B=HWH99=WWE(;[YGO%$LB/;;X*;4#5.P+TP.9;F_+?
M?.^PN#!>+)8W)):LAB95;>ID =5=+\1N3>T4Z)XY4ZD&4E@M3MR?&]GB%-J
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M(!0?Z4&AY!@1@9M[EB0G?+$,4B, W7;@@QL] %0,8\I_$23)VO5O!*#;$(H
MP;.SDF5$",X6+)N+5?&GC'\M[@%S0=,!"@FI8S5 !)B;-U\L>)VN=',O1)!/
MRZ+*216T&K=P8S\H4*1.WG"!(._GE^7BCF6VS7S="HH%J<.XCEE$R5^D!9/4
MQ@],'$V#QN(SH:#K 46$U/D<(@14=$*>">.[8J/*;#R1P?Q,S.?(&+>P=(1B
M1>KL[B 2!61_?KO%Z6?Q@UW%^]2)U9T W]'D8/*4O2K^?L+3G"=Q)'X239K^
MDWJ R>]^3H,RBL5O_J-7I*\ANT)P%N1W%8QE?C /@F6MERPI\O5/-A6T^?&O
MK1SA\S@5],5!<L7SV!(8;+K#>O>><L/9.\YS(6L[(YOML(*$3G+M3B\-)^,M
M@&.AT:S-4%"VFJ.%#LT25L&@894&&C*U7B9DB3]D=L5#D#"9HE6<!%FV$D9E
M=85)CPZP.UK $00$[\,2)1"OF> H#L4N(JG6VWY->TUSM'AD#Y",'-, Y2IC
MRR".SAZ7+,V9T*AI<<^R#I-ZB$"=T>*8/0!SD 8-^(! ]8-D_+-3#TALPA>T
MSYCX9?2YYEI+845>P8L@J5HBSSJ^9%FQNDJ"^F BEO"E-*(NF7&ZF7JA!4A=
M; T(XS1F5G-],IU72;#7\?Q>6+@_BT5!LJG'R-(-+6KJ A*(=1HHU4<.YH:1
ML1-:_-0%(0#;-/"Y86&95=G02WDF-!S/-QNB!4]=<-"P1T/V7>L3:FACADU=
M1*_FCH;D:P9LYAAF>-3=/_!23*_/<7 7)W$1L^H.VU:- ;NO!SX"7JQUN'/.
M54XT9EZ+:K#OSM0'+PC;%P8MBJ0=?,V]T?PJ6,G+U()5\9.L%$O+%@.&9=5E
M$+R0+AP:WI\]2N!>\H*MJ;:"J&R,%^WM"Y:!9QJ@= ]Y:_Y65GQL_?""O7VA
M@DF"!FKM@Q\<,W,O*&+>G!+.B$&D0 ,OE^UKR"[ES1WAC UH,]KQR4%ST_@S
M3^<%RQ;=!6!ZE\3SNG#:)4]#+6IR"*<1H%AZ<VGTM26=.1UG!EI0:R\"?3 #
M] <'A"DC!I83N143M%3"4?+F11GOC(:_5(Z4KV$ON*?(TC!U@H+LS94R$&1P
M"4+L^=?'(S:"#^R(J@=E7SQ?5^MUHB+8DA"E; Q%RIM'Q!D; \\T0&E=A+"E
MJ&VUA,+AS>?1:XU3<4L#B^,HJOS>07(5Q-%%>A(LX^*Y,I/"G:CK $7&FXO#
M&1D+[S0 NI85LU(6G059*C;'_#@,RT69R(3T4S:+0U/X&-(7"ILW/X<S;'")
MT$!07[$;8C/ $?+F[1C!.G@I)KS-;.H?'X7C3,X3 N;0@PY0NE*D?@>A<[_H
M?;_[19/?=<9^O6_D,^3ZO)D(Q1$$2MK$WQ-6$9E&QPM9B>,?U<^UF9O&>.Q(
M7]CC.TXC2YG&1M\]>(D9.\TJ&465W7_%LNK:-_3\J>^/?7]J /!N(J((:WUU
M_[@L[GD6_^-YW[#!N=T/^V+5:##J1$(7OHL\+UVA6_?!OFHU,FQ=4="%S%P]
MQ,!@G_(A'IUYHX+GJ8+(J"X^]WT0U!G[MM8 )!V$0PY-^/9G[(1]+6L<]&AO
M?%N$VG8];0?L^UECHD5QOW,LE:5CK<].Y]%I.!YFL&T.V15D>66RXP;Z8'(#
M/0\TX;/)\U!$"L[(XC\+]D2DW>>C[8 :57E@:6G*NWAN@>QFL<A[*SC298S&
M O>4']?4$  4]#%TP?9_N"%BY9T&1-="AH(&63[E5.A0PBL'6T.S:9H8NV'[
M..S"W[H_:9<"#<#JQ]H3Z2J-%F)KDGS)ZGE6R*P=L3T<KJ !)4$#MBWF')9
M?/^%*S1:;O<]$/S$6+T9?.;*"M";4F@WQG9@]-S%MOG==R@O><J[W*TK'5F-
M%$!7;$^'&\Q@6=!83*NBL2PO.J0:JP7I>V [.>"BYT".*"&EY:['Y,)W;O3%
MRBJ%O5]+60'9$#>:85>U<5PC53R2N\9WE?&'.(_EZ]2G3+ 5G<8/<<32Z)QG
MOP29?(7RE']-,UZFD6A;L%!*6P&9'*WO8.A%<X#(#N&1U"K;5LWCAR!.Y$W[
M6][RJ#8I>9^"/ Z!$Q0R$'K1G@%S&"XH&BBO$Y_7P<**1.FQB).R, 5XK!W1
M2_.XH0@4! W4?F&R)!V+CA^$ 3!O7I^8SBK"6P$.,)A]QT,OWN.&\3"Q$0X3
M36<G]T$Z9_E%:LB5[H2-O@>%C634J!EZ$J>3]N#_'BQY_J=)_0TB\:260/K=
ML@1U1[W_T5!X*_<8 "=-.]M$W=)PWW'<'O= NARUS3T*@(BIS2[$7PTG%55;
M8L!TU$J'0(O\=GT&"BC4JB0?+N-I=1/\,88 HNZVC]BH.6E%,3%MS2YMIWP1
MQ*I3XMHB4S<GAHI)XS9-3#5#K3@+C;RA+TSS<MMV3LVZ*788O0\<6HY[^U^$
M67G'<X;O.M/<1K8!:^F&'8#O S)($OL/^.8]9AO2NO;8X?H^$)MYWW]L=W3G
MV__:O&4B^[_JO619S"-!0580 !*>C]L_"=?_ZFN%$9!GN\\H2BVM,[]/RTRP
M=U515UVY6'L.6217+I;F@280TM9XQ['(+-&@Z=Q+4#2<K!KZ:_4>"6GS8-@9
M6D.AAHC*4PU+28PL@#"=M<S\<\'@V2/+PC@7OY"7X$KI?&TB<KFN@)0<<,!X
MV,E9=A0',D@.R%KO1D1R/2!V I8_*+LB\X3E39!TB3J6X>\-2BY9,9U-9\(\
M$.O("<_-\W+8D-AY6C \QQ ;+42-$W3@F-CY7%XQW<TT-1AN:]+62XDJJ%SQ
MYS8&=M86$+0^@MDM2+6"#$1).PAZ#M8@G"RR(7WJJ'3LDGVM?F,,:8&ZHZ=8
MC7**W)(':0AK]>N/X59_] RK<<Z'^X5BI7C5H]7])F'3%3US:I0)V)$#:=@:
MIV0OW#I]T5\U&V?2C8J<QD1Q2'U^2IC6&"K]AD)_U QFK@R1T_Z'MP1+L[@P
MW_%HMT%__@P\ ;<Y([1$]@XH_GI$X$&S 3%%2?\H\:BS-,*?/4-BBBY((KI+
M3.1[ I)*7G<^G<FWM\\3_E53_>?W\.H_<J1)-12];.TG+IV2M!6]<"],28*J
M+5I _VGU<\ZBB_3IMONQ@/VA+FENOPS>8RPZ)9RU:&[?G.HI,1H;J=<;JMY<
M+P.D[O/R*AF#]#CZOS*O'Q*[Y=<LY&D8)ZS#["T?;:;[^1IVLM!H.N83#!J+
MB',F"=&\(*](*4Q!XME#[;<(-IX@T&-K[(2=#;1#@ '"HX&R8#V3S[Z>LOK/
M%K--ICFHIB5X#.Q<HM'6=7?!407\*F/+();/A56VSKIX2QI5+M;C/&>%P3;L
M.QYV)E(/_&P*X")(=ROS8VUEIFPNC\;X5N8V_\=AR,M4/OVTDC?]Y+H7AEDI
MB(4\V-QW/.P4* ^*Y")(S..*+N-1+Y'JB7&S.E0)@"XC8.=+]5< 9U8I;23P
MG70,+Q&A#"L?[J'!LYE.R3,5QQ?I \M'<B$:QZ*3WS582P RH[$0B%VJ.5,=
MAW\OXXSU> ?090STU*\!@/'>7+\4LQ$NO#%6!@(Y9J-IB[OD7NANTCRA,LIN
M8AR+3H[;X-T$(#,:N\FU.$.OFM#Q)2_8^A"D1U;? SW5;0 8FR4"S%+9_WVA
ME@FKSCQ762S$LY0E+VJF]>!;NJ$GT(VF 2#Y8*J!X8)5WI0HS&$7AJJ+0AK/
M0/_AT-/NAJO", &,L\KK*RR'C$6YO*6IO+XIJ&N(4I>D;ZH..PV"GL4W#J3]
M9+<#( W7;0$(&GNCI^V-#QU 6C1,K#;1#85KVLTIS(9>4#R]N>=&VV@ATJ&!
M(YSE,8Y%#CDYY#%VE]R^'Z4EN_+_TJ/T($P(L2A=,R&C.!1FG_R%V&.Z/VBU
MK._=;$<JPJ2,JN>LPJK"\K4P(<]F,V8ZAN^:#JC.^K\G"C_"XV#U36NX)X6%
MZY__*ZX[TK_!ZD2J5AI%I7*X]7)$R3,YF.E1%(O&I:=RN4PJ\07)6GP7Z8QG
MBT#U)+@BAQ8Z %11_-_VA2N*HW1H&./KE^=DE5[0HWM/#:$0^;ODZRAO]9-[
M&XQ3045F]MX&C])C'AL>D-EJ"$7%WRW=@:@H&?=5RZ=%ZVF<APG/RXS)4$4:
M.BUOE8>SYV!0Q/S?Z04L=4,8]0JE[BY_/F+1 \M84"#']PV.@ J@+ )(E"/G
M=2)?"#YE>9C%RZ)Z4?!3F<<IRW-A[]V4BT60K::SFWB>QC/1*RV:[%=9[X,G
M<=AVPG1N#O]A<C!Y!DC^Q_-'Y'7A]6<F01I-F@_)G[<^-7G^UN3I8WB[U32;
M!VES3>3Y'G1]A>2J!<YTUGBJ@N3YAK3=:!QI>,3M?! 'S[HB%<^D;[="V3\)
M-G[S),M>E"#?CAY5-S??4T>"E=Z#>#+H%]=7U 0W0A:2?I;J%\$_;BZ"K1&J
MA:\[!N[S/!K.6@A:US#'89#?([)2"EAI7,=!7B=ZX:QXV,A==/1F<Y6LHYFX
M'S<G;M,83V%K NQ3<+,=XAS[+,P[QKH79B"[MZT?\AQ2([$Q26"\TYL4AC==
M#]]M3HJF,?:3?_9)0>J)U<V*83)CU&G/<1@">:H GUYUE B]63/L &T\2!\>
M^CE(3WZW_AMFC:X7?*;6>/ N@Z)R6*UAJU!8F6:][&;M]1+/GR#&*<4SY,ON
M^72V,<-7=HB; :#]L4M\^?0VN,G05YJMV(#$QX/DFCV(78E56]3-,HD+V'1U
MZ(]=2LO;S'66(8TYW)$!>.::>V'7SO(Y7R'RHH'LSS+Y^RPOXH5@S9#^L]D.
MNS"63_34,O&UJ@H+E2WB<)HJ"-6MI.8^V 6K_*V>$%G1F%=-<I@M>6PS$[9:
M*LQ)>/U'Q:Y?Y77%'4'>-#1'.LEX5OO&P%NML1-VN2F?N .DM?_5<<^#.*O?
M?GF6T$4JY%(N(*L&L#MV42J?:N(D01KK@%B[F*!!KEJGXK"0\*JJ2E.ASP8Y
MJ#-V>2J?@#M(CP;<[:JZURR15]NK2] .IRW@ .@%I_R>O)S$2 /[LR!+XW0N
M+T)5E^3!F%L[HA>>\HDU4&R>#FXM9US&4_'7L";ZFH7BCV1U'/%EH7T%%-P;
MO1B4M].<HP!I3-5+]E5'MZ-?VWTD]-I./B=S7\&^M+CGK:R1I(EZ'OF*>M8?
M?8UY$LXCO@GO6516#YAO7TJ4VG7/L^*698NZN%Y=I%'""LF=&&'LEQAK'5$\
ME/:P9WZ.Q4(0Q8E8PA[8#0O+K"H@<?8H;]ZS2)83D?9TN1;=IL'EI%KC?>LE
M1WK]84-OHVSR_PP;WGMUQBF%#6LO4T\%*?(T#-T7M!WV(]G4R*VO:Z5/\[=]
M*:]U^ZYQ2MSREO;;,B>&#HJ]8)KQ&H/#W6":=4S[7U@\OQ<T'3^P+)@S:0#8
M\ ,,@)WZXH 56!S>Y]K&M^66(0\YLF*0=4H9^V(GJ;C,'( 0/ 'Q_#I$&K6+
MOJX? EE]D0F+XD_0:M=[-.R<%#M8 P5%SX2K4]--)MP']?T("B;<7EZ4:,X1
MM^8"XYOM;%-C2[^\3!#@S8<NZ>UP% 7)?]Y\,]T@_59;&@BH]4>'0(O\=J%,
M"BC4JB1/P#RMCM6/,000=;=]Q$;-2<N2QXQG=FD[Y8L@-KS JFE.#!63QFT&
M)M4,/9^*QZU^O5&Y^0M;W+%,8UQI6V.?$8TZTZU?;>27AHNUH4T+1=-NHQGV
MV0^$@9KT+>'O::I=RQ&A?/"ZNK QK8Z\>5-RV7ZJV?+M]A\;V?.FMX*T?NRA
M<J0QH5O\*&_FKA>C:78M3^&0&_T#AL1>K/NH03^QT3OR#@OOG[(BB!/-6?E[
M7_']YJNO 7[" 7[U#87CXD1,D96 LTI?-J1_PKJ_X#"]DP!I["K=^RDG929%
MJ,=8TQQ[-_"<QZV7$ T0I\4]RY[I/,YS5N16+,V]L$\"7DOG >1% UF*I?3Q
M8U*^U_ QWW%X23;CH=IH_+UGHW%R^&HV$C8;QTL8LT241OX.#>_N?J3RD0J$
M#61FRV.PK6KC?8&&DOF9HAO:-I[0B(3Z!C+T::4>P!PH]/K15VT<1XXT@IQJ
M"B^#!;/%.^T]:6C*#F8@2&W:DAD80QW)**V,:UMPK]L*VTD#5=?-P[J"U?V/
M\NUG>+8GA"\T4CMP=3I>R!.O-TM@/3RROWUL8WW<;;Z+P0MUV\B09ADD:N>-
MIP>!GITWS==?73B[+&<\\ 9X#9GER;F1O_$2XX(>Q$0J.I$$>3Z=-=M[DT$Q
M+8N\$(N%8,(0@+#V1+-6_6'&'45 =5,RO31C2BYQ>W9I8,Z(9F&TTVY9]5P&
MH)"FOE_7-%PEK'9[O][?H')'8$RGKJX*UCQCU;<T?M6JT%.WS3Y(4D'V4*^C
M38!:KV&'%B(>0H5\# +T>P'B<QS*HH[20%A*TS%CT5/UQS4%QCL1+@.@&D8:
M76G+W%T8-(S9YG[_59 5JUMADN5!]<9P_FG5_HTY>.,RQCXL0CW8:KD@B8!I
M"X:HVM( QUTE#<#Y70+/Q33_[[(0_(@IGY[(>^79>MJ?"$Y99EP X=VQHQAZ
MS6HO@J[B\%46(?CM.H[F[+(23Y!\#NYX)GNOC&C8NV$'(F H0-GW)'W#00;F
M87,9@/RU+%>&*-D&LHC3=/83YU'E!6+9@S!R\AO^+!!5-6Q]'U0;K@<(FQ6N
M;=+P-*$Z;KEKO@J28G45K"KSA;>7!(C'VMP?;8$;AI CEU[1.H^SO)"LL*SR
ME@<)NV)9S'4%J0WMT1+.AZ-AE8*O5YTR_G\L+-:/2%4UZ#6"5S=%JV4T7.8F
MWFEL**T7(2Y20:Y8/PW'2G5KM$>V1ME$3!*@@9'Z 0\ 7-:.:,]@C8(<4"XT
M0&PVOOR\?J))L%H]QJ$'3]L![0VK44"SR,%7?<3&-CQGRI<=J^J!G29H+T -
MWW14O'H2:U6QSU#ML_5[M!>6A@MTBTM?EE(I%K- OKCY11@+F3#2M*]>JEKB
M/68T@J&D9YW&\BV]"=/92<:BV%3ANM,*[\6A459J%<LTP#AE2Y['ILWSN07>
MHT$C6:==5FD T-K$KYDI=7BK(=[#/6-;+VW&??EM@V5<!$G\#Q95>]!3PM^G
M59/LE0N"9+Q,<"-^DI4L:M[UT^T<PX:$HD?Q+#Z&,/WBG+!J!YS.9L)\DY?Y
MJ_.,&4A='RA2U [E -9V 46E(4]9 F8(-MM"14_M5&U@R6]LL OP^OBB"PGJ
M6D/%3NU<;&3*J^"_Q G+"YZR9E?32'R[&534%$_'.J;I93?7-?2-B<P?-8\"
MD2ASMX?/ NUILK)&D$H+]C4G&3N)C7!-^<\\G1<L6YRRN^)6?,R<9*ANO4=(
MJ!F@45-ADS9;\J"N/0TX3(IE 854N8.V?3R]2^)Y)4=]G?EUHHJY&W8JH5G7
MMNK2 42P_W?JG]XGJAAM' %ZA#7-R2?#F<GW>OQHO_J4G_ GPT5W#C&TQYY
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M^,G_ U!+ 0(4 Q0    (  >*#E$J_"<=$6T  !(L!0 1              "
M 0    !A=&YM+3(P,C P-C,P+GAM;%!+ 0(4 Q0    (  >*#E%N_=9K(0X
M %B-   1              "  4!M  !A=&YM+3(P,C P-C,P+GAS9%!+ 0(4
M Q0    (  >*#E&J4 68# L   :(   5              "  9![  !A=&YM
M+3(P,C P-C,P7V-A;"YX;6Q02P$"% ,4    "  'B@Y1JBJ+9<06  !3:0$
M%0              @ '/A@  871N;2TR,#(P,#8S,%]D968N>&UL4$L! A0#
M%     @ !XH.4>76^P05/P  28H# !4              ( !QIT  &%T;FTM
M,C R,# V,S!?;&%B+GAM;%!+ 0(4 Q0    (  >*#E%-IZK%-R8  "U^ @ 5
M              "  0[=  !A=&YM+3(P,C P-C,P7W!R92YX;6Q02P4&
/  8 !@"* 0  > ,!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
